CA2359795A1 - Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use - Google Patents

Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use Download PDF

Info

Publication number
CA2359795A1
CA2359795A1 CA002359795A CA2359795A CA2359795A1 CA 2359795 A1 CA2359795 A1 CA 2359795A1 CA 002359795 A CA002359795 A CA 002359795A CA 2359795 A CA2359795 A CA 2359795A CA 2359795 A1 CA2359795 A1 CA 2359795A1
Authority
CA
Canada
Prior art keywords
adenovirus
fiber
protein
tpl
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002359795A
Other languages
French (fr)
Inventor
Glen Robert Nemerow
Daniel J. Von Seggern
Paul L. Hallenbeck
Susan C. Stevenson
Yelena Skripchenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2359795A1 publication Critical patent/CA2359795A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B37/00—Manufacture or treatment of flakes, fibres, or filaments from softened glass, minerals, or slags
    • C03B37/01—Manufacture of glass fibres or filaments
    • C03B37/012—Manufacture of preforms for drawing fibres or filaments
    • C03B37/014—Manufacture of preforms for drawing fibres or filaments made entirely or partially by chemical means, e.g. vapour phase deposition of bulk porous glass either by outside vapour deposition [OVD], or by outside vapour phase oxidation [OVPO] or by vapour axial deposition [VAD]
    • C03B37/018—Manufacture of preforms for drawing fibres or filaments made entirely or partially by chemical means, e.g. vapour phase deposition of bulk porous glass either by outside vapour deposition [OVD], or by outside vapour phase oxidation [OVPO] or by vapour axial deposition [VAD] by glass deposition on a glass substrate, e.g. by inside-, modified-, plasma-, or plasma modified- chemical vapour deposition [ICVD, MCVD, PCVD, PMCVD], i.e. by thin layer coating on the inside or outside of a glass tube or on a glass rod
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B37/00—Manufacture or treatment of flakes, fibres, or filaments from softened glass, minerals, or slags
    • C03B37/01—Manufacture of glass fibres or filaments
    • C03B37/012—Manufacture of preforms for drawing fibres or filaments
    • C03B37/014—Manufacture of preforms for drawing fibres or filaments made entirely or partially by chemical means, e.g. vapour phase deposition of bulk porous glass either by outside vapour deposition [OVD], or by outside vapour phase oxidation [OVPO] or by vapour axial deposition [VAD]
    • C03B37/018—Manufacture of preforms for drawing fibres or filaments made entirely or partially by chemical means, e.g. vapour phase deposition of bulk porous glass either by outside vapour deposition [OVD], or by outside vapour phase oxidation [OVPO] or by vapour axial deposition [VAD] by glass deposition on a glass substrate, e.g. by inside-, modified-, plasma-, or plasma modified- chemical vapour deposition [ICVD, MCVD, PCVD, PMCVD], i.e. by thin layer coating on the inside or outside of a glass tube or on a glass rod
    • C03B37/01807—Reactant delivery systems, e.g. reactant deposition burners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B37/00—Manufacture or treatment of flakes, fibres, or filaments from softened glass, minerals, or slags
    • C03B37/01—Manufacture of glass fibres or filaments
    • C03B37/012—Manufacture of preforms for drawing fibres or filaments
    • C03B37/014—Manufacture of preforms for drawing fibres or filaments made entirely or partially by chemical means, e.g. vapour phase deposition of bulk porous glass either by outside vapour deposition [OVD], or by outside vapour phase oxidation [OVPO] or by vapour axial deposition [VAD]
    • C03B37/018—Manufacture of preforms for drawing fibres or filaments made entirely or partially by chemical means, e.g. vapour phase deposition of bulk porous glass either by outside vapour deposition [OVD], or by outside vapour phase oxidation [OVPO] or by vapour axial deposition [VAD] by glass deposition on a glass substrate, e.g. by inside-, modified-, plasma-, or plasma modified- chemical vapour deposition [ICVD, MCVD, PCVD, PMCVD], i.e. by thin layer coating on the inside or outside of a glass tube or on a glass rod
    • C03B37/01884—Means for supporting, rotating and translating tubes or rods being formed, e.g. lathes
    • C03B37/01892—Deposition substrates, e.g. tubes, mandrels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B2203/00—Fibre product details, e.g. structure, shape
    • C03B2203/10—Internal structure or shape details
    • C03B2203/22—Radial profile of refractive index, composition or softening point
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B2203/00—Fibre product details, e.g. structure, shape
    • C03B2203/10—Internal structure or shape details
    • C03B2203/22—Radial profile of refractive index, composition or softening point
    • C03B2203/26—Parabolic or graded index [GRIN] core profile
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Abstract

The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits.

Description

WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 Adenovirus Vectors. Packaqing Cell Lines. Compositions and Methods for Preparation and Use This application is a continuation-in-part of U.S. Application 09/423,783 filed November 12, 1999 and claims the benefit of the filing date of U.S.
Provisional Application 60/115,920 filed January 14, 1999.
This invention was made with U.S. government support under NIH Grant No.
HL 54352. The government has certain rights in the invention.
The present invention relates to gene therapy, especially to adenovirus-based gene therapy. In particular, novel packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. High-capacity adenovirus vectors are also disclosed herein, as are related compositions, kits, and methods of preparation and use of the disclosed vectors, cell lines and kits.
Enhanced transfer of DNA conjugates into cells has been achieved with adenovirus, a human DNA virus which readily infects epithelial cells (Horwitz, "Adenoviridae and Their Replication", in Virology, Fields and Knipe, eds., Raven Press, NY (1990) pp. 1679-1740).
There is a need in the art to obtain Adenovirus vectors capable of incorporating large segments of foreign DNA and capable of being targeted to specific cells, as well as to obtain cell lines which can package such adenovirus-gene deficient vectors or targeted vectors. These needs, as well as others, are met by the invention.
This invention utilizes recombinant adenovirus constructs which duplicate the cell receptor binding and DNA delivery properties of intact adenovirus virions and thus represents an improved method for gene therapy and cell targeting as well as for antisense-based antiviral therapy.
In contrast to the disadvantages of using intact adenovirus, modified adenovirus vectors requiring a helper plasmid or virus, or so-called replication-deficient adenovirus in the art, the use of recombinant adenovirus-derived vectors according to one aspect of the present invention provides certain advantages for gene delivery. First, the Ad-derived vectors of the present invention possess all of the functional properties required for gene therapy including binding to epithelial cell receptors and penetration of endocytic vesicles. Therapeutic viral vectors of the present invention may also be engineered to target the receptors of and achieve penetration of non-epithelial cells; means of engineering viral vectors to accomplish these ends are described in detail herein below.
Second, the vectors of the present invention have deletions of substantial portions of the Ad genome, which not only limits the ability of the Ad-derived vectors to "spread" to other host cells or tissues, but allows significant amounts of "foreign" (or non-native) nucleic acids to be incorporated into the viral genome without interfering with the reproduction and packaging of the viral genome.
Therefore, the vectors of the present invention are ideal for use in a wide variety of therapeutic applications.
Third, while the vectors disclosed herein are safe for use as therapeutic agents in the treatment of a variety of human afflictions, some of these vectors do not require the presence of any "helpers" for propagation and packaging, largely because of the novel cell lines in which they are reproduced. Such cell lines --referred to herein as packaging cell lines -- comprise yet another aspect of the invention.
To reduce the frequency of contamination with wild-type adenovirus, it is desirable to improve either the viral vector or the cell line to reduce the probability of recombination. For example, an adenovirus from a group with less homology to the group C viruses may be used to engineer recombinant viruses with little propensity for recombination with the Ad5 sequence contained in the packaging lines. The invention describes the preparation of packaging cells lines which stably expresses adenovirus proteins or polypeptides. These cell lines are useful for complementing viral vectors bearing deletions of regulatory and/or structural genes, irrespective of the serotype from which such a vector was derived.
It is also contemplated that the constructs and methods of the present invention will support the design and engineering of chimeric viral vectors which express amino acid residue sequences derived from two or more Ad serotypes.
Thus, unlike methods and constructs available prior to the advent of the present disclosure, this invention allows the greatest possible flexibility in the design and preparation of useful viral vectors and cell lines which support their construction and propagation -- all with a decreased risk of recombining with wild-type Ad to produce potentially-harmful recombinants.
In part, the present invention discloses a simpler, alternative means of reducing the recombination between viral and cellular sequences than those discussed in the art. One such means is to increase the size of the deletion in the recombinant virus and thereby reduce the extent of shared sequences between WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 that virus and any Ad genes present in a packaging cell line e.g., the Ad5 genes in 293 cells, or the various Ad genes in the novel cell lines of the present invention.
Deletions of all or portions of structural genes of the adenovirus have been considered undesirable because of the anticipated deleterious effects such deletions would have on viral reproduction and packaging. Indeed, the use of "helper" viruses or plasmids has often been recommended when using Ad-derived vectors containing large deletions in structural protein sequences precisely for this reason.
Contrary to what has been suggested in the art, however, this invention discloses the preparation, propagation and use of recombinant Ad-derived vectors having deletions of all or part of various gene sequences encoding Ad structural proteins, both as a way of reducing the risk of wild-type adenovirus contamination in virus preparations, as a way of allowing foreign DNA to be packaged in such vectors for a variety of diagnostic and therapeutic applications and as a way of targeting an adenovirus vector to a specific cell type.
The invention further discloses a wide variety of nucleic acid sequences and viral vectors. Thus, in one embodiment, the invention discloses a nucleic acid sequence encoding any one of the adenovirus fiber proteins mentioned in the specification, polypeptides or fragments thereof -- including, without limitation, those that include deletions or other mutations; those that are chimeric; and those that have linkers, foreign amino acid residues, or other molecules attached for various purposes as disclosed herein. Nucleic acid sequences encoding various other adenovirus structural and/or regulatory proteins or polypeptides are also within the scope of the present invention.
In various embodiments, the adenovirus is a Group C adenovirus selected from serotypes 1, 2, 5 or 6; while in other embodiments, adenovirus selected from other serotypes, such as for example Ad37 (subgroup D) are useful as disclosed herein.
The invention is also directed to an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL
exon 2 and complete TPL exon 3. A preferable embodiment of the invention may further comprise an intron operatively linked to the TPL, wherein said intron also WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 contains requisite processing signals for the intron's removal. Another preferable embodiment of the invention is directed to the isolated nucleic acid molecule wherein said TPL nucleotide sequence consists essentially of complete TPL exon operatively linked to complete TPL exon 2 operatively linked to complete TPL
exon 3. A related embodiment may further include an intron and appropriate processing signals. Additional embodiments of the invention are directed to nucleic acid molecules contained in plasmids selected from the group; consisting of pCLF, pDV60, pDV67, pDV69, pDV80 and PDV90. Packaging cell lines and adenovirus particles containing the nucleic acids described above are also included in the invention.
The invention is further directed to methods for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome comprising providing a) a packaging cell line which complements replication and packaging of said genome and b) a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles.
The genome is introduced into the cell line. Additional embodiments of the invention may also include the following steps; a) growing the cell line produced under conditions for producing particles; and/or b) harvesting an adenovirus vector particle containing said helper-independent fiberless recombinant adenovirus vector genome. The method may also include a cell line that expresses a fiber protein and complements a fiber mutation in the vector.
The invention is also directed to an adenovirus vector packaging cell line comprising a stably integrated nucleic acid molecule as described above, an operatively-linked promoter and a nucleic acid sequence which encodes an adenovirus structural protein, wherein said TPL sequence consists essentially of a first TPL exon operatively linked to a complete second TPL exon operatively linked to a complete third TPL exon, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL
exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL
exon 2 and complete TPL exon 3. Preferably, the cell line may have a complete first TPL exon. Another embodiment of the invention comprises adenovirus structural protein, such as adenovirus fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.
The invention is further directed to a recombinant adenovirus particle comprising a recombinant adenovirus vector genome wherein said genome:(a) does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene, and (b) encodes an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication. The invention is also directed to a helper-independent fiberless recombinant adenovirus vector genome comprising genes which (a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene and (b) encodes an exogenous protein. Either of the above embodiments may substitute a helper-dependent for a helper-independent recombinant adenovirus vector genome. In a preferable embodiment, no fiber protein is expressed. In yet another embodiment of the invention, the recombinant adenovirus particle fails to express sufficient fiber protein to allow fiber incorporation into the particle such that the particle can use the fiber pathway for infection.
The invention is further directed to a method for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome, said method comprising providing a packaging cell line which complements replication and packaging of said genome and a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL
nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon and harvesting said adenovirus particles produced by said cell line.. In a preferable embodiment the adenovirus particle further comprises an exogenous protein or a modified fiber protein. The method may also comprise a step of coating a particle (i.e. providing fiber protein in any way) with an adenovirus fiber protein.

WO-00/42208 cA 02359795 2001-07-12 pCT/EP00/00265 Another aspect of the invention is directed to a method for pseudotyping recombinant viral vectors comprising complementing a missing fiber gene of a helper-independent fiberless recombinant adenovirus vector genome by expressing in packaging cells a fiber gene from a different adenoviral serotype than said recombinant adenovirus vector, thereby pseudotyping said vector. An additional embodiment of the invention is directed to the method for pseudotyping recombinant viral vectors comprising: a) providing a packaging cell line for propagating a fiber gene deleted recombinant adenovirus vector, b) introducing into said cell line a helper-independent fiberless recombinant adenovirus vector genome, and c) complementing the missing fiber gene by expression in the cells of a fiber gene from a different adenoviral serotype thereby pseudotyping the vector.
The invention is further directed to a method for specifically targeting an adenovirus vector to a cell of choice comprising introducing a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome into a packaging cell line for producing a fiber gene-deleted adenovirus vector and providing, wherein said gene for a missing fiber protein is complemented with a gene for a desired modification for targeting the vector to a cell of choice The invention is further directed to a method for producing a modified adenovirus comprising providing in vitro an exogenous fiber protein to a fiberless adenovirus. Additional embodiments of the invention may provide any combination of all of the following steps such that the invention be directed to a method for producing a modified adenovirus comprising: a) providing a packaging cell line for producing a fiberless adenovirus vector, b) introducing into said cell line a helper-independent fiberless or helper-dependent fiberless recombinant adenovirus vector genome, c) growing and harvesting a fiberless adenovirus, d) maintaining the fiberless adenovirus in any suitable buffer, and e) providing exogenous fiber, wherein said fiber may be a modified fiber, to the fiberless adenovirus by adding conditioned media or a soluble fiber preparation or a fiber in any suitable buffer to a virus preparation thereby producing the modified adenovirus.
The invention is further directed to a method for producing a modified adenovirus comprising providing a packaging cell line for producing a helper-dependent fiberless adenovirus vector genome and providing a helper virus vector, wherein said cell line complements at least a deficient fiber protein gene, thereby producing the modified adenovirus. Another aspect of the invention is directed to a method for producing a modified adenovirus comprising: a) providing a packaging cell line for producing a fiberless adenovirus vector, b) introducing into said cell line a helper dependent fiberless recombinant adenovirus vector genome _ 7_ and a fiberless helper virus vector, c) growing and harvesting a fiberless adenovirus, and d)maintaining the fiberless adenovirus in infectious media, and e) providing exogenous fiber to the fiberless adenovirus by adding conditioned media or a soluble fiber preparation to a virus preparation thereby producing the modified adenovirus.
Additional aspects of the invention are directed to hybrid Ad/AAV vectors and to new helper-dependent vectors used with fiberless adenovirus vectors.
The invention is also directed to a method for delivering a heterologous gene to an EBV-infected B cells comprising infecting said B cells with a pseudotyped Ad5(3gal.~ F particle or other fiber-deleted adenovirus particle, said particle having a chimeric fiber with the receptor-binding knob domain of the adenovirus type fiber.
The invention is also directed to an isolated nucleic acid comprising a post-transcriptional regulatory element (PRE) and a TPL. Preferably the PRE is the woodchuck hepatitis virus PRE (WPRE).
The invention is further directed to a composition for preparing a therapeutic vector, said composition comprising a plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding a fiber protein or a genome that is incapable of expressing sufficient fiber to result in packaging.
Another aspect of the invention is directed to a method of delivering a heterologous gene to a human or any animal comprising providing an exogenous gene to a target cell comprising contacting said cell in vivo or ex vivo with an amount of a recombinant adenovirus particle sufficient to infect said cell.
The invention is also directed to A method for producing a gutless adenoviral vector particle comprising: a) delivering a helper adenovirus vector genome to an adenovirus vector packaging cell, wherein said helper adenovirus vector genome lacks any gene encoding adenovirus fiber protein or lacks the ability to encode sufficient adenovirus fiber protein to produce an adenoviral vector comprising fiber protein in the absence of complemetation by said packing cell and wherein said packaging cell comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to an adenoviral fiber protein or to a chimeric protein that includes an adenovirus fiber protein tail domain; (b) delivering a gutless adenovirus vector genome to said packaging cell; and (c) recovering the gutless adenoviral vector particle produced by said cell.
Another aspect of the invention is directed to a helper adenovirus particle comprising an adenovirus vector genome that does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-_ g_ containing adenovirus particle without complementation of said fiber gene, wherein said genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged. Packaging sequence are those sequences are those sequences involved in packaging the viral particle.
The invention is further directed to a helper adenovirus particle comprising an adenovirus vector genome with recombinase sites flanking its packaging sequence, wherein said vector genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene.
The invention is also directed to an adenovirus particle comprising a gutless adenoviral vector genome and a fiberless capsid, as well as an adenovirus particle comprising a gutless adenoviral vector genome and a capsid comprising a modified fiber protein.
Another aspect of the invention is directed to a packaging cell for the production of a fiberless or fiber-modified gutless adenovirus particle comprising an adenovirus vector complementing plasmid and a nucleotide sequence encoding a recombinase, wherein said complementing plasmid comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to a nucleotide sequence encoding an adenoviral fiber protein or a chimeric adenoviral fiber protein.
Preferably the cell line may comprise a recombinase. In an embodiment of the invention the recombinase may be Cre.
In another embodiment of the invention, the fiber-deleted adenovirus vectors of the invention and the fiber-complementing adenovirus packaging cells of the invention are used to produce a gutless adenovirus vector particle. Such particle comprises a gutless adenoviral vector genome in an adenoviral capsid. The fiber proteins of the capsid may be wild-type fiber, or the modified fiber proteins disclosed herein. Alternatively, such particle may have a fiberless capsid as disclosed herein. Preferably, the gutless genome contains at least one heterologous gene as described herein. As used herein, the term "gutless adenoviral vector genome" means an adenoviral vector genome from which all of the viral genes have been deleted..
The invention also discloses systems or kits for use in any of the aforementioned methods. The systems or kits may contain any appropriate combination of the within-described vectors, plasmids, cell lines, virus particles and additional therapeutic agents as disclosed. Preferably, each such kit or system includes a quantity of the appropriate therapeutic substance or sequence sufficient for at least one administration, and instructions for administration and use.
Thus, _ g_ one system further comprises an effective amount of a therapeutic agent which enhances the therapeutic effect of the therapeutic viral vector-containing composition. Another variation discloses that the composition and the therapeutic agent are each included in a separate receptacle or container.
It will also be appreciated that any combination of the preceding elements may also be efficacious as described herein, and that all related methods are also within the scope of the present invention.
< Figure 1 is a schematic diagram of the entire adenoviral E4 transcriptional unit with the open reading frames (ORF) indicated by blocked segments along with the promoter and terminator sequences. The location of primers for amplifying specific portions of E4 are also indicated as further described in Example 1A.
Figure 2 is a schematic map of plasmid pE4/Hygro as further described in Example 1 B.
Figure 3 is a schematic map of plasmid pCDNA3/Fiber as further described in Example 1 B.
Figure 4 is a schematic map of plasmid pCLF as further described in Example 1 B.
Figure 5 is a photograph of a Southern blot showing the presence of intact adenovirus E4 3.1 kilobase (kb) insert in the 211 cell line as further described in Example 1 C.
Figure 6 is an autoradiograph showing labeled fiber protein immunoprecipitated from cells and electrophoresed under native and denaturing electrophoresis conditions as described in Example 1 C. The 293 cells lack fiber while the sublines 211 A, 211 B and 211 R contain fiber protein detectable in functional trimerized form and denatured monomeric form.
Figure 7 is a schematic map of plasmid pDEX/E1 as further described in Example 1 D.
Figure 8 is a schematic map of plasmid pE1/Fiber as further described in Example 1 F1.
Figure 9 is a schematic map of plasmid pE4/Fiber as further described in Example 1 F2).
Figure 10 is a schematic illustration of linearized pD E1 Bb gal delivery plasmids for use in cotransfection and recombination to form a recombinant adenoviral vector having multiple adenoviral gene deletions. The plasmids and recombination event are more fully described in Example 2A.

CA 02359795 2001-07-12 pCT~P00/00265 Figure 11 is a schematic of plasmid p11.3 as further described in Example 2A used in the construction of pDV44 delivery plasmid.
Figure 12 is a schematic of plasmid 8.2.
Figure 13 shows the trimeric structure of the recombinant fiber. 293, 211A, 211 B, or 211 R cells as indicated were metabolically labeled with [35S)methionine, soluble protein extracts prepared, and fiber was immunoprecipitated. A portion of the precipitated protein was electrophoresed on an 8% SDS-PAGE gel under either semi-native or denaturing conditions. The positions of trimeric (T) and monomeric (M) fiber are indicated. As a control for electrophoretic conditions, recombinant Ad2 fiber produced in baculovirus-infected cells was run under identical conditions and stained with Coomassie blue. Figure 14 shows the complementation of a fiber mutant adenovirus by fiber-producing cells. The cell lines indicated (2x106 cells per sample) were infected with the temperature-sensitive fiber mutant adenovirus H5ts142 at 10 PFU/cell and incubated at either the permissive (32.5°C, stippled bars) or the restrictive (39.5°C, solid bars) temperature. 48 hours post-infection, virus was isolated by freeze-thaw lysis and yields determined by fluorescent focus assay on SW480 cells. Each value represents the mean of duplicate samples, and the data shown is representative of multiple experiments.
Figure 15 shows the incorporation of the recombinant Ad5 fiber into Ad3 particles. In Figure 15A, the alignment of the N-terminal (penton base-binding) domains of fiber proteins from several different adenovirus serotypes is shown.
From top to bottom, the five different serotypes are listed as SEQ ID NOs 21-25. In Figure 15B, type 3 adenovirus was propagated in 293, 211 B, or 211 R cells as indicated and purified by two sequential CsCI centrifugations. 10 Ng of the purified viral particles was then electrophoresed under denaturing conditions and transferred to a PVDF membrane. Ad5 fiber was detected with a polyclonal rabbit antibody raised against recombinant Ad2 fiber. As a positive control for detection, 400 ng of wild-type Ad2 was run in the lane marked "Ad2". Under these conditions, the mobilities of the Ad2 and Ad5 fibers are indistinguishable and the antibody reacts with both proteins.
Figure 16 shows the fiber deletion in pDV44 and the genomic structures of the AdS.[igal.~F and AdS.[igal.wt vectors: Figure 16A shows pDV44 that was constructed by removing the fiber gene and residual E3 sequences (nt 30819:32743 of AD5) from pBHGlO. Figures 16B shows viruses constructed by cotransfection of either pBHGlO or pDV44 with p0ElB[3gal. Both are E1/E3 deleted Ad5 vectors, and AdS.[igaI.OF has the additional fiber (L5) deletion as in pDV44.

Figure 17 shows the analysis of the viral chromosomes. Figure 17A shows the predicted EcoRl restriction maps of Ad5.~3gal.wt and AdS.(igaI.OF. The 5.9 kb fragment at the right end of the AdS.agal.wt genome is reduced to 4.0 kb by the deletion of fiber sequences in Ad5.~3gaI.OF. Figure 17B shows an ethidium bromide-stained gel of EcoRl-digested viral DNA. Figure 17C shows a Southern blot of the gel as described in Example 2 probed either with labeled fiber or sequences.
Figure 18 shows the analysis of vertex proteins in the viral particles. 293 (non-fiber expressing) or 211 B (fiber-expressing) cells were infected with AdS.~igal.wt ('wt') or with AdS.~igaI.OF('OF') and the resulting viral particles were purified on CsCI gradients. 10 Ng of purified virions was then electrophoresed on 5-16% gradient gels and Western blotted. Proteins were detected with polyclonal anti-fiber or anti-penton base antibodies.
Figure 19 shows the infectivity of Ad particles on THP-1 monocytic cells.
Figure 19A shows THP-1 cells that were infected with AdS.(3gal.wt or with fiberless AdS.~igaI.OF at 100,000 particles/cell. Forty-eight hours after infection, cells were fixed and stained with X-gal and the fraction of infected cells was determined by light microscopy. Figure 19B shows cells that were infected with 1000 particles per cell of AdS.~igal.wt or with 100,000 particles/cell of AdS.(3gaI.OF. As indicated, cells were pretreated with 100 pg/ml of recombinant penton base or with 20 Ng/ml of recombinant Ad2 fiber.
Figure 20 shows a schematic of improved fiber-complementing cell lines, 633 and 644 as further described in the Examples.
Figures 21 and 22 illustrates pseudotyping of fiberless particles with fiber proteins and infectivity data as further described in the Examples.
Figure 23 shows the Clal to Bglll fragment of AdS.
Figure 24 shows the plasmid pGRES-2/EBV
Figure 25 shows the plasmid pGRES-E1.
Figure 26 shows the plasmid pSE280-E2 BamHl-Smal.
Figure 27. The fiber-deleted adenovirus vector AdS.bgaI.DF was grown in cells expressing either no fiber (293; 'AdS.bgaI.DF/0'), the Ad5 fiber (633;
'AdS.bgaI.DF/5F'), or the Ad37 fiber with modifications as described in the text (705; 'AdS.bgaI.DF/37F') and CsCI-purified. 10 pg of the purified particles were electrophoresed and transferred to a nylon membrane. As controls, 10 Ng of wild-type Ad37 or the fiber gene-containing vector AdS.bgal.wt or a sample of purified recombinant Ad37 fiber knob were also run. The blot was probed with polyclonal antisera against recombinant Ad37 fiber or Ad2 fiber proteins. As a loading control, the same filter was reprobed with an antibody against the Ad2 penton base (the anti-Ad2 sera cross-recognized the very similar Ad5 fiber and Ad5 penton base proteins).
Figure 28 shows PCR analysis for fiber presence.
Figure 29 shows the transduction efficiency for fiberless virus with and without soluble fiber.
Figure 30 shows the transduction efficiency of ADSBgF- on HDF cell line with the presence of different amounts of 633 conditioned media.
To reduce the frequency of contamination with wild-type adenovirus, it is considered desirable to improve either the viral vector or the cell line to reduce the probability of recombination. For example, an adenovirus from a group with less homology to the group C viruses may be used to engineer recombinant viruses with little propensity for recombination with the Ad5 sequence in 293 cells.
Similarly, an epithelial cell line -- e.g. the cell line known as 293 -- may be used or further modified according to within-disclosed methods which stably expresses adenovirus proteins or polypeptides from Ad3 and/or proteins or polypeptides from another non-group-C or group C serotype; such a cell line would be useful to support adenovirus-derived viral vectors bearing deletions of regulatory and/or structural genes, irrespective of the serotype from which such a vector was derived.
It is also contemplated that the constructs and methods of the present invention will support the design and engineering of chimeric viral vectors which express amino acid residue sequences derived from two or more Ad serotypes.
Thus, unlike methods and constructs available prior to the advent of the present disclosure, this invention allows the greatest possible flexibility in the design and preparation of useful viral vectors and cell lines which support their construction and propagation -- all with a decreased risk of recombining with wild-type Ad to produce potentially-harmful recombinants.
In part, the present invention discloses a simpler, alternative means of reducing the recombination between viral and cellular sequences than those discussed in the art. One such means is to increase the size of the deletion in the recombinant virus and thereby reduce the extent of shared sequences between that virus and any Ad genes present in a packaging cell line -- e.g., the Ad5 genes in 293 cells, or the various Ad genes in the novel cell lines of the present invention.

CA 02359795 2001-07-12 PC'T/EP00/00265 Therefore, the present invention makes it feasible to engineer and produce novel viral vectors that are able to package and deliver significantly larger foreign nucleic acid sequences for efficacious use in a variety of therapeutic applications, without endangering the subject to whom they are administered, due to their impaired ability to self-replicate in non-complementing cell lines. Due to the fact that "helper" viruses or plasmids need not be used in conjunction with many of the viral vectors of the present invention, those vectors of the present invention are also simpler to use than those previously described in the art.
In order to provide a clearer understanding of the specification and claims, the following definitions are provided.
Adenoviral Vector or Ad-Derived Vector. Any adenovirus-derived plasmid, genome or virus into which a foreign DNA may be inserted or expressed. This term may also be used interchangeably with "viral vector." This "type" of vector may be utilized to carry nucleotide sequences encoding therapeutic proteins or polypeptides to specific cells or cell types in a subject in need of treatment, as described further herein below.
Amino Acid Residue: An amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxyl terminus of a polypeptide. Standard polypeptide nomenclature described in J. Biol. Chem., 243:3552-59 (1969) and adopted at 37 C.F.R. ~ ~ 1.821 - 1.822 is used.
It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino-terminus to carboxyl-terminus. In addition, the phrase "amino acid residue"
is broadly defined to include the amino acids listed in the Table of Correspondence and modified and unusual amino acids, such as those referred to in 37 C.F.R. ~
~
1.821-1.822, and incorporated herein by reference. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues or to an amino-terminal group such as NH2 or to a carboxyl-terminal group such as COOH.

Complementing Plasmid: This term is generally used herein to describe plasmid vectors used to deliver particular nucleotide sequences into a packaging cell line, with the intent of having said sequences stably integrate into the cellular genome.
Delivery Plasmid: This term is generally used herein to describe a plasmid vector that carries or delivers nucleotide sequences in or into a cell line (e.g., a packaging cell line) for the purpose of propagating therapeutic viral vectors of the present invention.
DNA Homolog: A nucleic acid having a preselected conserved nucleotide sequence and a sequence encoding a preferred polypeptide according to the present invention, where the nucleic acid is substantial homologous to a named preferred embodiment. By the term "substantially homologous" is meant having at least 80%, preferably at least 90%, most preferably at least 95% homology therewith.
The terms "homology" and "identity" are often used interchangeably. In this regard, percent homology or identity may be determined, for example, by comparing sequence information using a GAP computer program. The GAP
program utilizes the alignment method of Needleman and Wunsch (J. Mol. Biol.
48:443 (1970), as revised by Smith and Waterman (Adv. Appl. Math. 2:482 (1981).
Briefly, the GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program may include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov and Burgess, Nucl. Acids Res. 14:6745 (1986), as described by Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.
Whether any two nucleic acid molecules have nucleotide sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson and Lipman, Proc. Natl.
Acad.
Sci. USA 85:2444 (1988). Alternatively the BLAST function of the National Center for Biotechnology Information database may be used to determine identity In general, sequences are aligned so that the highest order match is obtained. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. (See, e.g.: Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H.
& Lipton, D., SIAM J Applied Math 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H. & Lipton, D., SIAM J Applied Math 48:1073 (1988). Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1):387 (1984)), BLASTP, BLASTN, FASTA (Atschul, S.F., et al., J Molec Bio1215:403 (1990)).
Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. For example, a test polypeptide may be defined as any polypeptide that is 90% or more identical to a reference polypeptide. As used herein, the term at least "90% identical to"
refers to percent identities from 90 to 99.99 relative to the reference polypeptides.
Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared. No more than 10% (i.e., 10 out of 100) amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons may be made between a test and reference polynucleotides. Such differences may be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they may be clustered in one or more locations of varying length up to the maximum allowable, e.g. 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, or deletions.
An embodiment of the invention may use polynucleotides at least 90% or 95% identical to those encoding the TPL nucleic acid sequences. A further embodiment of the invention may include those polynucleotides that encode a polypeptide of interest that are at least 95% identical when the variation in such a polynucleotide is due to more than merely degenerate changes.
Expression or Delivery Vector.' Any plasmid or virus into which a foreign DNA may be inserted for expression in a suitable host cell -- i.e., the protein or polypeptide encoded by the DNA is synthesized in the host cell's system.
Vectors capable of directing the expression of DNA segments (genes) encoding one or more proteins are referred to herein as "expression vectors." Also included are vectors which allow cloning of cDNA (complementary DNA) from mRNAs produced using reverse transcriptase.
Foreign Gene: This term is used to identify a DNA molecule not present in the exact orientation and position as the counterpart DNA molecule found in wild-type adenovirus. It may also refer to a DNA molecule from another organism or species (i.e., exogenous) or from another Ad serotype.
Gene: A nucleic acid whose nucleotide sequence encodes an RNA or polypeptide. A gene can be either RNA or DNA. Genes may include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons).
Isolated: This term is used to indicate a nucleic acid or polypeptide sequence separated from the genetic environment from which the sequences were obtained. It may also mean altered from the natural state. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated,"
but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Thus, a polypeptide or polynucleotide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" or an "isolated polynucleotide" are polypeptides or polynucleotides that have been purified, partially or substantially, from a recombinant host cell or from a native source. For example, a recombinantly produced version of a compounds can be substantially purified by the one-step method described in Smith and Johnson, Gene 6731-40 (1988). The terms isolated and purified are sometimes used interchangeably.
By "isolated" is meant that the DNA is free of the coding sequences of those genes that, in the naturally-occurring genome of the organism (if any) from which the DNA of the invention is derived, immediately flank the gene encoding the DNA
of the invention. The isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or synthetic DNA. It WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 may be identical to a native DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more nucleotides.
Isolated or purified as it refers to preparations made from biological cells or hosts should be understood to mean any cell extract containing the indicated DNA
or protein including a crude extract of the DNA or protein of interest. For example, in the case of a protein, a purified preparation can be obtained following an individual technique or a series of preparative or biochemical techniques and the DNA or protein of interest can be present at various degrees of purity in these preparations. The procedures may include for example, but are not limited to, ammonium sulfate fractionation, gel filtration, ion exchange change chromatography, affinity chromatography, density gradient centrifugation and electrophoresis.
A preparation of DNA or protein that is "pure" or "isolated" should be understood to mean a preparation free from naturally occurring materials with which such DNA or protein is normally associated in nature. "Essentially pure"
should be understood to mean a "highly" purified preparation that contains at least 95% of the DNA or protein of interest.
A cell extract that contains the DNA or protein of interest should be understood to mean a homogenate preparation or cell-free preparation obtained from cells that express the protein or contain the DNA of interest. The term "cell extract" is intended to include culture media, especially spent culture media from which the cells have been removed.
Packaging Cell line: A packaging cell line is a cell line that provides a missing gene product or its equivalent.
Particle: The adenovirus (Ad) particle is relatively complex and may be resolved into various substructures. The particle is the minimal structural or functional unit of a virus. A virus can refer to a single particle, a stock of particles or a viral genome.
Penton: The terms "penton" or "penton complex" are preferentially used herein to designate a complex of penton base and fiber. The term "penton" may also be used to indicate penton base, as well as penton complex. The meaning of the term "penton" alone should be clear from the context within which it is used.
Plasmid: An autonomous self-replicating extrachromosomal circular DNA
Post-transcriptional Regulatory Element (PRE) is a regulatory element found in viral or cellular messenger RNA that is not spliced, i.e. intronless messages.
Examples include, but are not limited to, human hepatitis virus, woodchuck WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 hepatitis virus, the TK gene and mouse histone gene. The PRE may be placed before a polyA sequence and after a heterologous DNA sequence.
Pseudotyping: This term as generally used herein describes the production of adenoviral vectors having modified capsid protein or capsid proteins from a different serotype than the serotype of the vector itself. One example, is the production of an adenovirus 5 vector particle containing a chimeric Ad3/Ad5 fiber protein. This may be accomplished by producing the adenoviral vector in packaging cell lines expressing different fiber proteins.
Promoter.' Useful promoters according to the present invention may be inducible or constitutive. Inducible promoters will initiate transcription only in the presence of an additional molecule; constitutive promoters, on the other hand, do not require the presence of any additional molecule to regulate gene expression.
A regulatable or inducible promoter may also be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli.
Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.
Receptor: Receptor is a term used herein to indicate a biologically active molecule that specifically binds to (or with) other molecules. The term "receptor protein" may be used to more specifically indicate the proteinaceous nature of a specific receptor.
Recombinant. As used herein, the term is intended to refer to any progeny formed as the result of genetic engineering. This may also be used to describe a virus formed by recombination of plasmids in a packaging cell.
Transgene or Therapeutic Nucleotide Sequence: As described and claimed herein, such a sequence includes DNA and RNA sequences encoding an RNA or polypeptide. Such sequences may be "native" or naturally-derived sequences;
they may also be "non-native" or "foreign" sequences which are naturally- or recombinantly-derived. The term "transgene," which may be used interchangeably herein with the term "therapeutic nucleotide sequence," is often used to describe a heterologous or foreign (exogenous) gene that is carried by a viral vector and transduced into a host cell.
Therefore, therapeutic nucleotide sequences may also include antisense sequences or nucleotide sequences which may be transcribed into antisense sequences. Therapeutic nucleotide sequences (or transgenes) further comprise sequences which function to produce a desired effect in the cell or cell nucleus into which said therapeutic sequences are delivered. For example, a therapeutic _ 19_ nucleotide sequence may encode a functional protein intended for delivery into a cell which is unable to produce that functional protein.
Adenovirus Fiber plays a crucial role in adenovirus infection by attaching the virus to a specific receptor on the cell surface. The fiber is an elongated protein which exists as a trimer of three identical polypeptides (polypeptide IV) of 582 amino acids in length. An adenovirus fiber consists of three domains: an N-terminal tail domain that interacts with penton base; a shaft composed of variable numbers of repeats of a 15-amino-acid segment that forms beta-sheet and beta-bends; and a knob at the C-terminus ("head domain") that contains the type-specific antigen and is responsible for binding to the cell surface receptor. The gene encoding the fiber protein from Ad2 has been expressed in human cells and has been shown to be correctly assembled into trimers, glycosylated and transported to the nucleus.
(See, e.g., Hong and Engler, Virology 185: 758-761, 1991 ). Thus, alteration of the fiber in recombinant Ad vectors can lead to alteration in gene delivery. This has great utility for a variety of gene therapy applications and is one of the objects of the present invention.
Hexon, penton and fiber capsomeres are the major components on the surface of the virion. Their constituent polypeptides, nos. II, III and IV, contain tyrosine residues that are exposed on the surface of the virion and can be labeled -- e.g., by iodination of intact particles.
The 35,000+ base pair (bp) genome of adenovirus type 2 has been sequenced and the predicted amino acid sequences of the major coat proteins (hexon, fiber and penton base) have been described. (See, e.g., Neumann et al., Gene 69: 153-157 (1988); Herisse et al., Nuc. Acids Res. 9: 4023-4041 (1981 );
Roberts et al., J. Biol. Chem. 259: 13968-13975 (1984); Kinloch et al., J.
Biol.
Chem. 259: 6431-6436 (1984); and Chroboczek etal., Virol. 161: 549-554, 1987).
The sequence of Ad5 DNA was completed more recently; its sequence includes a total of 35,935 bp. Portions of many other adenovirus genomes have also been sequenced. It is presently understood that the upper packaging limit for adenovirus virions is about 105% of the wild-type genome length. (See, e.g., Bett, et al., J. Virol. 67(10): 5911-21, 1993). Thus, for Ad2 and AdS, this would be an upper packaging limit of about 38kb of DNA.
Adenovirus DNA also includes inverted terminal repeat sequences (ITRs) ranging in size from about 100 to 150 bp, depending on the serotype. The inverted repeats enable single strands of viral DNA to circularize by base-pairing WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 of their terminal sequences, and the resulting base-paired "panhandle"
structures required for replication of the viral DNA.
For efficient packaging, the ITRs and the packaging signal (a few hundred by in length) comprise the "minimum requirement" for replication and packaging of a genomic nucleic acid into an adenovirus particle. Helper-dependent vectors lacking all viral ORFs but including these essential cis elements (the ITRs and contiguous packaging sequence) have been constructed, but the virions package less efficiently that the helper and package as multimers part of the time, which suggests that the virus may "want" to package a fuller DNA complement (see, e.g., Fisher, et al., Virology 217 11-22, 1996).
The viral vectors of the present invention may retain their ability to express the genome packaged within -- i.e., they may retain their "infectivity" --they do not act as infectious agents, however, to the extent that they cause disease in the subjects to whom they are administered for therapeutic purposes.
It is to be appreciated that Ad vectors have several distinct advantages over other viral vectors in the art. For example, recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to accommodate foreign genes of a fairly substantial size; and host proliferation is not required for expression of adenoviral proteins.
An extension of this invention is that the Ad-derived viral vectors disclosed herein may be used to target and deliver genes into specific cells by incorporating the attachment sequence for other receptors (such as CD4) onto the fiber protein by recombinant DNA techniques, thus producing a chimeric molecule. This should result in the ability to target and deliver genes into a wide range of cell types with the advantage of evading recognition by the host's immune system. The within-disclosed delivery systems thus provide for increased flexibility in gene design to enable gene delivery into proliferating and nonproliferating cell types.
For example, U.S. Patent Nos. 5,756,086 and 5,543,328 as well as, W095/26412 and WO 98/44121 and Krasnykh, et al. (J. Virol. 70: 6839-46, 1996) describe modifications that may be made to the adenovirus fiber protein. Such modifications are useful in altering the targeting mechanism and specificity of adenovirus and could readily be utilized in conjunction with the constructs of the present invention to target the novel viral vectors disclosed herein to different receptors and different cells. Moreover, modifications to fiber protein which alter its tropism may permit greater control over the localization of viral vectors in therapeutic applications.

WO 00/42208 CA 02359795 2001-07-12 pC'T~P00/00265 Similarly, incorporation of various structural proteins into cell lines of the present invention, whether or not those proteins are modified, is also contemplated by the present invention. Thus, for example, modified penton base polypeptides such as those described in Wickham, et al. (J. Virol. 70: 6831-8, 1996) may have therapeutic utility when used according to the within-disclosed methods.
While some of the Examples appearing below specifically recite fiber proteins, polypeptides, and fragments thereof, it is expressly provided herein that other structural and non-structural Ad proteins and polypeptides (e.g., regulatory proteins and polypeptides) may be used as components of the various disclosed vectors and cell lines. Moreover, chimeric molecules comprised of proteins, polypeptides, and/or fragments thereof which are derived from different Ad serotypes may be used in any of the within-disclosed methods, constructs and compositions. Similarly, recombinant DNA sequences of the present invention may be prepared using nucleic acid sequences derived from different Ad serotypes, in order to design useful constructs with broad applicability, as disclosed and claimed herein.
It should also be appreciated that, while the members of Group C or Group D adenovirus - i.e., Ad serotypes 1, 2, 5, 6 or 37 -- are specifically recited in various examples herein, the present invention is in no way limited to those serotypes alone. In view of the fact that the adenovirus serotypes are all closely-related in structure and functionality, therapeutic viral vectors, packaging cell lines, and plasmids of the present invention may be constructed from components of any and all Ad serotypes -- and the within-disclosed methods of making and using the various constructs and cell lines of the present invention apply to all of said serotypes.
The family of Adenoviridae includes many members with at least 47 known serotypes of human adenovirus (Ad1-Ad47) (Shenk, Virology, Chapter 67, in Fields et aL, eds. Lippincott-Raven, Philadelphia, 1996,) as well as members of the genus Mastadenovirus including human, simian, bovine, equine, porcine, ovine, canine and opossum viruses, and members of the Aviadenovirus genus, including bird viruses, e.g. CELO. Thus it is contemplated that the disclosed inventions can be applied to any adenovirus species, and the invention need not be so limited. One of skill in the art would have knowledge of the different adenoviruses as evidenced by (Shenk, Virology, Chapter 67, in Fields et al., eds.
Lippincott-Raven, Philadelphia, 1996,) which is herein incorporated by reference.

Packaging Cell Lines A. Adenovirus Complementation Genetics The first generation of recombinant adenoviral vectors currently available typically have a deletion in the first viral early gene region which is generally referred to as E1, which comprises the E1 a and E1 b regions. (These regions span genetic map units 1.30 to 9.24.) Figure 3 in chapter 67 of Fields Virology, 3d Ed. (Fields et al. eds, Lippincott-Raven Publ., Philadelphia, 1996, p.
2116) illustrates a transcription and translation map of adenovirus type 2 (Ad2).
Deletion of the viral E1 region renders the recombinant adenovirus defective for replication and incapable of producing infectious viral particles in subsequently-infected target cells. Thus, to generate E1-deleted adenovirus genome replication and to produce virus particles requires a system of complementation which provides the missing E1 gene product. E1 complementation is typically provided by a cell line expressing E1, such as the human embryonic kidney packaging cell line, i.e. an epithelial cell line, called 293.
Cell line 293 contains the E1 region of adenovirus, which provides E1 gene region products to "support" the growth of E1-deleted virus in the cell line (see, e.g., Graham et al., J. Gen. Virol. 36: 59-71, 1977). Additionally, cell lines that may be usable for production of defective adenovirus having a portion of the adenovirus E4 region have been reported (WO 96/22378). Multiply deficient adenoviral vectors and complementing cell lines have also been described (WO 95/34671, U.S. Patent No. 5,994,106). Nevertheless, inherent problems exist concerning first-generation recombinant adenoviruses.
B. Adenovirus Particle Packaging Cell Lines Packaging cell lines disclosed herein support viral vectors with deletions of major portions of the viral genome, without the need for helper viruses.
Additionally, the invention provides novel cell lines and helper viruses for use with helper-dependent vectors.
Thus, in one embodiment of the present invention, a packaging cell line is disclosed having DNA sequences stably integrated into the cellular genome wherein the DNA sequences encode one or more adenovirus regulatory and/or structural polypeptides which complement the genes deleted or mutated in the adenovirus vector genome to be replicated and packaged.
In another embodiment, the packaging cell line expresses one or more adenovirus structural proteins, polypeptides, or fragments thereof, wherein said structural protein is selected from the group consisting of penton base, hexon, fiber, polypeptide Illa, polypeptide V, polypeptide VI, polypeptide VII, polypeptide VIII, and biologically active fragments thereof.
In one variation, the sequences are constitutively expressed; in another, one or more sequences is under the control of a regulatable promoter. In a preferred embodiment expression is constitutive. In various preferred embodiments, the polypeptides expressed by the DNA sequences are biologically active.
In a further and preferred embodiment the packaging cell line of the present invention supports the production of a viral vector. In a preferred embodiment the viral vector is a therapeutic vector.
The present invention also discloses a packaging cell line which complements a viral vector having a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, regulatory polypeptides E1A and E1 B, and/or one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof.
Various useful packaging cells are contemplated which complement adenovirus. In one aspect of the present invention, each DNA sequence is introduced into the genome of the within-disclosed cell lines via a separate complementing plasmid. In other embodiments, two or more DNA sequences were introduced into the genome via a single complementing plasmid. In one variation, the complementing plasmid comprises a DNA sequence encoding adenovirus fiber protein, polypeptide or fragment thereof. An example of a useful complementing plasmid according to the present invention is a plasmid having the characteristics of pCLF (for deposit details, see Example 3) One embodiment discloses a packaging cell useful in the preparation of recombinant adenovirus viral vectors comprising a delivery plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding fiber. In one variation, the delivery plasmid further comprises a nucleotide sequence encoding a foreign polypeptide. A preferred delivery plasmid is pDV44, pE1 B gal, or pE1 spi B. In another variation, the cell further comprises a complementing plasmid containing a nucleotide sequence encoding fiber, the plasmid being stably integrated into the cellular genome of the cell.
In one embodiment, a composition comprises a cell containing first and second delivery plasmids wherein a first delivery plasmid comprises an adenovirus genome lacking a nucleotide sequence encoding fiber and incapable of directing the packaging of new viral particles in the absence of a second delivery plasmid, and a second delivery plasmid comprises an adenoviral genome capable of directing the packaging of new viral particles in the presence of the first delivery plasmid.
In another variation, the first and second delivery plasmids interact within the cell to produce a therapeutic viral vector. In yet another variation, the cell further comprises a complementing plasmid containing a nucleotide sequence encoding fiber, the plasmid being stably integrated into the cellular genome of the cell. In still another, the first or second delivery plasmid further comprises a nucleotide sequence encoding a foreign polypeptide. In various embodiments, the polypeptide is a therapeutic molecule.
Another embodiment discloses a composition as before, wherein the first delivery plasmid lacks adenovirus packaging signal sequences. In another aspect, the second delivery plasmid contains a LacZ reporter construct. In another variation, the second delivery plasmid further lacks a nucleotide sequence encoding an adenovirus regulatory protein. In one variation, the regulatory protein is E1. In one embodiment of the above-noted compositions, the complementing plasmid has the characteristics of pCLF.
In another embodiment, a composition is disclosed wherein the first delivery plasmid lacks a nucleotide sequence encoding an adenovirus structural protein and the second delivery plasmid lacks a nucleotide sequence encoding adenovirus E1 protein. In another, the first delivery plasmid lacks a nucleotide sequence encoding adenovirus E4 protein and the second delivery plasmid lacks a nucleotide sequence encoding adenovirus E1 protein. In still another, the cell contains at least one complementing plasmid encoding an adenoviral regulatory protein and a structural protein.
In one preferred variation of the present invention, a packaging cell line expresses fiber protein. In one embodiment, the fiber protein has been modified to include a non-native amino acid residue sequence which targets a specific receptor, but which does not disrupt trimer formation or transport of fiber into the nucleus. In another variation, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. In still another embodiment, the structural protein is fiber comprising amino acid residue sequences from more than one adenovirus serotype. As disclosed herein, the.
nucleotide sequences encoding fiber protein or polypeptide need not be modified solely at one or both termini; fiber protein -- and indeed, any of the adenovirus structural proteins, as taught herein -- may be modified "internally" as well as at the termini.

In one variation, the non-native amino acid residue sequence is coupled to the carboxyl terminus of the fiber. In yet another, the non-native amino acid residue sequence further includes a linker sequence. Alternatively, the fiber protein further comprises a ligand coupled to the linker. A suitable ligand may be selected from the group consisting of ligands that specifically bind to a cell surface receptor and ligands that can be used to couple other proteins or nucleic acid molecules. Typically, any of the packaging cell lines of this invention may have a DNA sequence encoding all or part of a fiber protein -- including modified or chimeric proteins -- stably integrated into the genome.
In various aspects of the present invention, a packaging cell line of the present invention is derived from a procaryotic cell line; in another, it is derived from a eucaryotic cell line. While various embodiments suggest the use of mammalian cells, and more particularly, epithelial cell lines, a variety of other, non-epithelial cell lines are used in various embodiments. Thus, while various embodiments disclose the use of a cell line selected from the group consisting of 293, A549, W 162, HeLa, Vero, 211, and 211 A cell lines, it is understood that various other cell lines are likewise contemplated for use as disclosed herein.
Therapeutic Viral Vectors and Related Systems A. Nucleic Acid Segments A therapeutic viral vector or composition of the present invention comprises a nucleotide sequence, nucleic acid molecule or segment as described herein.
Typically, the nucleic acid molecule or molecule encodes a protein or polypeptide molecule -- or a biologically active fragment thereof -- which may be used for therapeutic applications. A nucleotide sequence may further comprise an enhancer element or a promoter located 3' or 5' to and controlling the expression of such a therapeutic nucleotide sequence or gene.
A subject nucleotide sequence consists of a nucleic acid molecule that comprises at least 2 different operatively linked DNA segments. The DNA can be manipulated and amplified by PCR as described herein and by using standard techniques, such as those described in Molecular Cloning: A Laboratory Manual, 2nd Ed., Sambrook et al., eds., Cold Spring Harbor, New York (1989).
Typically, to produce a nucleotide sequence of the present invention, the sequence encoding the selected polypeptide and the promoter or enhancer are operatively linked to a DNA molecule capable of autonomous replication in a cell either in vivo or in vitro.

By operatively linking the enhancer element or promoter and the nucleotide sequence to the vector, the attached segments are replicated along with the vector sequences.
Thus, a recombinant DNA molecule (rDNA) of the present invention is a hybrid DNA molecule comprising at least 2 nucleotide sequences not normally found together in nature. In various preferred embodiments, one of the sequences is a sequence encoding an Ad-derived polypeptide, protein, or fragment thereof.
Stated another way, a nucleotide sequence of the present invention is one that encodes an expressible protein, polypeptide or fragment thereof, and it may further include an active constitutive or regulatable (e.g. inducible) promoter sequence.
A nucleotide sequence of the present invention is optimally from about 20 base pairs to about 40,000 base pairs in length. Preferably the nucleotide sequence is from about 50 by to about 38,000 by in length. In various embodiments, the nucleotide sequence is of sufficient length to encode one or more adenovirus proteins or functional polypeptide portions thereof. Since individual Ad polypeptides vary in length from about 19 amino acid residues to about 967 amino acid residues, corresponding nucleotide sequences will range from about 50 by up to about 3000 bp, depending on the number and size of individual polypeptide-encoding sequences that are "replaced" in the viral vectors by therapeutic nucleotide sequences of the present invention.
1. Tripartite Leader (TPL) Nucleic Acid Sequences In one aspect of the invention, it has been discovered that expression of adenovirus late proteins such as the structural proteins in a packaging cell line according to the present invention is substantially improved when the expression cassette present on the complementing plasmid or in the packaging cell line's genome contains an adenovirus tripartite leader (TPL) nucleic acid sequence.
Thus, the invention contemplates a nucleic acid molecule comprising a TPL
nucleotide sequence. Preferably, the TPL nucleotide sequence may be operatively linked to an intron containing RNA processing signals (such as for example, splice donor or splice acceptor sites) suitable for expression in the packaging cell line.
Most preferably, the intron contains a splice donor site and a splice acceptor site.
Alternatively, the TPL nucleotide sequence may not comprise an intron.
In one embodiment, a subject nucleic acid molecule of this invention is isolated, i.e., separated from the genetic environment from which the component sequences were obtained. Thus, molecular cloning of fragments of a gene will WO 00/42208 CA 02359795 2001-07-12 pC'T~P00/00265 produce an isolated nucleic acid, as will the chemical synthesis of an oligonucleotide to build a nucleic acid molecule.
The intron useful in the present invention is any nucleotide sequence which functions in the packaging cell line to provide RNA processing signals, as are well known in the art, including splicing signals. Introns have been well characterized from a large number of structural genes, and therefor the invention should not be considered as limited. Well characterized and preferred introns include a native intron 1 from adenovirus, such as Ad5's TPL intron 1; others include the SV40 VP
intron; the rabbit beta-globin intron, and synthetic intron constructs. See, for example, Petitclerc et al., J. Biothechnol., 40:169, 1995, and Choi et al., Mol. Cell.
Biol., 11:3070, 1991.
The TPL nucleotide sequence comprises either (a) first and second TPL
exons or (b) first, second and third TPL exons, where each TPL exon in the sequence is selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. A complete exon is one which contains the complete nucleic acid sequence based on the sequence found in the wild type viral genome. Preferably the TPL exons are from Ad2, Ad3, AdS, Ad7 and the like, however, they may come from any Ad serotype, as described herein. A preferred partial TPL exon 1 is described in the Examples.
The use of a TPL with a partial exon 1 has been reported (W098/13499).
The intron and the TPL exons can be operatively linked in a variety of configurations to provide a functional TPL nucleotide sequence, although in some embodiments of the invention, an intron may not be a part of the construct.
For example, the intron can be positioned between any of TPL exons 1, 2 or 3, and the exons can be in any order of first and second, or first/second/third. The intron can also be placed preceding the first TPL exon or following the last TPL exon. In a preferred embodiment, complete TPL exon 1 is operatively linked to complete TPL
exon 2 operatively linked to complete TPL exon 3. In a preferred variation, adenovirus TPL intron 1 is positioned between complete TPL exon 1 and complete TPL exon 2. It may also be possible to use analogous translational regulators from other viral systems such as rabiesvirus.
A preferred "complete" TPL nucleic acid molecule containing complete TPL
exons 1, 2 and 3 with adenovirus intron 1 inserted between exons 1 and 2 has a nucleotide sequence shown in SEQ ID NO: 32. A preferred "partial" TPL nucleic acid molecule containing partial TPL exon 1 and complete TPL exons 2 and 3 in that order has a nucleotide sequence shown in SEQ ID NO: 26. The construction of these preferred TPL nucleotide sequences is described in the Examples.

WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 Thus, preferred expression cassettes and complementing plasmids for expressing adenovirus structural genes, particularly fiber protein, contain an adenovirus TPt_ nucleotide sequence as described herein. Preferred packaging cell lines containing the subject nucleic acid molecules also contain a TPL
nucleotide sequence of the invention.
2. Complementing Plasmids The invention describes in a related embodiment nucleic acid molecules and nucleotide sequences, typically in the form of DNA plasmid vectors, which are capable of expression of an adenovirus structural protein or regulatory protein.
Because these expression plasmids are used to complement the defective genes of a recombinant adenovirus vector genome of this invention, the plasmids are referred to as complementing or complementation plasmids.
The complementing plasmid contains an expression cassette, a nucleotide sequence capable of expressing a protein product off the gene encoded by the nucleotide sequence. Expression cassettes are described in more detail herein, but typically contain a promoter and a structural gene operatively linked to the promoter and whose expression is controlled by the promoter. A preferred complementing plasmid further includes a TPL nucleotide sequence described herein to enhance expression of the structural gene product when used in the context of adenovirus genome replication and packaging.
In one embodiment, a complementing plasmid comprises a promoter nucleotide sequence operatively linked to a nucleotide sequence encoding an adenovirus structural polypeptide. The adenovirus structural polypeptide is selected from the group consisting of penton base; hexon; fiber; polypeptide Illa;
polypeptide V; polypeptide VI; polypeptide VII; polypeptide VIII; and biologically active fragments thereof. In another variation, a complementing plasmid further comprises a nucleotide sequence encoding a first adenovirus regulatory polypeptide, a nucleotide sequence encoding a second regulatory polypeptide, a nucleotide sequence encoding a third regulatory polypeptide; or any combination of the foregoing.
The present invention also discloses a complementing plasmid comprising a promoter nucleotide sequence operatively linked to a nucleotide sequence encoding an adenovirus structural protein, polypeptide or fragment thereof and a nucleotide sequence encoding an adenovirus regulatory protein, polypeptide or fragment thereof. In one variation, the early region polypeptide is E4; in another, WO 00/42208 CA 02359795 2001-07-12 pCT~, P00/00265 the plasmid comprises pE4/Hygro. In still another variation, the early region polypeptides are E1 and E4.
In another aspect of the present invention, the complementing plasmid used to transform a cell line of the present invention further comprises a DNA
sequence encoding an adenovirus regulatory protein, polypeptide or fragment thereof. In one variation, the regulatory protein is selected from the group consisting of E1A, E1 B, E2A, E2B, E3, E4 and L4 (also referred to as "the 100K protein"); an exemplary complementing plasmid has the characteristics of is pE4/Hygro (for deposit details, see the Examples). In another aspect, the complementing plasmid used to transform a cell line of the present invention further comprises a DNA
sequence encoding two or more of the above mentioned adenovirus regulatory proteins, polypeptides or fragments thereof.
Preferred complementing plasmids include pCLF, pDV60, pDV61, pDV67, pDV69, pDV80, pDV90 and the like plasmids described in the Examples. The nucleic acid sequence of particularly preferred complementing plasmids are shown in SEQ ID NO: 43 for pDV60, SEQ ID NO: 44 for pDV67, SEQ ID NO: 47 for pDV69, SEQ ID NO: 64 for pDV80 and SEQ ID NO: 65 for pDV90.
3. Nucleic Acid Molecule Synthesis A nucleic acid molecule comprising synthetic oligonucleotide sequences of the present invention can be prepared using any suitable method, such as, the phosphotriester or phosphodiester methods. See Narang et al., Meth. Enzymol., 68:90, (1979); U.S. Patent No. 4,356,270; and Brown et al., Meth. Enzymol., 68:109, (1979).
For oligonucleotide sequences in which a family of variants is preferred, the synthesis of the family members can be conducted simultaneously in a single reaction vessel, or can be synthesized independently and later admixed in preselected molar ratios. For simultaneous synthesis, the nucleotide residues that are conserved at preselected positions of the sequence of the family member can be introduced in a chemical synthesis protocol simultaneously to the variants by the addition of a single preselected nucleotide precursor to the solid phase oligonucleotide reaction admixture when that position number of the oligonucleotide is being chemically added to the growing oligonucleotide polymer.
The addition of nucleotide residues to those positions in the sequence that vary can be introduced simultaneously by the addition of amounts, preferably equimolar amounts, of multiple preselected nucleotide precursors to the solid phase oligonucleotide reaction admixture during chemical synthesis. For example, where all four possible natural nucleotides (A,T,G and C) are to be added at a preselected position, their precursors are added to the oligonucleotide synthesis reaction at that step to simultaneously form four variants.
This manner of simultaneous synthesis of a family of related oligonucleotides has been previously described for the preparation of "Degenerate Oligonucleotides" by Ausubel et al. (Current Protocols in Molecular Biology, Suppl.
8. p.2.11.7, John Wiley & Sons, Inc., New York ,1991), and can readily be applied to the preparation of the therapeutic oligonucleotide compositions described herein.
Nucleotide bases other than the common four nucleotides (A,T,G or C), or the RNA equivalent nucleotide uracil (U), can also be used in the present invention. For example, it is well known that inosine (I) is capable of hybridizing with A, T and G, but not C. Examples of other useful nucleotide analogs are known in the art and may be found referred to in 37 C.F.R. ~1.822.
Thus, where all four common nucleotides are to occupy a single position of a family of oligonucleotides, that is, where the preselected nucleotide sequence is designed to contain oligonucleotides that can hybridize to four sequences that vary at one position, several different oligonucleotide structures are contemplated. The composition can contain four members, where a preselected position contains A,T,G or C. Alternatively, a composition can contain two nucleotide sequence members, where a preselected position contains I or C, and has the capacity the hybridize at that position to all four possible common nucleotides. Finally, other nucleotides may be included at the preselected position that have the capacity to hybridize in a non-destabilizing manner with more than one of the common nucleotides ~n a manner similar to inosine.
Similarly, larger nucleic acid molecules can be constructed in synthetic oligonucleotide pieces, and assembled by complementary hybridization and ligation, as is well known.
B. Adenovirus Expression Vector Systems One key component of the present invention for producing gene therapy reagents comprised of recombinant adenovirus particles is the recombinant adenovirus vector genome which is encapsulated in the virus particle and which expresses exogenous genes in a gene therapy setting. Thus, the components of an recombinant adenovirus vector genome include the ability to express selected adenovirus structural genes, to express a desired exogenous protein, and to contain sufficient replication and packaging signals that the genome is packaged into a gene delivery vector particle. The preferred replication signal is an adenovirus inverted terminal repeat containing an adenovirus origin of replication, as is well known and described herein.
According to the present invention, a preferred recombinant adenovirus vector genome is "helper independent" which means the genome can replicate and be packaged without the help of a second, complementing helper virus. Instead, the complementation is provided by a packaging cell line of the present invention.
Additional embodiments of the invention, however, are drawn to a vector genome referred to as "gutless" which is "helper dependent."
In a preferred embodiment, the adenovirus vector genome does not encode a functional adenovirus fiber protein. A non-functional fiber gene refers to a deletion, mutation or other modification to the adenovirus fiber gene such that the gene does not express any or insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of the fiber gene by a complementing plasmid or packaging cell line. Such a genome is referred to as a "fiberless" genome, not to be confused with a fiberless particle.
Alternatively, a fiber protein may be encoded but is insufficiently expressed to result in a fiber containing particle.
Thus, the invention describes a helper-independent fiberless recombinant adenovirus vector genome comprising genes which (a) express all adenovirus structural gene products but express insufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene, (b) express an exogenous protein, and (c) contains an adenovirus packaging signal and inverted terminal repeats containing adenovirus origin of replication.
The introduction of exogenous DNA into eucaryotic cells has become one of the most powerful tools of the molecular biologist. The term "exogenous"
encompasses any therapeutic composition of this invention which is administered by the therapeutic methods of this invention. Thus, "exogenous" may also be referred to herein as "foreign," "non-native," and the like. The methods of this invention preferably require efficient delivery of the DNA into the nucleus of the recipient cell and subsequent identification of cells that are expressing the foreign DNA.
The adenovirus vector genome is propagated in the laboratory in the form of rDNA plasmids containing the genome, and upon introduction into an appropriate host, the viral genetic elements provide for viral genome replication and packaging rather than plasmid-based propagation. Exemplary methods for preparing an Ad-vector genome are described in the Examples.
A widely-used plasmid is pBR322, a vector whose nucleotide sequence and endonuclease cleavage sites are well known. Various other useful plasmid vectors are described in the Examples that follow.
A nucleic acid vector of the present invention comprises a nucleic acid (preferably DNA) molecule capable of autonomous replication in a cell and to which a DNA segment, e.g., a gene or polynucleotide, can be operatively linked so as to bring about replication of the attached segment. In the present invention, one of the nucleotide segments to be operatively linked to vector sequences encodes at least a portion of a therapeutic nucleic acid molecule -- in effect, a nucleic acid sequence that encodes one or more therapeutic proteins or polypeptides, or fragments thereof.
As one of skill in the art will note, in various embodiments of the present invention, different "types" of vectors are disclosed. For example, one "type"
of vector is used to deliver particular nucleotide sequences into a packaging cell line, with the intent of having said sequences stably integrate into the cellular genome;
these "types" of vectors are generally identified herein as complementing plasmids.
A further "type" of vector described herein carries or delivers nucleotide sequences in or into a cell line (e.g., a packaging cell line) for the purpose of propagating therapeutic viral vectors of the present invention; hence, these vectors are generally referred to herein as delivery plasmids. A third "type" of vector described herein is utilized to carry nucleotide sequences encoding therapeutic proteins or polypeptides to specific cells or cell types in a subject in need of treatment; these vectors are generally identified herein as therapeutic viral vectors or Ad-derived vectors and are in the form of a virus particle encapsulating a viral nucleic acid containing an expression cassette nucleic acid sequence for expressing the therapeutic gene.
1. Nucleic Acid Gene Expression Cassettes In various embodiments, a peptide-coding sequence of the therapeutic gene is inserted into an expression vector and expressed; however, it is also feasible to construct an expression vector which also includes some non-coding sequences as well. Preferably, however, non-coding sequences are excluded. Alternatively, a nucleotide sequence for a soluble form of a polypeptide may be utilized.
Another preferred therapeutic viral vector includes a nucleotide sequence encoding at least WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 a portion of a therapeutic nucleotide sequence operatively linked to the expression vector for expression of the coding sequence in the therapeutic nucleotide sequence.
As used herein with regard to DNA sequences or segments, the phrase "operatively linked" generally means the sequences or segments have been covalently joined into one piece of DNA, whether in single or double stranded form.
The choice of viral vector into which a therapeutic nucleotide sequence of this invention is operatively linked depends directly, as is well known in the art, on the functional properties desired, e.g., vector replication and protein expression, and the host cell to be transformed -- these being limitations inherent in the art of constructing recombinant DNA molecules. Although certain adenovirus serotypes are recited herein in the form of specific examples, it should be understood that the present invention contemplates the use of any adenovirus serotype, including hybrids and derivatives thereof. As one will observe, it is not unusual or outside the scope of the present invention to utilize nucleotide and/or amino acid residue sequences of two or more serotypes in constructs, compositions and methods of the invention.
A translatable nucleotide sequence is a linear series of nucleotides that provide an uninterrupted series of at least 8 codons that encode a polypeptide in one reading frame. Preferably, the nucleotide sequence is a DNA sequence. The vector itself may be of any suitable type, such as a viral vector (RNA or DNA), naked straight-chain or circular DNA, or a vesicle or envelope containing the nucleic acid material and any polypeptides that are to be inserted into the cell.
2. Promoters As noted elsewhere herein, an expression nucleic acid in an Ad-derived vector of the present invention may also include a promoter sequence.
In general, promoters are DNA segments that contain a DNA sequence that controls the expression of a gene located 3' or downstream of the promoter.
The promoter is the DNA sequence to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene, typically located 3' of the promoter: A promoter also includes DNA sequences which direct the initiation of transcription, including those to which RNA polymerase specifically binds. If more than one nucleic acid sequence encoding a particular polypeptide or protein is included in a therapeutic viral vector or nucleotide sequence, more than one promoter or enhancer element may be included, particularly if that would enhance WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 efficiency of expression. For purposes of the present invention, regulatable (inducible) as well as constitutive promoters may be used, either on separate vectors or on the same vector.
Both constitutive and regulatable (often called "inducible") promoters are useful in constructs and methods of the present invention. For example, some useful regulatable promoters are those of the CREB-regulated gene family and include inhibin, gonadotropin, cytochrome c, glucagon, and the like. (See, e.g., published International App. No. W096/14061.
A regulatable or inducible promoter may be described as a promoter wherein the rate of RNA polymerase binding and initiation is modulated by external stimuli. (See U.S. Patent Nos. 5,750,396 and 5,998,205). Such stimuli include various compounds or compositions, light, heat, stress, chemical energy sources, and the like. Inducible, suppressible and repressible promoters are considered regulatable promoters.
Regulatable promoters may also include tissue-specific promoters. Tissue-specific promoters direct the expression of the gene to which they are operably linked to a specific cell type. Tissue-specific promoters cause the gene located 3' of it to be expressed predominantly, if not exclusively, in the specific cells where the promoter expressed its endogenous gene. Typically, it appears that if a tissue-specific promoter expresses the gene located 3' of it at all, then it is expressed appropriately in the correct cell types (see, e.g., Palmiter et al., Ann.
Rev. Genet. 20: 465-499, 1986).
When a tissue-specific promoter controls the expression of a gene, that gene will be expressed in a small number of tissues or cell types rather than in substantially all tissues and cell types. Examples of tissue-specific promoters include the immunoglobulin promoter described by Brinster et al., Nature 306:
332-336 (1983) and Storb et al.; Nature 310: 238-231 (1984); the elastase-I
promoter described by Swift et al., Cell 38: 639-646 (1984); the globin promoter described by Townes et al., Mol. Cell. Biol. 5: 1977-1983 (1985), and Magram ef al., Mol. Cell. Biol. 9: 4581-4584 (1989), the insulin promoter described by Bucchini et al., PNAS USA, 83: 2511-2515 (1986) and Edwards et al., Cell 58: 161 (1989);
the immunoglobulin promoter described by Ruscon et al., Nature 314: 330-334 (1985) and Grosscheld et al., Cell 38: 647-658 (1984); the alpha actin promoter described by Shani, MoL Cell. Biol. 6: 2624-2631 (1986); the alpha crystalline promoter described by Overbeek et al., PNAS USA 82: 7815-7819 (1985); the prolactin promoter described by Crenshaw et al., Genes and Development 3:
959-972 (1989); the propiomelanocortin promoter described by Tremblay et al., PNAS USA 85: 8890-8894 (1988); the beta-thyroid stimulating hormone (BTSH) promoter described by Tatsumi et al., Nippon Rinsho 47: 2213-2220 (1989); the mouse mammary tumor virus (MMTV) promoter described by Muller et al., Cell 54:
105 (1988); the albumin promoter described by Palmiter et al., Ann. Rev.
Genet.
20: 465-499 (1986); the keratin promoter described by Vassar et al., PNAS USA
86: 8565-8569 (1989); the osteonectin promoter described by McVey et al., J.
Biol.
Chem. 263: 11,111-11,116 ( 1988); the prostate-specific promoter described by Allison et al., Mol. Cell. Biol. 9: 2254-2257 (1989); the opsin promoter described by Nathans et al., PNAS USA 81: 4851-4855 (1984); the olfactory marker protein promoter described by Danciger et al., PNAS USA 86: 8565-8569 (1989); the neuron-specific enolase (NSE) promoter described by Forss-Pelter et al., J.
Neurosci. Res. 16: 141-151 (1986); the L-7 promoter described by Sutcliffe, Trends in Genetics 3: 73-76 (1987) and the protamine 1 promoter described Peschon et al., Ann. Ne~nr York Acad. Sci. 564: 186-197 (1989) and Braun et al., Genes and Development 3: 793-802 (1989).
3. Adenovirus Vectors Although adenovirus consists of many proteins, not all adenovirus proteins are required for assembly of a recombinant adenovirus particle (vector) of this invention. Thus, deletion of the appropriate genes from a recombinant Ad vector as taught herein will thus allow the vector to accommodate even larger "foreign"
DNA
segments. Thus, if the sequences encoding one or more adenovirus polypeptides or proteins are supplanted by a recombinant nucleotide sequence of the present invention, the length of the recombinant sequence can conceivably extend nearly to the packaging limit of the relevant adenovirus-derived vector.
In view of the fact that preferred embodiments disclosed herein are helper-independent Ad-derived vectors, the entire wild-type Ad genome cannot be completely supplanted by recombinant nucleic acid molecules without transforming such a vector into a vector requiring "help" of some kind. However, most of the Ad-derived vectors of the present invention do not depend on a helper virus;
instead, the vectors of the present invention are propagated in cell lines stably expressing proteins or polypeptides that have been removed from said vectors to allow the addition of "foreign" DNA into the vectors. In various disclosed embodiments, specific early region and structural polypeptides are deleted from the vectors of the present invention, thereby enabling the vectors to accommodate recombinant nucleic acid sequences (or cassettes) of various lengths. For example, Ad-derived vectors of the present invention may easily include 12 kb or more of foreign (or "therapeutic") DNA sequences.
Thus, adenovirus viral vectors are also disclosed which comprise nucleotide sequences encoding a packaging signal and a foreign protein or polypeptide, wherein the nucleotide sequence encoding an adenovirus structural protein has been deleted.
In one variation, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 3 kb in length; in another, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA
molecule up to about 9.5 kb in length; in still another, the nucleotide sequence encoding the foreign protein or polypeptide is a DNA molecule up to about 12.5 kb in length. Nucleotide sequences of intermediate lengths are also contemplated by the present invention, as are sequences in excess of 12.5 kb.
The invention also discloses viral vectors wherein the sequence encoding a foreign protein or polypeptide is a sequence encoding an anti-tumor agent, a tumor suppressor protein, a suicide protein, or a fragment or functional equivalent thereof. In one variation, nucleotide sequences encoding one or more regulatory proteins have also been deleted from the vector. In another, the regulatory proteins are selected from the group consisting of E1A, E1 B, E2A, E2B, E3, E4, and L4 (100K protein).
A wide variety of therapeutic viral vectors are also embodiments of the present invention. In one embodiment, a therapeutic viral vector is disclosed which lacks a DNA sequence encoding fiber protein, or a portion thereof. In another variation, a therapeutic viral vector may further or alternatively comprise deletion of a DNA sequence encoding one or more regulatory proteins, polypeptides, or fragments thereof. In various embodiments, foreign DNA sequences are inserted in place of the DNA sequence encoding fiber protein in the viral vectors of the present invention. In other embodiments, the therapeutic viral vectors further comprise foreign DNA sequences inserted in place of the DNA sequences encoding one or more regulatory proteins, polypeptides, or fragments thereof, and/or one or more structural proteins, polypeptides, or fragments thereof.
The present invention further discloses a number of viral vectors. In one variation, a viral vector comprises a deletion or mutation of a DNA sequence encoding an adenovirus structural protein, polypeptide, or fragment thereof. A
vector may further comprise deletion or mutation of the DNA sequences encoding regulatory polypeptides E1 A and E1 B; and it may still further comprise deletion or mutation of the DNA sequence encoding one or more of the following regulatory proteins or polypeptides: E2A, E2B, E3, E4, L4, or fragments thereof. In another variation, in a viral vector of the present invention, the structural protein comprises fiber. Any combination of the foregoing is also contemplated by the present invention. The viral vectors of the present invention are suitable for the preparation of pharmaceutical compositions comprising any of the therapeutic viral vectors disclosed herein -- including combinations thereof -- are also disclosed herein. A further use of the viral vectors of the present invention is for targeting specific cells in a cell population comprising different cell types.
Yet another variation discloses that a foreign DNA sequence encoding one or more foreign proteins, polypeptides or fragments thereof has been inserted in place of any of the deletions in the therapeutic viral vector. In one embodiment, the foreign DNA encodes a tumor-suppressor protein or a biologically active fragment thereof. In another embodiment, the foreign DNA encodes a suicide protein or a biologically active fragment thereof.
The invention further contemplates that a viral vector comprises a foreign DNA sequence encoding one or more foreign proteins, polypeptides or fragments thereof wherein said DNA sequence has been inserted in place of any structural and/or regulatory proteins (or portions thereof) that have been deleted. Thus, in one embodiment, the foreign DNA encodes a therapeutic molecule such as a tumor-suppressor protein; a suicide protein; a cystic fibrosis transmembrane conductance regulator (CFTR) protein; or a biologically active fragment of any of them.
The therapeutic (or foreign) nucleotide sequence can be a gene or gene fragment that encodes a protein or polypeptide -- or a biologically active fragment thereof. (See, e.g., Crystal, et al., Nature Genetics 8: 42-51 (1994); Zabner, et al., Cell 75: 207-216 (1993); Knowles, et al., NEJM 333(13): 823-831 (1995); and Rosenfeld, et al., Cell 68: 143-155 (1992).
It is further contemplated that a therapeutic protein or polypeptide expressed by a therapeutic viral vector of the present invention may be used in conjunction with another therapeutic agent when appropriate -- e.g., a thymidine kinase metabolite may be used in conjunction with the gene encoding thymidine kinase and its gene product -- in order to be even more effective.
Alternatively, a therapeutic viral vector can include a DNA or RNA
oligonucleotide sequence that exhibits therapeutic activity without needing to be translated into a polypeptide product before exerting a therapeutic effect.
Examples of the latter include antisense oligonucleotides that will inhibit the transcription of deleterious genes or ribozymes that act as site-specific ribonucleases for cleaving selected mutated gene sequences. In another variation, a therapeutic nucleotide sequence of the present invention may comprise a DNA
construct capable of generating therapeutic nucleotide molecules, including ribozymes and antisense DNA, in high copy numbers in target cells, as described in published PCT application No. WO 92/06693 (the disclosure of which is incorporated herein by reference). Other preferred therapeutic nucleotide sequences according to the present invention are capable of delivering HIV
antisense oligonucleotides to latently-infected T cells via CD4. Similarly, delivery of Epstein-Barr Virus (EBV) EBNa-1 antisense oligonucleotides to B cells via is capable of effecting therapeutic results.
A preferred recombinant adenovirus vector genome is based on the vector described in the Examples and designated AdS.~igaI.OF. This vector is a helper independent, fiberless vector genome which can host, upon insertion, an exogenous gene for expression of an exogenous or therapeutic protein. The genome of AdS.~igaI.OF has a nucleotide sequence shown in SEQ ID NO: 27. A
virus particle containing AdS.~gaI.OF vector genome has been prepared as described in the Examples and is deposited with the ATCC as Accession No. VR-The Ad5.~3gaI.OF genome nucleic acid can be manipulated to contain any exogenous gene in place of the beta-galactosidase gene present in the construct, as described herein.
Construction of Therapeutic Viral Vectors for Gene Delivery A. Adenovirus Particles Various methods of making and using the vectors, plasmids, cell lines and other compositions and constructs of the present invention are also disclosed herein. The following methods are considered exemplary and not limiting.
Thus, in one variation, the invention discloses a method of constructing therapeutic viral vectors, comprising introducing a delivery plasmid into an Ad fiber-expressing complementing cell line, wherein the DNA sequence encoding Ad fiber protein has been deleted from the delivery plasmid. In one variation, the delivery plasmid further includes a DNA sequence encoding a foreign protein, polypeptide, or fragment thereof. In other embodiments, a combination of pDV44 and p~E1 B~3gal or a similar construct such as, for example, that found in pDV44, p0E1 B~3gal or the equivalent.

A recombinant adenovirus particle may be produced with a fiber protein, or it may be produced without a fiber protein ("fiberless particle") according to the present invention. Where the particle is made without fiber, such as by passaging the fiberless viral vector genome, e.g., AdS.~igaI.OF in the 293 cells, a fiberless genome is replicated and packaged in a fiberless particle. In contrast, where the fiberless genome Ad5.~3gaI.OF is passaged in the 211 B or other fiber expressing cells, a fiberless genome is replicated and packaged into a fiber-containing particle.
Recombinant adenovirus particles may be made such that they include no fiber proteins, modified fiber proteins or other exogenous proteins. They may also be produced in systems using either helper-independent or helper-dependent adenovirus recombinant genomes, i.e. with or without helper viruses.
B. Targeting of Particles to Tissues - Virus Trophism A preferred viral vector particle in which therapeutic nucleotide compositions of this invention are present is derived from adenovirus (Ad). As taught herein, viral vector particles of this invention may be designed and constructed in such a way that they specifically target a preselected recipient cell type, depending on the nature of therapy one seeks to administer. Methods of making and using therapeutic viral vectors that target specific cells are further described in the Examples that follow.
Novel vectors, viral particles or compositions may also be designed and prepared to preferentially target cells that might not otherwise be targeted by wild-type adenovirus virions. For example, in order to target non-epithelial cells, one following the teachings of the present _ specification may be able to prepare a therapeutic vector particle including a nucleotide sequence encoding a foreign protein, polypeptide or other ligand directed to a non-epithelial cell or to a different receptor than that generally targeted by a particular adenovirus. Examples of useful ligands directed to specific receptors (identified in parentheses) include the V3 loop of HIV gp120 (CD4); transferring (transferrin receptor); LDL, apolipoprotein B100, apolipoprotein E (LDL receptors); and deglycosylated proteins (asialoglycoprotein receptor). Various useful ligands which may be added to adenovirus fiber -- and methods for preparing and attaching same -- are set forth in U.S. Patent Nos. 5,756,086 and 5,543,328.
In yet another embodiment, the non-native amino acid residue sequence is incorporated into the fiber amino acid residue sequence at a location other than one of the fiber termini. Alternatively, the non-native amino acid residue sequence alters the binding specificity of the fiber for a targeted cell type. In other embodiments, the linker sequence alters the binding specificity of the fiber for a targeted cell type. The expressed fiber may, in various embodiments, bind to a specific targeted cell type not usually targeted by adenovirus and/or may comprise amino acid residue sequences from more than one adenovirus serotype.
Useful ligands may be encoded by a foreign nucleotide sequence contained within a viral vector of the present invention, or may be linked to proteins or polypeptides, include antibodies and attachment sequences, as well as receptors themselves. For example, antibodies to cell receptor molecules such as integrins and the like, MHC Class I and Class II, asialoglycoprotein receptor, transferrin receptors, LDL receptors, CD4, and CR2 are but a few which are useful according to the present invention. It is also understood that the ligands typically bound by receptors, as well as analogs to those ligands, may be used as cellular targeting agents, as disclosed herein.
Therapeutic Methods The recombinant adenovirus vectors of the present invention, typically in the form of an adenovirus particle encapsulating a recombinant adenovirus vector genome containing an expression cassette for expressing a therapeutic gene, are particularly suited for gene therapy. Thus, various therapeutic methods are contemplated by the present invention.
For example, it has now been discovered that Ad-derived viral vectors are capable of delivering a therapeutic nucleotide sequence to a specific cell or tissue, based on the tissue tropism of the particle, thereby expanding and enhancing treatment options available in numerous conditions in which more conventional therapies are of limited efficacy. Accordingly, methods of gene therapy utilizing a recombinant adenovirus particle containing a modified fiber or chimeric fiber which targets a preselected tissue, as described herein, is within the scope of the invention. Vector particles are typically purified and then an effective amount is administered in vivo or ex vivo (in vitro)into the subject.
For in vitro or ex vivo gene transfer, administration is often accomplished by first isolating a selected cell population from a patient such as lung epithelial cells, lymphocytes and the like followed by in vitro or ex vivo gene transfer of the therapeutic compositions of this invention and the replacement of the cells into the patient. In vivo therapy is also contemplated, e.g., via the administration of WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 therapeutic compositions of this invention by various delivery means. For example, aerosol administration and administration via subcutaneous, intravenous, intraperitoneal, intramuscular, ocular means and the like are also within the scope of the present invention.
Other gene-delivery methods are also useful in conjunction with the methods, compositions and constructs of the present invention; see, e.g., published International Application No. WO 95/11984.
The present invention also contemplates various methods of targeting specific cells -- e.g., cells in a subject in need of diagnosis and/or treatment. As discussed herein, the present invention contemplates that the viral vectors and compositions of the present invention may be directed to specific receptors or cells, for the ultimate purpose of delivering those vectors and compositions to specific cells or cell types. The viral vectors and constructs of the present invention are particularly useful in this regard.
In general, adenovirus attachment and uptake into cells are separate but cooperative events that result from the interaction of distinct viral coat proteins with a receptor for attachment and av integrin receptors for internalization.
Adenovirus attachment to the cell surface via the fiber coat proteins has been discovered to be dissociable and distinct from the subsequent step of internalization, and the present invention is able to take advantage of and function in conjunction with these differing receptors.
The invention also discloses methods of transforming a pathologic hyperproliferative mammalian cell comprising contacting the cell with any of the vectors described herein. In another embodiment, methods of infecting a mammalian target cell with a viral vector containing a preselected foreign nucleotide sequence are disclosed. One such variation comprises the following steps: (a) infecting the target cell with a viral vector of the present invention, the viral vector carrying a preselected foreign nucleotide sequence; and (b) expressing the foreign nucleotide sequence in the targeted cell.
The invention also encompasses mammalian target cells infected with a preselected foreign nucleotide sequence produced by the methods disclosed herein. In one variation, the target cells are selected from the group consisting of replicating, slow-replicating and non-replicating human cells.
Methods of treating an acquired or hereditary disease are also disclosed.
One method comprises (a) administering a pharmaceutically acceptable dose of a viral vector to a target cell, wherein the vector comprises a preselected therapeutic nucleotide sequence; and (b) expressing the therapeutic sequence in the target cell for a time period sufficient to ameliorate the acquired or hereditary disease in the cell. Method of gene therapy comprising administering to a subject an effective amount of a therapeutic viral vector produced by a packaging cell line of the present invention are also disclosed.
Also contemplated by the present invention are various methods of inhibiting the proliferation of a tumor in a subject comprising administering an effective amount of a therapeutic viral vector of the present invention under suitable conditions to the subject. In one variation, the gene encodes an anti-tumor agent.
In another variation, the agent is a tumor-suppressor gene. In still another embodiment, the agent is a suicide gene or a functional equivalent thereof. In another variation, the vector is administered via intra-tumoral injection.
A composition of this invention may be used prophylactically or therapeutically in vivo to disrupt HIV infection and mechanisms of action by inhibiting gene expression or activation, via delivery of antisense HIV
sequences or ribozymes to T cells or monocytes. Using methods of the present invention, one may target therapeutic viral vectors as disclosed herein to specific cells and tissues, including hematopoietic cells, as infection of such cells appears to be mediated by distinct integrins to which viral vectors of the present invention may readily be targeted. (See, e.g., Huang, et al., J. Virol. 70: 4502-8, 1996).
Other useful therapeutic nucleotide sequences include antisense nucleotide sequences complementary to EBV EBNa-1 gene. Use of such therapeutic sequences may remediate or prevent latent infection of B cells with EBV. As discussed herein and in the Examples below, targeting and delivery may be accomplished via the use of various ligands, receptors, and other appropriate targeting agents.
Thus, in one embodiment, a therapeutic method of the present invention comprises contacting the cells of a subject infected with EBV or HIV with a therapeutically effective amount of a pharmaceutically acceptable composition comprising a therapeutic nucleotide sequence of this invention. In a related embodiment, the contacting involves introducing the therapeutic nucleotide sequence composition into cells having an EBV or HIV-mediated infection.
Methods of gene therapy are well known in the art (see, e.g., Larrick and Burck, Gene Therapy: Application of Molecular Biology, Elsevier Science Publ.
Co., Inc., New York, NY (1991 ); Kriegler, Gene Transfer and Expression: A
Laboratory Manual, W. H. Freeman and Company, New York, 1990). The term "subject" should be understood to include any animal -- particularly mammalian --WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 patient, such as any murine, rat, bovine, porcine, canine, feline, equine, ursine, or human patient.
When the foreign gene carried in the vector encodes a tumor suppressor gene or another anti-tumor protein, the vector is useful to treat or reduce hyperproliferative cells in a subject, to inhibit tumor proliferation in a subject or to ameliorate a particular, related pathology.
The present invention also contemplates methods of depleting suitable samples of pathologic mammalian hyperproliferative cells contaminating hematopoietic precursors during bone marrow reconstitution via the introduction of a wild-type tumor suppressor gene into the cell preparation using a vector of this invention. As used herein, a suitable sample is defined as a heterogeneous cell preparation obtained from a patient, e.g., a mixed population of cells containing both phenotypically normal and pathogenic cells.
Administration includes -- but is not limited to -- the introduction of therapeutic agents of the present invention into a cell or subject via various means, including direct injection, intravenously, intraperitoneally, via intra-tumor injection, via aerosols, or topically. Therapeutic agents as disclosed herein may also be combined for administration of an effective amount of the agents with a pharmaceutically-acceptable carrier, as described herein.
As used herein, "effective amount" generally means the amount of vector particle (or proteins produced/released thereby) which achieves a positive outcome in the subject to whom the vector is administered. The total volume administered will necessarily vary depending on the mode of administration, as those of skill in the relevant art will appreciate, and dosages may vary as well.
The dose of a biologic vector (particle) is somewhat complex and may be described in terms of the concentration (in plaque-forming units per milliliter (pfu/ml)), the total dose (in pfus), or the estimated number of particles administered per cell (the estimated multiplicity of infection or MOI). Thus, if a vector is administered via infusion -- say, across nasal epithelium -- at a constant total volume, the respective concentration, etc. may be described as follows:

W~ 00/42208 CA 02359795 2001-07-12 In general, when recombinant adenoviral vector particles are administered via infusion across the nasal epithelium (e.g. an area of nasal epithelium containing 2 x 10' cells,) administered amounts producing an estimated MOI
(multiplicity of infection) of about 10 or greater are much more effective than lower Concentration Volume Dose Estimated fu/ml ml ~fu~ MOI

107 2 2 x 107 1 108 2 2 x 108 10 109 2 2 x 109 100 1010 2 2 x 1010 1000 Table 2 dosages. (See, e.g., Knowles, et al., New Eng. J. Med. 333: 823-831, 1995).
Similarly, when direct injection is the preferred treatment modality -- e.g., direct injection of a viral vector into a tumor -- doses of 1 x 109 pfu or greater are generally preferred. (See, e.g., published International App. No. W095/11984.) Thus, depending on the mode of administration, an effective amount administered in a single dose preferably contains from about 106 to about 1015 infectious units. A typical course of treatment would be one such dose per day over a period of five days. As those of skill in the art will appreciate, an effective amount may vary depending on (1) the pathology or other condition to be treated, (2) the status and sensitivity of the patient, and (3) various other factors well known to those of skill in the art, such as the patient's tolerance to other courses of treatment that may have been applied previously. Thus, those of skill in the art may easily and precisely determine effective amounts of the agents/vectors of the present invention which may be administered to a particular patient, based on their understanding of and evaluation of such factors.
The present invention also contemplates methods of ameliorating pathologies characterized by hyperproliferative cells or genetic defects in a subject, by administering to the subject an effective amount of a vector as described herein.
Such vectors preferably contain a foreign gene encoding a gene product (e.g.
polypeptide or protein) having the ability to ameliorate the pathology, under suitable conditions. As used herein, the term "genetic defect" means any disease, WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 condition or abnormality which results from inherited factors, e.g.
Huntington's Disease, Tay-Sachs Disease, or Sickle Cell Disease.
The present invention further provides methods for reducing the proliferation of tumor cells in a subject by introducing into the tumor mass an effective amount of an adenoviral expression vector containing an anti-tumor gene other than a tumor suppressor gene. The anti-tumor gene can encode, for example, thymidine kinase (TK). An effective amount of a therapeutic agent is then administered to the subject; the therapeutic agent, in the presence of the anti-tumor gene, is toxic to the cell.
Using thymidine kinase as exemplary, the therapeutic agent is a thymidine kinase metabolite such as ganciclovir (GCV), 6-methoxypurine arabinonucleoside (araM), or a functional equivalent thereof. Both the thymidine kinase gene and the thymidine kinase substrate must be used concurrently in order to exert a toxic effect on the host cell. In the presence of the TK gene, GCV is phosphorylated and becomes a potent inhibitor of DNA synthesis, whereas araM is converted to the cytotoxic anabolite araATP. Thus, the precise method of action or synergism is not relevant to therapeutic efficacy; what is relevant is the fact that the concurrent use of appropriate genes and therapeutic agents may effectively ameliorate a specific disease condition.
Another useful example contemplates use of a vector of the present invention which expresses the enzyme cytosine deaminase. Such a vector could be used in conjunction with administration of the drug 5-fluorouracil (Austin and Huber, Mol. Pharm. 43: 380-387, 1993) or the recently-described E. coli Deo gene in combination with 6-methyl-purine-2'-deoxyribonucleoside (Sorscher et al., Gene Therapy 1: 233-238, 1994).
As with the use of the tumor suppressor genes described previously, the use of other anti-tumor genes, either alone or in combination with the appropriate therapeutic agent, provides a treatment for the uncontrolled cell growth or proliferation characteristic of tumors and malignancies. Thus, the present invention provides therapies to halt the uncontrolled cellular growth in a patient, thereby alleviating the symptoms or the disease or cachexia present in the patient.
The effect of this treatment includes, but is not limited to, prolonged survival time of the patient, reduction in tumor mass or burden, apoptosis of tumor cells, or the reduction in the number of circulating tumor cells. Means of quantifying the beneficial effects of this therapy are well known to those of skill in the art.
The present invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of one or more adenoviral structural WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 protein genes, such as the gene encoding fiber, which allows the vector to accommodate a therapeutic, foreign nucleic acid sequence encoding a functional foreign polypeptide, protein, or biologically active fragment thereof. A
therapeutic gene sequence may be introduced into a tumor mass by combining the adenoviral expression vector with a suitable pharmaceutically acceptable carrier.
Introduction can be accomplished, for example, via direct injection of the recombinant Ad vector into the tumor mass.
A method of tumor-specific delivery of a tumor-suppressor gene is accomplished by contacting target tissue in a subject with an effective amount of a recombinant Ad-derived vector of this invention. In the case of anti-tumor therapy, the gene is intended to encode an anti-tumor agent, such as a functional tumor suppressor gene product or suicide gene product. The term "contacting" is intended to encompass any delivery method for the efficient transfer of the vector, such as via intra-tumoral injection.
In another example, adenovirus vectors of the present invention can be used to transfer genes to central nervous system (CNS) tumors in vivo.
The present invention also contemplates methods for determining the efficacy of the within-disclosed therapeutic compositions and methods. One such method for confirming efficacy utilizes the human/SCID (severe combined immunodeficient) mouse model of EBV-induced LPD (lymphoproliferative disease) to ascertain whether EBV-antisense therapeutic nucleotide sequences block tumor formation. (See, e.g., Pisa, et al., Blood 79: 173-179 (1992); Rowe, et al., Curr.
Top. MicrobioL Immunol. 166: 325 (1990); and Cannon, et aL, J. Clin. Invest.
85:
1333-1337 (1990).
Finally, the use of Ad vectors of the present invention to prepare medicaments for the treatment, therapy and/or diagnosis of various diseases is also contemplated by this invention. Moreover, other anti-tumor genes may be used in combination with the corresponding therapeutic agent to reduce the proliferation of tumor cells. Such other gene-and-therapeutic-agent combinations are known to those of skill in the art and may be applied as taught herein.
A. Therapeutic Compositions In various alternative embodiments of the present invention, therapeutic sequences and compositions useful for practicing the therapeutic methods described herein are contemplated. Therapeutic compositions of the present invention may contain a physiologically tolerable carrier together with one or more therapeutic nucleotide sequences of this invention, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the composition is not immunogenic or otherwise able to cause undesirable side effects when administered to a subject for therapeutic purposes.
As used herein, the terms "pharmaceutically acceptable," "physiologically tolerable" and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a subject -- e.g., a mammal --without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.
For example, the present invention comprises therapeutic compositions useful in the specific targeting of epithelial or non-epithelial cells as well as in delivering a therapeutic nucleotide sequence to those cells. Therapeutic compositions designed to preferentially target to epithelial cells may comprise a recombinant adenovirus-derived vector particle including a therapeutic nucleotide sequence. As described herein, a number of adenovirus-derived moieties are described, including particles lacking fiber, particles that contain wild type adenovirus fiber, and particles that contain modified or chimeric fiber, each type providing a different tissue tropism to the particle.
The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art.
Typically such compositions are prepared as injectables -- either as liquid solutions or suspensions -- however, solid forms suitable for solution or suspension in liquid prior to use can also be prepared. A preparation can also be emulsified, or formulated into suppositories, ointments, creams, dermal patches, or the like, depending on the desired route of administration.
Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.
Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

A therapeutic composition typically contains an amount of a therapeutic material, i.e., a nucleotide sequence or adenovirus vector particle of the present invention, sufficient to deliver a therapeutically effective amount to the target tissue, typically an amount of at least 0.1 weight percent to about 90 weight percent of therapeutic material per weight of total therapeutic composition. A weight percent is a ratio by weight of therapeutic material, e.g., a nucleotide sequence, to total composition. Thus, for example, 0.1 weight percent is 0.1 grams of DNA
segment per 100 grams of total composition.
Other Applications The cell lines, viral vectors and methods of the present invention may also be used for purposes other than the direct administration of therapeutic nucleotide sequences. In one such application, the production of large quantities of biologically active proteins or polypeptides in cells transfected with the within-disclosed viral vectors is contemplated herein. For example, human lymphoblastoid cells may be transfected with a viral vector of the present invention carrying a human hematopoietic growth factor such as the gene for erythropoietin (EPO); cells so transfected are thus able to produce biologically active EPO.
(See, e.g., Lopez et al., Gene 148: 285-91, 1994).
Various other applications and uses of the within-described methods, cell lines, plasmids, vectors, and compositions of the present invention shall become apparent upon closer examination of the Examples that follow.
The following examples are intended to illustrate, but not limit, the present invention. As such, the following description provides details of the manner in which particular embodiments of the present invention may be made and used.
This description, while exemplary of the present invention, is not to be construed as specifically limiting the invention. Variations and equivalents, now known or later developed, which would be within the understanding and technical competence of one skilled in this art are to be considered as falling within the scope of this invention.
Example 1 Preparation of Adenovirus Packaging Cell Lines Cell lines that are commonly used for growing adenovirus are useful as host cells for the preparation of adenovirus packaging cell lines. Preferred cells include 293 cells, an adenovirus-transformed human embryonic kidney cell line obtained from the ATCC, having Accession Number CRL 1573; HeLa, a human epithelial carcinoma cell line (ATCC Accession Number CCL-2); A549, a human lung carcinoma cell line (ATCC Accession Number CCL 1889); and the like epithelial-derived cell lines. As a result of the adenovirus transformation, the 293 cells contain the E1 early region regulatory gene. All cells were maintained in complete DMEM + 10% fetal calf serum unless otherwise noted.
The cell lines of this invention allow for the production and propagation of novel adenovirus-based gene delivery vectors having deletions in preselected gene regions, that are obtained by cellular complementation of adenoviral genes.
To provide the desired complementation of such deleted adenoviral genomes in order to generate a novel viral vector of the present invention, plasmid vectors that contain preselected functional units were designed as described herein. Such units include but are not limited to E1 early region, E4 and the viral fiber gene. The preparation of plasmids providing such complementation, thereby being "complementary plasmids or constructs," that are stably inserted into host cell chromosomes are described below.
A. Preparation of an E4-Expressing Plasmid for Complementation of E4-Gene-Deleted Adenoviruses The viral E4 regulatory region contains a single transcription unit which is alternately spliced to produce several different mRNAs. The E4-expressing plasmid prepared as described herein and used to transfect the 293 cell line contains the entire E4 transcriptional unit as shown in Figure 1. A DNA
fragment extending from 175 nucleotides upstream of the E4 transcriptional start site including the natural E4 promoter to 153 nucleotides downstream of the E4 polyadenylation signal including the natural E4 terminator signal, corresponding to nucleotides 32667-35780 of the adenovirus type 5 (hereinafter referred to as Ad5) genome as described in Chroboczek et al. (Virol., 186:280-285 (1992), GenBank Accession Number M73260), was amplified from Ad5 genomic DNA, obtained from the ATCC, via the polymerase chain reaction (PCR). Sequences of the primers used were 5'CGGTACACAGAATTCAGGAGACACAACTCC3' (forward or 5' primer referred to as E4L) (SEQ ID NO: 1) and 5'GCCTGGATCCGGGAAGTTACGTAACGTGGGAAAAC3' (SEQ ID NO: 2) (backward or 3' primer referred to as E4R). To facilitate cloning of the PCR
fragment, these oligonucleotides were designed to create novel sites for the restriction enzymes EcoRl and BamHl, respectively, as indicated with underlined nucleotides. DNA was amplified via PCR using 30 cycles of 92 C for 1 minute, C for 1 minute, and 72 C for 3 minutes resulting in amplified full-length E4 gene products.
The amplified DNA E4 products were then digested with EcoRl and BamHl for cloning into the compatible sites of pBluescript/SK+ by standard techniques to create the plasmid pBS/E4. A 2603 base pair (bp) cassette including the herpes simplex virus thymidine kinase promoter, the hygromycin resistance gene, and the thymidine kinase polyadenylation signal was excised from the plasmid pMEP4 (Invitrogen, San Diego, CA) by digestion with Fspl followed by addition of BamHl linkers (5'CGCGGATCCGCG3') (SEQ ID NO: 3) for subsequent digestion with BamHl to isolate the hygromycin-containing fragment. The isolated BamHl-modified fragment was then cloned into the BamHl site of pBS/E4 containing the E4 region to create the plasmid pE4/Hygro containing 8710 by (Figure 2). The pE4/Hygro plasmid has been deposited with the ATCC as described in Example 3.
The complete nucleotide sequence of pE4/Hygro is listed in SEQ ID NO: 4.
Position number 1 of the linearized vector corresponds to approximately the middle portion of the pBS/SK+ backbone as shown in Figure 2 as a thin line between the 3' BamHl site in the hygromycin insert and the 3' EcoRl site in the E4 insert.
The 5' and 3' ends of the E4 gene are located at respective nucleotide positions 3820 and 707 of SEQ ID NO: 4 while the 5' and 3' ends of the hygromycin insert are located at respective nucleotide positions 3830 and 6470. In the clone that was selected for use, the E4 and hygromycin resistance genes were divergently transcribed.

B. Preparation of a Fiber-Expressing Plasmid for Complementation of Fiber-Gene-Deleted Adenoviruses To prepare a fiber-encoding construct, primers were designed to amplify the fiber coding region from Ad5 genomic DNA with the addition of unique BamHl and Notl sites at the 5' and 3' ends of the fragment, respectively. The Ad5 nucleotide sequence is available with the GenBank Accession Number M18369. The 5' and 3' primers had the respective nucleotide sequences of 5'ATGGGATCCAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 5) and 5'CATAACGCGGCCGCTTCTTTATTCTTGGGC3' (SEQ ID NO: 6), where the inserted BamHl and Notl sites are indicated by underlining. The 5' primer also contained a nucleotide substitution 3 nucleotides 5' of the second ATG codon (C to A) that is the initiation site. The nucleotide substitution was included so as to improve the consensus for initiation of fiber protein translation.
The amplified DNA fragment was inserted into the BamHl and Notl sites of pcDNA3 (Invitrogen) to create the plasmid designated pCDNA3/Fiber having 7148 bp, the plasmid map of which is shown in Figure 3. The parent plasmid contained the CMV promoter, the bovine growth hormone (BHG) terminator and the gene for conferring neomycin resistance. The viral sequence included in this construct corresponds to nucleotides 31040-32791 of the Ad5 genome.
The complete nucleotide sequence of pCDNA3/Fiber is listed in SEQ ID NO:
7 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 vector sequence. The 5' and 3' ends of the fiber gene are located at respective nucleotide positions 916 with ATG and 2661 with TAA.
To enhance expression of fiber protein by the constitutive CMV promoter provided by the pcDNA vector, a Bglll fragment containing the tripartite leader (TPL) of adenovirus type 5 was excised from pRD112a (Sheay et al., BioTechniques, 15:856-862 (1993) and inserted into the BamHl site of pCDNA3/Fiber to create the plasmid pCLF having 7469 bp, the plasmid map of which is shown in Figure 4. The adenovirus tripartite leader sequence, present at the 5' end of all major late adenoviral mRNAs as described by Logan et al., Proc.
Natl. Acad. Sci., USA, 81:3655-3659 (1984) and Berkner, BioTechniques, 6:616-629 (1988), also referred to as a "partial TPL" since it contains a partial exon 1, shows correspondence with the Ad5 leader sequence having three spatially separated exons corresponding to nucleotide positions 6081-6089 (the 3' end of the first leader segment), 7111-7182 (the entire second leader segment), and 9644-9845 (the third leader segment and sequence downstream of that segment).
The corresponding cDNA sequence of the partial tripartite leader sequence present in pCLF is listed in SEQ ID NO: 8 bordered by BamHl/Bglll 5' and 3' sites at respective nucleotide positions 907-912 to 1228-1233. The nucleotide sequence of an isolated partial TPL of the present invention is also listed separately as SEQ
ID NO: 26 with the noted 5' and 3' restriction sites and with the following nucleotide regions identified: 1-6 nt Bglll site; 1-18 nt polylinker; 19-27 nt last 9 nt of the first leader segment (exon 1 ); 28-99 nt second leader segment (exon 2); 100-187 nt third leader segment (exon 3); 188-301 nt contains the nt sequence immediately following the third leader in the genome with an unknown function; and 322-327 nt Bglll site.
The pCLF plasmid has been deposited with the ATCC as described in Example 3. The complete nucleotide sequence of pCLF is listed in SEQ ID NO: 8 where the nucleotide position 1 corresponds to approximately the middle of the pcDNA3 parent vector sequence. The 5' and 3 ends of the Ad5 fiber gene are located at respective nucleotide positions 1237-1239 with ATG and 2980-2982 with TAA. The rest of the vector construct has been previously described above.
C. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E4 and Fiber Proteins The 293 cell line was selected for preparing the first adenovirus packaging line as it already contains the E1 gene as prepared by Graham et al., J. Gen.
Virol., 36:59-74 (1977) and as further characterized by Spector, Virol., 130:533-538 (1983). Before electroporation, 293 cells were grown in RPMI medium + 10%
fetal calf serum. Four x 106 cells were electroporated with 20 Ng each of pE4/Hygro DNA and pCLF DNA using a BioRad GenePulser and settings of 300 V, 25 NF.
DNA for electroporation was prepared using the Qiagen system according to the manufacturer's instructions (Bio-Rad, Richmond, CA).
Following electroporation, cells were split into fresh complete DMEM + 10%
fetal calf serum containing 200 pg/ml Hygromycin B (Sigma, St. Louis, MO).
From expanded colonies, genomic DNA was isolated using the "MICROTURBOGEN" system (Invitrogen) according to manufacturer's instructions.
The presence of integrated E4 DNA was assessed by PCR using the primer pair E4R and ORF6L (5'TGCTTAAGCGGCCGCGAAGGAGA AGTCC3') (SEQ ID NO:
9), the latter of which is a 5' forward primer near adenovirus 5 open reading frame 6. Refer to Figure 1 for position of the primers relative to the E4 genes.

One clone, designated 211, was selected exhibiting altered growth properties relative to that seen in parent cell line 293. The 211 clone contained the expected product, indicating the presence of inserted DNA corresponding to most, if not all, of the E4 fragment contained in the pE4/Hygro plasmid. The 211 cell line has been deposited with the ATCC as described in Example 3. This line was further evaluated by amplification using the primer pair E4UE4R described above, and a product corresponding to the full-length E4 insert was detected. Genomic Southern blotting was performed on DNA restricted with EcoRl and BamHl. The E4 fragment was then detected at approximately one copy/genome compared to standards with the EcoRl/BamHl E4 fragment as cloned into pBS/E4 for use as a labeled probe with the Genius system according to manufacturer's instructions (Boehringer Mannheim, Indianapolis, IN). In DNA from the 211 cell line, the expected labeled internal fragment pE4/Hygro hybridized with the isolated E4 sequences. In addition, the probe hybridized to a larger fragment which may be the result of a second insertion event (Figure 5).
Although the 211 cell line was not selected by neomycin resistance, thus indicating the absence of fiber gene, to confirm the lack of fiber gene, the 211 cell line was analyzed for expression of fiber protein by indirect immunofluorescence with an anti-fiber polyclonal antibody and a FITC-labeled anti-rabbit IgG
(KPL) as secondary. No immunoreactivity was detected. Therefore, to generate 211 clones containing recombinant fiber genes, the 211 clone was expanded by growing in RPMI medium and subjected to additional electroporation with the fiber-encoding pCLF plasmid as described above.
Following electroporation, cells were plated in DMEM + 10% fetal calf serum and colonies were selected with 200 Ng/ml 6418 (Gibco, Gaithersburg, MD).
Positive cell lines remained hygromycin resistant. These candidate sublines of were then screened for fiber protein expression by indirect immunofluorescence as described above. The three sublines screened, 211 A, 211 B and 211 R, along with a number of other sublines, all exhibited nuclear staining qualitatively comparable to the positive control of 293 cells infected with AdRSV~gal (1 pfu/cell) and stained 24 hours post-infection.
Lines positive for nuclear staining in this assay were then subjected to Western blot analysis under denaturing conditions using the same antibody.
Several lines in which the antibody detected a protein of the expected molecular weight (62 kd for the Ad5 fiber protein) were selected for further study including 211 A, 211 B and 211 R. The 211 A cell line has been deposited with ATCC as described in Example 3.

Immunoprecipitation analysis using soluble nuclear extracts from these three cell lines and a seminative electrophoresis system demonstrated that the fiber protein expressed is in the functional trimeric form characteristic of the native fiber protein as shown in Figure 6. The predicted molecular weight of a trimerized fiber is 186 kd. The lane marked 293 lacks fiber while the sublines contain detectable fiber. Under denaturing conditions, the trimeric form was destroyed resulting in detectable fiber monomers as shown in Figure 6. Those clones containing endogenous E1, newly expressed recombinant E4 and fiber proteins were selected for use in complementing adenovirus gene delivery vectors having the corresponding adenoviral genes deleted as described in Example 2.
D. Preparation of an E1-Expressing Plasmid for Complementation of E1-Gene-Deleted Adenoviruses In order to prepare adenoviral packaging cell lines other than those based on the E1-gene containing 293 cell line as described in Example 1C above, plasmid vectors containing E1 alone or in various combinations with E4 and fiber genes are constructed as described below.
The region of the adenovirus genome containing the E1 a and E1 b gene is amplified from viral genomic DNA by PCR as previously described. The primers used are E1 L, the 5' or forward primer, and E1 R, the 3' or backward primer, having the respective nucleotide sequences 5'CCG AGCTAGC GACTGAAAATGAG3' (SEQ ID NO: 10) and 5'CCTCTCGAG AGACAGC AAGACAC3' (SEQ ID NO: 11 ).
The E1 L and E1 R primers include the respective restriction sites Nhel and Xhol as indicated by the underlines. The sites are used to clone the amplified E1 gene fragment into the Nhel/Xhol sites in pMAM commercially available from Clontech (Palo Alto, CA) to form the plasmid pDEX/E1 having 11152 bp, the plasmid map of which is shown in Figure 7.
The complete nucleotide sequence of pDEX/E1 is listed in SEO ID NO: 12 where the nucleotide position 1 corresponds to approximately 1454 nucleotides from the 3' end of the pMAM backbone vector sequence. The pDEX/E1 plasmid includes nucleotides 552 to 4090 of the adenovirus genome positioned downstream (beginning at nucleotide position 1460 and ending at 4998 in the pDEX/E1 plasmid) of the glucocorticoid-inducible mouse mammary tumor virus (MMTV) promoter of pMAM. The pMAM vector contains the E. coli gpt gene that allows stable transfectants to be isolated using CA 02359795 2001-07-12 PC'T/EP00/00265 hypoxanthine/aminopterin/thymidine (HAT) selection. The pMAM backbone occupies nucleotide positions 1-1454 and 5005-11152 of SEQ ID NO: 12.
E. Generation of an Adenovirus Packaging Cell Line Carrying Plasmids Encoding Functional E1, and Fiber Proteins To create separate adenovirus packaging cell lines equivalent to that of the 211 sublines, 211 A, 211 B and 211 R, as described in Example 1 C, alternative cell lines lacking adenoviral genomes are selected for transfection with the plasmid constructs as described below. Acceptable host cells include A549, Hela, Vero and the like cell lines as described in Example 1. The selected cell line is transfected with the separate plasmids, pDEX/EI and pCLF, respectively for expressing E1, and fiber complementary proteins. Following transfection procedures as previously described, clones containing stable insertions of the two plasmids are isolated by selection with neomycin and HAT. Integration of full-length copy of the E1 gene is assessed by PCR amplification from genomic DNA
using the primer set E1 L/E1 R , as described above. Functional insertion of the fiber gene is assayed by staining with the anti-fiber antibody as previously described.
The resultant stably integrated cell line is then used as a packaging cell system to complement adenoviral gene delivery vectors having the corresponding adenoviral gene deletions as described in Example 2.
F. Preparation of a Plasmid Containing Two or More Adenoviral Genes for Complementing Gene-Deleted Adenoviruses The methods described in the preceding Examples rely on the use of two plasmids, pE4/Hygro and pCLF, or, pCLF and pDEX/E1 for generating adenoviral cell packaging systems. In alternative embodiments contemplated for use with the methods of this invention, complementing plasmids containing two or more adenoviral genes for expressing of encoded proteins in various combinations are also prepared as described below. The resultant plasmids are then used in various cell systems with delivery plasmids having the corresponding adenoviral gene deletions. The selection of packaging cell, content of the delivery plasmids and content of the complementing plasmids for use in generating recombinant adenovirus viral vectors of this invention thus depends on whether other adenoviral genes are deleted along with the adenoviral fiber gene, and, if so, which ones.
1. Preparation of a Complementing Plasmid Containing Fiber and E1 Adenoviral Genes A DNA fragment containing sequences for the CMV promoter, adenovirus tripartite leader, fiber gene and bovine growth hormone terminator is amplified from pCLF prepared in Example 1 B using the forward primer 5'GACGGATCGGGAGATCTCC3' (SEQ ID NO: 13), that anneals to the nucleotides 1-19 of the pCDNA3 vector backbone in pCLF, and the backward primer 5'CCGCCTCAGAAGCCATAGAGCC3' (SEO ID NO: 14) that anneals to nucleotides 1278-1257 of the pCDNA3 vector backbone. The fragment is amplified as previously described and then cloned into the pDEX/E1 plasmid, prepared in Example 1 D. For cloning in the DNA fragment, the pDEX/E1 vector is first digested with Ndel, that cuts at a unique site in the pMAM vector backbone in pDEX/E1, then the ends are repaired by treatment with bacteriophage T4 polymerase and dNTPs.
The resulting plasmid containing E1 and fiber genes, designated pE1/Fiber, provides both dexamethasone-inducible E1 function as described for DEX/E1 and expression of Ad5 fiber protein as described above. A schematic plasmid map of pE1/Fiber, having 14455 bp, is shown in Figure 8.
The complete nucleotide sequence of pE1/Fiber is listed in SEQ ID NO: 15 where the nucleotide position 1 corresponds to approximately to 1459 nucleotides from the 3' end of the parent vector pMAM sequence. The 5' and 3 ends of the Ad5 E1 gene are located at respective nucleotide positions 1460 and 4998 followed by pMAM backbone and then separated from the Ad5 fiber from pCLF by the filled-in blunt ended Ndel site. The 5' and 3' ends of the pCLF fiber gene fragment are located at respective nucleotide positions 10922-14223 containing elements as previously described for pCLF.
The resultant pE1/Fiber plasmid is then used to complement one or more delivery plasmids expressing E1 and fiber.
The pE1/Fiber construct is then used to transfect a selected host cell as described in Example 1 E to generate stable chromosomal insertions preformed as previously described followed by selection on HAT medium. The stable cells are then used as packaging cells as described in Example 2.

WO 00/42208 CA 02359795 2001-07-12 pCT~, P00/00265 2. Preparation of a Complementing Plasmid Containing E4 and Fiber Adenoviral Genes pCLF prepared as described in Example 1 B is partially digested with Bglll to cut only at the site in the pCDNA3 backbone. The pE4/Hygro plasmid prepared in Example 1A is digested with BamHl to produce a fragment containing E4. The E4 fragment is then inserted into the BamHl site of pCLF to form plasmid pE4/Fiber.
The resultant plasmid provides expression of the fiber gene as described for pCLF
and E4 function as described for pE4/Hygro.
A schematic plasmid map of pE4/Fiber, having 10610 bp, is shown in Figure 9. The complete nucleotide sequence of pE4/Fiber is listed in SEQ ID NO: 16 where the nucleotide position 1 corresponds to approximately 14 by from the 3' end of the parent vector pCDNA3 backbone sequence. The 5' and 3 ends of the Ad5 E4 gene are located at respective nucleotide positions 21 and 3149 followed by fused Bglll/BamHl sites and pCDNA3 backbone including the CMV promoter again followed by Bglll/BamHl sites. The adenovirus leader sequence begins at nucleotide position 4051 and extends to 4366 followed by fused BamHl/Bglll sites and the 5' and 3' ends of the fiber gene located at respective nucleotide positions 4372 and 6124.
Stable chromosonal insertions of pE4/Fiber in host cells are obtained as described above.
Example 2 Preparation of Adenoviral Gene Delivery Vectors Using Adenoviral Packaging Cell Lines Adenoviral delivery vectors of this invention are prepared to separately lack the combinations of E1/fiber and E4/fiber. Such vectors are more replication-defective than those previously in use due to the absence of multiple viral genes.
A preferred adenoviral delivery vector of this invention that is replication competent but only via a non-fiber means is one that only lacks the fiber gene but contains the remaining functional adenoviral regulatory and structural genes. Furthermore, the adenovirus delivery vectors of this invention have a higher capacity for insertion of foreign DNA.

WO 00/42208 CA 02359795 2001-07-12 pCT~, P00/00265 A. Preparation of Adenoviral Gene Delivery Vectors Having Specific Gene Deletions and Methods of Use To construct the E1/ fiber deleted viral vector containing the LacZ reporter gene construct, two new plasmids were constructed. The plasmid p~ E1 B~igal was constructed as follows. A DNA fragment containing the SV40 regulatory sequences and E. coli a-galactosidase gene was isolated from pSVagal (Promega) by digesting with Vspl, filling the overhanging ends by treatment with Klenow fragment of DNA polymerase I in the presence of dNTP's and digesting with Bam H1. The resulting fragment was cloned into the EcoRV and BamHl sites in the polylinker of p0 E1 spi B (Microbix Biosystems, Hamilton, Ontario) to form p~E1 B~3gal that therefore contained the left end of the adenovirus genome with the Ela region replaced by the LacZ cassette (nucleotides 6690 to 4151 ) of pSV~3gal.
Plasmid DNA may be prepared by the alkaline lysis method as described by Birnboim and Doly, Nuc. Acids Res., 7:1513-1523 (1978) or by the Quiagen method according to the manufacturer's instruction, from transformed cells used to expand the plasmid DNA was then purified by CsCI-ethidium bromide density gradient centrifugation. Alternatively, plasmid DNAs may be purified from E.
coli by standard methods known in the art (e.g. see Sambrook et al.) The second plasmid (pDV44), prepared as described herein, is derived from pBHGlO, a vector prepared as described by Bett et al., Proc. Natl. Acad. Sci., USA, 91:8802-8806 (1994), now described in International Application Publication Number WO 9500655, with methodology well known to one of ordinary skill in the art and also is commercially available from Microbix, which contains an Ad5 genome with the packaging signals at the left end deleted and the E3 region (nucleotides 28133:30818) replaced by a linker with a unique site for the restriction enzyme Pacl. An 11.9 kb BamHl fragment, which contains the right end of the adenovirus genome, is isolated from pBHGlO and cloned into the BamHl site of pBS/SK(+) to create plasmid p11.3 having approximately 14,658 bp. A schematic of the plasmid map is shown in Figure 13. The p11.3 plasmid was then digested with Pacl and Sall to remove the fiber, E4, and inverted terminal repeat (ITR) sequences.
This fragment was replaced with a 3,4 kb fragment containing the ITR
segments and the E4 gene which was generated by PCR amplification from pBHGlO using the following ofigonucleotide sequences (5' TGTACACCG
GATCCGGCGCACACC3' SEQ ID NO: 17) and (5'CACAACGAGCTC

WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 AATTAATTAATTGCCACATCCTC3' SEQ ID NO: 18). These primers incorporated sites for Pacl and BamHl. Cloning this fragment into the Pacl and blunt ended Sall sites of the p11.3 backbone resulted in a substitution of the fused ITRs, E4 region and fiber gene present in pBHGlO, by the ITRs and E4 region alone. The resultant p11.3 plasmid containing the ITR and E4 regions, now called plasmid pDV43a, was then digested with BamHl. This BamHl fragment was then used to replace a BamHl fragment in pBHGlO thereby creating pDV44 in a pBHGlO backbone.
In an alternative approach to preparing pDV44 with an additional subcloning step to facilitate the incorporation of restriction cloning sites, the following cloning procedure was performed. pDV44 as above was constructed by removing the fiber gene and some of the residual E3 sequences from pBHGlO (Microbix Biosystems).
As above, to simplify manipulations, the 11.9 kb BamHl fragment including the rightmost part of the Ad5 genome was removed from pBHGlO and inserted into pBS/SK. The resulting plasmid was termed p11.3. The 3.4 kb DNA fragment corresponding to the E4 region and both ITRs of adenovirus type 5 was amplified as described above from pBHGlO using the oligonucleotides listed above and subcloned into the vector pCR2.1 (Invitrogen) to create pDV42. This step is the additional cloning step to facilitate the incorporation of a Sall restriction site.
pDV42 was then digested with Pacl, which cuts at a unique site (bold type) in one of the PCR primers, and with Sall, which cuts at a unique site in the pCR2.1 polylinker. This fragment was used to replace the corresponding Pacl/Xhol fragment of p11.3 (the pBS polylinker adjacent to the Ad DNA fragment contains a unique Xhol site), creating pDV43. Finally, pDV44 was constructed by replacing the 11.9 kb BamHl fragment of pBHGlO by the analogous BamHl fragment of pDV43. As generated in the first procedure, pDV44 therefore differs from pBHGlO
by the deletion of Ad5 nucleotides 30819:32743 (residual E3 sequences and all but the 3'-most 41 nucleotides of the fiber open reading frame).
Thus, to summarize, the cloning procedures described above result in the production of a fiber-deleted Ad5 genomic plasmid (pDV44) that was constructed by removing the fiber gene and some of the residual E3 sequences from pBHGlO
(Figure 16A). pDV44 contains a wild-type E4 region, but only the last 41 nucleotides of the fiber ORF (this sequence was retained to avoid affecting expression of the adjacent E4 transcription unit). Both pBHGlO and pDV44 contain unpackageable Ad5 genomes, and must be rescued by cotransfection and subsequent homologous recombination with DNA carrying functional packaging signals. In order to generate vectors marked with a reporter gene, either pDV44 or pBHGlO was cotransfected with p0E1Bf3gal, which contains the left end of the Ad5 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 genome with an SV40-driven f3-galactosidase reporter gene inserted in place of the E1 region.
In general, and as described below, the method for virus production by recombination of plasmids followed by complementation in cell culture involves the isolation of recombinant viruses by cotransfection of any one of the adenovirus packaging cell systems prepared in Example 1, namely 211 A, 211 B, 211 R, A549, Vero cells, and the like, with plasmids carrying sequences corresponding to viral gene delivery vectors.
A selected cell line is plated in dishes and cotransfected with pDV44 and p0E1 Bf3gal using the calcium phosphate method as described by Bett et al., Proc.
Natl. Acad. Sci., USA, 91:8802-8806 (1994). Recombination between the overlapping adenovirus sequences in the two plasmids leads to the creation of a full-length viral chromosome where pDV44 and p~E1 Bf3gal recombine to form a recombinant adenovirus vector having multiple deletions. The deletion of E1 and of the fiber gene from the viral chromosome is compensated for by the sequences integrated into the packaging cell genome, and infectious virus particles are produced. The plaques thus generated are isolated and stocks of the recombinant virus are produced by standard methods.
A pDV44-derived virus is expected to be replication-defective due to the fiber deletion, so that the cells in which it is grown must complement this defect.
The 211 B cell line (a derivative of 293 cells which expresses the wild-type (wt) AD5 fiber and is equivalent to 211A on deposit with ATCC as described in Example 3) was used for rescue and propagation of the virus described here. pDV44 and p0E1 Bf3gal were cotransfected into 211 B cells, and the monolayers were observed for evidence of cytopathic effect (CPE). Briefly, for virus construction, cells were transfected with the indicated plasmids using the Gibco Calcium Phosphate Transfection system according to the manufacturer's instructions and observed daily for evidence of CPE.
One of a total of 58 transfected dishes showed evidence of spreading cell death at day 15. A crude freeze-thaw lysate was prepared from these cells and the resulting virus (termed Ad5.f3gaI.OF) was plaque purified twice and then expanded.
To prepare purified viral preparations, cells were infected with the indicated Ad and observed for completion of CPE. Briefly, at day zero, 211 B cells were plated in DMEM plus 10% fetal calf serum at approximately 1 X 10' cells/150 cm2 flask or equivalent density. At day one, the medium was replaced with one half the original volume of fresh DMEM containing the indicated Ad, in this case Ad5.f3gal.~F, at approximately 100 particles/cell. At day two, an equal volume of medium was WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 added to each flask and the cells were observed for CPE. Two to five days after infection, cells were collected and virus isolated by lysis via four rapid freeze-thaw cycles. Virus was then purified by centrifugation on preformed 15-40% CsCI
gradients (111,000 x g for three hours at 4°C). The bands were harvested, dialyzed into storage buffer (10 mM Tris-pH 8.1, 0.9% NaCI, and 10% glycerol), aliquoted and stored at - 70°C. Purified Ad5.f3gaI.OF virus particles containing human adenovirus Ad5.f3gal. OFgenome (described further below) have been deposited with the ATCC on January 15, 1999 as further described in Example 3.
For viral titering, as necessary in the below Examples, Ad preparations were titered by plaque assay on 211 B cells. Cells were plated on polylysine-coated well plates at 1.5 x 106 cells/well. Duplicate dilutions of virus stock were added to the plates in 1 ml/well of complete DMEM. After a five hour incubation at 37°C, virus was removed and the wells overlaid with 2 ml of 0.6% low-melting agarose in Medium 199 (Gibco). An additional 1 ml of overlay was added at five day intervals.
As a control, the first-generation virus Ad5.f3 gal.wt, which is identical to Ad5.f3gal. ~F except for the fiber deletion, was constructed by cotransfection of pBHGlO and p~E1 Bf3gal (Figure 16B). In contrast to the low efficiency of recovery of the fiberless genome (1/58 dishes), all of 9 dishes cotransfected with p0E1 Bf3gal and pBHGlO produced virus.
In a preferred embodiment of this invention as more fully described herein and below, a delivery plasmid is prepared that does not require the above-described recombination events to prepare a viral vector having a fiber gene deletion. In one embodiment, a single delivery plasmid containing all the adenoviral genome necessary for packaging but lacking the fiber gene is prepared from plasmid pFG140 containing full-length Ad5 that is commercially available from Microbix. The resultant delivery plasmid referred to as pFG140-f is then used with pCLF stably integrated cells as described above to prepare a viral vector lacking fiber. In a preferred aspect of this invention, the fiber gene is replaced with a therapeutic gene of interest for preparing a therapeutic delivery adenoviral vector.
Other embodiments including production of fiberless vector with a complete TPL
are described in Example 5.
Vectors for the delivery of any desired gene and preferably a therapeutic gene are prepared by cloning the gene of interest into the multiple cloning sites in the polylinker of commercially available p0E1 sp1 B (Microbix Biosystems), in an analogous manner as performed for preparing p E1 B~3gal as described above.
The same cotransfection and recombination procedure is then followed as described herein to obtain viral gene delivery vectors as further discussed in later Examples.

WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 1. Characterization of the Ad5.~3gaI.~F Genome To confirm that the vector genomes had the expected structures and that the fiber gene was absent from the Ad5.f3gal.~F chromosome, the DNA isolated from viral particles was analyzed. Briefly, purified viral DNA was obtained by adding 10 ~I of 10 mg/ml proteinase K, 40 pl of 0.5 M EDTA and 50 NI of 10% SDS to 800 pl of adenovirus-containing culture supernatant. The suspension was then incubated at 55C for 60 minutes. The solution was then extracted once with 400 NI of a 24:1 mixture of chloroform:isoamyl alcohol. The aqueous phase was then removed and precipitated with sodium acetate/ethanol. The pellet was washed once with 70% ethanol and lightly dried. The pellet was then suspended in 40 pl of 10 mM Tris-HCI, pH 8.0, 1 mM EDTA. Genomic DNA from both Ad5.f3gal.wt and AdS.~gaI.OF produced the expected restriction patterns (Figure 17A) following digestion with either EcoRl (Figure 17B) or with Ndel (data not shown). Southern blotting, performed with standard methods, with labeled fiber DNA as a probe demonstrated the presence of fiber sequence in Ad5.f3gal.wt but not in Ad5.f3gal. OF DNA (Figure 17C). As a positive control, the blot was stripped and reprobed with labeled E4 sequence. Fiber and E4 sequences were detected by using labeled inserts from pCLF and pE4/Hygro, respectively. As expected, signal was readily detectable in both genomes at equal intensities (Figure 17C).
The complete nucleotide sequence of AdS.~igaI.BF is presented in SEQ ID
NO: 27 and is contained in the virus particle on deposit with ATCC.
2. Characterization of the Fiberless Adenovirus AdS.~igaI.OF
To verify that Ad5.f3gal.~F was fiber-defective, 293 cells (which are permissive for growth of E1-deleted Ad vectors but do not express fiber) were infected with Ad5.f3gal. OF or with AdS.(3gal.wt. Twenty-four hours post infection, the cells were stained with polyclonal antibodies directed either against fiber or against the penton base protein. Cells infected with either virus were stained by the anti-penton base antibody, while only cells infected with the AdS.(3gal.wt control virus reacted with the anti-fiber antibody. This confirms that the fiber-deleted Ad mutant does not direct the synthesis of fiber protein.
3. Growth of the Fiber-Deleted AdS.~igaI.OF Vector in Complementing Cells WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 AdS.~igaI.OF was found to readily be propagated in 211 B cells. As assayed by protein concentration, CsCI-purified stocks of either AdS.~igaI.OF or Ad5.f3gal.wt contained similar numbers of viral particles (Table 1 ), and the particles appeared to band normally on CsCI gradients. However, infectivity of the AdS.~igaI.OF
particles was lower than the Ad5.f3gal.wt control, as indicated by an increased particle/PFU
ratio (Table 1 ). This is likely due to a reduced amount of fiber protein incorporated into mutant particles during growth in the WO '00/42208 PCT/EP00/00265 Virus CsCI- Cell Particles/PFU/ml ParticleFiber source purifiedline mla /PFU

preen ratio AdS.(3gal.wt1 211 7.4 x 7.5 x 10 Ad 10"

B 10' chromosom a 2 211 3.0 x 5.0 x 60 Ad 10" 10y B chromosom a AdS.(3gaI.OF3 211 7.7 x 3.5 x 2200 Packaging 10" 10 B cells 4 211 1.9 x 2.3 x 808 Packaging 10'2 109 B cells 5 293 4.5 x 9.5 x 47400 None 10" 106 6 293 3.4 x 3.5 x 9700 None 10" 10' aCalculated from viral protein concentration (1 ug of protein = 4 x 109 particles).
bAssayed by plaguing on 211 B cells.
Table 3 *Particle numbers and infectious titers of representative adenovirus preps.
Each line represents a single CsCI-purified preparation of the indicated virus.
Particle numbers were calculated from viral protein concentration (1 Ng protein = 4 x 109 particles). Pfu was assayed by plaguing on 211 B cells (see above).
211 B cells (see below). AdS.~igaI.OF was also found to plaque more slowly than the control virus. When plated on 211 B cells, Ad5.f3gal.wt plaques appeared within 5-7 days, while plaques of Ad5.~3gaI.OF continued to appear until as much as 15-18 days post infection. Despite their slower formation, the morphology of AdS.~igaI.OF
plaques was essentially normal.

4. Production of Fiberless Ad5.f3gal. OF Particles As AdS.~igaI.OF represents a true fiber null mutation and its stocks are free of helper virus, the fiber mutant phenotype was readily investigated. A single round of growth in cells (such as 293) which do not produce fiber generating a homogeneous preparation of fiberless Ad allowed for the determination of whether such particles would be stable and/or infectious. Either Ad5.f3gal.wt or AdS.~igal.~F was grown in 293 or 211 B cells, and the resulting particles purified on CsCI gradients as previously described. Ad5.~3gaI.OF particles were readily produced in 293 cells at approximately the same level as the control virus and behaved similarly on the gradients, indicating that there was not a gross defect in morphogenesis of fiberless capsids (Table 1 ).
As shown in Figure 18, particles of either virus contained similar amounts of penton base regardless of the cell type in which they were grown. This demonstrated that fiber is not required for assembly of the penton base complex into virions. However, as predicted, the AdS.~igal.~F particles produced in 293 cells did not contain fiber protein. 211 B-grown AdS.~igaI.OF also contained less fiber than the Ad5.f3gal.wt control virus (Figure 18). Importantly, the infectivities of the different viral preparations on epithelial cells (Table 1 ) correlated with the amount of fiber protein present. The fiberless Ad particles were several thousand-fold less infectious than the first-generation vector control on a per-particle basis, while infectivity of 211 B-grown AdS.~gaI.~F was only 50-100 fold less than that of Ad5.f3gal.wt. These studies confirmed fiber's crucial role in infection of epithelial cells via CAR binding.
5. Composition and Structure of the Fiberless Ad5.f3gal.
OF Particles The proteins contained in particles of 293-grown Ad5.~3gaI.OF were compared to those in AdS.Bgal.wt, to determine whether proteolysis or particle assembly was defective in this fiber null mutant (data not shown). The overall pattern of proteins in the fiberless particles was observed to be quite similar to that of a first-generation vector, with the exception of reduced intensity of the composite band resulting from both proteins Illa and IV (fiber) (data not shown). The fiberless particles also had a reduced level of protein VII. Although substantial amounts of uncleaved precursors to proteins VI, VII, and VIII were not seen, it is possible that the low-molecular weight bands migrating ahead of protein VII represent either aberrantly cleaved viral proteins or their breakdown products.
Cryo-electron microscopy was used to more closely examine the structure of the 293 grown AdS.~gaI.OF and of Ad5(3gal.wt. The fiber, which consists of an extended stalk with a knob at the end, was faintly visible in favorable orientations of wild-type Ad5 particles, but not in images of the fiberless particles (data not shown).
Filamentous material likely corresponding to free viral DNA was seen in micrographs of fiberless particles. This material was also present in micrographs of the first-generation control virus, albeit at much lower levels.
Three-dimensional image reconstructions of fiberless and wild-type particles at ~20 ~ resolution showed similar sizes and overall features, with the exception that fiberless particles lacked density corresponding to the fiber protein. The densities corresponding to other capsid proteins, including penton base and proteins Illa, VI, and IX, were comparable in the two structures. This confirms that absence of fiber does not prevent assembly of these components into virions. The fiber was truncated in the wild-type structure as only the lower portion of its flexible shaft follows icosahedral symmetry. The RGD protrusions on the fiberless penton base were angled slightly inward relative to those of the wild-type structure.
Another difference between the two penton base proteins was that there is a ~30 ~
diameter depression in the fiberless penton base around the five-fold axis where the fiber would normally sit. The Ad5 reconstructions confirm that capsid assembly, including addition of penton base to the vertices, is able to proceed in the complete absence of fiber.
6. Integrin-Dependent Infectivity of Fiberless AdS.(3gal. OF
Particles While attachment via the viral fiber protein is a critical step in the infection of epithelial cells, an alternative pathway for infection of certain hematopoietic cells has been described. In this case, penton base mediates both binding to the cells (via f32 integrins) and internalization (through interaction with av integrins).
Particles lacking fiber might therefore be expected to be competent for infection of these cells, even though on a per-particle basis they are several thousand-fold less infectious than normal Ad vectors on epithelial cells.

To investigate this, THP-1 monocytic cells were infected with Ad5.f3gal.wt or with AdS.(3gaI.OF grown in the absence of fiber. Infection of THP-1 cells was assayed by infecting 2 x 105 cells at the indicated m.o.i. in 0.5 ml of complete RPMI.
Forty-eight hours post-infection, the cells were fixed with glutaraldehyde and stained with X-gal, and the percentage of stained cells was determined by light microscopy.
The results of the infection assay showed that the fiberless particles were only a few-fold less infectious than first-generation Ad on THP-1 cells (Figure 19A).
In contrast to this, very large differences were seen in plaquing efficiency on epithelial (211 B) cells (Table 1 ). Infection of THP-1 cells by either Ad5.~3gaI.OF or Ad5.f3gal.wt was not blocked by an excess of soluble recombinant fiber protein, but could be inhibited by the addition of recombinant penton base (Figure 19B).
These results indicate that the fiberless Ad particles use a fiber-independent pathway to infect these cells. Furthermore, the lack of fiber protein did not prevent AdS.~igaI.OF
from internalizing into the cells and delivering its genome to the nucleus, demonstrating that fiberless particles are properly assembled and are capable of uncoating.
The foregoing results with the recombinant viruses thus produced indicates that they can be used as gene delivery tools both in cultured cells and in vivo as described more fully in the Examples. For example, for studies of the effectiveness and relative immunogenicity of multiply-deleted vectors, virus particles are produced by growth in the packaging lines described in Example 1 and are purified by CsCI
gradient centrifugation. Following titering, virus particles are administered to mice via systemic or local injection or by aerosol delivery to lung. The LacZ
reporter gene allows the number and type of cells which are successfully transduced to be evaluated. The duration of transgene expression is evaluated in order to determine the long-term effectiveness of treatment with multiply-deleted recombinant adenoviruses relative to the standard technologies which have been used in clinical trials to date. The immune response to the improved vectors described here is determined by assessing parameters such as inflammation, production of cytotoxic T
lymphocytes directed against the vector, and the nature and magnitude of the antibody response directed against viral proteins.
Versions of the vectors which contain therapeutic genes such as CFTR for treatment of cystic fibrosis or tumor suppressor genes for cancer treatment are evaluated in the animal system for safety and efficiency of gene transfer and expression. Following this evaluation, they are used as experimental therapeutic agents in human clinical trials.

B. Retargeting of Adenoviral Gene Delivery Vectors by Producing Viral Particles Containing Different or Altered Fiber Proteins As the specificity of adenovirus binding to target cells is largely determined by the fiber protein, viral particles that incorporate modified fiber proteins or fiber proteins from different adenoviral serotypes (pseudotyped vectors) have different specificities. Thus, the methods of expression of the native Ad5 fiber protein in adenovirus packaging cells as described above is also applicable to production of different fiber proteins.
In one aspect of invention, chimeric fiber proteins are produced according to the methods of Stevenson et al., J. Virol., 69:2850-2857 (1995). The authors showed that the determinants for fiber receptor binding activity are located in the head domain of the fiber and that isolated head domain is capable of trimerization and binding to cellular receptors. The head domains of adenovirus type 3 (Ad3) and Ad5 were exchanged in order to produce chimeric fiber proteins. Similar constructs for encoding chimeric fiber proteins for use in the methods of this invention are contemplated. Thus, instead of the using the intact Ad5 fiber-encoding construct prepared in Example 1 as a complementing viral vector in adenoviral packaging cells, the constructs described herein are used to transfect cells along with and/or E1-encoding constructs.
Briefly, full-length Ad5 and Ad3 fiber genes were amplified from purified adenovirus genomic DNA as a template. The Ad5 and Ad3 nucleotides sequences are available with the respective GenBank Accession Numbers M18369 and M12411. Oligonucleotide primers are designed to amplify the entire coding sequence of the full-length fiber genes, starting from the start codon, ATG, and ending with the termination codon TAA. For cloning purposes, the 5' and 3' primers contain the respective restriction sites BamHl and Notl for cloning into pcDNA
plasmid as described in Example 1A. PCR is performed as described above.
The resultant products are then used to construct chimeric fiber constructs by PCR gene overlap extension, as described by Horton et al., BioTechniques, 8:525-535 (1990). The Ad5 fiber tail and shaft regions (STS; the nucleotide region encoding amino acid residue positions 1 to 403) are connected to the Ad3 fiber head region (3H; the nucleotide region encoding amino acid residue positions 136 to 319) to form the 5TS3H fiber chimera. Conversely, the Ad3 fiber tail and shaft regions (3TS; the nucleotide region encoding amino acid residues positions 1 to 135) are connected to the Ad5 fiber head region (5H; the nucleotide region encoding the amino acid residue positions 404 to 581 ) to form the 3TS5H fiber chimera. The fusions are made at the conserved TLWT (SEQ ID NO: 19) sequence at the fiber shaft-head junction.
The resultant chimeric fiber PCR products are then digested with BamHl and Notl for separate directional ligation into a similarly digested pcDNA 3.1.
The TPL
sequence is then subcloned into the BamHl as described in Example 1 A for preparing an expression vector for subsequent transfection into 211 cells as described above or into the alternative packaging cell systems as previously described. The resultant chimeric fiber construct-containing adenoviral packaging cell lines are then used to complement adenoviral delivery vectors as previously described. Other fiber chimeric constructs are obtained using a similar approach with the various adenovirus serotypes known.
In an alternative embodiment, the methods of this invention contemplate the use of the modified proteins including novel epitopes as described by Michael et al., Gene Therapy, 2:660-668 (1995) and in International Publication WO 95/26412.
Both publications describe the construction of a cell-type specific therapeutic viral vector having a new binding specificity incorporated into the virus concurrent with the destruction of the endogenous viral binding specificity. In particular, the authors described the production of an adenoviral vector encoding a gastrin releasing peptide (GRP) at the 3' end of the coding sequence of the Ad5 fiber gene. The resulting fiber-GRP fusion protein was expressed and shown to assemble functional fiber trimers that were correctly transported to the nucleus of HeLa cells following synthesis.
Based on the teachings in the paper and International Publication, similar constructs are contemplated for use in the complementing adenoviral packaging cell systems of this invention for generating new adenoviral gene delivery vectors that are targetable, replication-deficient and less immunogenic. Heterologous ligands contemplated for use herein to redirect fiber specificity range from as few as amino acids in size to large globular structures, some of which necessitate the addition of a spacer region so as to reduce or preclude steric hindrance of the heterologous ligand with the fiber or prevent trimerization of the fiber protein. The ligands are inserted at the end or within the linker region. Preferred ligands include those that target specific cell receptors or those that are used for coupling to other moieties such as biotin and avidin.

A preferred spacer includes a short 12 amino acid peptide linker composed of a series of serines and alanine flanked by a proline residue at each end. One of ordinary skill in the art is familiar with the preparation of linkers to accomplish sufficient protein presentation and for altering the binding specificity of the fiber protein without compromising the cellular events that follow viral internalization.
Moreover, within the context of this invention, preparation of modified fibers having ligands positioned internally within the fiber protein and at the carboxy terminus as described below are contemplated for use with the methods described herein.
The preparation of a fiber having a heterologous binding ligand is prepared essentially as described in the above-cited paper. Briefly, for the ligand of choice, site-directed mutagenesis is used to insert the coding sequence for a linker into the 3' end of the Ad5 fiber construct in pCLF as prepared in Example 1.
The 3' or antisense or mutagenic oligonucleotide encodes a preferred linker sequence of ProSerAlaSerAlaSerAlaSerAlaProGIySer (SEQ ID NO: 20) followed by a unique restriction site and two stop codons, respectively, to allow the insertion of a coding sequence for a selected heterologous ligand and to ensure proper translation termination. Flanking this linker sequence, the mutagenic oligonucloetide contains sequences that overlap with the vector sequence and allo its incorporation into the construct. Following mutagenesis of the pCLF sequence adding the linker and stop codon sequences, a nucleotide sequence encoding a preselected ligand is obtained, linkers corresponding to the unique restriction site in the modified construct are attached and then the sequence is cloned into linearized corresponding restriction site. The resultant fiber-ligand construct is then used to transfect 211 or the alternative cell packaging systems previously described to produce complementing viral vector packaging systems for use with the methods of this invention.
In a further embodiment, intact fiber genes from different Ad serotypes are expressed by 211 cells or an alternative packaging system as previously described.
A gene encoding the fiber protein of interest is first cloned to create a plasmid analogous to pCLF, and stable cell lines producing the fiber protein are generated as described above for Ad5 fiber. The adenovirus vector described which lacks the fiber gene is then propagated in the cell line producing the fiber protein relevant for the purpose at hand. As the only fiber gene present is the one in the packaging cells, the adenoviruses produced contain only the fiber protein of interest and therefore have the binding specificity conferred by the complementing protein.
Such viral particles are used in studies such as those described above to determine their properties in experimental animal systems.

Example 3 Deposit of Materials The following cell lines and plasmids have been deposited on September 25, 1996, with the American Type Culture Collection, 10801 University Blvd, Manassas, Virginia, USA (ATCC) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty):Plasmid pE4/Hygro (accession number 97739), Plasmid pCLF (accession number 97737), 211 Cell Line (accession number CRL-12193) and 211A Cel! Line (accession number CRL-12194) The following virus, AdS.[igaL~F , deposit was deposited on January 15, 1999, with the ATCC as listed above and provided with accession number VR2636.
Additionally, plasmids pDV60, pDV67, pDV69, pDV80 and pDV90 were also deposited at the ATCC on 5 January, 2000 and provided with accession numbers PTA-1144, PTA-1145, PTA-1146, PTA-1147 and PTA-1148 respectively.
Example 4 Complementation of Fiber-Defective and Fiber-Modified Virus The native fiber protein is a homotrimer (Henry L.J. et al., J. Virol.
68:5239-5246 (1994)), and trimerization is essential for assembly of the penton/fiber complex (Novelli A et al., J. Bivl. Chem. 266.9299-9303 (i 991 )). To assess the multimeric structure of the recombinant fiber protein produced by the cell fines, cells were labeled with 50 NCi/ml [35S] Translabel (ICN) for two hours at 37°C, lysed in RIPA buffer, and fiber protein was immunoprecipitated as described (Harlow E
et a., Antibodies. Cold Spring Harbour Laboratory, Cold Spring Harbor (1988). Immune complexes were collected on Protein A-Sepharose beads (Pierce), extensively washed with RIPA buffer, and incubated at room temperature in 0.1 M
triethylamine, pH 11.5 to release bound fiber protein. A portion of th~ precipitated fiber was electrophoresed on a 8% SDS-PAGE gel under denaturing (1 % SDS in loading buffer, samples boiled for 5 minutes) or semi-native (0.1% SDS in loading buffer, samples not heated) conditions.
As seen in Fig. 13, lines 211 A, 2i i B, and 211 R, but not the control 293 cells, expressed an immunologically reactive protein which migrated at the predicted molecular weight for trimer (186 kD) under seminative conditions and for monomer (62 kD) under denaturing conditions. The behavior of the precipitated fiber was indistinguishable from that of purified baculovirus-produced recombinant Ad2 fiber (Wickham T et aL, Cell 73:309-319 (1993)) (the 58 kD Ad2 and 62 kD Ad5 fibers have very similar mobilities under these conditions).
To determine whether the fiber-expressing lines could support the growth of a fiber-defective adenovirus, we performed one-step growth experiments using the temperature-sensitive fiber mutant Ad H5ts142 (the gift of Harold Ginsberg).
At the restrictive temperature (39.5°C), this mutant produces an underglycoslyated fiber protein which is not incorporated into mature virions (Chee-Sheung C. C et al., J.
Virol42: 932-950 (1982)). This results in the accumulation of non-infectious viral particles. We asked whether the recombinant fiber protein expressed by our cell lines could complement the H5ts142 defect and rescue viral growth.
Cell lines 293, 211 A, 211 B and 211 R (2 x 106 cells/sample) were infected with H5ts142 at 10 pfu/cell. 48 hours later, cells were detached with 25 mM EDTA
and virus was harvested by four rapid freeze-thaw cycles. Debris was removed by a minute spin at 1500 x g, and viral titers determined by fluorescent focus assay (Thiel J.F et al., Proc. Soc. Exp. Biol. Med. 125:892-895 (1967)) on SW480 cells with a polyclonal anti-penton base Ab (Wickham T et al., Cell 73:309-319 (1993)). As shown in Fig. 14, the fiber mutant virus replicated to high titers in 293 cells at 32.5°C
(the permissive temperature), but to a much lower extent at the restrictive temperature of 39.5°C. The fiber-producing packaging lines 211 A, 211 B, or 211 R
supported virus production at 39°C to levels within two- to three-fold of those seen at the permissive temperature in 293 cells, indicating that these cells provided partial complementation of the fiber defect.
Interestingly, virus yields from the fiber-producing cell lines were also somewhat higher than those from 293 cells at 32.5°C (the 'permissive' temperature).
This suggests that fiber produced by the ts142 virus may be partially defective even at the permissive temperature. Alternatively, a non-specific increase in adenoviral titer could result when viruses are grown in the packaging cells, by a mechanism not involving fiber complementation. However, it was found that viruses with wild type fiber genes (such as Ad.RSV~3gal) replicate to identical levels either in our packaging lines or in 293 cells (data not shown). Taken together, these results demonstrate that the observed increase in H5ts142 growth is due to specific complementation of the fiber mutation.
Even in the fiber-expressing cell lines, the fiber mutant grows to higher titers at 32°C than at 39.5°C. This incomplete complementation may be due to the packaging lines' expression of fiber at a level somewhat below that seen in a wild-type infection (data not shown). A recent study reported an E4-deleted vector which coincidentally reduced fiber protein expression, resulting in a large reduction in the titer of virus produced (Brough et al., J. Virol. 70:6497-6501 (1996)).
Another possibility is that the defective ts142 fiber protein produced at the restrictive temperature might form complexes with some of the wild type protein produced by the cells and prevent its assembly into particles.
Although the fiber proteins of different Ad serotypes differ in the length of their shaft domains and in their receptor-binding knob domains, the N-terminal regions responsible for interaction with the viral penton base are highly conserved Arnberg N et aL, Virology 227.239-244 (1997)) (Figure 15A). This suggests that fibers from many viral serotypes, with their different cell-binding specificities, may be amenable for use in producing gene delivery vectors.
In order to determine whether the recombinant Ad5 fiber produced by the packaging cells could be incorporated into particles of another adenovirus serotype, adenovirus type 3 was grown either in fiber-producing cell lines or in 293 cells. Viral particles were purified by two sequential centrifugations (3 h at 111,000 x g) on preformed 15-40% CsCI gradients to remove soluble cellular proteins and then dialyzed extensively against 10 mM Tris-HCI, pH 8.1, 150 mM NaCI, 10%
glycerol.
Ad5 fiber protein was detected by immunoblotting using the polyclonal anti-fiber serum, followed by detection with a horseradish peroxidase-conjugated goat anti-rabbit antibody (Kirkegaard and Perry Laboratories) and the ECL
chemiluminescence substrate (Amersham). The purified Ad3 particles contained Ad5 fiber protein after a single passage through a fiber-expressing cell line but not after passage through 293 cells (Figure 15B). Previous work has demonstrated that Ad2 fiber is capable of interacting in vitro with Ad3 penton base (Fender et al., Nature Biotech.15:52-(1997)), and our result demonstrates that the type 5 fiber protein produced by the cells is capable of assembling into complete Ad3 particles.
A vector based on Ad5 but containing the gene for the Ad7 fiber protein has been described (Gall J. et al., J. Virol. 70:2116-2123 (1996)), as well as Ads containing chimeric fiber genes (Krasnykh et al., J. Virol. 70:6839-6846 (1996) and Stevenson et al., J. Virol. 69.2850-2857 (1995)). Chimeric Ad5/Ad3 vectors have also been reported (Stevenson, S. et al., J. ViroL 71:4782-4790, (1997).
Addition of a short peptide linker to the fiber in order to confer binding to a different cellular protein has also been reported (Michael etal., Gene Therapy2:660-668 (1995).
By using packaging technology such as that presented here, Ad vectors equipped with different fiber proteins may be produced simply by growth in cells expressing the fiber of interest, without the time-consuming step of generating a new vector genome for each application.
Replacing or modifying the fiber gene in the vector chromosome would also require that the new fiber protein bind a receptor on the surface of the cells it which it is to be grown. The packaging cell approach will allow the generation of Ad particles containing a fiber which can no longer bind to its host cells, by a single round of growth in cells expressing the desired fiber gene. This will greatly expand the repertoire of fiber proteins which can be incorporated into particles, as well as simplifying the process of retargeting gene delivery vectors.
Finally, a novel fiber-independent pathway of infection has recently been described in hematopoietic cells, in which penton base provides the initial virus-cell interaction by binding to integrin amb2 (Huang S. et al., J. Virol 70: 4502-(1996)). This suggests that viral particles lacking fiber protein may be useful in targeting gene delivery to specific cell types via this pathway.
Example 5 Preparation of Alternative TPLs The present invention contemplates the use of tripartite leader sequences (TPLs) that are useful in enhancing the expression of complementing adenoviral proteins, particularly fiber protein, for use in preparing an adenoviral gene delivery vector. One preferred TPL is the complete Ad5 tripartite leader contained in complementing vectors such as pDV67 and pDV69, both of which are prepared as described below. The complete Ad5 TPL was constructed by assembling PCR
fragments. First, the third TPL exon (exon 3) (nt 9644-9731 of the Ad5 genome) was amplified from Ad5 genomic DNA using the synthetic oligonucleotide primers 5'CTCAACAATTGTGGATCCGTACTCC3'(SEQ ID NO: 28) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 29). The resulting product was cloned to the BamHl and Bglll sites of p~E1 Sp1 a (Microbix Biosystems) using novel sites in the primers (shown in bold) to create plasmid pDV52. A fragment corresponding to the first TPL exon (exon 1 ), the natural first intron (intron 1 ), and the second TPL exon (exon 2) (Ad5 nt 6049-7182) was then amplified using primers 5'GGCGCGTTCGGATCCACTCTCTTCC3' (SEQ ID N0:30) and 5'CTA
CATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID NO: 31), and cloned into the BamHl site of pDV52 (again using novel sites in the primers) to create pDV55.
This plasmid contains a 1.2 kb BamHl/Bglll fragment consisting of the first TPL exon, the natural first intron, and the fused second and third TPL exons. The nucleotide sequence of the complete TPL containing the noted 5' and 3' restriction sites is shown in SEQ ID NO: 32 with the following nucleotide regions identified: 1-6 nt BamHl site; 7-47 nt first leader segment (exon 1 ); 48-1068 nt natural first intron (intron 1 ); 1069-1140 nt second leader segment (exon 2); 1141-1146 nt fused BamHl and Bglll sites; 1147-1234 nt third leader segment (exon 3); and 1235-1240 nt Bglll site.
TPLs fragments containing two of the three exons, exons in non-native order, or containing either the first or second TPL intron are also constructed for use in preparing complementing plasmids for use in the methods of the present invention.
Briefly, DNA fragments containing any combination of 2 TPL exons can be constructed as follows: Exon 1 is amplified from genomic DNA as prepared above by using the oligonucleotides 5'GGCGCGTTCGGATCCACTCTCTTCC3'(SEQ ID
NO: 33) and 5'GGGAGTAGATCTCCCAACAG3' (SEQ ID NO: 34). Exon 2 is similarly amplified from the same genomic DNA using oligonucleotides 5'CCCTTTTTTTTGGATCCCTCGCGG3' (SEQ ID NO: 35) and 5'CTACATGCTAGGCAGATCTCGTTCGGAG3' (SEQ ID NO: 36). Exon 3 is amplified using the oligonucleotides 5'CTCAACAATTGTTGGATCCGTACTCC3' (SEQ ID NO: 37) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 38).
The amplified exons are ligated together in any desired number and/or order by virtue of the unique BamHl and Bglll restriction sites (bold) in the primers for subsequent ligation into a construct analogous to pDV67, prepared as described below, for expression of viral structural genes.
Similarly, a fragment consisting of the first TPL exon (exon 1), the native first intron (intron 1 ), and the second TPL exon (exon 2) is produced by amplification from Ad5 genomic DNA with the oligonucleotide pair 5'GGCGCGTTCGGATCC
ACTCTCTTCC3' (SEQ ID NO: 39) and 5'CTACATGCTAGGCAGATCT
CGTTCGGAG3' (SEQ ID NO: 40). Finally, a fragment consisting of the second TPL
exon (exon 2), the native second intron (intron 2), and the third TPL exon (exon 3) is produced by amplification using the oligonucleotides 5'CCCTTTTTTTTGGATCC
CTCGCGG3' (SEQ ID NO: 41) and 5'GTGCTCAGCAGATCTTGCGACTGTG3' (SEQ ID NO: 42). Either of the intron-containing fragments are used either alone or in combination with another TPL fragments) in constructs analogous to pDV67.
Introns in addition to adenoviral intron 1 used herein that have been shown to increase the expression of recombinant proteins when included in expression constructs include SV40 VP1 intron, rabbit (i-globin intron among others. The use of these alternative intron sequences are contemplated for use in preparing a TPL
in the present invention.
Example 6 Preparation and Use of Adenoviral Packaging Cell Lines Containing Plasmids Containing Alternative TPLs Plasmids were first constructed as described below that contained TPLs are described above. The resultant plasmids containing different selectable markers such as neomycin or zeocin were then used to prepare stable cell lines for use as complementing vectors for preparing adenoviral vectors for use in the present invention. In a preferred embodiment, the resulting cell lines represent improvements over preexisting fiber-complementing cell lines in that fiber expression is enhanced with the use of alternative TPLs.
A. pDV60 pDV60 was constructed by inserting this TPL cassette of SEQ ID NO: 32 into the BamHl site upstream of the Ad5 fiber gene in pcDNA3/Fiber, a neomycin selectable plasmid, prepared as described in Example 1 and also as described by Von Seggern et al., J. Gen Virol., 79: 1461 (1998). The nucleotide sequence of pDV60 is listed in SEQ ID NO: 43.
B. pDV61 To construct pDV61, an Asp718/Notl fragment containing the CMV promoter, partial Ad5 TPL, wildtype Ad5 fiber gene, and bovine growth hormone terminator was transferred from pCLF, prepared as described in Example 1 and also as described by Von Seggern et al., J. Gen Virol., 79: 1461 (1998), to a zeocin selectable cloning vector referred to as pCDNA3.1/Zeo (+) (commercially available from Invitrogen and the sequence is also available).
C. pDV67 _77_ In an analogous process, pDV67 containing complete TPL was constructed by transferring an Asp 718/Xbal fragment from pDV60 to the pcDNA3.1/Zeo(+) backbone. The nucleotide sequence of pDV67 is listed in SEQ ID NO: 44.
D. pDV69 To prepare pDV69 containing a modified fiber protein, the chimeric Ad3/Ad5 fiber gene was amplified from pGEM5TS3H (Stevenson et al., J. Virol., 69:
2850-2857, 1995)) using the primers 5'ATGGGAT
CAAGATGAAGCGCGCAAGACCG3' (SEQ ID NO: 45) and 5'CACTATAGCGGCCGCATTCTCAGTCATCTT3' (SEQ ID NO: 46), and cloned to the BamHl and Notl sites of pcDNA3.1/Zeo(+) via novel BamHl and Notl sites engineered into the primers to create pDV68. Finally, the complete TPL
fragment described above was then added to the unique BamH1 site of pDV68 to create pDV69. The nucleotide sequence of pDV69 is listed in SEQ ID NO: 47.
E. Preparation of Stable Adenovirus Packaging Cell Lines E1-2a S8 cells are derivatives of the A549 lung carcinoma line (ATCC # CCL
185) with chromosomal insertions of the plasmids pGRES-2.E1 (also referred to as GRES-E1-SV40-Hygro construct and listed in SEQ ID NO: 48) and pMNeoE2a-3.1 (also referred to as MMTV-E2a-SV40-Neo construct and listed in SEQ ID NO: 49), which provide complementation of the adenoviral E1 and E2a functions, respectively. This line and its derivatives were grown in Richter's modified medium (BioWhitaker) + 10% FCS. E1-2a S8 cells were electroporated as previously described (Von Seggern et al., J. Gen Virol., 79: 1461 (1998)) with pDV6l, pDV67, or with pDV69, and stable lines were selected with zeocin (600 Ng/ml). The cell line generated with pDV61 is designated 601. The cell line generated with pDV67 is designated 633 while that generated with pDV69 is designated 644. Candidate clones were evaluated by immunofluorescent staining with a polyclonal antibody raised against the Ad2 fiber. Lines expressing the highest level of fiber protein were further characterized.
For the S8 cell complementing cell lines, to induce E1 expression, 0.3 NM of dexamethasone was added to cell cultures 16-24 hours prior to challenge with virus for optimal growth kinetics. For preparing viral plaques, 5 X 105 cells/well in 6 well plates are prepared and pre-induced with the same concentration of dexamethasone CA 02359795 2001-07-12 pCT~, P00/00265 the day prior to infection with 0.5 NM included at a final concentration in the agar overlay after infection.
F. Development of Cell Lines for Complementation of E1%E2a- Vectors This example shows the construction of S.8 cells The Adenovirus 5 genome was digested with Scal enzyme, separated on an agarose gel, and the 6,095 by fragment comprising the left end of the virus genome was isolated. The complete Adenovirus 5 genome is registered as Genbank accession #M73260, incorporated herein by reference, and the virus is available from the American Type Culture Collection, Manassas, Virginia, U.S.A., under accession number VR-5. The Scal 6,095 by fragment was digested further with Clal at by 917 and Bglll at by 3,328. The resulting 2,411 by Clal to Bglll fragment was purified from an agarose gel and ligated into the superlinker shuttle plasmid pSE280 (Invitrogen, San Diego, CA), which was digested with Clal and Bglll, to form pSE280-E. (Figure 23).
Polymerase chain reaction (PCR) was performed to synthesize DNA encoding an Xhol and Sall restriction site contiguous with Adenovirus 5 DNA by 552 through 924. The primers which were employed were as follows:
5' end, Ad5 by 552-585:
5'-GTCACTCGAGGACTCGGTC-GACTGAAAATGAGACATATTATCTGCCACGGAC
C-3' (SEQ ID NO: 66) 3' end, Ad5 by 922-891:
5'-CGAGATCGATCACCTCCGGTAGAAGGTTTGGCATAG-3' (SEQ ID NO: 67) This amplified DNA fragment (sometimes hereinafter referred to as Fragment A) then was digested with Xhol and Clal, which cleaves at the native Clal site (bp 917), and ligated to the Xhol and Clal sites of pSE280-E, thus reconstituting the 5( end of the E1 region beginning 8 by upstream of the ATG codon.
PCR then was performed to amplify Adenovirus 5 DNA from by 3,323 through 4,090 contiguous with an EcoRl restriction site. The primers which were employed were as follows:
5' end, Ad5 by 3323-3360:
5'-CATGAAGATCTGGAAGGTGCTGAGGTACGATGAGACC-3' (SEQ ID NO: 68) 3' end, Ad5 by 4090-4060:

_ 79 _ 5'-GCGACTTAAGCAGTCAGCTG-AGACAGCAAGACACTTGCTTGATCCAAATCC-3 ' (SEQ ID NO: 69) This amplified DNA fragment (sometimes hereinafter referred to as Fragment B) was digested with Bglll, thereby cutting at the Adenovirus 5 Bglll site (bp 3,382) and EcoRl, and ligated to the Bglll and EcoRl sites of pSE280-AE to reconstruct the complete E1 a and E1 b region from Adenovirus 5 by 552 through 4,090. The resulting plasmid is referred to as pSE280-E1 (Figure 23).
A construct containing the intact E1 alb region under the control of the synthetic promoter GRE5 was prepared as follows. The intact E1 a/b region was excised from pSE280-E1, which was modified previously to contain a BamHl site 3' to the E1 gene, by digesting with Xhol and BamHl. The Xhol to BamHl fragment containing the E1a/b fragment was cloned into the unique Xhol and BamHl sites of pGRES-2/EBV
(Figure 4, U.S. Biochemicals, Cleveland, Ohio) to form pGRES-E1 (Figure 24).
Bacterial transformants containing the final construct were identified.
Plasmid DNA was prepared and purified by banding in CsTFA prior to use for transfection of cells.
Construction of plasmid including Adenovirus 5 E2A sequence.
The Adenovirus 5 genome was digested with BamHl and Spel, which cut at by 21,562 and 27,080, respectively. Fragments were separated on an agarose gel and the 5,518 by BamHl to Spel fragment was isolated. The 5,518 by BamHl to Spel fragment was digested further with Smal, which cuts at by 23,912. The resulting 2,350 by BamHl to Smal fragment was purified from an agarose gel, and ligated into the superlinker shuttle plasmid pSE280, and digested with BamHl and Smal to form pSE280-E2 BamHl-Smal (Figure 26).
PCR then was performed to amplify Adenovirus 5 DNA from the Smal site at by 23,912 through 24,730 contiguous with Nhel and EcoRl restriction sites. The primers which were employed were as follows:
5' end, Ad5 by 24,732-24,708:
5'-CACGAATTCGTCAGCGCTTCTCGTCGCGTCCAAGACCC-3' (SEQ ID NO: 70) 3' end, Ad5 by 23,912-23,934:
5'-CACCCCGGGGAGGCGGCGGCGACGGGGACGGG-3' (SEQ ID NO: 71 ) This amplified DNA fragment was digested with Smal and EcoRl, and ligated to the Smal and EcoRl sites of pSE280-E2 Bam-Sma to reconstruct the complete E2a region from Ad5 by 24,730 through 21,562. The resulting construct is pSE280-E2a.
(Figure 27.) In order to convert the BamHl site at the 3' end of E2a to a Sall site, the E2a region was excised from pSE280-E2a by cutting with BamHl and Nhel, and recloned into the unique BamHl and Nhel sites of pSE280. (Figure 6.) Subsequently, the E2a region was excised from this construction with Nhel and Sall in order to clone into the Nhel and Sall sites of the pMAMneo (Clonetech, Palo Alto, CA) multiple cloning site in a 5' to 3' orientation, respectively. The resulting construct is pMAMneo E2a. (Figure 27).
Bacterial transformants containing the final pMAMneo-E2a were identified.
Plasmid DNA was prepared and purified by banding in CsTFA. Circular plasmid DNA was linearized at the Xmnl site within the ampicillin resistance gene of pMAMneo-E2a, and further purified by the phenol/chloroform extraction and ethanol precipitation prior to use for transfection of cells.
Transfection and selection of cells.
In general, this process involved the sequential introduction, by calcium phosphate precipitation, or other means of DNA delivery, of two plasmid constructions each with a different viral gene, into a single tissue culture cell. The cells were transfected with a first construct and selected for expression of the associated drug resistance gene to establish stable integrants. Individual cell clones were established and assayed for function of the introduced viral gene.
Appropriate candidate clones then were transfected with a second construct including a second viral gene and a second selectable marker. Transfected cells then were selected to establish stable integrants of the second construct, and cell clones were established.
Cell clones were assayed for functional expression of both viral genes.
In order to determine the most suitable cell lines for the above-mentioned transfections, sequential transfections and selections were carried out with the following parental cell types:
A549 (ATCC Accession No. CCL-185);
Hep-2 (ATCC Accession No. CCL-23); or KB (ATCC Accession No. CCL-17).
Appropriate selection conditions were established for both 6418 and hygromycin B for all three cell lines by standard kill curve determination.
Transfection of cell lines with plasmids including E1 and E2a regions.
pMAMNeo-E2a was linearized with Xmnl with the AmpR gene, introduced into cells by transfection, and cells were selected for stable integration of this plasmid by 6418 selection until drug resistant colonies arose. The clones were isolated and screened for E2a expression by staining for E2a protein with a polyclonal antiserum, WO 00/42208 CA 02359795 2001-07-12 pCT~, P00/00265 and visualizing by immunofluorescence. E2a function was screened by complementation of the temperature-sensitive mutant Ad5ts125 virus which contains a temperature-sensitive mutation in the E2a gene. (Van Der Vliet, et al., J.
Virology, Vol. 15, pgs. 348-354 (1975)). Positive clones expressing the E2a gene were identified and used for transfection with the 7 kb EcoRV to Xmnl fragment from pGRES-E1 (Figure 5), which contains the GRE5 promoted E1 alb region plus the hygromycinR gene. Cells were selected for hygromycin resistance and assayed for E1 a/b expression by staining with a monoclonal antibody for the E1 protein (Oncogene Sciences, Uniondale; N.Y.). E1 function was assayed by ability to complement an E1-deleted vector. At this point, expression and function of E2a was verified as described above, thus establishing the expression of both E1a/b and E2a in the positive cell clones.
One of the transfected A549 cell lines showed good E1 a/b and E2a expression and was selected for further characterization. It was designated the S8 cell line.
G. Preparation of Adenoviral Vectors Containing Ad5.~3gaI.~F Genome in S8 Improved Fiber-Complementing Cell Lines To prepare adenoviral vectors containing AdS.~gaI.OF in S8 cells containing alternative forms of TPL for enhancing the expression of fiber proteins, the protocol as described in Example 2 for preparing AdS.~igaI.OF in 211 B cells was followed with the exception of pretreatment with 0.3 pM dexamethasone for 24 hours as described above. Thus, viral particles with the wildtype Ad5 fiber protein on their surface and containing the fiberless AdS.~gaI.OF genome were produced in 633 cells. Particles produced in 644 cells also contained the fiberless AdS.agaI.OF
genome, but had the chimeric 5T3H fiber protein, with the Ad3 fiber knob, on their surface.
The preparation of the cell lines and demonstration of stable nuclear expression of either wild-type Ad5 fiber protein or chimeric Ad5/Ad3 protein is shown in Figure 20. In the figure, schematic diagrams are presented of the constructs used to generate the cell lines as well as immunofluorescence results indicating the presence of expressed fiber protein in the nucleus of the cells. An indirect immunofluorescence assay of A549 based cell lines which stably express the different Ad fibers is shown. Line 633 expresses the native Ad5 fiber protein and line 644 expresses a chimeric fiber protein with the tail and shaft domains of the Ad5 protein and the knob domain of the Ad3 fiber. Previous work (Stevenson et al., 1996) showed that a virus containing this protein had the tropism expected for Ad3.
Thus, these viral preparations, prepared as described herein and in Example 2, are useful for targeting delivery of Ad5.~3gaI.OF fiberless genome with either wild-type or modified fibers, embodiments of which uses have been previously discussed and as further exemplified with the pseudotyping and infectivity results described in Example 7.
Example 7 Pseudotyping and Infectivity of Recombinant Adenoviral Vectors Produced with Improved Fiber-Complementing Cell Lines A. Pseudotyping of Ad5.~3gaI.OF
To verify that adenoviral vectors were produced had altered tropisms, viral particles were purified from either 633 (expressing wilt type Ad5 fiber) or 644 cells (expressing the chimeric Ad5/Ad3 fiber) l0p.g of the purified particles were Western blotted and probed with a polyclonal rabbit antibody against the Ad2 fiber (which detects both the Ad5 and chimeric 5T3H fiber proteins.). Equal amounts of purified Ad.~igal.wt or Av9LacZ ( which has the chimeric fiber gene in the viral chromosome) were run as controls. The results are shown in Figure 21 where both fiber proteins were detectable confirming pseudotyping.
B. Infectivity of Cells with 633 or 644 Generated Virus Particles The cell lines, 633 or 644, prepared as described above, were infected with the indicated number of particles/cell of Ad5.~3gaI.OF and virus particles produced.
Virus was then used to infect, as previously described, selected cell lines as shown in Figure 22, including 211 B, MRC-5 human fibroblasts, A-10 rat aortic endothelial cells, and THP-1 human monocytic cells. Unbound virus was removed by washing the cells and the cells were further incubated at 37°C for 48 hours.
Cells were then fixed with glutaraldehyde and stained with X-gal. The percentage of stained cells was then determined by light microscopy where all experiments were done in triplicate.
The results shown in Figure 22 indicate that adenoviral vectors could be retargeted by pseudotyping using packaging cell lines expressing different fiber WO b0/42208 PCT/EP00/00265 proteins. The data marked with "none" indicates virus grown in 293 cells and lacking fiber, while "Ad5" indicates virus prepared in 633 cells (containing the wild type fiber) and Ad3 indicates virus prepared in 644 cells (containing the chimeric 5T3H
fiber.) Particles containing either fiber were equally infectious on 211 B cells, while MRC-5 fibroblasts and THP-1 cells were more readily infected by virus containing the chimeric fiber. The A-10 rat endothelial cells were more readily infected by particles containing the wildtype Ad5 fiber protein.
Example 8 Targeted Gene Delivery Using Viral Vector Particles Lacking Fiber Protein An alternative mode of entry for adenoviral infection of hematopoietic cells has been described by Huang, et al., J. Virol., 69:2257-2263 (1995) which does not involve the fiber protein-host cell receptor interaction. As infection of most other cell types does require the presence of fiber protein, vector particles which lack fiber may preferentially infect hematopoietic cells, such as monocytes or macrophages.
To produce a fiber-free adenovirus vector particle, a vector lacking the fiber gene as described above in Example 2A but containing a gene of interest for delivery is amplified by growth in cells which do not produce a fiber protein, such as the 211 cells prepared in Example 1 or 293 or S8 cells as described herein, thereby producing large numbers of particles lacking fiber protein. The recovered fiber-free viral particles are then used to deliver the inserted gene of interest following the methods of this invention via targeting mechanisms provided by other regions of the adenoviral vector, i.e., via the native penton base.
A. Construction of an Adenovirus Vector Deleted for E1, E3, and Fiber, and Carrying a Therapeutic Gene of Interest A general method of constructing a fiber-deleted Ad vector containing a therapeutic gene of interest (in this example, the Herpes Simplex Virus Thymidine Kinase (TK) gene) is described here. Linear viral DNA is isolated from a preparation of AdS.~igaI.OF particles. This DNA is digested with the restriction enzyme Clal, which removes the leftmost viral sequences including the left ITR, the packaging signals, and part of the SV40-driven ~3-galactosidase gene. The large Clal fragment with the remainder of the fiber-deleted viral genome is then isolated by centrifugation on a sodium chloride or sucrose gradient. The plasmid pAdShuttIeTK, which contains the left part of the Ad chromosome with an RSV-driven TK gene inserted in place of the E1 region, is linearized by digestion with Notl. The nucleotide sequence of the pAdShuttIeTK is shown in SEQ ID NO: 50. The large Clal fragment of AdS.~gaI.OF and the linearized pAdShuttIeTK are cotransfected into 211 B cells, and an infectious adenovirus genome is generated by homologous recombination. A virus deleted for E1, E3, and fiber that contains the TK
cassette in the place of the E1 deletion is thus recovered. A virus containing any desired therapeutic gene of interest can be created in this manner by replacing the TK
gene of the example with the gene of interest.
An alternative method of constructing a fiber-deleted genome containing a therapeutic gene (in this example the retinal degeneration-slow (RDS) gene driven by the CMV immediate early promoter) is described here. RDS is a protein expressed in photoreceptors, and essential for their proper development and functioning. RDS mutations have been implicated in retinal degenerative disorders, and transfer of the wildtype RDS gene by means of an Ad vector provides an avenue towards treating such disorders.
A plasmid (pDV50) analogous to p0E1 B~gal but containing a CMV-driven RDS gene was constructed as follows. First, a fragment containing the CMV
promoter and enhancer was excised from pCHaMIEP by digestion with Hindlll, filling the overhanging ends with the large fragment of E. coli DNA polymerase 1, ligation of BamHl linkers (5'CGCGGATCCCG3' SEO ID NO: 51) to the blunt ends, and digesting with BamHl. The resulting fragment was then ligated into the BamHl site of p0E1 sp1 a (Mikrobix) to create pDV45. A fragment containing the SV40 polyadenylation signal was amplified from pSV~3gal (Promega) using the oligonucleotides 5'CTGACAAACTCAGATCTTGTTTATTG3' (SEQ ID NO: 51 ) and 5'GTCGACTCTAGAGGATCCAGA3' (SEQ ID NO: 52). This fragment was ligated into the Bglll site of pDV45 to create pDV46, using the unique BamHl and Bglll sites (bold type) in the primers. Finally, the human RDS open reading frame was amplified from the plasmid pRDS-T7 using the oligonucleotides 5'CCGGACTCT
AGATGGCAACCATGGCGCTAC3' (SEQ ID NO: 53) and 5'GGA
GGGGAAGCTTGGCCCTCAGCCAGCCTCT3' (SEQ ID NO: 54). This fragment was inserted into the Hindlll and Xbal sites of pDV46, again using unique restriction sites in the primers, to create pDV50. pDV50 therefore contains a cassette WO b0/42208 PCT/EP00/00265 consisting of the CMV promoter, the RDS open reading frame, and the SV40 terminator sequences inserted in place of the Ad5 E1 region.
In a manner analogous to the construction of Ad5.~3gaI.OF , pDV50 and pDV44 are then co-transfected into 211 B cells, and an infectious Ad genome (AdS.RDS.OF) is recovered. A fiber-deleted Ad vector containing any desired gene to be expressed can be constructed by replacing the RDS gene of this example with the gene of interest.
Example 9 Transient Transcomplementation Human adenovirus type 5 (Ad5) is being developed as a vector for gene therapy. Its ability to deliver therapeutic genes to cells is mediated by the interaction of the adenoviral fiber protein with the coxsackievirus-adenoviral receptor (CAR).
Because a wide-range of cells express CAR, it can be difficult to use adenoviruses to deliver genes to specific cell types. One way to address this is to target the virus to a particular cell type by genetically altering the fiber. However, the genetic manipulations involved in cloning and production of the viruses with altered fibers can be time-consuming. Thus it would be a significant advancement in the field of adenoviral gene therapy to have a more streamlined system for testing modified fiber genes. An in vitro system has thus been developed that involves infection of tissue culture cells with a fiber-deleted Ad and transient co-transfection with a plasmid directing fiber expression. This system allows one to produce and evaluate such modified fibers in the context of a viral particle easily and quickly. In addition this system can be envisioned to actually produce therapeutic quantities of adenoviral vectors with modified fiber proteins, with such fibers having a new tropism added by insertion of a desired ligand into the fiber gene. These fibers may also have the natural tropism (i.e. binding to CAR) ablated.
Plasmids used were pDV60 and pDV55, prepared as described herein.
pDV60 is an pcDNA3.1-based expression plasmid that contains the CMV promoter, Ad5 tripartite leader, an intron, and the Ad5 fiber gene sequence. pDV55 contains no fiber gene and serves as the negative control. Ad5.~3gaI.~F and 211 B are described above. 293T cells are identical to 293 cells except they express an integrated SV40 large T antigen gene. HDF cells are human diploid fibroblasts.
293T cells express CAR and o~, integrins; HDF cells express a~, integrins but no CAR. Transfections with fiber expression plasmids were performed with Lipofectamine (GIBCO-BRL) using 20mg DNA and 50m1 Lipofectamine per l5cm dish. Cells were maintained in DMEM supplemented with 10% fetal bovine serum.
The fiber deletion mutation of AdS.~gaI.OF is complemented in traps by passaging virions through 211 B, a cell line that stably expresses functional Ad5 fiber. The present system was designed to complement Ad5.~3gaI.OF by modified fibers expressed from transfected episomal plasmids in 293T cells. The result is a simplified and rapid method to incorporate modified fibers on a viral particle containing the Ad5.~3gaI.OF genome that does not require propagation of the virus.
The feasibility of transcomplementation of AdS.~igaI.OF with episomal fiber-expressing plasmids was demonstrated in the following experiment. 293T
cells were transfected with one of two plasmids: pDV55, which expresses no fiber or pDV60, which expresses wildtype Ad5 fiber. Fiber expression persists for at least six days, suggesting that the plasmid is stable as an episome for this amount of time Twenty-four hours after transfection, these cells were infected at 2000 particles/cell with AdS.~gaI.~F passaged through 211 B cells. Seventy-two hours later, a crude viral lysate (CVL) was generated by exposing the cells to five freeze-thaw cycles.
Viral particles were purified by cesium chloride gradient centrifugation. The resulting virions incorporated the fiber expressed from the episomal plasmid, as confirmed by Western blots performed with an antibody specific to the Ad5 fiber.
To demonstrate the functionality of these virions, the transduction efficiency was tested. The virions containing no fiber (pDV55) or wildtype fiber (pDV60) were applied to monolayers of 293T and HDF cells at different multiplicity of infection (MOTs). 293T cells express CAR and a a"'integrins; HDF cells express a"
integrins but no CAR. After 2 days, the cells were fixed and stained with X-gal to detect the ~galactosidase reporter gene activity. The results showed low transduction efficiency for the pDV55-complemented virions in both cell lines. As expected, the pDV60-complemented virions transduced 293T cells to a high degree but did not transduce HDF cells, indicating that functional fiber proteins had been expressed from the episomal plasmids and incorporated into the virions. This transduction efficiency was comparable to or better than that of Ad5.~3gaI.OF virions passaged through the 211 B cells.
Episomal plasmid transcomplementation system is suitable for quickly expressing and evaluating the properties of modified fibers in the context of a viral particle. Episomal plasmid transcomplementation will also be of great utility for quickly evaluating a bank of modified fibers for other binding properties, including novel tropism and the ablation of the native tropism. In addition to the rapid generation and testing of large numbers of modified fibers, there are other advantages to the AdS.~igaI.OF transcomplementation system in terms of production and safety. Episomal plasmid transcomplementation has the inherent advantage over transcomplementation in that it is not necessary to make a stable cell line for every modified fiber with which you want to complement AdS.~igaI.OF . Because the AdS.~igaI.OF is deleted in E1, E3 and fiber, there is an additional gene deletion compared to other first generation vectors. This makes Ad5.~3gaI.OF more replication defective and presumably safer. In addition, the presence of the fiber gene deletion decreases the opportunity to generate replication-competent virus via recombination in the packaging cells. In terms of production a single Ad vector prep could be retargeted to any number of different cell types simply by transfecting the cells with the appropriate fiber-expression construct.
Example 10 Adenoviral Gene Delivery Vectors Containing the Ad37 Fiber Protein Adenovirus type 37 (subgroup D) has been associated with infections of the eye and genital tract, and may be useful for targeting these tissues or other mucous membranes, as well as other cell types. The tropism of Ad37 is due to the binding preference of its fiber protein, which binds to an as yet-unidentified receptor located on the surface of cells including Chang C, conjunctival epithelial cell line (Huang et al., J. Virology 73(4):2798-2802 (1999)). As this fiber directs viral infection to cell types different than those infected by AdS, it is likely to provide a method for targeting gene delivery. This example describes construction of packaging cell lines expressing the Ad37 fiber protein, and their use in generating particles of a fiber-deleted Ad vector (such as AdS.~igaI.OF ) containing this fiber protein. The fiber protein is attached to the viral capsid by binding to the penton base protein through its N-terminus, and the Ad37 fiber was modified in order to make its N-terminal sequence more closely match that of the Ad5 protein to ensure that it would efficiently bind the Ad5 penton base in these vectors.
1. Construction of an Expression Plasmid for the Ad37 Fiber Protein (pDV80) This plasmid uses the same regulatory elements as contained in pDV60, pDV67, and pDV69 to express the Ad37 fiber in packaging lines, and was constructed in two steps. First, the Ad37 fiber open reading frame was amplified from Ad37 genomic DNA (obtained from the ATCC - accession number VR-929)using the synthetic oligonucleotides primers L37 (5' TGT CTT GGA TCC AAG
ATG AAG CGC GCC CGC CCC AGC GAA GAT GAC TTC 3') (SEQ ID NO: 56) and 37FR (5' AAA CAC GGC GGC CGC TCT TTC ATT CTT G 3') (SEQ ID NO: 57). L37 contains nucleotides that differ from the Ad37 genomic sequence in order to add an unique Bam H1 site (bold in the above sequence) and create point mutations to make the N-terminal sequence of the fiber more closely match that of the Ad6 protein (underlined in the above sequence; the start codon is italicized).

incorporates changes to create a unique Not 1 site (bold). The PCR product was inserted into the Bam H1 and Not 1 sites of pCDNA3.izeo(+) (Invitrogen) to create pDV78. The correct sequence of the Ad37 fiber gene, including the predicted changes, was confirmed by sequencing.
Second, a 1.2 kb Bam H1/Bgl II fragment containing an adenovirus type 5 tripartite leader was excised from pDV55 (DVS 1999) and inserted into the Bam site of pDV78 to create pDV80 (SEQ ID N0:64) 2. Isolation of Cell Lines Expressing the Ad37 Fiber Protein pDV80 DNA was purified using the Qiagen method and electroporated into the adenovirus-complementing cell line E1-2a S8 (Gorziglia et al., J. Virology 70(5):4173-4178 (1996)) as previously described (Von Seggern, et al., J. Gen.
Virol.
79:1461-1418), and stable clones were selected with 600 Ng/ml zeocin (Invitrogen).
Clones were expanded and screened for fiber expression by indirect immunofluorescence using a rabbit polyclonal antibody directed against the Ad37 fiber. Two clones (lines 705 and 731) that expressed the protein at a uniformly high level were selected for further study.
3. Production of Pseudotyped Ad Vector Particles To generate vector particles equipped ('pseudotyped') with the Ad37 fiber protein, the Ad37 fiber-expressing 705 cells were infected (approximately 1000 particles/cell) with AdS.~igaI.OF or with AdS.GFP.OF.

AdS.~gaI.OF is prepared as previously described. AdS.GFP.OF was constructed by recombination in bacteria using a modification of the method of (He, et al., PNAS 95:2509-2514 (1998)). First, a fiber-deleted genomic plasmid was constructed by removing the fiber gene from pAdEasyl (He, et al., PNAS 95:2509-2514 (1998)). pDV43 (Von Seggern, et al., J. Virol. 73:1601-1608 (1999)) was digested with Pac 1, the ends blunted by treatment with the large fragment of E. coli DNA polymerase and dNTPs, and the product re-ligated. The resulting plasmid, pDV76, is identical to pDV43 except for loss of the Pac 1 site and contains the right end of the Ad5 genome with E3 and fiber deletions. A 4.2 kb fragment was amplified from pDV76 using the oligonucleotides primers 5' CGC GCT GAC TCT TA GGA
CTA GTT TC 3' (SEQ ID NO: 58) (including the unique Spe 1 site in the Ad5 genome, bold) and 5' GCG CTT AAT TAA CAT CAT CAA TAA TAT ACC TTA TTT T
3' (SEQ ID NO: 59) (including a novel Pac 1 site (bold) adjacent to the right Ad5 ITR). This PCR fragment therefore contains nucleotides 27,082 to 35,935 of the Ad5 genome with a deletion of nucleotides 28133 to 32743 (the E3 and fiber genes), and was used to replace the corresponding Spe 1/Pac 1 fragment of PAdEasyl to create pDV77.
E. coli strain BJ5183 was electroporated with a mixture of pDV77 and Pme 1-linearized pAdTrack as described (He et al., 1998), and DNA was isolated from kanamycin-resistant colonies. The resulting plasmid, pDV83, contains a complete E1-, E3-, and fiber-deleted Ad5 genome with a CMV-driven GFP reporter gene inserted at the site of the E1 deletion. The full-length Ad chromosome was isolated by Pac 1 digestion, and transfected to the E1- and fiber-complementing 633 cells (Von Seggern et al., J. Virol January 2000). The recovered virus was then plaque purified by plating on 633 cells and stocks were prepared.
Ad5-pseudotyped particles were generated by virus growth in 633 cells, which express the wild type Ad5 fiber protein. Viral particles were isolated and purified over CsCI gradients as previously described (Von Seggern et al., J. Virol.
73:1601-1608, 1999). For analysis of viral proteins, ten Ng of the purified particles were electrophoresed on 8-16% gradient gels and the protein transferred to nylon membranes. The blot was then probed with rabbit polyclonal antibodies raised against recombinant Ad37 fiber or Ad5 fiber or penton base proteins expressed in baculovirus-infected cells (Figure 27).
Example 11 Construction of a Fiber Expression Construct Containing a Post-Transcriptional Regulatory Element Previous studies have shown that mRNA transcribed from the woodchuck hepatitis virus (WHV) genome contains an element (the WHV post-transcriptional regulatory element, or WPRE) which can increase expression of a protein encoded by the mRNA via a post-transcriptional mechanism (Loeb et al., Human Gene Therapy 10:2295-2305 (1999)). The WPRE has also been shown to enhance expression of transgenes delivered by retroviral vectors. (Zufferey, R. et al., J. Virol.
73:2886-2892 (1999)). This example describes the construction of a fiber expression construct (pDV90) containing a WPRE as well as the promoter and TPL
sequences as contained in pDV67.
A plasmid (pBS/WPRE) which contains the WPRE was obtained from Dr.
Thomas Hope, Salk Institute. Digestion of pBS/WPRE with CIa1 releases a 600 by fragment containing the WPRE (nt 193-1684 of the WHV genome.) Following CIa1 digestion, the ends of this fragment were filled by treatment with the large fragment of E, coli DNA polymerase 1 in the presence of dNTPs to render them blunt.
pDV67 DNA was digested with Xba1 (which cuts at a unique site in the transcribed region downstream of the Ad5 fiber open reading frame) and the ends filled by the same treatment. The filled WPRE fragment was then ligated into the filled Xba 1 site of pDV67 to create pDV90 (SEQ ID NO: 65). The sequence is found at GenBank accession no. J04514 (entire genome) in Zufferey, R. et al., J. Virol. 73:2886-(1999).
pDV90 was electroporated into E1-2a SS cells and stable clones expressing fiber isolated as described previously for pDV80.
Example 12 Construction of an Ad5 Fiber Protein with Heterologous Peptide Sequences Inserted in the HI Loop The receptor-binding knob domain of the Ad5 fiber protein contains several surface loops which are attractive candidates for the insertion of heterologous peptide sequence, as an additional ligand for vector targeting. This example describes the construction of a fiber gene which encodes a fiber protein containing a 6 amino acid peptide linker in the HI loop, and retains the ability to trimerize. The modified gene also contains a unique novel restriction site at the position of the linker insertion to facilitate addition of the targeting ligand into the HI
loop.
The Ad5 fiber gene was amplified from Ad5 genomic DNA (ATCC accession number VR-5) using the primers Fiber ATG (5' TGA AGC GCG CAA GAC CGT CTG
AAG 3') (SEQ ID NO: 60) and Fiber TAA (5' CAT AAC ACT GCA GAT TCT TTA
TTC TTG G 3') (SEQ ID NO: 61 ), and cloned to the Nde1 (filled with the large fragment of E. coli DNA polymerase 1 in the presence of dNTPs) and Pst 1 sites of pT7-7 using a unique Pst 1 site (bold) in the 'Fiber TAA' oligo. The resulting plasmid, pT7/fiber, was digested with Xba 1 and Pst 1 to excise the fiber gene, which was then cloned into the Pst 1 and Xba 1 sites of pUC119 to create pUC/fiber.
This pUC-derived plasmid contains an origin for single-stranded DNA replication and can therefore be used to create template DNA for site-directed mutagenesis.
Site-directed mutagenesis was carried out according to the method of Kunkel (T.A. Kunkel, PNAS 82:488-492 (1985)) using the oligonucleotide primer T542 (5' GGT ACA CAG GAA ACA GGA GGT TCC GGA GGT GGA GGA GAC ACA ACT CC
3') (SEQ ID NO: 62). This results in the addition of 18 new bases (underlined) encoding the sequence Gly Gly Ser Gly Gly Gly (SEQ ID NO: 63), with a novel BspEi site (bold) for the addition of further sequences. The inserted sequence is between Thr542 and GIy543 of the Ad5 fiber protein, in the HI loop. The modified plasmid is termed pDVl4.
Finally, the modified fiber gene was excised from pDVl4 by digestion with Pst 1 and Xba 1 and cloned into the Pst 1 and Xba 1 sites of pGEM3Z (Promega) to create pDVl8. In vitro transcription/translation experiments with pDVl8 (using the TNTT"" kit, Promega) demonstrated that the modified fiber gene encoded a protein which was capable of trimerizing.
Alternatively an Ad5 fiber open reading frame (ORF) is amplified from Ad5 genomic DNA (wildtype Ad5 was purchased from the ATCC) using the oligonucleotides 5' ATG GGA TCC AAG ATG AAG CGC GCA AGA CCG 3' (SEQ ID
NO: 72) and 5' CAT AAC CTG CAG GAT TCT TTA TTC TTG GGC 3' (SEQ ID N0:,73) and inserted into the BamM and Psf 1 sites of pGEM-3Zf(+) (Promega Inc., Madison, WI) via novel restriction sites (bold type) designed into the primers. The 5' oligonucleotide also contains a G to A change 3 nucleotides 5' of the initial ATG
codon (underlined), designed to improve the consensus for translation initiation.
Site-directed mutagenesis is performed by the method of Kunkel (Proc. Nat.
Acad. Sci. 82:488-492 (1985)), using the synthetic oligonucleotide 5' GGT ACA
CAG
GAA ACA GGA GGT TCC GGA GGT GGA GGA GAC ACA ACT CC 3' ((SEQ ID

NO: 74). This operation introduced sequence (bold type) encoding 6 novel amino acids (Gly Gly Ser Gly Gly Gly) immediately following Threonine 542 of the Ad5 fiber, and including a unique restriction site for the insertion of further heterologous sequences (underlined). The resulting plasmid (pDVl8A) contains the modified fiber gene under the control of the T7 promoter in the parental pGEM-3Zf(+) and can be used for in vitro transcription/translation reactions to produce labeled fiber protein.
Example 13 Use of the Fiber Expression System to Retarget ('Pseudotype') Hybrid Ad/AAV Vectors Adenoviral vectors which lack essentially all Ad genes ('helper-dependent' or 'gutless' vectors) have recently been developed. In a modification of this idea, vectors ('hybrid' vectors) which contain an adeno-associated virus (AAV) or retroviral genome have been generated. As AAV and retroviral genomes integrate into the chromosome of the target cells, the hybrid Ad/AAV or Ad/retroviral vectors have the potential to provide very long-term gene expression.
Lieber et al., (J. Virol. 73(11):9314-9324) describe an Ad vector (Ad.AAV1) which contains an AAV vector genome (a transgene insert flanked by the AAV
inverted terminal repeats) inserted into the E1 region. When 293 cells are infected by Ad.AAV1, recombination between the AAV sequences generates a minimal Ad chromosome which carries the Ad inverted terminal repeats and packaging signal flanking the AAV vector genome. This chromosome cannot direct the synthesis of Ad proteins, but can be packaged into Ad vector particles. The remaining unrecombined Ad chromosomes provide the Ad structural proteins in trans, and both the full-length and minimal genomes are packaged into particles. The particles carrying the minimal Ad/AAV hybrid vector are then isolated by CsCI
centrifugation.
These particles have the capsid structure of adenovirus, and infect cells using the efficient fiber- and penton base-mediated pathway used by Ad. Following infection, the hybrid genome is able to integrate into the cell's chromosomes by virtue of its AAV sequences. In this example, the AAV vector genome is inserted into the E1 region of a fiber-deleted vector, and the resulting vector is grown in packaging lines expressing either the Ad5 or Ad37 fiber proteins. The particles recovered therefore have the tropisms expected from the respective fiber proteins combined with the ability to integrate their AAV genome into target cells.
Such pseudotyping should be possible with any of a number of modified fiber proteins, as for the fiber-deleted vectors already described by us.
The Ad vector is constructed in a manner analogous to that described for AdS.(igaI.OF , by recombination between pAd.AAV1 (Lieber et al. J. Virol.
73:9314-9324, 1999) and pDV44 (as described earlier in the specification.) pAd.AAV1 carries an MLV promoter-driven secreted alkaline phosphatase gene (SEAP) as a reporter, and an SV40-driven neomycin phosphotransferase (neo) gene to allow the selection of cells stable transduced by the AAV cassette. The resulting vector (Ad.AAVI.OF) has the AAV vector cassette of Ad.AAV1 inserted into the E1 region of a genome with the fiber deletion of AdS.~gaI.OF . Growth of Ad.AAVI.~F in cells results in particles carrying the AAV genome and the Ad5 fiber, and which have the tropism associated with AdS. Growth of Ad.AAVI.OF in 705 cells produces particles bearing the Ad37 fiber and therefore having its associated different tropism.
Tropism is evaluated by infecting Chang C cells (which express the Ad37 receptor) and A549 cells which do not express this protein but do express the Ad5 receptor (CAR). The extent of infection is monitored by assaying alkaline phosphatase expression, and the fraction of cells stable transduced is assayed by selection with neomycin. By using purified recombinant Ad5 or Ad37 fiber proteins as competitors during infection, the usage of the expected receptors by the pseudotyped particles is evaluated.
Example 14 Use of the Fiber Expression System to Retarget ('Pseudotype') Helper-dependent Ad Vectors Gutted Ad vectors are those from which most or all viral genes have been deleted. They are grown by co-infection of the producing cells with a "helper"
virus (such as using an E1-deleted Ad vector). The helper virus traps-complements the missing Ad functions, including production of the viral structural proteins needed for particle assembly. In one embodiment of this invention, the helper virus is a fiber-deleted Ad (such as that described in Von Seggern et al., J. Virol. 73:1601-(1999)). The vector is prepared in a fiber expressing cell line such as has been previously described by Von Seggern et al., J. Gen. Virol. 79:1461-1468 (1998), Von Seggern ef al., J. Virol. 74:354-362 (2000). All the necessary Ad proteins except fiber are provided by the fiber-deleted helper virus, and the particles are equipped with the particular fiber expressed by the host cells. A concern with gutted vectors has been contamination of a vector preparation with residual helper virus. As the helper virus in one aspect of this invention is deleted for both E1 and for fiber, it is more replication defective and therefore safer than those currently used.
A helper adenovirus vector gename and a gutless adenoviral vector genome are delivered to the packaging cells of the invention. The cells are maintained under standard cell maintenance or growth conditions, whereby the helper vector genome and the packaging cell together provide the complementing proteins for the packaging of the adenoviral vector particle. Such gutless adenoviral vector particles are recovered by standard techniques. The helper vector genome may be delivered in the form of a plasmid or similar construct by standard transfection techniques, or it may be delivered through infection by a viral particle containing the genome.
Such viral particle is commonly called a helper virus. Similarly, the gutless adenoviral vector genome may be delivered to the cell by transfection or viral infection.
The helper virus genome is preferably the fiberless adenovirus vector genome as disclosed herein. Preferably, such genome also lacks the genes encoding the adenovirus EiA and E1B proteins. More preferably, the genome further lacks the adenovirus genes encoding the adenovirus E3 proteins. Alternatively, the genes encoding such proteins may be present but mutated so that they do not encode functional E1 A, E1 B and E3 proteins. Furthermore, such vector genome may not encode other functional early proteins, such as E2A, E2B, and E4 proteins.
Alternatively, the genes encoding such other early proteins may be present but mutated so that they do not encode functional proteins.
The helper virus genome is used in conjunction with the packaging cell of the invention. As disclosed elsewhere herein, the packaging cell also provides proteins necessary for the complementation of the gutless vector so that an adenovirus particle containing the gutless vector genome may be produced. Thus, the packaging cell can provide wild-type or modified fiber protein as described herein.
Alternatively, the cell could package a fiberless particle which could be used by itself or to which exogenously provided fiber could be added as described elsewhere herein.
1n producing the gutless vectors, the helper virus genome is also packaged, thereby producing helper virus. In order the minimize the amount of helper virus produced and maximize the amount of gutless vector particles produced, it is preferable to delete or otherwise modify the packaging sequence in the helper virus genome, so that packaging of the genome is prevented or limited. Since the gutless vector genome will have a packaging sequence, it will be preferentially packaged.

One way to do this is to mutate the packaging sequence by deleting one or more of the nucleotides comprising the sequence or otherwise mutating the sequence to inactivate or hamper the packaging function. An alternative approach is to engineer the helper genome so that recombinase target sites flank the packaging sequence and to provide a recombinase in the packaging cell. The action of recombinase on such sites results in the removal of the packaging sequence from the helper virus genome. Preferably, the recombinase is provided by a nucleotide sequence in the packaging cell that encodes the recombinase. Most preferably, such sequence is stably integrated into the genome of the packaging cell. Various kinds of recombinase are known by those skilled in the art. The preferred recombinase is Cre recombinase, which operates on so-called lox sites, which are engineered on either side of the packaging sequence as discussed above. Further information about the use of Cr~-IoxP recombination is found in U.S. Pat. No. 5,919,676 and Morsy and Caskey, Molecular Medicine Today, Jan. 1999, pgs. 18-24, both incorporated herein by reference.
This example demonstrates how the fiber-expressing packaging lines can be used to generate pseudotyped particles of helper-dependent or'gutless' vectors with altered tropisms. As the gutless vectors lack many or all Ad genes, they must be grown as mixed cultures in the presence of a helper virus which can provide the missing functions. To date, such helper viruses have provided all Ad functions except E1, and E1 is complemented by growth in 293 cells or the equivalent.
The resulting virus particles are harvested, and the helper virus is typically removed by CsCI gradient centrifugation (the vector chromosome is generally shorter than the helper chromosome, resulting in a difference in buoyant density between the two particles).
An example of a gutless vector is pAdeRSVDys (Haecker et al., Human Gene Therapy 71907-1914 (1996)). This plasmid contains a full-length human dystrophin cDNA driven by the RSV promoter and flanked by Ad inverted terminal repeats and packaging signals. 293 cells are infected with a first-generation Ad which serves as a helper virus, and then transfected with purified pAd~RSVDys DNA. Both the helper Ad genome and the pAdORSVDys DNA are replicated as Ad chromosomes, and packaged into particles using the viral proteins produced by the helper virus.
Particles are isolated and the pAd~RSVDys-containing particles separated from the helper by virtue of their smaller genome size and therefore different density on CsCI
gradients.

To generate pseudotyped particles containing the pAdORSVDys genome, the vector is grown in either 633 or 705 cells and Ad5.~3gal.OF is used as a helper virus.
As in the published method, both the AdS.(igaLOF and AdORSVDys genomes replicate and are packaged into particles. The AdS.~gaI.OF h~lper provides all the essential Ad proteins except fiber, and the fiber protein is that produced by the cells (Ad5 fiber in 633 cells and Ad37 fiber in the case of 705 cells). The particles containing AdaRSVDys genomes are then isolated by centrifugation.
Tropism is evaluated by infecting Chang C cells (which express the Ad37 receptor) and A549 cells which do not express this protein but do express the natural Ad5 receptor (CAR). The extent of infection is assessed by immunofluorescence staining of the infected cells with an anti-dystrophin antibody. By using purified recombinant Ad5 and Ad37 fiber proteins as competitors during infection, the usage of the expected receptors by the pseudotyped particles is evaluated.
Example 15 Targeting EBV Infected B Cells There are a number of cell types, such as EBV-transformed B-lymphocytes, that are involved in human disease which are not transducible using standard Ad vectors. To address this problem 'pseudotyped' AdS.(igaL~F particles containing either the wildtype Ad5 fiber protein or a chimeric fiber with the receptor-binding knob domain of the adenovirus type 3 (Ad3) fiber were generated. (Von Seggem et al., J. Virol. January, 2000). The strategy used for targeting the B-cells should be broadly applicable for targeting gene delivery to other specific cell types.
Cells and Viruses. THP-1, MRC-5, FaDu, and A-10 cells were purchased from the ATCC. 211 B is a 293-derived cell line that expresses the wild-type Ad5 fiber protein (Von Seggem et al., J. Gen. Virol. 79:1461-1468 (1998)). E1- 2a (Gorziglia et al., J. Virvl. 70:4173-4178 (1996)) is an A549-derived cell line which complements adenoviral E1 and E2a functions. The JR, TO, and TL LCL lines were established as described (Huang et aL, Proc. Natl. Acad. Sci. 94:8156-8161 (1997) _97_ by EBV infection of lymphocytes from three normal donors. THP-1 and all LCL
lines were maintained in RPMI 1640 medium (Gibco) + 10% fetal calf serum (FCS) (Hyclone). 211 B, MRC-5, and A-10 cells were grown in DMEM + 10% FCS. E1-2a and its derivatives were grown in Richter's modified medium (BioWhitaker) +
10%
FCS. Peripheral blood mononuclear cells were isolated from normal human blood (General Clinical Research Center, Scripps Clinic) by sedimentation on Ficoll-Paque (Pharmacia) per the manufacturer's instructions. Wild type Ad2 and Ad3 were purchased from the ATCC. Construction of AdS.~igal.wt and AdS.~igal.~F (Von Seggern et al., J. Virol. 73:1601-1608 (1999)) has been previously described.
Av1 LacZ4 (Mitttereder et al., J. Virol. 70:7498-7509 (1996)) is a first-generation Ad5 vector containing an RSV-driven a-galactosidase reporter gene. Av9LacZ4 (Stevenson et al., J. Virol. 71:4782-4790 (1997)) is identical to Av1 LacZ4 except that the fiber gene in the vector chromosome was replaced by a recombinant gene encoding a chimeric fiber protein with the receptor-binding domain of the Ad3 fiber (Stevenson et al., J. virol. 69:2850-2857 (1995)). Accession numbers for the above are as follows. THP-1: TIB-202, MRC-5: CCL-171, FaDu: HTB-43, A-10: CRL-1476, Ad2: VR-846, Ad3: VR-3.
DNA constructs. The complete Ad5 tripartite leader contained in pDV67 and pDV69 was constructed by assembly of PCR fragments. pDV55 was constructed similar to Example 5. This plasmid contains a 1.2 kb Bam HIlBgI II fragment consisting of the first TPL exon, the natural first intron, and the fused second and third TPL exons. Finally, pDV60 was constructed by inserting this TPL cassette into the Bam HI site upstream of the Ad5 fiber gene in pcDNA3/Fiber (Von Seggern et al., J. Gen. Virol. 79:1461-1468 (1998)). pDV61 and pDV67 were then constructed similar to example 6.
The chimeric Ad3/Ad5 fiber gene was amplified from pGEM5T3H (Stevenson et al., J.Virol. 69:2850-2857 (1995) using the primers 5' ATG GGA TCC AAG ATG
AAG CGC GCA AGA CCG 3'(SEQ ID NO: 75) and 5' CAC TAT AGC GGC CGC ATT
CTC AGT CAT CTT 3' (SEQ ID N0:76) , and cloned to the Bam HI and Not I sites of pcDNA3.1/Zeo(+) via novel Bam HI and Not I sites (bold) engineered into the primers to create pDV68. Finally, the complete TPL fragment described above was then added to the unique Bam HI site of this plasmid to create pDV69.
Construction of Stable Cell Lines. E1-2a cells were electroporated as previously described (Von Seggern et al., J. Gen. Virol. 79:1461-1468 (1998)) with pDV61, pDV67, or pDV69, and stable lines were selected with 600 Ng/ml Zeocin (Invitrogen). Candidate clones were evaluated by immunofluorescence (Von Seggern et al., J. Gen. Virol. 79:1461-1468 (1998)) using a polyclonal antibody generated against the Ad2 fiber (Wickham et al., Cell 73:309-319 (1993). Those lines expressing the highest level of nuclear fiber expression were further characterized. Line 601 and 633 were produced by transfection of pDV61 and pDV67, respectively, and therefore express the wildtype Ad5 fiber. Line 644 contains pDV69 and expresses the chimeric 5T3H fiber.
Virus Growth and Analysis. Adenovirus stocks were prepared in the indicated cell lines, and plaque-titered on 633 cells essentially as described (Von Seggern et al., J. Virol. 73:1601-1608 (1999)). E1-2a cells (Gorziglia et al., J. Virol.
70:4173-4178 (1996). and their derivatives contain a dexamethasone-inducible construct for complementation of Ela. 601, 633, or 644 cells were therefore treated with 0.3 uM
dexamethasone for 24 hours prior to infection, and 0.5 NM dexamethasone was included in the overlay for plaque assays. Protein concentration of viral preparations was determined using the BioRad Protein Assay (BioRad) with purified bovine serum albumin as a standard. Particle number was calculated using the formula 1 Ng protein = 4 x 109 viral particles. Western blotting was performed as described (Von Seggern et al., J. Gen. Virol. 79:1461-1468 (1998)) using polyclonal rabbit antibodies raised against either the Ad2 (Wickham et al., Cell 73:309-(1993) or Ad3 fibers (Stevenson et al., J. Virol. 71:4782-4790 (1997).
Determination of infection and binding to receptor was performed using methods known to those of skill in the art. 2 x 105 cells in a total volume of were incubated with the indicated Ad preparation for three hours at 37 °C. Cells were then washed twice with fresh medium, and returned to 37 °C. Two days later, cells were fixed and stained with X-gal and counted by light microscopy as described (Von Seggern et al., J. Virol. 73:1601-1608 (1999)). For competition assays, cells were pre-incubated on ice for one hour with either recombinant Ad3 fiber (10 Nglml) purified from baculovirus or with a crude baculovirus lysate (100 Ng/ml) containing the recombinant Ad2 fiber protein (Wickham et al., Cell 73:309-319 (1997)).
Expression of oW integrins on cell surfaces was assayed by FACS assay using monoclonal antibodies (the gift of David Cheresh, TSRI) against either a"~33 (LM609) or a"~35 (P1 F6) as previously described (Huang et al., Proc. Natl. Acad. Sci.
USA
94:8156-8161 (1997)). For virus binding assays, CsCI-purified Ad2 or Ad3 was labeled with '251 using lodogen tubes (Pierce). Free iodine was removed by filtration with a PD-10 Sephadex column (Pharmacia). Cells (1 x 106 cells in a volume of NI either with or without a 100-fold excess of unlabeled virus) were rocked at 4 °C for WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 two hours with 1 x 106 cpm of the labeled virus, washed three times with PBS
and counted.
Altered in vitro tropism and infection of B lymphoid cell lines.
Experiments with genetically modified viruses showed that a number of different cell types are more readily infected through interaction with the Ad3 receptor than by the CAR-dependent pathway used by Ad5 (Stevenson et al., J.
Virol. 71:4782-4790 (1997)). In order to further evaluate the pseudotyping system, the ability of AdS.~igaI.OF carrying either the Ad5 or chimeric 5T3H fibers to infect several cell lines was assayed: FaDu (a head and neck tumor line), THP-1 monocytic cells, and MRC-5 fibroblasts were assayed. Consistent with the previous studies (Stevenson et al., J. Virol. 71:4782-4790 (1997)), use of the chimeric Ad5/Ad3 fiber protein increased infection of all of these lines at equal particle/cell ratios. In contrast, the rat smooth muscle cell line A-10 was infected somewhat more readily by Ad5- than by Ad3-pseudotyped particles.
Gene delivery to EBV-infected B cells could allow the development of therapies for a variety of lymphoproliferative disorders. For example, ex vivo purging of donor marrow to eliminate infected cells could reduce the risk of EBV-associated lymphoproliferative disease, and EBV-induced malignancies such as AIDS-associated lymphoma are also potential targets. However, neither B cells nor EBV-transformed lymphoblastoid cell lines (LCLs) are efficiently infected by Ad5-based vectors. As the tropism of Ad3-pseudotyped particles appeared to be somewhat broader, it was asked whether EBV-infected LCLs could be infected using this system. The ability of Ad3-pseudotyped particles to infect LCLs generated by EBV
infection of lymphocytes from three different normal human donors was tested.
In agreement with previous reports, there was little or no infection of these by particles carrying the Ad5 fiber. In contrast, virus particles equipped with the chimeric fiber protein were able to efficiently infect all of these lines. At equal particle/cell ratios, all LCLs examined were at least 10-fold more infectible using the Ad3 receptor.
Further studies were performed to correlate the efficiency of infection with the level of attachment and internalization receptors expressed by the cells. The three LCL lines tested all bound very low levels of radiolabeled Ad2 particles, indicating that they expressed little or no CAR. In contrast, all three were able to specifically bind labeled Ad3 particles. This result suggested that fiber receptor distribution was largely responsible for the increased infection of these cells by Ad3-pseudotyped particles. Selective gene delivery to EBV infected cells. The results above suggested that the minority of EBV-infected B cells present in donor marrow or peripheral blood would be preferentially infected by vectors using the Ad3 receptor.
To test this hypothesis, a mixing experiment with normal uninfected peripheral blood mononuclear cells (PBMCs) and EBV-infected cells was performed. JR-LCL cells were mixed at varying ratios with PBMCs isolated from a normal human donor, and the mixture was then infected with AdS.~igal.~F particles containing the 5T3H
fiber protein. No infection of normal PBMCs alone was detected. Moreover, the percent of total cells infected increased with the fraction of JR cells added. These experiments indicate that EBV-infected cells can be selectively infected in vitro by relatively short (3 hours) exposure to a retargeted Ad vector.
Example i6 Production of Adenovirus Vectors by Addition of Exogenous Fiber The production of fiberless viruses by growth in a complementing cell line may result in a preparation that also contains contaminating fiber genome resulting from recombination in the complementing cell lines. This disadvantage is eliminated by addition of exogenous fiber to a fiberless adenovirus vector.
Production of fiberless virus by standard methods may include a two-step preparation protocol. This has been described in the earlier examples and is briefly described here again as follows:
Step I - amplification of fiber containing fiberless virus (AdS/F-/F+ or AdS.agaI.OF - fiberless, but there is fiber on the surface, not encoded in genome) on 211 B cell line (which stably expresses fiber), followed by CsCI-purification and characterization.
Step II - preparation of virus particles lacking fiber (AdSF-) by infection of S.8 cell line with Ad5/F-/F+, followed by CsCI purification and characterization.
This produces a large stock of particles which do not contain fiber.
Step 1 is necessary because the infection efficiency of fiberless virus is extremely low, e.g. the dose of 20,000 particles/cell of Ad5/~ig F- gives only 10%
infected cells.
Contrary to the above, the production of fiberless virus by addition of exogenous fiber involves only a one-step protocol. The fiberless virus is amplified using the S.8 cell line with addition of exogenous fiber into infection media.
The amount of exogenous fiber necessary for production is very low, no more than 75ng of purified fiber required per roller bottle. If desired the process may be followed by CsCI purification. As mentioned above, one advantage to this protocol is that it should provide no chance for recombination of adenovector during preparation.
A 10 roller bottle (RB) preparation of fiberless virus was made using the above two-step procedure. The yield of adenovector was 6.6x10'2 particles -total Ad/~igalF-. A 1 RB preparation of fiberless adenovector was also made from the same initial material using a one-step procedure with exogenous fiber. The total yield was 2.5x10" particles - Ad5~galF- (one step procedure).
DNA was isolated from both preparations and a PCR assay for fiber contamination was performed. (Figure 28). The PCR assay was developed for detection of very low amounts of fiber contamination, as low as 10-'$g. PCR
assay showed much lower contamination for the preparation which was done by adding exogenous fiber (10-'Sg one-step procedure) vs. 10-$ two-step procedure).
Therefore, less contamination was obtained by simpler one-step approach.
Experiments were done using soluble purified fiber which does not have His-taq on the end (AdSFiber = 5F) and with His-taq on the end (AdSFiber His =
5FHis).
These experiments showed that addition of AdSFiber can dramatically increase transduction efficiency of fiberless adenovector by simply adding it exogenously to a fiberless vector. The presence of the His tag on the AdSFiberHis doesn't have any effect.
The results of these experiments suggest that the fiber is self-assembling with the fiberless vector. This self-assembled virus can then infect cell through the normal entry pathway. (Figure 29) Also, an experiment was done using conditioned media from 633 cell line, which can stably express fiber. A Western blot analysis for 633 condition media, showed that soluble fiber was present in the media during the period of cultivation of this cell line. Presence of soluble fiber in the media gives the possibility to increase transduction efficiency of fiberless adenovector on the HDF
cell line. (Figure 30) Because the HDF cell line doesn't have a CAR-receptor, it is especially difficult to transduce this particular cell line, not only with fiberless vector, but also with regular fiber containing adenovector. Different amounts of 633 conditioned media (250N1, 500N1 or 10001) were added to infectious media during the incubation period with fiberless adenovector.

WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 This experiment also showed a role of soluble fiber in the process of cell entry. The conclusion is that by adding any fiber (wild-type, mutated, with ligand fusions) as long as on has the wild-type shaft (or region necessary to bind penton) one can retarget fiberless vector with any genome inside (gutless, oncolytic, expressing any transgene, etc.) to any cell type that your fiber is specific to. The advantage of this approach is that one does not have to make vectors with each new ligand. Just one fiberless vector need be made that can then be used to make different backbones by adding an exogenous "targetable" fiber off the shelf.
The foregoing specification, including the specific embodiments and examples, is intended to be illustrative of the present invention and is not to be taken as limiting. Numerous other variations and modifications can be effected without departing from the true spirit and scope of the present invention. All publications, patents and patent applications cited herein are incorporated by reference in their entirety into the present disclosure.

SEQUENCE LISTING
<110> Novartis Ag The SCRIPPS RESEARCH INSTITUTE
<120> ADENOVIRUS VECTORS, PACKAGING CELL LINES, COMPOSITIONS, AND METHODS FOR PREPARATION AND USE
<130> 1294.0010001 <140>
<141>
<160> 76 <170> PatentIn Ver. 2.1 <210> 1 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 1 cggtacacag aattcaggag acacaactcc 30 <210> 2 <211> 35 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 2 gcctggatcc gggaagttac gtaacgtggg aaaac 35 <210> 3 <211> 12 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: linker <900> 3 cgcggatccg cg 12 <210> 9 <211> 8710 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 4 cacctaaatt gtaagcgtta atattttgtt aaaattcgcg ttaaattttt gttaaatcag 60 ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac 120 cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga 180 ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccatc 240 accctaatca agttttttgg ggtcgaggtg ccgtaaagca ctaaatcgga accctaaagg 300 gagcccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaagggaa 360 gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgta gcggtcacgc tgcgcgtaac 420 caccacaccc gccgcgctta atgcgccgct acagggcgcg tcccattcgc cattcaggct 480 gcgcaactgt tgggaagggc gatcggtgcg ggcctcttcg ctattacgcc agctggcgaa 540 agggggatgt gctgcaaggc gattaagttg ggtaacgcca gggttttccc agtcacgacg 600 ttgtaaaacg acggccagtg aattgtaata cgactcacta tagggcgaat tgggtaccgg 660 gccccccctc gaggtcgacg gtatcgataa gcttgatatc gaattcagga gacacaactc 720 caagtgcata ctctatgtca ttttcatggg actggtctgg ccacaactac attaatgaaa 780 tatttgccac atcctcttac actttttcat acattgccca agaataaaga atcgtttgtg 840 ttatgtttca acgtgtttat ttttcaattg cagaaaattt caagtcattt ttcattcagt 900 agtatagccc caccaccaca tagcttatac agatcaccgt accttaatca aactcacaga 960 accctagtat tcaacctgcc acctccctcc caacacacag agtacacagt cctttctccc 1020 cggctggcct taaaaagcat catatcatgg gtaacagaca tattcttagg tgttatattc 1080 cacacggttt cctgtcgagc caaacgctca tcagtgatat taataaactc cccgggcagc 1140 tcacttaagt tcatgtcgct gtccagctgc tgagccacag gctgctgtcc aacttgcggt 1200 tgcttaacgg gcggcgaagg agaagtccac gcctacatgg gggtagagtc ataatcgtgc 1260 atcaggatag ggcggtggtg ctgcagcagc gcgcgaataa actgctgccg ccgccgctcc 1320 gtcctgcagg aatacaacat ggcagtggtc tcctcagcga tgattcgcac cgcccgcagc 1380 ataaggcgcc ttgtcctccg ggcacagcag cgcaccctga tctcacttaa atcagcacag 1440 taactgcagc acagcaccac aatattgttc aaaatcccac agtgcaaggc gctgtatcca 1500 aagctcatgg cggggaccac agaacccacg tggccatcat accacaagcg caggtagatt 1560 aagtggcgac ccctcataaa cacgctggac ataaacatta cctcttttgg catgttgtaa 1620 ttcaccacct cccggtacca tataaacctc tgattaaaca tggcgccatc caccaccatc 1680 ctaaaccagc tggccaaaac ctgcccgccg gctatacact gcagggaacc gggactggaa 1740 caatgacagt ggagagccca ggactcgtaa ccatggatca tcatgctcgt catgatatca 1800 atgttggcac aacacaggca cacgtgcata cacttcctca ggattacaag ctcctcccgc 1860 gttagaacca tatcccaggg aacaacccat tcctgaatca gcgtaaatcc cacactgcag 1920 ggaagacctc gcacgtaact cacgttgtgc attgtcaaag tgttacattc gggcagcagc 1980 ggatgatcct ccagtatggt agcgcgggtt tctgtctcaa aaggaggtag acgatcccta 2040 ctgtacggag tgcgccgaga caaccgagat cgtgttggtc gtagtgtcat gccaaatgga 2100 acgccggacg tagtcatatt tcctgaagca aaaccaggtg cgggcgtgac aaacagatct 2160 gcgtctccgg tctcgccgct tagatcgctc tgtgtagtag ttgtagtata tccactctct 2220 caaagcatcc aggcgccccc tggcttcggg ttctatgtaa actccttcat gcgccgctgc 2280 cctgataaca tccaccaccg cagaataagc cacacccagc caacctacac attcgttctg 2340 cgagtcacac acgggaggag cgggaagagc tggaagaacc atgttttttt ttttattcca 2400 aaagattatc caaaacctca aaatgaagat ctattaagtg aacgcgctcc cctccggtgg 2460 cgtggtcaaa ctctacagcc aaagaacaga taatggcatt tgtaagatgt tgcacaatgg 2520 cttccaaaag gcaaacggcc ctcacgtcca agtggacgta aaggctaaac ccttcagggt 2580 gaatctcctc tataaacatt ccagcacctt caaccatgcc caaataattc tcatctcgcc 2640 accttctcaa tatatctcta agcaaatccc gaatattaag tccggccatt gtaaaaatct 2700 gctccagagc gccctccacc ttcagcctca agcagcgaat catgattgca aaaattcagg 2760 ttcctcacag acctgtataa gattcaaaag cggaacatta acaaaaatac cgcgatcccg 2820 taggtccctt cgcagggcca gctgaacata atcgtgcagg tctgcacgga ccagcgcggc 2880 cacttccccg ccaggaacct tgacaaaaga acccacactg attatgacac gcatactcgg 2940 agctatgcta accagcgtag ccccgatgta agctttgttg catgggcggc gatataaaat 3000 gcaaggtgct gctcaaaaaa tcaggcaaag cctcgcgcaa aaaagaaagc acatcgtagt 3060 catgctcatg cagataaagg caggtaagct ccggaaccac cacagaaaaa gacaccattt 3120 ttctctcaaa catgtctgcg ggtttctgca taaacacaaa ataaaataac aaaaaaacat 3180 ttaaacatta gaagcctgtc ttacaacagg aaaaacaacc cttataagca taagacggac 3240 tacggccatg ccggcgtgac cgtaaaaaaa ctggtcaccg tgattaaaaa gcaccaccga 3300 cagctcctcg gtcatgtccg gagtcataat gtaagactcg gtaaacacat caggttgatt 3360 catcggtcag tgctaaaaag cgaccgaaat agcccggggg aatacatacc cgcaggcgta 3420 gagacaacat tacagccccc ataggaggta taacaaaatt aataggagag aaaaacacat 3480 aaacacctga aaaaccctcc tgcctaggca aaatagcacc ctcccgctcc agaacaacat 3540 acagcgcttc acagcggcag cctaacagtc agccttacca gtaaaaaaga aaacctatta 3600 aaaaaacacc actcgacacg gcaccagctc aatcagtcac agtgtaaaaa agggccaagt 3660 gcagagcgag tatatatagg actaaaaaat gacgtaacgg ttaaagtcca caaaaaacac 3720 ccagaaaacc gcacgcgaac ctacgcccag aaacgaaagc caaaaaaccc acaacttcct 3780 caaatcgtca cttccgtttt cccacgttac gtaacttccc ggatccgcgg cattcacagt 3840 tctccgcaag aattgattgg ctccaattct tggagtggtg aatccgttag cgaggtgccg 3900 ccggcttcca ttcaggtcga ggtggcccgg ctccatgcac cgcgacgcaa cgcggggagg 3960 cagacaaggt atagggcggc gcctacaatc catgccaacc cgttccatgt gctcgccgag 4020 gcggcataaa tcgccgtgac gatcagcggt ccagtgatcg aagttaggct ggtaagagcc 4080 gcgagcgatc cttgaagctg tccctgatgg tcgtcatcta cctgcctgga cagcatggcc 4140 tgcaacgcgg gcatcccgat gccgccggaa gcgagaagaa tcataatggg gaaggccatc 4200 cagcctcgcg tcgcgaacgc cagcaagacg tagcccagcg cgtcggccgc catgccctgc 4260 ttcatccccg tggcccgttg ctcgcgtttg ctggcggtgt ccccggaaga aatatatttg 4320 catgtcttta gttctatgat gacacaaacc ccgcccagcg tcttgtcatt ggcgaattcg 4380 aacacgcaga tgcagtcggg gcggcgcggt cccaggtcca cttcgcatat taaggtgacg 4440 cgtgtggcct cgaacaccga gcgaccctgc agcgacccgc ttaacagcgt caacagcgtg 4500 ccgcagatcc cgggcaatga gatatgaaaa agcctgaact caccgcgacg tctgtcgaga 4560 agtttctgat cgaaaagttc gacagcgtct ccgacctgat gcagctctcg gagggcgaag 4620 aatctcgtgc tttcagcttc gatgtaggag ggcgtggata tgtcctgcgg gtaaatagct 4680 gcgccgatgg tttctacaaa gatcgttatg tttatcggca ctttgcatcg gccgcgctcc 4740 cgattccgga agtgcttgac attggggaat tcagcgagag cctgacctat tgcatctccc 4800 gccgtgcaca gggtgtcacg ttgcaagacc tgcctgaaac cgaactgccc gctgttctgc 4860 agccggtcgc ggaggccatg gatgcgatcg ctgcggccga tcttagccag acgagcgggt 4920 tcggcccatt cggaccgcaa ggaatcggtc aatacactac atggcgtgat ttcatatgcg 4980 cgattgctga tccccatgtg tatcactggc aaactgtgat ggacgacacc gtcagtgcgt 5040 ccgtcgcgca ggctctcgat gagctgatgc tttgggccga ggactgcccc gaagtccggc 5100 acctcgtgca cgcggatttc ggctccaaca atgtcctgac ggacaatggc cgcataacag 5160 cggtcattga ctggagcgag gcgatgttcg gggattccca atacgaggtc gccaacatct 5220 tcttctggag gccgtggttg gcttgtatgg agcagcagac gcgctacttc gagcggaggc 5280 atccggagct tgcaggatcg ccgcggctcc gggcgtatat gctccgcatt ggtcttgacc 5340 aactctatca gagcttggtt gacggcaatt tcgatgatgc agcttgggcg cagggtcgat 540 0 gcgacgcaat cgtccgatcc ggagccggga ctgtcgggcg tacacaaatc gcccgcagaa 5460 gcgcggccgt ctggaccgat ggctgtgtag aagtactcgc cgatagtgga aaccgacgcc 5520 ccagcactcg tccgagggca aaggaatagg ggagatgggg gaggctaact gaaacacgga 5580 aggagacaat accggaagga acccgcgcta tgacggcaat aaaaagacag aataaaacgc 5640 acgggtgttg ggtcgtttgt tcataaacgc ggggttcggt cccagggctg gcactctgtc 5700 gataccccac cgagacccca ttggggccaa tacgcccgcg tttcttcctt ttccccaccc 5760 caccccccaa gttcgggtga aggcccaggg ctcgcagcca acgtcggggc ggcaggccct 5820 gccatagcca ctggccccgt gggttaggga cggggtcccc catggggaat ggtttatggt 5880 tcgtgggggt tattattttg ggcgttgcgt ggggtctggt ccacgactgg actgagcaga 5940 cagacccatg gtttttggat ggcctgggca tggaccgcat gtactggcgc gacacgaaca 6000 ccgggcgtct gtggctgcca aacacccccg acccccaaaa accaccgcgc ggatttctgg 6060 cgcccagtgc cgtcgaccgg tcatggctgc gccccgacac ccgccaacac ccgctgacgc 610 gccctgacgg gcttgtctgc tcccggcatc cgcttacaga caagctgtga ccgtctccgg 6180 gagctgcatg tgtcagaggt tttcaccgtc atcaccgaaa cgcgcgaggc agccggatca 6240 taatcagcca taccacattt gtagaggttt tacttgcttt aaaaaacctc cccacctccc 6300 cctgaacctg aaacataaaa tgaatgcaat tgttgttgtt aacttgttta ttgcagctta 6360 taatggttac aaataaagca atagcatcac aaatttcaca aataaagcat ttttttcact 6420 gcattctagt tgtggtttgt ccaaactcat caatgtatct tatcatgtct ggatccacta 6480 gttctagagc ggccgccacc gcggtggagc tccagctttt gttcccttta gtgagggtta 6540 atttcgagct tggcgtaatc atggtcatag ctgtttcctg tgtgaaattg ttatccgctc 6600 acaattccac acaacatacg agccggaagc ataaagtgta aagcctgggg tgcctaatga 6660 gtgagctaac tcacattaat tgcgttgcgc tcactgcccg ctttccagtc gggaaacctg 6720 tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga gaggcggttt gcgtattggg 6780 cgctcttccg cttcctcgct cactgactcg ctgcgctcgg tcgttcggct gcggcgagcg 6840 gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga taacgcagga 6900 aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc cgcgttgctg 6960 gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg ctcaagtcag 7020 aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg aagctccctc 7080 gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt tctcccttcg 7140 ggaagcgtgg cgctttctca tagctcacgc tgtaggtatc tcagttcggt gtaggtcgtt 7200 cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc 7260 ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact ggcagcagcc 7320 actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg 7380 tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct gctgaagcca 7440 gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc 7500 ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat 7560 cctttgatct tttctacggg gtctgacgct cagtggaacg aaaactcacg ttaagggatt 7620 ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt 7680 tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca atgcttaatc 7740 agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc 7800 gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata 7860 ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg 7920 gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat taattgttgc 7980 cgggaagcta, gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct 8040 acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc cggttcccaa 8100 cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag ctccttcggt 8160 cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca 8220 ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtgagtac 8280 tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgtca 8340 atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaacgt 8400 tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaaccc 8460 actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc tygggtgagca 8520 aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata 8580 ctcatactct tcctttttca atattattga agcatttatc agggttattg tctcatgagc 8640 ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg cacatttccc 8700 cgaaaagtgc <210> 5 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 5 30 atgggatcca agatgaagcg cgcaagaccg <210> 6 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 6 30 cataacgcgg ccgcttcttt attcttgggc <210> 7 <211> 7198 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 7 gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60 gccatagcca ctggccccgt gggttaggga cggggtcccc catggggaa ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540 atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780 gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840 ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc 900 gagctcggat ccaagatgaa gcgcgcaaga ccgtctgaag ataccttcaa ccccgtgtat 960 ccatatgaca cggaaaccgg tcctccaac.t gtgccttttc ttactcctcc ctttgtatcc 1020 cccaatgggt ttcaagagag tccccctggg gtactctctt tgcgcctatc cgaacctcta 1080 gttacctcca atggcatgct tgcgctcaaa atgggcaacg gcctctctct ggacgaggcc 1140 ggcaacctta cctcccaaaa tgtaaccact gtgagcccac ctctcaaaaa aaccaagtca 1200 aacataaacc tggaaatatc tgcacccctc acagttacct cagaagccct aactgtggct 1260 gccgccgcac ctctaatggt cgcgggcaac acactcacca tgcaatcaca ggccccgcta 1320 accgtgcacg actccaaact tagcattgcc acccaaggac ccctcacagt gtcagaagga 1380 aagctagccc tgcaaacatc aggccccctc accaccaccg atagcagtac ccttactatc 1440 actgcctcac cccctctaac tactgccact ggtagcttgg gcattgactt gaaagagccc 1500 atttatacac aaaatggaaa actaggacta aagtacgggg ctcctttgca tgtaacagac 1560 gacctaaaca ctttgaccgt agcaactggt ccaggtgtga ctattaataa tacttccttg 1620 caaactaaag ttactggagc cttgggtttt gattcacaag gcaatatgca acttaatgta 1680 gcaggaggac taaggattga ttctcaaaac agacgcctta tacttgatgt tagttatccg 1740 tttgatgctc aaaaccaact aaatctaaga ctaggacagg gccctctttt tataaactca 1800 gcccacaact tggatattaa ctacaacaaa ggcctttact tgtttacagc ttcaaacaat 1860 tccaaaaagc ttgaggttaa cctaagcact gccaaggggt tgatgtttga cgctacagcc 1920 atagccatta atgcaggaga tgggcttgaa tttggttcac ctaatgcacc aaacacaaat 1980 cccctcaaaa caaaaattgg ccatggccta gaatttgatt caaacaaggc tatggttcct 2040 aaactaggaa ctggccttag ttttgacagc acaggtgcca ttacagtagg aaacaaaaat 2100 aatgataagc taactttgtg gaccacacca gctccatctc ctaactgtag actaaatgca 2160 gagaaagatg ctaaactcac tttggtctta acaaaatgtg gcagtcaaat acttgctaca 2220 gtttcagttt tggctgttaa aggcagtttg gctccaatat ctggaacagt tcaaagtgct 2280 catcttatta taagatttga cgaaaatgga gtgctactaa acaattcctt cctggaccca 2340 gaatattgga actttagaaa tggagatctt actgaaggca cagcctatac aaacgctgtt 2400 ggatttatgc ctaacctatc agcttatcca aaatctcacg gtaaaactgc caaaagtaac 2460 attgtcagtc aagtttactt aaacggagac aaaactaaac ctgtaacact aaccattaca 2520 ctaaacggta cacaggaaac aggagacaca actccaagtg catactctat gtcattttca 2580 tgggactggt ctggccacaa ctacattaat gaaatatttg ccacatcctc ttacactttt 2640 tcatacattg cccaagaata aagaagcggc cgctcgagca tgcatctaga gggccctatt 2700 ctatagtgtc acctaaatgc tagagctcgc tgatcagcct cgactgtgcc ttctagttgc 2760 cagccatctg ttgtttgccc ctcccccgtg ccttccttga ccctggaagg tgccactccc 2820 actgtccttt cctaataaaa tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct 2880 attctggggg gtggggtggg gcaggacagc aagggggagg attgggaaga caatagcagg 2940 catgctgggg atgcggtggg ctctatggct tctgaggcgg aaagaaccag ctggggctct 3000 agggggtatc cccacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg 3060' cgcagcgtga ccgctacact tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct 3120 tcctttctcg ccacgttcgc cggctttccc cgtcaagctc taaatcgggg catcccttta 3180 gggttccgat ttagtgcttt acggcacctc gaccccaaaa aacttgatta gggtgatggt 3240 tcacgtagtg ggccatcgcc ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg 3300 ttctttaata gtggactctt gttccaaact ggaacaacac tcaaccctat ctcggtctat 3360 tcttttgatt tataagggat tttggggatt tcggcctatt ggttaaaaaa tgagctgatt 3420 taacaaaaat ttaacgcgaa ttaattctgt ggaatgtgtg tcagttaggg tgtggaaagt 3480 ccccaggctc cccaggcagg cagaagtatg caaagcatgc atctcaatta gtcagcaacc 3540 aggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 3600 tagtcagcaa ccatagtccc gcccctaact ccgcccatcc cgcccctaac tccgcccagt 3660 tccgcccatt ctccgcccca tggctgacta atttttttta tttatgcaga ggccgaggcc 3720 gcctctgcct ctgagctatt ccagaagtag tgaggaggct tttttggagg cctaggcttt 3780 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 tgcaaaaagc tcccgggagc ttgtatatcc attttcggat ctgatcaaga gacaggatga 3840 ggatcgtttc gcatgattga acaagatgga ttgcacgcag gttctccggc cgcttgggtg 3900 gagaggctat tcggctatga ctgggcacaa cagacaatcg gctgctctga tgccgccgtg 3960 ttccggctgt cagcgcaggg gcgcccggtt ctttttgtca agaccgacct gtccggtgcc 4020 ctgaatgaac tgcaggacga ggcagcgcgg ctatcgtggc tggccacgac gggcgttcct 4080 tgcgcagctg tgctcgacgt tgtcactgaa gcgggaaggg actggctgct attgggcgaa 4140 gtgccggggc aggatctcct gtcatctcac cttgctcctg ccgagaaagt atccatcatg 4200 gctgatgcaa tgcggcggct gcatacgctt gatccggcta cctgcccatt cgaccaccaa 4260 gcgaaacatc gcatcgagcg agcacgtact cggatggaag ccggtcttgt cgatcaggat 4320 gatctggacg aagagcatca ggggctcgcg ccagccgaac tgttcgccag gctcaaggcg 4380 cgcatgcccg acggcgagga tctcgtcgtg acccatggcg atgcctgctt gccgaatatc 4440 atggtggaaa atggccgctt ttctggattc atcgactgtg gccggctggg tgtggcggac 4500 cgctatcagg acatagcgtt ggctacccgt gatattgctg aagagcttgg cggcgaatgg 4560 gctgaccgct tcctcgtgct ttacggtatc gccgctcccg attcgcagcg catcgccttc 4620 tatcgccttc ttgacgagtt cttctgagcg ggactctggg gttcgaaatg accgaccaag 4680 cgacgcccaa cctgccatca cgagatttcg attccaccgc cgccttctat gaaaggttgg 4740 gcttcggaat cgttttccgg gacgccggct ggatgatcct ccagcgcggg gatctcatgc 4800 tggagttctt cgcccacccc aacttgttta ttgcagctta taatggttac aaataaagca 4860 atagcatcac aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt 4920 ccaaactcat caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg 4980 cgtaatcatg gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca 5040 acatacgagc cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca 5100 cattaattgc gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc 5160 attaatgaat cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt 5220 cctcgctcac tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact 5280 caaaggcggt aatacggtta tccacagaat caggggataa cgcaggaaag aacatgtgag 5340 caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata 5400 ggctccgccc ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc 5460 cgacaggact ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg 5520 ttccgaccct gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc 5580 tttctcaatg ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg 5640 gctgtgtgca cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc 5700 ttgagtccaa cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga 5760 ttagcagagc gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg 5820 gctacactag aaggacagta tttggtatct gcgctctgct gaagccagtt accttcggaa 5880 aaagagttgg tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg 5940 tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt 6000 ctacggggtc tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat 6060 tatcaaaaag gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct 6120 aaagtatata tgagtaaact tggtctgaca gttaccaatg cttaatcagt gaggcaccta 6180 tctcagcgat ctgtctattt cgttcatcca tagttgcctg actccccgtc gtgtagataa 6240 ctacgatacg ggagggctta ccatctggcc ccagtgctgc aatgataccg cgagacccac 6300 gctcaccggc tccagattta tcagcaataa accagccagc cggaagggcc ga,gcgcagaa 6360 gtggtcctgc aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagctagag 6420 taagtagttc gccagttaat agtttgcgca acgttgttgc cattgctaca ggcatcgtgg 6480 tgtcacgctc gtcgtttggt atggcttcat tcagctccgg ttcccaacga tcaaggcgag 6540 ttacatgatc ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg 6600 tcagaagtaa gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc 6660 ttactgtcat gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcat 6720 tctgagaata gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata 6780 ccgcgccaca tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa 6840 aactctcaag gatcttaccg ctgttgagat ccagttcgat gtaacccact cgtgcaccca 6900 actgatcttc agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc 6960 aaaatgccgc aaaaaaggga ataagggcga cacggaaatg ttgaatactc atactcttcc 7020 tttttcaata ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg 7080 aatgtattta gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac 7140_ ctgacgtc <210> 8 <211> 7469 <212> DNA

_7_ <213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 8 gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggac tatttacggt aaactgccca cttggcag~c gcctgggtgt 480 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatgg catt 540 atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780 gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840 ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc 900 gagctcggat ctgaattcga gctcgctgtt gggctcgcgg ttgaggacaa actcttcgcg 960 gtctttccag tactcttgga tcggaaaccc gtcggcctcc gaacggtact ccgccaccga 1020 gggacctgag cgagtccgca tcgaccggat cggaaaacct ctcgagaaag gcgtctaacc 1080 agtcacagtc gcaaggtagg ctgagcaccg tggcgggcgg cagcgggtgg cggtcggggt 1140 tgtttctggc ggaggtgctg ctgatgatgt aattaaagta ggcggtcttg agacggcgga 1200 tggtcgaggt gaggtgtggc aggcttgaga tccaagatga agcgcgcaag accgtctgaa 1260 gataccttca accccgtgta tccatatgac acggaaaccg gtcctccaac tgtgcctttt 1320 cttactcctc cctttgtatc ccccaatggg tttcaagaga gtccccctgg ggtactctct 1380 ttgcgcctat ccgaacctct agttacctcc aatggcatgc ttgcgctcaa aatgggcaac 1440 ggcctctctc tggacgaggc cggcaacctt acctcccaaa atgtaaccac tgtgagccca 1500 cctctcaaaa aaaccaagtc aaacataaac ctggaaatat ctgcacccct cacagttacc 1560 tcagaagccc taactgtggc tgccgccgca cctctaatgg tcgcgggcaa cacactcacc 1620 atgcaatcac aggccccgct aaccgtgcac gactccaaac ttagcattgc cacccaagga 1680 cccctcacag tgtcagaagg aaagctagcc ctgcaaacat caggccccct caccaccacc 1740 gatagcagta cccttactat cactgcctca ccccctctaa ctactgccac tggtagcttg 1800 ggcattgact tgaaagagcc catttataca caaaatggaa aactaggact aaagtacggg 1860 gctcctttgc atgtaacaga cgacctaaac actttgaccg tagcaactgg tccaggtgtg 1920 actattaata atacttcctt gcaaactaaa gttactggag ccttgggttt tgattcacaa 1980 ggcaatatgc aacttaatgt agcaggagga ctaaggattg attctcaaaa cagacgcctt 2040 atacttgatg ttagttatcc gtttgatgct caaaaccaac taaatctaag actaggacag 2100 ggccctcttt ttataaactc agcccacaac ttggatatta actacaacaa aggcctttac 2160 ttgtttacag cttcaaacaa ttccaaaaag cttgaggtta acctaagcac tgccaagggg 2220 ttgatgtttg acgctacagc catagccatt aatgcaggag atgggcttga atttggttca 2280 cctaatgcac caaacacaaa tcccctcaaa acaaaaattg gccatggcct agaatttgat 2340 tcaaacaagg ctatggttcc taaactagga actggcctta gttttgacag cacaggtgcc 2900 attacagtag gaaacaaaaa taatgataag ctaactttgt ggaccacacc agctccatct 2460 cctaactgta gactaaatgc agagaaagat gctaaactca ctttggtctt aacaaaatgt 2520 ggcagtcaaa tacttgctac agtttcagtt ttggctgtta aaggcagttt ggctccaata 2580 tctggaacag ttcaaagtgc tcatcttatt ataagatttg acgaaaatgg agtgctacta 2640 aacaattcct tcctggaccc agaatattgg aactttagaa atggagatct tactgaaggc 2700 acagcctata caaacgctgt tggatttatg cctaacctat cagcttatcc aaaatctcac 2760 ggtaaaactg ccaaaagtaa cattgtcagt caagtttact taaacggaga caaaactaaa 2820 cctgtaacac taaccattac actaaacggt acacaggaaa caggagacac aactccaagt 2880 gcatactcta tgtcattttc atgggactgg tctggccaca actacattaa tgaaatattt 2940 gccacatcct cttacacttt ttcatacatt gcccaagaat aaagaagcgg ccgctcgagc 3000_ atgcatctag agggccctat tctatagtgt cacctaaatg ctagagctcg ctgatcagcc 3060 tcgactgtgc cttctagttg ccagccatct gttgtttgcc cctcccccgt gccttccttg 3120 accctggaag gtgccactcc cactgtcctt tcctaataaa atgaggaaat tgcatcgcat 3180 tgtctgagta ggtgtcattc tattctgggg ggtggg9tgg ggcaggacag caagggggag 3240 gattgggaag acaatagcag gcatgctggg gatgcggtgg gctctatggc ttctgaggcg 3300 gaaagaacca gctggggctc tagggggtat ccccacgcgc cctgtagcgg cgcattaagc 3360 _g_ gcggcgggtg tggtggttac gcgcagcgtg accgctacac ttgccagcgc cctagcgccc 3420 gctcctttcg ctttcttccc ttcctttctc gccacgttcg ccggctttcc ccgtcaagct 3480 ctaaatcggg gcatcccttt agggttccga tttagtgctt tacggcacct cgaccccaaa 3540 aaacttgatt agggtgatgg ttcacgtagt gggccatcgc cctgatagac ggtttttcgc 3600 cctttgacgt tggagtccac gttctttaat agtggactct tgttccaaac tggaacaaca 3660 ctcaacccta tctcggtcta ttcttttgat ttataaggga ttttggggat ttcggcctat 3720 tggttaaaaa atgagctgat ttaacaaaaa tttaacgcga attaattctg tggaatgtgt 3780 gtcagttagg gtgtggaaag tccccaggct ccccaggcag gcagaagtat gcaaagcatg 3840 catctcaatt agtcagcaac caggtgtgga aagtccccag gctccccagc aggcagaagt 3900 atgcaaagca tgcatctcaa ttagtcagca accatagtcc cgcccctaac tccgcccatc 3960 ccgcccctaa ctccgcccag ttccgcccat tctccgcccc atggctgact aatttttttt 4020 atttatgcag aggccgaggc cgcctctgcc tctgagctat tccagaagta gtgaggaggc 4080 ttttttggag gcctaggctt ttgcaaaaag ctcccgggag cttgtatatc cattttcgga 4140 tctgatcaag agacaggatg aggatcgttt cgcatgattg aacaagatgg attgcacgca 4200 ggttctccgg ccgcttgggt ggagaggcta ttcggctatg actgggcaca acagacaatc 4260 ggctgctctg atgccgccgt gttccggctg tcagcgcagg ggcgcccggt tctttttgtc 4320 aagaccgacc tgtccggtgc cctgaatgaa ctgcaggacg aggcagcgcg gctatcgtgg 4380 ctggccacga cgggcgttcc ttgcgcagct gtgctcgacg ttgtcactga agcgggaagg 4440 gactggctgc tattgggcga agtgccgggg caggatctcc tgtcatctca ccttgctcct 4500 gccgagaaag tatccatcat ggctgatgca atgcggcggc tgcatacgct tgatccggct 4560 acctgcccat tcgaccacca agcgaaacat cgcatcgagc gagcacgtac tcggatggaa 4620 gccggtcttg tcgatcagga tgatctggac gaagagcatc aggggctcgc c~ccagccgaa 4680 ctgttcgcca ggctcaaggc gcgcatgccc gacggcgagg atctcgtcgt gacccatggc 4740 gatgcctgct tgccgaatat catggtggaa aatggccgct tttctggatt catcgactgt 4800 ggccggctgg gtgtggcgga ccgctatcag gacatagcgt tggctacccg tgatattgct 4860 gaagagcttg gcggcgaatg ggctgaccgc ttcctcgtgc tttacggtat cgccgctccc 4920 gattcgcagc gcatcgcctt ctatcgcctt cttgacgagt tcttctgagc gggactctgg 4980 ggttcgaaat gaccgaccaa gcgacgccca acctgccatc acgagatttc gattccaccg 5040 ccgccttcta tgaaaggttg ggcttcggaa tcgttttccg ggacgccggc tggatgatcc 5100 tccagcgcgg ggatctcatg ctggagttct tcgcccaccc caacttgttt attgcagctt 5160 ataatggtta caaataaagc aatagcatca caaatttcac aaataaagca tttttttcac 5220 tgcattctag ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc tgtataccgt 5280 cgacctctag ctagagcttg gcgtaatcat ggtcatagct gtttcctgtg tgaaattgtt 5340 atccgctcac aattccacac aacatacgag ccggaagcat aaagtgtaaa gcctggggtg 5400 cctaatgagt gagctaactc acattaattg cgttgcgctc actgcccgct ttccagtcgg 5460 gaaacctgtc gtgccagctg cattaatgaa tcggccaacg cgcggggaga ggcggtttgc 5520 gtattgggcg ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc 5580 ggcgagcggt atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata 5640 acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg 5700 cgttgctggc gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct 5760 caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa 5820 gctccctcgt gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc 5880 tcccttcggg aagcgtggcg ctttctcaat gctcacgctg taggtatctc agttcggtgt 5940 aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg 6000 ccttatccgg taactatcgt cttgagtcca acccggtaag acacgactta tcgccactgg 6060 cagcagccac tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct 6120 tgaagtggtg gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc 6180 tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg 6240 ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc 6300 aagaagatcc tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt 6360 aagggatttt ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa 6420 aatgaagttt taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat 6480 gcttaatcag tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct 6590 gactccccgt cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg 6600 caatgatacc gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag 6660 ccggaagggc cgagcgcaga agtggtcctg caactttatc cgcctccatc cagtctatta 6720_ attgttgccg ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg 6780 ccattgctac aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg 6840 gttcccaacg atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa gcggttagct 6900 ccttcggtcc tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta 6960 tggcagcact gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg 7020 gtgagtactc aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc 7080 cggcgtcaat acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg 7140 gaaaacgttc ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga 7200 tgtaacccac tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg 7260 ggtgagcaaa aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat 7320 gttgaatact catactcttc ctttttcaat attattgaag catttatcag ggttattgtc 7380 tcatgagcgg atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca 7440 catttccccg aaaagtgcca cctgacgtc 7469 <210> 9 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 9 tgcttaagcg gccgcgaagg agaagtcc 28 <210> 10 v <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 10 ccgagctagc gactgaaaat gag 23 <210> 11 <211> 23 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 11 cctctcgaga gacagcaaga cac 23 <210> 12 <211> 11152 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 12 aagcttgggc agaaatggtt gaactcccga gagtgtccta cacctagggg agaagcagcc 60 aaggggttgt ttcccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120 aaagacatat tcattctctg ctgcaaactt ggcatagctc tgctttgcct ggggctattg 180 ggggaagttg cggttcgtgc tcgcagggct ctcacccttg actcttttaa tagctcttct 240 gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300 cagccaactt cctcttacaa gccgcatcga ttttgtcctt cagaaataga aataagaatg 360 cttgctaaaa attatatttt taccaataag accaatccaa taggtagatt attagttact 420 atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480 atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540 ttgaccacag gcctagaagt aaaaaaggga aaaaagagtg tttttgtcaa aataggagac 600 aggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgccccc 660 ttaccatata caggaagata tgacttaaat tgggataggt gggttacagt caatggctat 720 aaagtgttat atagatccct cccttttcgt gaaagactcg ccagagctag acctccttgg 780 tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatttat 840 ctaggaacag gaatgcactt ttggggaaag attttccata ccaaggaggg gacagtggct 900 ggactaatag aacattattc tgcaaaaact catggcatga gttattatga atagccttta 960 ttggcccaac cttgcggttc ccagggctta agtaagtttt tggttacaaa ctgttcttaa 1020 aacgaggatg tgagacaagt ggtttcctga cttggtttgg tatcaaaggt tctgatctga 1080 gctctgagtg ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaatgc 1140 ttatgtaaac caagatataa aagagtgctg attttttgag taaacttgca acagtcctaa 1200 cattcacctc ttgtgtgttt gtgtctgttc gccatcccgt ctccgctcgt cacttatcct 1260 tcactttcca gagggtcccc ccgcagaccc cggcgaccct caggtcggcc gactgcggca 1320 gctggcgccc gaacagggac cctcggataa gtgacccttg tctctatttc tactatttgg 1380 tgtttgtctt gtattgtctc tttcttgtct ggctatcatc acaagagcgg aacggactca 1440 ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500 accgaagaaa tggccgccag tcttttggac cagctgatcg aagaggtact ggctgataat 1560 cttccacctc ctagccattt tgaaccacct acccttcacg aactgtatga tttagacgtg 1620 acggcccccg aagatcccaa cgaggaggcg gtttcgcaga tttttcccga ctctgtaatg 1680 ttggcggtgc aggaagggat tgacttactc acttttccgc cggcgcccgg ttctccggag 1740 ccgcctcacc tttcccggca gcccgagcag ccggagcaga gagccttggg ~ccggtttct 1800 atgccaaacc ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860 agtgacgacg aggatgaaga gggtgaggag tttgtgttag attatgtgga gcaccccggg 1920 cacggttgca ggtcttgtca ttatcaccgg aggaatacgg gggacccaga tattatgtgt 1980 tcgctttgct atatgaggac ctgtggcatg tttgtctaca gtaagtgaaa attatgggca 2040 gtgggtgata gagtggtggg tttggtgtgg taattttttt tttaattttt acagttttgt 2100 ggtttaaaga attttgtatt gtgatttttt taaaaggtcc tgtgtctgaa cctgagcctg 2160 agcccgagcc agaaccggag cctgcaagac ctacccgccg tcctaaaatg gcgcctgcta 2220 tcctgagacg cccgacatca cctgtgtcta gagaatgcaa tagtagtacg gatagctgtg 2280 actccggtcc ttctaacaca cctcctgaga tacacccggt ggtcccgctg tgccccatta 2340 aaccagttgc cgtgagagtt ggtgggcgtc gccaggctgt ggaatgtatc gaggacttgc 2400 ttaacgagcc tgggcaacct ttggacttga gctgtaaacg ccccaggcca taaggtgtaa 2460 acctgtgatt gcgtgtgtgg ttaacgcctt tgtttgctga atgagttgat gtaagtttaa 2520 taaagggtga gataatgttt aacttgcatg gcgtgttaaa tggggcgggg cttaaagggt 2580 atataatgcg ccgtgggcta atcttggtta catctgacct catggaggct tgggagtgtt 2640 tggaagattt ttctgctgtg.cgtaacttgc tggaacagag ctctaacagt acctcttggt 2700 tttggaggtt tctgtggggc tcatcccagg caaagttagt ctgcagaatt aaggaggatt 2760 acaagtggga atttgaagag cttttgaaat cctgtggtga gctgtttgat tctttgaatc 2820 tgggtcacca ggcgcttttc caagagaagg tcatcaagac tttggatttt tccacaccgg 2880 ggcgcgctgc ggctgctgtt gcttttttga gttttataaa ggataaatgg agcgaagaaa 2940 cccatctgag cggggggtac ctgctggatt ttctggccat gcatctgtgg agagcggttg 3000 tgagacacaa gaatcgcctg ctactgttgt cttccgtccg cccggcgata ataccgacgg 3060 aggagcagca gcagcagcag gaggaagcca ggcggcggcg gcaggagcag agcccatgga 3120 acccgagagc cggcctggac cctcgggaat gaatgttgta caggtggctg aactgtatcc 3180 agaactgaga cgcattttga caattacaga ggatgggcag gggctaaagg gggtaaagag 3240 ggagcggggg gcttg'tgagg ctacagagga ggctaggaat ctagctttta gcttaatgac 3300 cagacaccgt cctgagtgta ttacttttca acagatcaag gataattgcg ctaatgagct 3360 tgatctgctg gcgcagaagt attccataga gcagctgacc acttactggc tgcagccagg 3420 ggatgatttt gaggaggcta ttagggtata tgcaaaggtg gcacttaggc cagattgcaa 3480 gtacaagatc agcaaacttg taaatatcag gaattgttgc tacatttctg ggaacggggc 3540 cgaggtggag atagatacgg aggatagggt ggcctttaga tgtagcatga taaatatgtg 3600 gccgggggtg cttggcatgg acggggtggt tattatgaat gtaaggttta ctggccccaa 3660 ttttagcggt acggttttcc tggccaatac caaccttatc ctacacggtg taagcttcta 3720 tgggtttaac aatacctgtg tggaagcctg gaccgatgta agggttcggg gctgtgcctt 3780 ttactgctgc tggaaggggg tggtgtgtcg ccccaaaagc agggcttcaa ttaagaaatg 3840 cctctttgaa aggtgtacct tgggtatcct gtctgagggt aactccaggg tgcgccacaa 3900 tgtggcctcc gactgtggtt gcttcatgct agtgaaaagc gtggctgtga ttaagcataa 3960 catggtatgt ggcaactgcg aggacagggc ctctcagatg ctgacctgct cggacggcaa 4020 ctgtcacctg ctgaagacca ttcacgtagc cagccactct cgcaaggcct ggccagtgtt 4080 tgagcataac atactgaccc gctgttcctt gcatttgggt aacaggaggg gggtgttcct 4140 accttaccaa tgcaatttga gtcacactaa gatattgctt gagcccgaga gcatgtccaa 4200 ggtgaacctg aacggggtgt ttgacatgac catgaagatc tggaaggtgc tgaggtacga 4260 tgagacccgc accaggtgca gaccctgcga gtgtggcggt aaacatatta ggaaccagcc 4320 tgtgatgctg gatgtgaccg aggagctgag gcccgatcac ttggtgctgg cctgcacccg 9380 cgctgagttt ggctctagcg atgaagatac agattgaggt actgaaatgt gtgggcgtgg 4440 cttaagggtg ggaaagaata tataaggtgg gggtcttatg tagttttgta tctgttttgc 4500 agcagccgcc gccgccatga gcaccaactc gtttgatgga agcattgtga gctcatattt 4560 gacaacgcgc atgcccccat gggccggggt gcgtcagaat gtgatgggct ccagcattga 4620 tggtcgcccc gtcctgcccg caaactctac taccttgacc tacgagaccg tgtctggaac 4680 gccgttggag actgcagcct ccgccgccgc ttcagccgct gcagccaccg cccgcgggat 4740 tgtgactgac tttgctttcc tgagcccgct tgcaagcagt gcagcttccc gttcatccgc 4800 ccgcgatgac aagttgacgg ctcttttggc acaattggat tctttgaccc gggaacttaa 4860 tgtcgtttct cagcagctgt tggatctgcg ccagcaggtt tctgccctga aggcttcctc 4920 ccctcccaat gcggtttaaa acataaataa aaaaccagac tctgtttgga tttggatcaa 4980 gcaagtgtct tgctgtctct cgagggatct ttgtgaagga accttacttc tgtggtgtga 5040 cataattgga caaactacct acagagattt aaagctctaa ggtaaatata aaatttttaa 5100 gtgtataatg tgttaaacta ctgattctaa ttgtttgtgt attttagatt ccaacctatg 5160 gaactgatga atgggagcag tggtggaatg cctttaatga ggaaaacctg ttttgctcag 5220 aagaaatgcc atctagtgat gatgaggcta ctgctgactc tcaacattct actcctccaa 5280 aaaagaagag aaaggtagaa gaccccaagg actttccttc agaattgcta agttttttga 5340 gtcatgctgt gtttagtaat agaactcttg cttgctttgc tatttacacc acaaaggaaa 5400 aagctgcact gctatacaag aaaattatgg aaaaatattc tgtaaccttt ataagtaggc 5460 ataacagtta taatcataac atactgtttt ttcttactcc acacaggcat ~gagtgtctg 5520 ctattaataa ctatgctcaa aaattgtgta cctttagctt tttaatttgt aaaggggtta 5580 ataaggaata tttgatgtat agtgccttga ctagagatca taatcagcca taccacattt 5640 gtagaggttt tacttgcttt aaaaaacctc ccacacctcc ccctgaacct gaaacataaa 5700 atgaatgcaa ttgttgttgt taacttgttt attgcagctt ataatggtta caaataaagc 5760 aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag ttgtggtttg 5820 tccaaactca tcaatgtatc ttatcatgtc tggatccggc tgtggaatgt gtgtcagtta 5880 gggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 5990 tagtcagcaa ccaggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc 6000 atgcatctca attagtcagc aaccatagtc ccgcccctaa ctccgcccat cccgccccta 6060 actccgccca gttccgccca ttctccgccc catggctgac taattttttt tatttatgca 6120 gaggccgagg ccgcctcggc ctctgagcta ttccagaagt agtgaggagg cttttttgga 6180 ggcctaggct tttgcaaaaa gcttggacac aagacaggct tgcgagatat gtttgagaat 6240 accactttat cccgcgtcag ggagaggcag tgcgtaaaaa gacgcggact catgtgaaat 6300 actggttttt agtgcgccag atctctataa tctcgcgcaa cctattttcc cctcgaacac 6360 tttttaagcc gtagataaac aggctgggac acttcacatg agcgaaaaat acatcgtcac 6420 ctgggacatg ttgcagatcc atgcacgtaa actcgcaagc cgactgatgc cttctgaaca 6480 atggaaaggc attattgccg taagccgtgg cggtctggta ccgggtgcgt tactggcgcg 6540 tgaactgggt attcgtcatg tcgataccgt ttgtatttcc agctacgatc acgacaacca 6600 gcgcgagctt aaagtgctga aacgcgcaga aggcgatggc gaaggcttca tcgttattga 6660 tgacctggtg gataccggtg gtactgcggt tgcgattcgt gaaatgtatc caaaagcgca 6720 ctttgtcacc atcttcgcaa aaccggctgg tcgtccgctg gttgatgact atgttgttga 6780 tatcccgcaa gatacctgga ttgaacagcc gtgggatatg ggcgtcgtat tcgtcccgcc 6840 aatctccggt cgctaatctt ttcaacgcct ggcactgccg ggcgttgttc tttttaactt 6900 caggcgggtt acaatagttt ccagtaagta ttctggaggc tgcatccatg acacaggcaa 6960 acctgagcga aaccctgttc aaaccccgct ttaaacatcc tgaaacctcg acgctagtcc 7020 gccgctttaa tcacggcgca caaccgcctg tgcagtcggc ccttgatggt aaaaccatcc 7080 ctcactggta tcgcatgatt aaccgtctga tgtggatctg gcgcggcatt gacccacgcg 7140 aaatcctcga cgtccaggca cgtattgtga tgagcgatgc cgaacgtacc gacgatgatt 7200 tatacgatac ggtgattggc taccgtggcg gcaactggat ttatgagtgg gccccggatc 7260 tttgtgaagg aaccttactt ctgtggtgtg acataattgg acaaactacc tacagagatt 7320 taaagctcta aggtaaatat aaaattttta agtgtataat gtgttaaact actgattcta 7380 attgtttgtg tattttagat tccaacctat ggaactgatg aatgggagca gtggtggaat 7490 gcctttaatg aggaaaacct gttttgctca gaagaaatgc catctagtga tgatgaggct 7500 actgctgact ctcaacattc tactcctcca aaaaagaaga gaaaggtaga agaccccaag 7560 gactttcctt cagaattgct aagttttttg agtcatgctg tgtttagtaa tagaactctt 7620 gcttgctttg ctatttacac cacaaaggaa aaagctgcac tgctatacaa gaaaattatg 7680 gaaaaatatt ctgtaacctt tataagtagg cataacagtt ataatcataa catactgttt 7740 tttcttactc cacacaggca tagagtgtct gctattaata actatgctca aaaattgtgt 7800 acctttagct ttttaatttg taaaggggtt aataaggaat atttgatgta tagtgccttg 7860 actagagatc ataatcagcc ataccacatt tgtagaggtt ttacttgctt taaaaaacct 7920 CA 02359795 2001-07-12 pCT~, P00/00265 cccacacctc cccctgaacc tgaaacataa aatgaatgca attgttgttg ttaacttgtt 7980 tattgcagct tataatggtt acaaataaag caatagcatc acaaatttca caaataaagc 8040 atttttttca ctgcattcta gttgtggttt gtccaaactc atcaatgtat cttatcatgt 8100 ctggatcccc aggaagctcc tctgtgtcct cataaaccct aacctcctct acttgagagg 8160 acattccaat cataggctgc ccatccaccc tctgtgtcct cctgttaatt aggtcactta 8220 acaaaaagga aattgggtag gggtttttca cagaccgctt tctaagggta attttaaaat 8280 atctgggaag tcccttccac tgctgtgttc cagaagtgtt ggtaaacagc ccacaaatgt 8340' caacagcaga aacatacaag ctgtcagctt tgcacaaggg cccaacaccc tgctcatcaa 8400 gaagcactgt ggttgctgtg ttagtaatgt gcaaaacagg aggcacattt tccccacctg 8460 tgtaggttcc aaaatatcta gtgttttcat ttttacttgg atcaggaacc cagcactcca 8520 ctggataagc attatcctta tccaaaacag ccttgtggtc agtgttcatc tgctgactgt 8580 caactgtagc attttttggg gttacagttt gagcaggata tttggtcctg tagtttgcta 8640 acacaccctg cagctccaaa ggttccccac caacagcaaa aaaatgaaaa tttgaccctt 8700 gaatgggttt tccagcacca ttttcatgag ttttttgtgt ccctgaatgc aagtttaaca 8760 tagcagttac cccaataacc tcagttttaa cagtaacagc ttcccacatc aaaatatttc 8820 cacaggttaa gtcctcattt aaattaggca aaggaattct tgaagacgaa agggcctcgt 8880 gatacgccta tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcaggtgg 8940 cacttttcgg ggaaatgtgc gcggaacccc tatttgttta tttttctaaa tacattcaaa 9000 tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa 9060 gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcct 9120 tcctgttttt gctcacccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg 9180 tgcacgagtg ggttacatcg aactggatct caacagcggt aagatccttg agagttttcg 9240 ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt 9300 atcccgtgtt gacgccgggc aagagcaact cggtcgccgc atacactatt ctcagaatga 9360 cttggttgag tactcaccag tcacagaaaa gcatcttacg gatggcatga cagtaagaga 9420 attatgcagt gctgccataa ccatgagtga taacactgcg gccaacttac ttctgacaac 9480 gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc atgtaactcg 9540 ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac 9600 gatgcctgca gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct 9660 agcttcccgg caacaattaa tagactggat ggaggcggat aaagttgcag gaccacttct 9720 gcgctcggcc cttccggctg gctggtttat tgctgataaa tctggagccg gtgagcgtgg 9780 gtctcgcggt atcattgcag cactggggcc agatggtaag ccctcccgta tcgtagttat 9840 ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg 9900 tgcctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata tactttagat 9960 tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt ttgataatct 10020 catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa 10080 gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa 10140 aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa ctctttttcc 10200 gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag tgtagccgta 10260 gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaatcct 10320 gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg actcaagacg 10380 atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca cacagcccag 10440 cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc 10500 cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg tcggaacagg 10560 agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt 10620 tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 10680 gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc cttttgctca 10740 catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagtg 10800 agctgatacc gctcgccgca gccgaacgac cgagcgcagc gagtcagtga gcgaggaagc 10860 ggaagagcgc ctgatgcggt attttctcct tacgcatctg tgcggtattt cacaccgcat 10920 atggtgcact ctcagtacaa tctgctctga tgccgcatag ttaagccagt atacactccg 10980 ctatcgctac gtgactgggt catggctgcg ccccgacacc cgccaacacc cgctgacgcg 11040 ccctgacggg cttgtctgct cccggcatcc gcttacagac aagctgtgac cgtctccggg 11100 agctgcatgt gtcagaggtt ttcaccgtca tcaccgaaac gcgcgaggca gc 11152 <210> 13 <211> 19 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 13 gacggatcgg gagatctcc 19 <210> 14 <211> 22 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 19 ccgcctcaga agccatagag cc 22 <210> 15 <211> 14455 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 15 aagcttgggc agaaatggtt gaactcccga gagtgtccta cacctagggg agaagcagcc 60 aaggggttgt ttcccaccaa ggacgacccg tctgcgcaca aacggatgag cccatcagac 120 aaagacatat tcattctctg ctgcaaactt ggcatagctc tgctttgcct ggggctattg 180 ggggaagttg cggttcgtgc tcgcagggct ctcacccttg actcttttaa tagctcttct 240 gtgcaagatt acaatctaaa caattcggag aactcgacct tcctcctgag gcaaggacca 300 cagccaactt cctcttacaa gccgcatcga ttttgtcctt cagaaataga aataagaatg 360 cttgctaaaa attatatttt taccaataag accaatccaa taggtagatt ~ttagttact 420 atgttaagaa atgaatcatt atcttttagt actattttta ctcaaattca gaagttagaa 480 atgggaatag aaaatagaaa gagacgctca acctcaattg aagaacaggt gcaaggacta 540 ttgaccacag gcctagaagt aaaaaaggga aaaaagagtg tttttgtcaa aataggagac 600 aggtggtggc aaccagggac ttatagggga ccttacatct acagaccaac agatgccccc 660 ttaccatata caggaagata tgacttaaat tgggataggt gggttacagt caatggctat 720 aaagtgttat atagatccct cccttttcgt gaaagactcg ccagagctag acctccttgg 780 tgtatgttgt ctcaagaaga aaaagacgac atgaaacaac aggtacatga ttatatttat 840 ctaggaacag ,gaatgcactt ttggggaaag attttccata ccaaggaggg gacagtggct 900 ggactaatag aacattattc tgcaaaaact catggcatga gttattatga atagccttta 960 ttggcccaac cttgcggttc ccagggctta agtaagtttt tggttacaaa ctgttcttaa 1020 aacgaggatg tgagacaagt ggtttcctga cttggtttgg tatcaaaggt tctgatctga 1080 gctctgagtg ttctattttc ctatgttctt ttggaattta tccaaatctt atgtaaatgc 1140 ttatgtaaac caagatataa aagagtgctg attttttgag taaacttgca acagtcctaa 1200 cattcacctc ttgtgtgttt gtgtctgttc gccatcccgt ctccgctcgt cacttatcct 1260 tcactttcca gagggtcccc ccgcagaccc cggcgaccct caggtcggcc gactgcggca 1320 gctggcgccc gaacagggac cctcggataa gtgacccttg tctctatttc tactatttgg 1380 tgtttgtctt gtattgtctc tttcttgtct ggctatcatc acaagagcgg aacggactca 1440 ccatagggac caagctagcg actgaaaatg agacatatta tctgccacgg aggtgttatt 1500 accgaagaaa tggccgccag tcttttggac cagctgatcg aagaggtact ggctgataat 1560 cttccacctc ctagccattt tgaaccacct acccttcacg aactgtatga tttagacgtg 1620 acggcccccg aagatcccaa cgaggaggcg gtttcgcaga tttttcccga ctctgtaatg 1680 ttggcggtgc aggaagggat tgacttactc acttttccgc cggcgcccgg ttctccggag 1740_ ccgcctcacc tttcccggca gcccgagcag ccggagcaga gagccttggg tccggtttct 1800 atgccaaacc ttgtaccgga ggtgatcgat cttacctgcc acgaggctgg ctttccaccc 1860 agtgacgacg aggatgaaga gggtgaggag tttgtgttag attatgtgga gcaccccggg 1920 cacggttgca_ggtcttgtca ttatcaccgg aggaatacgg gggacccaga tattatgtgt 1980 tcgctttgct atatgaggac ctgtggcatg tttgtctaca gtaagtgaaa attatgggca 2040 gtgggtgata gagtggtggg tttggtgtgg taattttttt tttaattttt acagttttgt 2100 CA 02359795 2001-07-12 pCT~P00/00265 ggtttaaaga attttgtatt gtgatttttt taaaaggtcc tgtgtctgaa cctgagcctg 2160 agcccgagcc agaaccggag cctgcaagac ctacccgccg tcctaaaatg gcgcctgcta 2220 tcctgagacg cccgacatca cctgtgtcta gagaatgcaa tagtagtacg gatagctgtg 2280 actccggtcc ttctaacaca cctcctgaga tacacccggt ggtcccgctg tgccccatta 2340 aaccagttgc cgtgagagtt ggtgggcgtc gccaggctgt ggaatgtatc gaggacttgc 2400 ttaacgagcc tgggcaacct ttggacttga gctgtaaacg ccccaggcca taaggtgtaa 2460 acctgtgatt gcgtgtgtgg ttaacgcctt tgtttgctga atgagttgat gtaagtttaa 2520 taaagggtga gataatgttt aacttgcatg gcgtgttaaa tggggcgggg cttaaagggt 2580 atataatgcg ccgtgggcta atcttggtta catctgacct-catggaggct tgggagtgtt 2640 tggaagattt ttctgctgtg cgtaacttgc tggaacagag ctctaacagt acctcttggt 2700 tttggaggtt tctgtggggc tcatcccagg caaagttagt ctgcagaatt aaggaggatt 2760 acaagtggga atttgaagag cttttgaaat cctgtggtga gctgtttgat tctttgaatc 2820 tgggtcacca ggcgcttttc caagagaagg tcatcaagac tttggatttt tccacaccgg 2880 ggcgcgctgc ggctgctgtt gcttttttga gttttataaa ggataaatgg agcgaagaaa 2940 cccatctgag cggggggtac ctgctggatt ttctggccat gcatctgtgg agagcggttg 3000 tgagacacaa gaatcgcctg ctactgttgt cttccgtccg cccggcgata ataccgacgg 3060 aggagcagca gcagcagcag gaggaagcca ggcggcggcg gcaggagcag agcccatgga 3120 acccgagagc cggcctggac cctcgggaat gaatgttgta caggtggctg aactgtatcc 3180 agaactgaga cgcattttga caattacaga ggatgggcag gggctaaagg gggtaaagag 3240 ggagcggggg gcttgtgagg ctacagagga ggctaggaat ctagctttta gcttaatgac 3300 cagacaccgt cctgagtgta ttacttttca acagatcaag gataattgcg ctaatgagct 3360 tgatctgctg gcgcagaagt attccataga gcagctgacc acttactggc ~gcagccagg 3420 ggatgatttt gaggaggcta ttagggtata tgcaaaggtg gcacttaggc cagattgcaa 3480 gtacaagatc agcaaacttg taaatatcag gaattgttgc tacatttctg ggaacggggc 3540 cgaggtggag atagatacgg aggatagggt ggcctttaga tgtagcatga taaatatgtg 3600 gccgggggtg cttggcatgg acggggtggt tattatgaat gtaaggttta ctggccccaa 3660 ttttagcggt acggttttcc tggccaatac caaccttatc ctacacggtg taagcttcta 3720 tgggtttaac aatacctgtg tggaagcctg gaccgatgta agggttcggg gctgtgcctt 3780 ttactgctgc tggaaggggg tggtgtgtcg ccccaaaagc agggcttcaa ttaagaaatg 3840 cctctttgaa aggtgtacct tgggtatcct gtctgagggt aactccaggg tgcgccacaa 3900 tgtggcctcc gactgtggtt gcttcatgct agtgaaaagc gtggctgtga ttaagcataa 3960 catggtatgt ggcaactgcg aggacagggc ctctcagatg ctgacctgct cggacggcaa 4020 ctgtcacctg ctgaagacca ttcacgtagc cagccactct cgcaaggcct ggccagtgtt 4080 tgagcataac atactgaccc gctgttcctt gcatttgggt aacaggaggg gggtgttcct 4140 accttaccaa tgcaatttga gtcacactaa gatattgctt gagcccgaga gcatgtccaa 4200 ggtgaacctg aacggggtgt ttgacatgac catgaagatc tggaaggtgc tgaggtacga 4260 tgagacccgc accaggtgca gaccctgcga gtgtggcggt aaacatatta ggaaccagcc 4320 tgtgatgctg gatgtgaccg aggagctgag gcccgatcac ttggtgctgg cctgcacccg 9380 cgctgagttt ggctctagcg atgaagatac agattgaggt actgaaatgt gtgggcgtgg 4440 cttaagggtg.ggaaagaata tataaggtgg gggtcttatg tagttttgta tctgttttgc 4500 agcagccgcc gccgccatga gcaccaactc gtttgatgga agcattgtga gctcatattt 4560 gacaacgcgc atgcccccat gggccggggt gcgtcagaat gtgatgggct ccagcattga 4620 tggtcgcccc gtcctgcccg caaactctac taccttgacc tacgagaccg tgtctggaac 4680 gccgttggag actgcagcct ccgccgccgc ttcagccgct gcagccaccg cccgcgggat 4740 tgtgactgac tttgctttcc tgagcccgct tgcaagcagt gcagcttccc gttcatccgc 4800 ccgcgatgac aagttgacgg ctcttttggc acaattggat tctttgaccc gggaacttaa 4860 tgtcgtttct cagcagctgt tggatctgcg ccagcaggtt tctgccctga aggcttcctc 4920 ccctcccaat gcggtttaaa acataaataa aaaaccagac tctgtttgga tttggatcaa 4980 gcaagtgtct tgctgtctct cgagggatct ttgtgaagga accttacttc tgtggtgtga 5040 cataattgga caaactacct acagagattt aaagctctaa ggtaaatata aaatttttaa 5100 gtgtataatg tgttaaacta ctgattctaa ttgtttgtgt attttagatt ccaacctatg 5160 gaactgatga atgggagcag tggtggaatg cctttaatga ggaaaacctg ttttgctcag 5220 aagaaatgcc atctagtgat gatgaggcta ctgctgactc tcaacattct actcctccaa 5280 aaaagaagag aaaggtagaa gaccccaagg actttccttc agaattgcta agttttttga 5340 gtcatgctgt gtttagtaat agaactcttg cttgctttgc tatttacacc acaaaggaaa 5400 aagctgcact gctatacaag aaaattatgg aaaaatattc tgtaaccttt ataagtaggc 5460 ataacagtta taatcataac atactgtttt ttcttactcc acacaggcat agagtgtctg 5520 ctattaataa ctatgctcaa aaattgtgta cctttagctt tttaatttgt aaaggggtta 5580 ataaggaata tttgatgtat agtgccttga ctagagatca taatcagcca taccacattt 5640 gtagaggttt tacttgcttt aaaaaacctc ccacacctcc ccctgaacct gaaacataaa 5700 atgaatgcaa ttgttgttgt taacttgttt attgcagctt ataatggtta caaataaagc 5760 aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag ttgtggtttg 5820 tccaaactca tcaatgtatc ttatcatgtc tggatccggc tgtggaatgt gtgtcagtta 5880 gggtgtggaa agtccccagg ctccccagca ggcagaagta tgcaaagcat gcatctcaat 5940 tagtcagcaa ccaggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc 6000 atgcatctca attagtcagc aaccatagtc ccgcccctaa ctccgcccat cccgccccta 6060 actccgccca gttccgccca ttctccgccc catggctgac taattttttt tatttatgca 6120 ,gaggccgagg ccgcctcggc ctctgagcta ttccagaagt agtgaggagg cttttttgga 6180 ggcctaggct tttgcaaaaa gcttggacac aagacaggct tgcgagatat gtttgagaat 6240 accactttat cccgcgtcag ggagaggcag tgcgtaaaaa gacgcggact catgtgaaat 6300 actcjgttttt agtgcgccag atctctataa tctcgcgcaa cctattttcc cctcgaacac 6360 tttttaagcc gtagataaac aggctgggac acttcacatg agcgaaaaat acatcgtcac 6420 ctgggacatg ttgcagatcc atgcacgtaa actcgcaagc cgactgatgc cttctgaaca 6480 atggaaaggc attattgccg taagccgtgg cggtctggta ccgggtgcgt tactggcgcg 6540 tgaactgggt attcgtcatg tcgataccgt ttgtatttcc agctacgatc acgacaacca 6600 gcgcgagctt aaagtgctga aacgcgcaga aggcgatggc gaaggcttca tcgttattga 6660 tgacctggtg gataccggtg gtactgcggt tgcgattcgt gaaatgtatc caaaagcgca 6720 ctttgtcacc atcttcgcaa aaccggctgg tcgtccgctg gttgatgact atgttgttga 6780 tatcccgcaa gatacctgga ttgaacagcc gtgggatatg ggcgtcgtat tcgtcccgcc 6840 aatctccggt cgctaatctt ttcaacgcct ggcactgccg ggcgttgttc tttttaactt 6900 caggcgggtt acaatagttt ccagtaagta ttctggaggc tgcatccatg acacaggcaa 6960 acctgagcga aaccctgttc aaaccccgct ttaaacatcc tgaaacctcg acgctagtcc 7020 gccgctttaa tcacggcgca caaccgcctg tgcagtcggc ccttgatggt aaaaccatcc 7080 ctcactggta tcgcatgatt aaccgtctga tgtggatctg gcgcggcatt ~acccacgcg 7140 aaatcctcga cgtccaggca cgtattgtga tgagcgatgc cgaacgtacc gacgatgatt 7200 tatacgatac ggtgattggc taccgtggcg gcaactggat ttatgagtgg gccccggatc 7260 tttgtgaagg aaccttactt ctgtggtgtg acataattgg acaaactacc tacagagatt 7320 taaagctcta aggtaaatat aaaattttta agtgtataat gtgttaaact actgattcta 7380 attgtttgtg tattttagat tccaacctat ggaactgatg aatgggagca gtggtggaat 7440 gcctttaatg aggaaaacct gttttgctca gaagaaatgc catctagtga tgatgaggct 7500 actgctgact ctcaacattc tactcctcca aaaaagaaga gaaaggtaga agaccccaag 7560 gactttcctt cagaattgct aagttttttg agtcatgctg tgtttagtaa tagaactctt 7620 gcttgctttg ctatttacac cacaaaggaa aaagctgcac tgctatacaa gaaaattatg 7680 gaaaaatatt ctgtaacctt tataagtagg cataacagtt ataatcataa catactgttt 7740 tttcttactc cacacaggca tagagtgtct gctattaata actatgctca aaaattgtgt 7800 acctttagct ttttaatttg taaaggggtt aataaggaat atttgatgta tagtgccttg 7860 actagagatc ataatcagcc ataccacatt tgtagaggtt ttacttgctt taaaaaacct 7920 cccacacctc cccctgaacc tgaaacataa aatgaatgca attgttgttg ttaacttgtt 7980 tattgcagct tataatggtt acaaataaag caatagcatc acaaatttca caaataaagc 8040 atttttttca ctgcattcta gttgtggttt gtccaaactc atcaatgtat cttatcatgt 8100 ctggatcccc aggaagctcc tctgtgtcct cataaaccct aacctcctct acttgagagg 8160 acattccaat cataggctgc ccatccaccc tctgtgtcct cctgttaatt aggtcactta 8220 acaaaaagga aattgggtag gggtttttca cagaccgctt tctaagggta attttaaaat 8280 atctgggaag tcccttccac tgctgtgttc cagaagtgtt ggtaaacagc ccacaaatgt 8340 caacagcaga aacatacaag ctgtcagctt tgcacaaggg cccaacaccc tgctcatcaa 8400 gaagcactgt ggttgctgtg ttagtaatgt gcaaaacagg aggcacattt tccccacctg 8460 tgtaggttcc aaaatatcta gtgttttcat ttttacttgg atcaggaacc cagcactcca 8520 ctggataagc attatcctta tccaaaacag ccttgtggtc agtgttcatc tgctgactgt 8580 caactgtagc attttttggg gttacagttt gagcaggata tttggtcctg tagtttgcta 8640 acacaccctg cagctccaaa ggttccccac caacagcaaa aaaatgaaaa tttgaccctt 8700 gaatgggttt tccagcacca ttttcatgag ttttttgtgt ccctgaatgc aagtttaaca 8760 tagcagttac cccaataacc tcagttttaa cagtaacagc ttcccacatc aaaatatttc 8820 cacaggttaa gtcctcattt aaattaggca aaggaattct tgaagacgaa agggcctcgt 8880 gatacgccta tttttatagg ttaatgtcat gataataatg gtttcttaga cgtcaggtgg 8940 cacttttcgg ggaaatgtgc gcggaacccc tatttgttta tttttctaaa tacattcaaa 9000 tatgtatccg ctcatgagac aataaccctg ataaatgctt caataatatt gaaaaaggaa 9060 gagtatgagt attcaacatt tccgtgtcgc ccttattccc ttttttgcgg cattttgcct 9120 tcctgttttt gctcacccag aaacgctggt gaaagtaaaa gatgctgaag atcagttggg 9180 tgcacgagtg ggttacatcg aactggatct caacagcggt aagatccttg agagttttcg 9240 ccccgaagaa cgttttccaa tgatgagcac ttttaaagtt ctgctatgtg gcgcggtatt 9300 atcccgtgtt gacgccgggc aagagcaact cggtcgccgc atacactatt ctcagaatga 9360 cttggttgag tactcaccag tcacagaaaa gcatcttacg gatggcatga cagtaagaga 9420 attatgcagt gctgccataa ccatgagtga taacactgcg gccaacttac ttctgacaac 9480 gatcggagga ccgaaggagc taaccgcttt tttgcacaac atgggggatc atgtaactcg 9540 WO 00/42208 cA 02359795 2001-07-12 pCT/EP00/00265 ccttgatcgt tgggaaccgg agctgaatga agccatacca aacgacgagc gtgacaccac 9600 gatgcctgca gcaatggcaa caacgttgcg caaactatta actggcgaac tacttactct 9660 agcttcccgg caacaattaa tagactggat ggaggcggat aaagttgcag gaccacttct 9720 gcgctcggcc cttccggctg gctggtttat tgctgataaa tctggagccg gtgagcgtgg 9780 gtctcgcggt atcattgcag cactggggcc agatggtaag ccctcccgta tcgtagttat 9840 ctacacgacg gggagtcagg caactatgga tgaacgaaat agacagatcg ctgagatagg 9900 tgcctcactg attaagcatt ggtaactgtc agaccaagtt tactcatata tactttagat 9960 tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt ttgataatct 10020 catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc ccgtagaaaa 10080 gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct tgcaaacaaa 10140 aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa ctctttttcc 10200 gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag tgtagccgta 10260 gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc tgctaatcct 10320 gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg actcaagacg 10380 atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca cacagcccag 10440 cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat gagaaagcgc 10500 cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg tcggaacagg 10560 agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc ctgtcgggtt 10620 tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc ggagcctatg 10680 gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc cttttgctca 10740 catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg cctttgagtg 10800 agctgatacc gctcgccgca gccgaacgac cgagcgcagc gagtcagtga ~cgaggaagc 10860 ggaagagcgc ctgatgcggt attttctcct tacgcatctg tgcggtattt cacaccgcat 10920 accgcctcag aagccataga gcccaccgca tccccagcat gcctgctatt gtcttcccaa 10980 tcctccccct tgctgtcctg ccccacccca ccccccagaa tagaatgaca cctactcaga 11040 caatgcgatg caatttcctc attttattag gaaaggacag tgggagtggc accttccagg 11100 gtcaaggaag gcacggggga ggggcaaaca acagatggct ggcaactaga aggcacagtc 11160 gaggctgatc agcgagctct agcatttagg tgacactata gaatagggcc ctctagatgc 11220 atgctcgagc ggccgcttct ttattcttgg gcaatgtatg aaaaagtgta agaggatgtg 11280 gcaaatattt cattaatgta gttgtggcca gaccagtccc atgaaaatga catagagtat 11340 gcacttggag ttgtgtctcc tgtttcctgt gtaccgttta gtgtaatggt tagtgttaca 11400 ggtttagttt tgtctccgtt taagtaaact tgactgacaa tgttactttt ggcagtttta 11460 ccgtgagatt ttggataagc tgataggtta ggcataaatc caacagcgtt tgtataggct 11520 gtgccttcag taagatctcc atttctaaag ttccaatatt ctgggtccag gaaggaattg 11580 tttagtagca ctccattttc gtcaaatctt ataataagat gagcactttg aactgttcca 11640 gatattggag ccaaactgcc tttaacagcc aaaactgaaa ctgtagcaag tatttgactg 11700 ccacattttg ttaagaccaa agtgagttta gcatctttct ctgcatttag tctacagtta 11760 ggagatggag ctggtgtggt ccacaaagtt agcttatcat tatttttgtt tcctactgta 11820 atggcacctg tgctgtcaaa actaaggcca gttcctagtt taggaaccat agccttgttt 11880 gaatcaaatt ctaggccatg gccaattttt gttttgaggg gatttgtgtt tggtgcatta 11990 ggtgaaccaa attcaagccc atctcctgca ttaatggcta tggctgtagc gtcaaacatc 12000 aaccccttgg cagtgcttag gttaacctca agctttttgg aattgtttga agctgtaaac 12060 aagtaaaggc ctttgttgta gttaatatcc aagttgtggg ctgagtttat aaaaagaggg 12120 ccctgtccta gtcttagatt tagttggttt tgagcatcaa acggataact aacatcaagt 12180 ataaggcgtc tgttttgaga atcaatcctt agtcctcctg ctacattaag ttgcatattg 12240 ccttgtgaat caaaacccaa ggctccagta actttagttt gcaaggaagt attattaata 12300 gtcacacctg gaccagttgc tacggtcaaa gtgtttaggt cgtctgttac atgcaaagga 12360 gccccgtact ttagtcctag ttttccattt tgtgtataaa tgggctcttt caagtcaatg 12420 cccaagctac cagtggcagt agttagaggg ggtgaggcag tgatagtaag ggtactgcta 12480 tcggtggtgg tgagggggcc tgatgtttgc agggctagct ttccttctga cactgtgagg 12540 ggtccttggg tggcaatgct aagtttggag tcgtgcacgg ttagcggggc ctgtgattgc 12600 atggtgagtg tgttgcccgc gaccattaga ggtgcggcgg cagccacagt tagggcttct 12660 gaggtaactg tgaggggtgc agatatttcc aggtttatgt ttgacttggt ttttttgaga 12720 ggtgggctca cagtggttac attttgggag gtaaggttgc cggcctcgtc cagagagagg 12780 ccgttgccca ttttgagcgc aagcatgcca ttggaggtaa ctagaggttc ggataggcgc 12840 aaagagagta ccccaggggg actctcttga aacccattgg gggatacaaa gggaggagta 12900 agaaaaggca cagttggagg accggtttcc gtgtcatatg gatacacggg gttgaaggta 12960 tcttcagacg gtcttgcgcg cttcatcttg gatctcaagc ctgccacacc tcacctcgac 13020 catccgccgt ctcaagaccg cctactttaa ttacatcatc agcagcacct ccgccagaaa 13080 caaccccgac cgccacccgc tgccgcccgc cacggtgctc agcctacctt gcgactgtga 13140 ctggttagac gcctttctcg agaggttttc cgatccggtc gatgcggact cgctcaggtc 13200 cctcggtggc ggagtaccgt tcggaggccg acgggtttcc gatccaagag tactggaaag 13260 accgcgaaga gtttgtcctc aaccgcgagc ccaacagcga gctcgaattc agatccgagc 13320 tcggtaccaa gcttgggtct ccctatagtg agtcgtatta atttcgataa gccagtaagc 13380 agtgggttct ctagttagcc agagagctct gcttatatag acctcccacc gtacacgcct 13440 accgcccatt tgcgtcaatg gggcggagtt gttacgacat tttggaaagt cccgttgatt 13500 ttggtgccaa aacaaactcc cattgacgtc aatggggtgg agacttggaa atccccgtga 13560 gtcaaaccgc tatccacgcc cattgatgta ctgccaaaac cgcatcacca tggtaatagc 13620 gatgactaat acgtagatgt actgccaagt aggaaagtcc cataaggtca tgtactgggc 13680 ataatgccag gcgggccatt taccgtcatt gacgtcaata gggggcgtac ttggcatatg 13740 atacacttga tgtactgcca agtgggcagt ttaccgtaaa tagtccaccc attgacgtca 13800 atggaaagtc cctattggcg ttactatggg aacatacgtc attattgacg tcaatgggcg 13860 ggggtcgttg ggcggtcagc caggcgggcc atttaccgta agttatgtaa cgcggaactc 13920 catatatggg ctatgaacta atgaccccgt aattgattac tattaataac tagtcaataa 13980 tcaatgtcaa cgcgtatatc tggcccgtac atcgcgaagc agcgcaaaac gcctaaccct 14040 aagcagattc ttcatgcaat tgtcggtcaa gccttgcctt gttgtagctt aaattttgct 14100 cgcgcactac tcagcgacct ccaacacaca agcagggagc agatactggc ttaactatgc 14160 ggcatcagag cagattgtac tgagagtcga ccatagggga tcgggagatc tcccgatccg 14220 tctatggtgc actctcagta caatctgctc tgatgccgca tagttaagcc agtatacact 14280 ccgctatcgc tacgtgactg ggtcatggct gcgccccgac acccgccaac acccgctgac 14340 gcgccctgac gggcttgtct gctcccggca tccgcttaca gacaagctgt gaccgtctcc 14400 gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag gcagc 14455 <210> 16 <211> 10610 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 16 gacggatcgg gagatccgcg cggtacacag aattcaggag acacaactcc aagtgcatac 60 tctatgtcat tttcatggga ctggtctggc cacaactaca ttaatgaaat atttgccaca 120 tcctcttaca ctttttcata cattgcccaa gaataaagaa tcgtttgtgt tatgtttcaa 180 cgtgtttatt tttcaattgc agaaaatttc aagtcatttt tcattcagta gtatagcccc 240 accaccacat agcttataca gatcaccgta ccttaatcaa actcacagaa ccctagtatt 300 caacctgcca cctccctccc aacacacaga gtacacagtc ctttctcccc ggctggcctt 360 aaaaagcatc atatcatggg taacagacat attcttaggt gttatattcc acacggtttc 420 ctgtcgagcc aaacgctcat cagtgatatt aataaactcc ccgggcagct cacttaagtt 480 catgtcgctg tccagctgct gagccacagg ctgctgtcca acttgcggtt gcttaacggg 540 cggcgaagga gaagtccacg cctacatggg ggtagagtca taatcgtgca tcaggatagg 600 gcggtggtgc tgcagcagcg cgcgaataaa ctgctgccgc cgccgctccg tcctgcagga 660 atacaacatg gcagtggtct cctcagcgat gattcgcacc gcccgcagca taaggcgcct 720 tgtcctccgg gcacagcagc gcaccctgat ctcacttaaa tcagcacagt aactgcagca 780 cagcaccaca atattgttca aaatcccaca gtgcaaggcg ctgtatccaa agctcatggc 840 ggggaccaca gaacccacgt ggccatcata ccacaagcgc aggtagatta agtggcgacc 900 cctcataaac acgctggaca taaacattac ctcttttggc atgttgtaat tcaccacctc 960 ccggtaccat ataaacctct gattaaacat ggcgccatcc accaccatcc taaaccagct 1020 ggccaaaacc tgcccgccgg ctatacactg cagggaaccg ggactggaac aatgacagtg 1080 gagagcccag gactcgtaac catggatcat catgctcgtc atgatatcaa tgttggcaca 1140 acacaggcac acgtgcatac acttcctcag gattacaagc tcctcccgcg ttagaaccat 1200 atcccaggga acaacccatt cctgaatcag cgtaaatccc acactgcagg gaagacctcg 1260 cacgtaactc acgttgtgca ttgtcaaagt gttacattcg ggcagcagcg gatgatcctc 1320 cagtatggta gcgcgggttt ctgtctcaaa aggaggtaga cgatccctac tgtacggagt 1380 gcgccgagac aaccgagatc gtgttggtcg tagtgtcatg ccaaatggaa cgccggacgt 1440 agtcatattt cctgaagcaa aaccaggtgc gggcgtgaca aacagatctg cgtctccggt 1500 ctcgccgctt agatcgctct gtgtagtagt tgtagtatat ccactctctc aaagcatcca 1560 ggcgccccct ggcttcgggt tctatgtaaa ctccttcatg cgccgctgcc ctgataacat 1620 ccaccaccgc agaataagcc acacccagcc aacctacaca ttcgttctgc gagtcacaca 1680 cgggaggagc gggaagagct ggaagaacca tgtttttttt tttattccaa aagattatcc 1740 aaaacctcaa aatgaagatc tattaagtga acgcgctccc ctccggtggc gtggtcaaac 1800 tctacagcca aagaacagat aatggcattt gtaagatgtt gcacaatggc ttccaaaagg 1860 caaacggccc tcacgtccaa gtggacgtaa aggctaaacc cttcagggtg aatctcctct 1920 ataaacattc cagcaccttc aaccatgccc aaataattct catctcgcca ccttctcaat 1980 atatctctaa gcaaatcccg aatattaagt ccggccattg taaaaatctg ctccagagcg 2040 ccctccacct tcagcctcaa gcagcgaatc atgattgcaa aaattcaggt tcctcacaga.2100 cctgtataag attcaaaagc ggaacattaa caaaaatacc gcgatcccgt aggtcccttc 2160 gcagggccag ctgaacataa tcgtgcaggt ctgcacggac cagcgcggcc acttccccgc 2220 caggaacctt gacaaaagaa cccacactga ttatgacacg catactcgga gctatgctaa 2280 ccagcgtagc cccgatgtaa gctttgttgc atgggcggcg atataaaatg caaggtgctg 2340 ctcaaaaaat caggcaaagc ctcgcgcaaa aaagaaagca catcgtagtc atgctcatgc 2400 agataaaggc aggtaagctc cggaaccacc acagaaaaag acaccatttt tctctcaaac 2960 atgtctgcgg gtttctgcat aaacacaaaa taaaataaca aaaaaacatt taaacattag 2520 aagcctgtct tacaacagga aaaacaaccc ttataagcat aagacggact acggccatgc 2580 cggcgtgacc gtaaaaaaac tggtcaccgt gattaaaaag caccaccgac agctcctcgg 2640 tcatgtccgg agtcataatg taagactcgg taaacacatc aggttgattc atcggtcagt 2700 gctaaaaagc gaccgaaata gcccggggga atacataccc gcaggcgtag agacaacatt 2760 acagccccca taggaggtat aacaaaatta ataggagaga aaaacacata aacacctgaa 2820 aaaccctcct gcctaggcaa aatagcaccc tcccgctcca gaacaacata cagcgcttca 2880 cagcggcagc ctaacagtca gccttaccag taaaaaagaa aacctattaa aaaaacacca 2940 ctcgacacgg caccagctca atcagtcaca gtgtaaaaaa gggccaagtg cagagcgagt 3000 atatatagga ctaaaaaatg acgtaacggt taaagtccac aaaaaacacc cagaaaaccg 3060 cacgcgaacc tacgcccaga aacgaaagcc aaaaaaccca caacttcctc aaatcgtcac 3120 ttccgttttc ccacgttacg taacttcccg gatcctctcc cgatccccta ~ggtcgactc 3180 tcagtacaat ctgctctgat gccgcatagt taagccagta tctgctccct gcttgtgtgt 3240 tggaggtcgc tgagtagtgc gcgagcaaaa tttaagctac aacaaggcaa ggcttgaccg 3300 acaattgcat gaagaatctg cttagggtta ggcgttttgc gctgcttcgc gatgtacggg 3360 ccagatatac gcgttgacat tgattattga ctagttatta atagtaatca attacggggt 3420 cattagttca tagcccatat atggagttcc gcgttacata acttacggta aatggcccgc 3480 ctggctgacc gcccaacgac ccccgcccat tgacgtcaat aatgacgtat gttcccatag 3540 taacgccaat agggactttc cattgacgtc aatgggtgga ctatttacgg taaactgccc 3600 acttggcagt acatcaagtg tatcatatgc caagtacgcc ccctattgac gtcaatgacg 3660 gtaaatggcc cgcctggcat tatgcccagt acatgacctt atgggacttt cctacttggc 3720 agtacatcta cgtattagtc atcgctatta ccatggtgat gcggttttgg cagtacatca 3780 atgggcgtgg atagcggttt gactcacggg gatttccaag tctccacccc attgacgtca 3840 atgggagttt gttttggcac caaaatcaac gggactttcc aaaatgtcgt aacaactccg 3900 ccccattgac gcaaatgggc ggtaggcgtg tacggtggga ggtctatata agcagagctc 3960 tctggctaac tagagaaccc actgcttact ggcttatcga aattaatacg actcactata 4020 gggagaccca agcttggtac cgagctcgga tctgaattcg agctcgctgt tgggctcgcg 4080 gttgaggaca aactcttcgc ggtctttcca gtactcttgg atcggaaacc cgtcggcctc 4140 cgaacggtac tccgccaccg agggacctga gcgagtccgc atcgaccgga tcggaaaacc 4200 tctcgagaaa ggcgtctaac cagtcacagt cgcaaggtag gctgagcacc gtggcgggcg 4260 gcagcgggtg gcggtcgggg ttgtttctgg cggaggtgct gctgatgatg taattaaagt 4320 aggcggtctt gagacggcgg atggtcgagg tgaggtgtgg caggcttgag atccaagatg 4380 aagcgcgcaa gaccgtctga agataccttc aaccccgtgt atccatatga cacggaaacc 4440 ggtcctccaa ctgtgccttt tcttactcct ccctttgtat cccccaatgg gtttcaagag 4500 agtccccctg gggtactctc tttgcgccta tccgaacctc tagttacctc caatggcatg 4560 cttgcgctca aaatgggcaa cggcctctct ctggacgagg ccggcaacct tacctcccaa 4620 aatgtaacca ctgtgagccc acctctcaaa aaaaccaagt caaacataaa cctggaaata 4680 tctgcacccc tcacagttac ctcagaagcc ctaactgtgg ctgccgccgc acctctaatg 4740 gtcgcgggca acacactcac catgcaatca caggccccgc taaccgtgca cgactccaaa 4800 cttagcattg ccacccaagg acccctcaca gtgtcagaag gaaagctagc cctgcaaaca 9860 tcaggccccc tcaccaccac cgatagcagt acccttacta tcactgcctc accccctcta 4920 actactgcca ctggtagctt gggcattgac ttgaaagagc ccatttatac acaaaatgga 4980 aaactaggac taaagtacgg ggctcctttg catgtaacag acgacctaaa cactttgacc 5040 gtagcaactg gtccaggtgt gactattaat aatacttcct tgcaaactaa agttactgga 5100 gccttgggtt ttgattcaca aggcaatatg caacttaatg tagcaggagg actaaggatt 5160 gattctcaaa acagacgcct tatacttgat gttagttatc cgtttgatgc tcaaaaccaa 5220 ctaaatctaa gactaggaca gggccctctt tttataaact cagcccacaa cttggatatt 5280 aactacaaca aaggccttta cttgtttaca gcttcaaaca attccaaaaa gcttgaggtt 5340 aacctaagca ctgccaaggg gttgatgttt gacgctacag ccatagccat taatgcagga 5400 gatgggcttg aatttggttc acctaatgca ccaaacacaa atcccctcaa aacaaaaatt 5460 ggccatggcc tagaatttga ttcaaacaag gctatggttc ctaaactagg aactggcctt 5520 agttttgaca gcacaggtgc cattacagta ggaaacaaaa ataatgataa gctaactttg 5580 tggaccacac cagctccatc tcctaactgt agactaaatg cagagaaaga tgctaaactc 5640 actttggtct taacaaaatg tggcagtcaa atacttgcta cagtttcagt tttggctgtt 5700 aaaggcagtt tggctccaat atctggaaca gttcaaagtg ctcatcttat tataagattt 5760 gacgaaaatg gagtgctact aaacaattcc ttcctggacc cagaatattg gaactttaga 5820 aatggagatc ttactgaagg cacagcctat acaaacgctg ttggatttat gcctaaccta 5880 tcagcttatc caaaatctca cggtaaaact gccaaaagta acattgtcag tcaagtttac 5940 ttaaacggag acaaaactaa acctgtaaca ctaaccatta cactaaacgg tacacaggaa 6000 acaggagaca caactccaag tgcatactct atgtcatttt catgggactg gtctggccac 6060 aactacatta atgaaatatt tgccacatcc tcttacactt tttcatacat tgcccaagaa 6120 taaagaagcg gccgctcgag catgcatcta gagggcccta ttctatagtg tcacctaaat 6180 gctagagctc gctgatcagc ctcgactgtg ccttctagtt gccagccatc tgttgtttgc 6240 ccctcccccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct ttcctaataa 6300 aatgaggaaa.ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg gggtggggtg 6360 gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcatgctgg ggatgcggtg 6420 ggctctatgg cttctgaggc ggaaagaacc agctggggct ctagggggta tccccacgcg 6480 ccctgtagcg gcgcattaag cgcggcgggt gtggtggtta cgcgcagcgt gaccgctaca 6540 cttgccagcg ccctagcgcc cgctcctttc gctttcttcc cttcctttct cgccacgttc 6600 gccggctttc cccgtcaagc tctaaatcgg ggcatccctt tagggttccg atttagtgct 6660 ttacggcacc tcgaccccaa aaaacttgat tagggtgatg gttcacgtag tgggccatcg 6720 ccctgataga cggtttttcg ccctttgacg ttggagtcca cgttctttaa tagtggactc 6780 ttgttccaaa ctggaacaac actcaaccct atctcggtct attcttttga tttataaggg 6840 attttgggga tttcggccta ttggttaaaa aatgagctga tttaacaaaa ~tttaacgcg 6900 aattaattct gtggaatgtg tgtcagttag ggtgtggaaa gtccccaggc tccccaggca 6960 ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa ccaggtgtgg aaagtcccca 7020 ggctccccag caggcagaag tatgcaaagc atgcatctca attagtcagc aaccatagtc 7080 ccgcccctaa ctccgcccat cccgccccta actccgccca gttccgccca ttctccgccc 7140 catggctgac taattttttt tatttatgca gaggccgagg ccgcctctgc ctctgagcta 7200 ttccagaagt agtgaggagg cttttttgga ggcctaggct tttgcaaaaa gctcccggga 7260 gcttgtatat ccattttcgg atctgatcaa gagacaggat gaggatcgtt tcgcatgatt 7320 gaacaagatg gattgcacgc aggttctccg gccgcttggg tggagaggct attcggctat 7380 gactgggcac aacagacaat cggctgctct gatgccgccg tgttccggct gtcagcgcag 7440 gggcgcccgg ttctttttgt caagaccgac ctgtccggtg ccctgaatga actgcaggac 7500 gaggcagcgc ggctatcgtg gctggccacg acgggcgttc cttgcgcagc tgtgctcgac 7560 gttgtcactg aagcgggaag ggactggctg ctattgggcg aagtgccggg gcaggatctc 7620 ctgtcatctc accttgctcc tgccgagaaa gtatccatca tggctgatgc aatgcggcgg 7680 ctgcatacgc ttgatccggc tacctgccca ttcgaccacc aagcgaaaca tcgcatcgag 7740 cgagcacgta ctcggatgga agccggtctt gtcgatcagg atgatctgga cgaagagcat 7800 caggggctcg cgccagccga actgttcgcc aggctcaagg cgcgcatgcc cgacggcgag 7860 gatctcgtcg tgacccatgg cgatgcctgc ttgccgaata tcatggtgga aaatggccgc 7920 ttttctggat tcatcgactg tggccggctg ggtgtggcgg accgctatca ggacatagcg 7980 ttggctaccc gtgatattgc tgaagagctt ggcggcgaat gggctgaccg cttcctcgtg 8040 ctttacggta tcgccgctcc cgattcgcag cgcatcgcct tctatcgcct tcttgacgag 8100 ttcttctgag cgggactctg gggttcgaaa tgaccgacca agcgacgccc aacctgccat 8160 cacgagattt cgattccacc gccgccttct atgaaaggtt gggcttcgga atcgttttcc 8220 gggacgccgg ctggatgatc ctccagcgcg gggatctcat gctggagttc ttcgcccacc 8280 ccaacttgtt tattgcagct tataatggtt acaaataaag caatagcatc acaaatttca 8340 caaataaagc atttttttca ctgcattcta gttgtggttt gtccaaactc atcaatgtat 8400 cttatcatgt ctgtataccg tcgacctcta gctagagctt ggcgtaatca tggtcatagc 8460 tgtttcctgt gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca 8520 taaagtgtaa agcctggggt gcctaatgag tgagctaact cacattaatt gcgttgcgct 8580 cactgcccgc tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcggccaac 8640 gcgcggggag aggcggtttg cgtattgggc gctcttccgc ttcctcgctc actgactcgc 8700 tgcgctcggt cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt 8760 tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg 8820 ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg 8880 agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat 8940 accaggcgtt tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta 9000 ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcaa tgctcacgct 9060 gtaggtatct cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc 9120 ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa 9180 gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg 9290 taggcggtgc tacagagttc ttgaagtggt ggcctaacta cggctacact agaaggacag 9300 tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt 9360 gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta 9420 cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 9480 agtggaacga aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca 9540 cctagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa 9600 cttggtctga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat 9660 ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct 9720 taccatctgg ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt 9780 tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat 9840 ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta 9900 atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg 9960 gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt 10020 tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg 10080 cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg 10140 taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc 10200 ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa 10260 ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac 10320 cgctgttgag atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt 10380 ttactttcac cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg 10440 gaataagggc gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa 10500 gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata 10560 aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc Y 10610 <210> 17 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Primer <400> 17 tgtacaccgg atccggcgca cacc 24 <210> 18 <211> 35 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: Primer <400> 18 cacaacgagc tcaattaatt aattgccaca tcctc 35 <210> 19 <211> 4 <212> PRT
<213> adenovirus <400> 19 Thr Leu Trp Thr <210> 20 <211> 12 <212> PRT
<213> adenovirus <400> 20 Pro Ser SerAla SerAlaSer AlaPro GlySer Ala <210> 21 <211> 44 <212> PRT

<213> adenovirus <400> 21 Met Lys AlaArg ProSerGlu AspThr PheAsn Pro Val Tyr Arg Pro Tyr Asp GluThr GlyProPro ThrVal ProPhe Leu Thr Pro Thr Pro Phe Val ProAsn GlyPheGln GluSer ProPro Ser <210> 22 <211> 43 <212> PRT

<213> adenovirus <400> 22 Met Ala Lys Arg Ala Leu ThrSer Phe Asn Pro Val Arg Ser Tyr Pro Tyr Glu Asp Glu Ser Ser HisPro Phe Ile Asn Pro Ser Gln Gly Phe Ile Ser Pro Asp Gly Thr SerPro Asn Phe Gln <210> 23 <211> 43 <212> PRT

<213> adenovirus <400> 23 Met Ser Lys Arg Leu Arg Val Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr Gly Tyr Ala Arg Asn Gln Asn Ile Pro Phe Leu Thr Pro Pro Phe Val Ser Ser Asp Gly Phe Lys Asn Phe Pro Pro <210> 24 <211> 42 <212> PRT
<213> adenovirus <400> 24 Met Lys Arg Ala Arg Phe Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 Glu His Tyr Asn Pro Leu Asp Ile Pro Phe Ile Thr Pro Pro Phe Ala 20 ~ 25 30 Ser Ser Asn Gly Leu Gln Glu Lys Pro Pro <210> 25 <211> 42 <212> PRT
<213> adenovirus <400> 25 Met Lys Arg Thr Arg Ile Glu Asp Asp Phe Asn Pro Val Tyr Pro Tyr 1 ' S 10 15 Asp Thr Ser Ser Thr Pro Ser Ile Pro Tyr Val Ala Pro Pro Phe Val Ser Ser Asp Gly Leu Gln Glu Asn Pro Pro <210> 26 <211> 327 <212> DNA
<213> adenovirus <400> 26 agatctgaat tcgagctcgc tgttgggctc gcggttgagg acaaactctt cgcggtcttt 60 ccagtactct tggatcggaa acccgtcggc ctccgaacgg tactccgcca ccgagggacc 120 tgagcgagtc cgcatcgacc ggatcggaaa acctctcgag aaaggcgtct aaccagtcac 180 agtcgcaagg taggctgagc accgtggcgg gcggcagcgg gtggcggtcg gggttgtttc 240 tggcggaggt gctgctgatg atgtaattaa agtaggcggt cttgagacgg cggatggtcg 300 aggtgaggtg tggcaggctt gagatct 327 <210> 27 <211> 32480 <212> DNA
<213> adenovirus <400> 27 catcatcaat aatatacctt attttggatt gaagccaata tgataatgag ggggtggagt 60 ttgtgacgtg gcgcggggcg tgggaacggg gcgggtgacg tagtagtgtg gcggaagtgt 120 gatgttgcaa gtgtggcgga acacatgtaa gcgacggatg tggcaaaagt gacgtttttg 180 gtgtgcgccg gtgtacacag gaagtgacaa ttttcgcgcg gttttaggcg gatgttgtag 240 taaatttggg cgtaaccgag taagatttgg ccattttcgc gggaaaactg aataagagga 300 agtgaaatct gaataatttt gtgttactca tagcgcgtaa tctctagcat cgatgtcgac 360 aagcttgaat tcgattaatg tgagttagct cactcattag gcaccccagg ctttacactt 420 tatgcttccg gctcgtatgt tgtgtggaat tgtgagcgga taacaatttc acacaggaaa 480 cagctatgac catgattacg aattcggcgc agcaccatgg cctgaaataa cctctgaaag 540 aggaacttgg ttaggtacct tctgaggcgg aaagaaccag ctgtggaatg tgtgtcagtt 600 agggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca tgcatctcaa 660 ttagtcagca accaggtgtg gaaagtcccc aggctcccca gcaggcagaa gtatgcaaag 720 catgcatctc aattagtcag caaccatagt cccgccccta actccgccca tcccgcccct 780 aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt ttatttatgc 840 agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag gcttttttgg 900 aggcctaggc ttttgcaaaa agcttgggat ctctataatc tcgcgcaacc tattttcccc 960 tcgaacactt tttaagccgt agataaacag gctgggacac ttcacatgag cgaaaaatac 1020 atcgtcacct gggacatgtt gcagatccat gcacgtaaac tcgcaagccg actgatgcct 1080 tctgaacaat ggaaaggcat tattgccgta agccgtggcg gtctggtacc ggtgggtgaa 1140 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 gaccagaaac agcacctcga actgagccgc gatattgccc agcgtttcaa cgcgctgtat 1200 ggcgagatcg atcccgtcgt tttacaacgt cgtgactggg aaaaccctgg cgttacccaa 1260 cttaatcgcc ttgcagcaca tccccctttc gccagctggc gtaatagcga agaggcccgc 1320 accgatcgcc cttcccaaca gttgcgcagc ctgaatggcg aatggcgctt tgcctggttt 1380 ccggcaccag aagcggtgcc ggaaagctgg ctggagtgcg atcttcctga ggccgatact 1440 gtcgtcgtcc cctcaaactg gcagatgcac ggttacgatg cgcccatcta caccaacgta 1500 acctatccca ttacggtcaa tccgccgttt gttcccacgg agaatccgac gggttgttac 1560 tcgctcacat ttaatgttga tgaaagctgg ctacaggaag gccagacgcg aattattttt 1620 gatggcgtta actcggcgtt tcatctgtgg tgcaacgggc gctgggtcgg ttacggccag 1680 gacagtcgtt tgccgtctga atttgacctg agcgcatttt tacgcgccgg agaaaaccgc 1740 ctcgcggtga tggtgctgcg ttggagtgac ggcagttatc tggaagatca ggatatgtgg 1800 cggatgagcg gcattttccg tgacgtctcg ttgctgcata aaccgactac acaaatcagc 1860 gatttccatg ttgccactcg ctttaatgat gatttcagcc gcgctgtact ggaggctgaa 1920 gttcagatgt gcggcgagtt gcgtgactac ctacgggtaa cagtttcttt atggcagggt 1980 gaaacgcagg tcgccagcgg caccgcgcct ttcggcggtg aaattatcga tgagcgtggt 2040 ggttatgccg atcgcgtcac actacgtctg aacgtcgaaa acccgaaact gtggagcgcc 2100 gaaatcccga atctctatcg tgcggtggtt gaactgcaca ccgccgacgg cacgctgatt 2160 gaagcagaag cctgcgatgt cggtttccgc gaggtgcgga ttgaaaatgg tctgctgctg 2220 ctgaacggca agccgttgct gattcgaggc gttaaccgtc acgagcatca tcctctgcat 2280 ggtcaggtca tggatgagca gacgatggtg caggatatcc tgctgatgaa gcagaacaac 2340 tttaacgccg tgcgctgttc gcattatccg aaccatccgc tgtggtacac gctgtgcgac 2400 cgctacggcc tgtatgtggt ggatgaagcc aatattgaaa cccacggcat ggtgccaatg 2460 aatcgtctga ccgatgatcc gcgctggcta ccggcgatga gcgaacgcgt aacgcgaatg 2520 gtgcagcgcg atcgtaatca cccgagtgtg atcatctggt cgctggggaa tgaatcaggc 2580 cacggcgcta atcacgacgc gctgtatcgc tggatcaaat ctgtcgatcc ttcccgcccg 2640 gtgcagtatg aaggcggcgg agccgacacc acggccaccg atattatttg cccgatgtac 2700 gcgcgcgtgg atgaagacca gcccttcccg gctgtgccga aatggtccat caaaaaatgg 2760 ctttcgctac ctggagagac gcgcccgctg atcctttgcg aatacgccca cgcgatgggt 2820 aacagtcttg gcggtttcgc taaatactgg caggcgtttc gtcagtatcc ccgtttacag 2880 ggcggcttcg tctgggactg ggtggatcag tcgctgatta aatatgatga aaacggcaac 2940 ccgtggtcgg cttacggcgg tgattttggc gatacgccga acgatcgcca gttctgtatg 3000 aacggtctgg tctttgccga ccgcacgccg catccagcgc.tgacggaagc aaaacaccag 3060 cagcagtttt tccagttccg tttatccggg caa3ccatcg aagtgaccag cgaatacctg 3120 ttccgtcata gcgataacga gctcctgcac tggatggtgg cgctggatgg taagccgctg 3180 gcaagcggtg aagtgcctct ggatgtcgct ccacaaggta aacagttgat tgaactgcct 3240 gaactaccgc agccggagag cgccgggcaa ctctggctca cagtacgcgt agtgcaaccg 3300 aacgcgaccg catggtcaga agccgggcac atcagcgcct ggcagcagtg gcgtctggcg 3360 gaaaacctca gtgtgacgct ccccgccgcg tcccacgcca tcccgcatct gaccaccagc 3420 gaaatggatt tttgcatcga gctgggtaat aagcgttggc aatttaaccg ccagtcaggc 3480 tttctttcac agatgtggat tggcgataaa aaacaactgc tgacgccgct gcgcgatcag 3540 ttcacccgtg caccgctgga taacgacatt ggcgtaagtg aagcgacccg cattgaccct 3600 aacgcctggg tcgaacgctg gaaggcggcg ggccattacc aggccgaagc agcgttgttg 3660 cagtgcacgg cagatacact tgctgatgcg gtgctgatta cgaccgctca cgcgtggcag 3720 catcagggga aaaccttatt tatcagccgg aaaacctacc ggattgatgg tagtggtcaa 3780 atggcgatta ccgttgatgt tgaagtggcg agcgatacac cgcatccggc gcggattggc 3840 ctgaactgcc agctggcgca ggtagcagag cgggtaaact ggctcggatt agggccgcaa 390b gaaaactatc ccgaccgcct tactgccgcc tgttttgacc gctgggatct gccattgtca 3960 gacatgtata ccccgtacgt cttcccgagc gaaaacggtc tgcgctgcgg gacgcgcgaa 4020 ttgaattatg gcccacacca gtggcgcggc gacttccagt tcaacatcag ccgctacagt 4080 caacagcaac tgatggaaac cagccatcgc catctgctgc acgcggaaga aggcacatgg 4140 ctgaatatcg acggtttcca tatggggatt ggtggcgacg actcctggag cccgtcagta 4200 tcggcggaat tccagctgag cgccggtcgc taccattacc agttggtctg gtgtcaaaaa 4260 taataataac cgggcaggcc atgtctgccc gtatttcgcg taaggaaatc cattatgtac 4320 tatttaaaaa acacaaactt ttggatgttc ggtttattct ttttctttta cttttttatc 4380 atgggagcct acttcccgtt tttcccgatt tggctacatg acatcaacca tatcagcaaa 4440 agtgatacgg gtattatttt tgccgctatt tctctgttct cgctattatt ccaaccgctg 4500 tttggtctgc tttctgacaa actcggaact tgtttattgc agcttataat ggttacaaat 4560 aaagcaatag catcacaaat ttcacaaata aagcattttt ttcactgcat tctagttgtg 4620 gtttgtccaa actcatcaat gtatcttatc atgtctggat ccagatctgg gcgtggctta 4680 agggtgggaa agaatatata aggtgggggt cttatgtagt tttgtatctg ttttgcagca 4740 gccgccgccg ccatgagcac caactcgttt gatggaagca ttgtgagctc atatttgaca 4800 acgcgcatgc ccccatgggc cggggtgcgt cagaatgtga tgggctccag cattgatggt 4860 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 cgccccgtcc tgcccgcaaa ctctactacc ttgacctacg agaccgtgtc tggaacgccg 4920 ttggagactg cagcctccgc cgccgcttca gccgctgcag ccaccgcccg cgggattgtg 4980 actgactttg ctttcctgag cccgcttgca agcagtgcag cttcccgttc atccgcccgc 5040 gatgacaagt tgacggctct tttggcacaa ttggattctt tgacccggga acttaatgtc 5100 gtttctcagc agctgttgga tctgcgccag caggtttctg ccctgaaggc ttcctcccct 5160 cccaatgcgg tttaaaacat aaataaaaaa ccagactctg tttggatttg gatcaagcaa 5220 gtgtcttgct gtctttattt aggggttttg cgcgcgcggt aggcccggga ccagcggtct 5280 cggtcgttga gggtcctgtg tattttttcc aggacgtggt aaaggtgact ctggatgttc 5340 agatacatgg gcataagccc gtctctgggg tggaggtagc accactgcag agcttcatgc 5400 tgcggggtgg tgttgtagat gatccagtcg tagcaggagc gctgggcgtg gtgcctaaaa 5460 atgtctttca gtagcaagct gattgccagg ggcaggccct tggtgtaagt gtttacaaag 5520 cggttaagct gggatgggtg catacgtggg gatatgagat gcatcttgga ctgtattttt 5580 aggttggcta tgttcccagc catatccctc cggggattca tgttgtgcag aaccaccagc 5640 acagtgtatc cggtgcactt gggaaatttg tcatgtagct tagaaggaaa tgcgtggaag 5700 aacttggaga cgcccttgtg acctccaaga ttttccatgc attcgtccat aatgatggca 5760 atgggcccac gggcggcggc ctgggcgaag atatttctgg gatcactaac gtcatagttg 5820 tgttccagga tgagatcgtc ataggccatt tttacaaagc gcgggcggag ggtgccagac 5880 tgcggtataa tggttccatc cggcccaggg gcgtagttac cctcacagat ttgcatttcc 5940 cacgctttga gttcagatgg ggggatcatg tctacctgcg gggcgatgaa gaaaacggtt 6000 tccggggtag gggagatcag ctgggaagaa agcaggttcc tgagcagctg cgacttaccg 6060 cagccggtgg gcccgtaaat cacacctatt accgggtgca actggtagtt aagagagctg 6120 cagctgccgt catccctgag caggggggcc acttcgttaa gcatgtccct gactcgcatg 6180 ttttccctga ccaaatccgc cagaaggcgc tcgccgccca gcgatagcag ttcttgcaag 6240 gaagcaaagt ttttcaacgg tttgagaccg tccgccgtag gcatgctttt gagcgtttga 6300 ccaagcagtt ccaggcggtc ccacagctcg gtcacctgct ctacggcatc tcgatccagc 6360 atatctcctc gtttcgcggg ttggggcggc tttcgctgta cggcagtagt cggtgctcgt 6420 ccagacgggc cagggtcatg tctttccacg ggcgcagggt cctcgtcagc gtagtctggg 6480 tcacggtgaa ggggtgcgct ccgggctgcg cgctggccag ggtgcgcttg aggctggtcc 6540 tgctggtgct gaagcgctgc cggtcttcgc cctgcgcgtc ggccaggtag catttgacca 6600 tggtgtcata gtccagcccc tccgcggcgt ggcccttggc gcgcagcttg cccttggagg 6660 aggcgccgca cgaggggcag tgcagacttt tgagggcgta gagcttgggc gcgagaaata 6720 ccgattccgg ggagtaggca tccgcgccgc aggccccgca gacggtctcg cattccacga 6780 gccaggtgag ctctggccgt tcggggtcaa aaaccaggtt tcccccatgc tttttgatgc 6840 gtttcttacc tctggtttcc atgagccggt gtccacgctc ggtgacgaaa aggctgtccg 6900 tgtccccgta tacagacttg agaggcctgt cctcgagcgg tgttccgcgg tcctcctcgt 6960 atagaaactc ggaccactct gagacaaagg ctcgcgtcca ggccagcacg aaggaggcta 7020 agtgggaggg gtagcggtcg ttgtccacta gggggtccac tcgctccagg gtgtgaagac 7080 acatgtcgcc ctcttcggca tcaaggaagg tgattggttt gtaggtgtag gccacgtgac 7140 cgggtgttcc tgaagggggg ctataaaagg gggtgggggc gcgttcgtcc tcactctctt 7200 ccgcatcgct gtctgcgagg gccagctgtt ggggtgagta ctccctctga aaagcgggca 7260 tgacttctgc gctaagattg tcagtttcca aaaacgagga ggatttgata ttcacctggc 7320 ccgcggtgat gcctttgagg gtggccgcat ccatctggtc agaaaagaca atctttttgt 7380 tgtcaagctt ggtggcaaac gacccgtaga gggcgttgga cagcaacttg gcgatggagc 7440 gcagggtttg gtttttgtcg cgatcggcgc gctccttggc cgcgatgttt agctgcacgt 7500 attcgcgcgc aacgcaccgc cattcgggaa agacggtggt gcgctcgtcg ggcaccaggt 7560 gcacgcgcca accgcggttg tgcagggtga caaggtcaac gctggtggct acctctccgc 7620 gtaggcgctc gttggtccag cagaggcggc cgcccttgcg cgagcagaat ggcggtaggg 7680 ggtctagctg cgtctcgtcc ggggggtctg cgtccacggt aaagaccccg ggcagcaggc 7740 gcgcgtcgaa gtagtctatc ttgcatcctt gcaagtctag cgcctgctgc catgcgcggg 7800 cggcaagcgc gcgctcgtat gggttgagtg ggggacccca tggcatgggg tgggtgagcg 7860 cggaggcgta catgccgcaa atgtcgtaaa cgtagagggg ctctctgagt attccaagat 7920 atgtagggta gcatcttcca ccgcggatgc tggcgcgcac gtaatcgtat agttcgtgcg 7980 agggagcgag gaggtcggga ccgaggttgc tacgggcggg ctgctctgct cggaagacta 8040 tctgcctgaa gatggcatgt gagttggatg atatggttgg acgctggaag acgttgaagc 8100 tggcgtctgt gagacctacc gcgtcacgca cgaaggaggc gtaggagtcg cgcagcttgt 8160 tgaccagctc ggcggtgacc tgcacgtcta gggcgcagta gtccagggtt tccttgatga 8220 tgtcatactt atcctgtccc ttttttttcc acagctcgcg gttgaggaca aactcttcgc 8280 ggtctttcca gtactcttgg atcggaaacc cgtcggcctc cgaacggtaa gagcctagca 8340 tgtagaactg gttgacggcc tggtaggcgc agcatccctt ttctacgggt agcgcgtatg 8900 cctgcgcggc cttccggagc gaggtgtggg tgagcgcaaa ggtgtccctg accatgactt 8460 tgaggtactg gtatttgaag tcagtgtcgt cgcatccgcc ctgctcccag agcaaaaagt 8520 ccgtgcgctt tttggaacgc ggatttggca gggcgaaggt gacatcgttg aagagtatct 8580 ttcccgcgcg aggcataaag ttgcgtgtga tgcggaaggg tcccggcacc tcggaacggt 8640 tgttaattac ctgggcggcg agcacgatct cgtcaaagcc gttgatgttg tggcccacaa 8700 tgtaaagttc caagaagcgc gggatgccct tgatggaagg caatttttta agttcctcgt 8760 aggtgagctc ttcaggggag ctgagcccgt gctctgaaag ggcccagtct gcaagatgag 8820 ggttggaagc gacgaatgag ctccacaggt cacgggccat tagcatttgc aggtggtcgc 8880 gaaaggtcct aaactggcga cctatggcca ttttttctgg ggtgatgcag tagaaggtaa 8940 gcgggtcttg ttcccagcgg tcccatccaa ggttcgcggc taggtctcgc gcggcagtca 9000 ctagaggctc atctccgccg aacttcatga ccagcatgaa gggcacgagc tgcttcccaa 9060 aggcccccat ccaagtatag gtctctacat cgtaggtgac aaagagacgc tcggtgcgag 9120 gatgcgagcc gatcgggaag aactggatct cccgccacca attggaggag tggctattga 9180 tgtggtgaaa gtagaagtcc ctgcgacggg ccgaacactc gtgctggctt ttgtaaaaac 9240 gtgcgcagta ctggcagcgg tgcacgggct gtacatcctg cacgaggttg acctgacgac 9300 cgcgcacaag gaagcagagt gggaatttga gcccctcgcc tggcgggttt ggctggtggt 9360 cttctactt~ ggctgcttgt ccttgaccgt ctggctgctc gaggggagtt acggtggatc 9420 ggaccaccac gccgcgcgag cccaaagtcc agatgtccgc gcgcggcggt cggagcttga 9480 tgacaacatc gcgcagatgg gagctgtcca tggtctggag ctcccgcggc gtcaggtcag 9540 gcgggagctc ctgcaggttt acctcgcata gacgggtcag ggcgcgggct agatccaggt 9600 gatacctaat ttccaggggc tggttggtgg cggcgtcgat ggcttgcaag aggccgcatc 9660 cccgcggcgc gactacggta ccgcgcggcg ggcggtgggc cgcgggggtg tccttggatg 9720 atgcatctaa aagcggtgac gcgggcgagc ccccggaggt agggggggct ccggacccgc 9780 cgggagaggg ggcaggggca cgtcggcgcc gcgcgcgggc aggagctggt gctgcgcgcg 9840 taggttgctg gcgaacgcga cgacgcggcg gttgatctcc tgaatctggc gcctctgcgt 9900 gaagacgacg ggcccggtga gcttgagcct gaaagagagt tcgacagaat caatttcggt 9960 gtcgttgacg gcggcctggc gcaaaatctc ctgcacgtct cctgagttgt cttgataggc 10020 gatctcggcc atgaactgct cgatctcttc ctcctggaga tctccgcgtc cggctcgctc 10080 cacggtggcg gcgaggtcgt tggaaatgcg ggccatgagc tgcgagaagg cgttgaggcc 10140 tccctcgttc cagacgcggc tgtagaccac gcccccttcg gcatcgcggg cgcgcatgac 10200 cacctgcgcg agattgagct ccacgtgccg ggcgaagacg gcgtagtttc gcaggcgctg 10260 aaagaggtag ttgagggtgg tggcggtgtg ttctgccacg aagaagtaca taacccagcg 10320 tcgcaacgtg gattcgttga tatcccccaa ggcctcaagg cgctccatgg cctcgtagaa 10380 gtccacggcg aagttgaaaa actgggagtt gcgcgccgac acggttaact cctcctccag 10940 aagacggatg agctcggcga cagtgtcgcg cacctcgcgc tcaaaggcta caggggcctc 10500 ttcttcttct tcaatctcct cttccataag ggcctcccct tcttcttctt ctggcggcgg 10560 tgggggaggg gggacacggc ggcgacgacg gcgcaccggg aggcggtcga caaagcgctc 10620 gatcatctcc ccgcggcgac ggcgcatggt ctcggtgacg gcgcggccgt tctcgcgggg 10680 gcgcagttgg aagacgccgc ccgtcatgtc ccggttatgg gttggcgggg ggctgccatg 10740 cggcagggat acggcgctaa cgatgcatct caacaattgt tgtgtaggta ctccgccgcc 10800 gagggacctg agcgagtccg catcgaccgg atcggaaaac ctctcgagaa aggcgtctaa 10860 ccagtcacag tcgcaaggta ggctgagcac cgtggcgggc ggcagcgggc ggcggtcggg 10920 gttgtttctg gcggaggtgc tgctgatgat gtaattaaag taggcggtct tgagacggcg 10980 gatggtcgac agaagcacca tgtccttggg tccggcctgc tgaatgcgca ggcggtcggc 11040 catgccccag gcttcgtttt gacatcggcg caggtctttg tagtagtctt gcatgagcct 11100 ttctaccggc acttcttctt ctccttcctc ttgtcctgca tctcttgcat ctatcgctgc 11160 ggcggcggcg gagtttggcc gtaggtggcg ccctcttcct cccatgcgtg tgaccccgaa 11220 gcccctcatc ggctgaagca gggctaggtc ggcgacaacg cgctcggcta atatggcctg 11280 ctgcacctgc gtgagggtag actggaagtc atccatgtcc acaaagcggt ggtatgcgcc 11340 cgtgttgatg gtgtaagtgc agttggccat aacggaccag ttaacggtct ggtgacccgg 11400 ctgcgagagc tcggtgtacc tgagacgcga gtaagccctc gagtcaaata cgtagtcgtt 11460 gcaagtccgc accaggtact ggtatcccac caaaaagtgc ggcggcggct ggcggtagag 11520 gggccagcgt agggtggccg gggctccggg ggcgagatct tccaacataa ggcgatgata 11580 tccgtagatg tacctggaca tccaggtgat gccggcggcg gtggtggagg cgcgcggaaa 11640 gtcgcggacg cggttccaga tgttgcgcag cggcaaaaag tgctccatgg tcgggacgct 11700 ctggccggtc aggcgcgcgc aatcgttgac gctctagacc gtgcaaaagg agagcctgta 11760 agcgggcact cttccgtggt ctggtggata aattcgcaag ggtatcatgg cggacgaccg 11820 gggttcgagc cccgtatccg gccgtccgcc gtgatccatg cggttaccgc ccgcgtgtcg 11880 aacccaggtg tgcgacgtca gacaacgggg gagtgctcct tttggcttcc ttccaggcgc 11940 ggcggctgct gcgctagctt ttttggccac tggccgcgcg cagcgtaagc ggttaggctg 12000 gaaagcgaaa gcattaagtg gctcgctccc tgtagccgga gggttatttt ccaagggttg 12060 agtcgcggga cccccggttc gagtctcgga ccggccggac tgcggcgaac gggggtttgc 12120 ctccccgtca tgcaagaccc cgcttgcaaa ttcctccgga aacagggacg agcccctttt 12180 ttgcttttcc cagatgcatc cggtgctgcg gcagatgcgc ccccctcctc agcagcggca 12240 agagcaagag cagcggcaga catgcagggc accctcccct cctcctaccg cgtcaggagg 12300 ggcgacatcc gcggttgacg cggcagcaga tggtgattac gaacccccgc ggcgccgggc 12360 ccggcactac ctggacttgg aggagggcga gggcctggcg cggctaggag cgccctctcc 12420 tgagcggtac ccaagggtgc agctgaagcg tgatacgcgt gaggcgtacg tgccgcggca 12480 gaacctgttt cgcgaccgcg agggagagga gcccgaggag atgcgggatc gaaagttcca 12590 cgcagggcgc gagctgcggc atggcctgaa tcgcgagcgg ttgctgcgcg aggaggactt 12600 tgagcccgac gcgcgaaccg ggattagtcc cgcgcgcgca cacgtggcgg ccgccgacct 12660 ggtaaccgca tacgagcaga cggtgaacca ggagattaac tttcaaaaaa gctttaacaa 12720 ccacgtgcgt acgcttgtgg cgcgcgagga ggtggctata ggactgatgc atctgtggga 12780 ctttgtaagc gcgctggagc aaaacccaaa tagcaagccg ctcatggcgc agctgttcct'12840 tatagtgcag cacagcaggg acaacgaggc attcagggat gcgctgctaa acatagtaga 12900 gcccgagggc cgctggctgc tcgatttgat aaacatcctg cagagcatag tggtgcagga 12960 gcgcagcttg agcctggctg acaaggtggc cgccatcaac tattccatgc ttagcctggg 13020 caagttttac gcccgcaaga tataccatac cccttacgtt cccatagaca aggaggtaaa 13080 gatcgagggg ttctacatgc gcatggcgct gaaggtgctt accttgagcg acgacctggg 13140 cgtttatcgc aacgagcgca tccacaaggc cgtgagcgtg agccggcggc gcgagctcag 13200 cgaccgcgag ctgatgcaca gcctgcaaag ggccctggct ggcacgggca gcggcgatag 13260 agaggccgag tcctactttg acgcgggcgc tgacctgcgc tgggccccaa gccgacgcgc 13320 cctggaggca gctggggccg gacctgggct ggcggtggca cccgcgcgcg ctggcaacgt 13380 cggcggcgtg gaggaatatg acgaggacga tgagtacgag ccagaggacg gcgagtacta 13440 agcggtgatg tttctgatca gatgatgcaa gacgcaacgg acccggcggt gcgggcggcg 13500 ctgcagagcc agccgtccgg ccttaactcc acggacgact ggcgccaggt catggaccgc 13560 atcatgtcgc tgactgcgcg caatcctgac gcgttccggc agcagccgca ggccaaccgg 13620 ctctccgcaa ttctggaagc ggtggtcccg gcgcgcgcaa accccacgca cgagaaggtg 13680 ctggcgatcg taaacgcgct ggccgaaaac agggccatcc ggcccgacga ggccggcctg 13740 gtctacgacg cgctgcttca gcgcgtggct cgttacaaca gcggcaacgt gcagaccaac 13800 ctggaccggc tggtggggga tgtgcgcgag gccgtggcgc agcgtgagcg cgcgcagcag 13860 cagggcaacc tgggctccat ggttgcacta aacgccttcc tgagtacaca gcccgccaac 13920 gtgccgcggg gacaggagga ctacaccaac tttgtgagcg cactgcggct aatggtgact 13980 gagacaccgc aaagtgaggt gtaccagtct gggccagact attttttcca gaccagtaga 14040 caaggcctgc agaccgtaaa cctgagccag gctttcaaaa acttgcaggg gctgtggggg 14100 gtgcgggctc ccacaggcga ccgcgcgacc gtgtctagct tgctgacgcc caactcgcgc 14160 ctgttgctgc tgctaatagc gcccttcacg gacagtggca gcgtgtcccg ggacacatac 14220 ctaggtcact tgctgacact gtaccgcgag gccataggtc aggcgcatgt ggacgagcat 14280 actttccagg agattacaag tgtcagccgc gcgctggggc aggaggacac gggcagcctg 14340 gaggcaaccc taaactacct gctgaccaac cggcggcaga agatcccctc gttgcacagt 14400 ttaaacagcg aggaggagcg cattttgcgc tacgtgcagc agagcgtgag ccttaacctg 14460 atgcgcgacg gggtaacgcc cagcgtggcg ctggacatga ccgcgcgcaa catggaaccg 14520 ggcatgtatg cctcaaaccg gccgtttatc aaccgcctaa tggactactt gcatcgcgcg 14580 gccgccgtga accccgagta tttcaccaat gccatcttga acccgcactg gctaccgccc 14640 cctggtttct acaccggggg attcgaggtg cccgagggta acgatggatt cctctgggac 14700 gacatagacg acagcgtgtt ttccccgcaa ccgcagaccc tgctagagtt gcaacagcgc 14760 gagcaggcag aggcggcgct gcgaaaggaa agcttccgca ggccaagcag cttgtccgat 14820 ctaggcgctg cggccccgcg gtcagatgct agtagcccat ttccaagctt gatagggtct 14880 cttaccagca ctcgcaccac ccgcccgcgc ctgctgggcg aggaggagta cctaaacaac 14910 tcgctgctgc agccgcagcg cgaaaaaaac ctgcctccgg catttcccaa caacgggata 15000 gagagcctag tggacaagat gagtagatgg aagacgtacg cgcaggagca cagggacgtg 15060 ccaggcccgc gcccgcccac ccgtcgtcaa aggcacgacc gtcagcgggg tctggtgtgg 15120 gaggacgatg actcggcaga cgacagcagc gtcctggatt tgggagggag tggcaacccg 15180 tttgcgcacc ttcgccccag gctggggaga atgttttaaa aaaaaaaaag catgatgcaa 15240 aataaaaaac tcaccaaggc catggcaccg agcgttggtt ttcttgtatt ccccttagta 15300 tgcggcgcgc ggcgatgtat gaggaaggtc ctcctccctc ctacgagagt gtggtgagcg 15360 cggcgccagt ggcggcggcg ctgggttctc ccttcgatgc tcccctggac ccgccgtttg 15420 tgcctccgcg gtacctgcgg cctaccgggg ggagaaacag catccgttac tctgagttgg 15480 cacccctatt cgacaccacc cgtgtgtacc tggtggacaa caagtcaacg gatgtggcat 15540 ccctgaacta ccagaacgac cacagcaact ttctgaccac ggtcattcaa aacaatgact 15600 acagcccggg ggaggcaagc acacagacca tcaatcttga cgaccggtcg cactggggcg 15660 gcgacctgaa aaccatcctg cataccaaca tgccaaatgt gaacgagttc atgtttacca 15720 ataagtttaa ggcgcgggtg atggtgtcgc gcttgcctac taaggacaat caggtggagc 15780 tgaaatacga gtgggtggag ttcacgctgc ccgagggcaa ctactccgag accatgacca 15840 tagaccttat gaacaacgcg atcgtggagc actacttgaa agtgggcaga cagaacgggg 15900 ttctggaaag cgacatcggg gtaaagtttg acacccgcaa cttcagactg gggtttgacc 15960 ccgtcactgg tcttgtcatg cctggggtat atacaaacga agccttccat ccagacatca 16020 ttttgctgcc aggatgcggg gtggacttca cccacagccg cctgagcaac ttgttgggca 16080 tccgcaagcg gcaacccttc caggagggct ttaggatcac ctacgatgat ctggagggtg 16140 gtaacattcc cgcactgttg gatgtggacg cctaccaggc gagcttgaaa gatgacaccg 16200 aacagggcgg gggtggcgca ggcggcagca acagcagtgg cagcggcgcg gaagagaact 16260 ccaacgcggc agccgcggca atgcagccgg tggaggacat gaacgatcat gccattcgcg 16320 gcgacacctt tgccacacgg gctgaggaga agcgcgctga ggccgaagca gcggccgaag 16380 ctgccgcccc cgctgcgcaa cccgaggtcg agaagcctca gaagaaaccg gtgatcaaac 16440 ccctgacaga ggacagcaag aaacgcagtt acaacctaat aagcaatgac agcaccttca 16500 cccagtaccg cagctggtac cttgcataca actacggcga ccctcagacc ggaatccgct 16560 catggaccct gctttgcact cctgacgtaa cctgcggctc ggagcaggtc tactggtcgt 16620 tgccagacat gatgcaagac cccgtgacct tccgctccac gcgccagatc agcaactttc 16680 cggtggtggg cgccgagctg ttgcccgtgc actccaagag cttctacaac gaccaggccg 16740 tctactccca actcatccgc cagtttacct ctctgaccca cgtgttcaat cgctttcccg 16800 agaaccagat tttggcgcgc ccgccagccc ccaccatcac caccgtcagt gaaaacgttc 16860 ctgctctca~ agatcacggg acgctaccgc tgcgcaacag catcggagga gtccagcgag 16920 tgaccattac tgacgccaga cgccgcacct gcccctacgt ttacaaggcc ctgggcatag 16980 tctcgccgcg cgtcctatcg agccgcactt tttgagcaag catgtccatc cttatatcgc 17040 ccagcaataa cacaggctgg ggcctgcgct tcccaagcaa gatgtttggc ggggccaaga 17100 agcgctccga ccaacaccca gtgcgcgtgc gcgggcacta ccgcgcgccc tggggcgcgc 17160 acaaacgcgg ccgcactggg cgcaccaccg tcgatgacgc catcgacgcg gtggtggagg 17220 aggcgcgcaa ctacacgccc acgccgccac cagtgtccac agtggacgcg gccattcaga 17280 ccgtggtgcg cggagcccgg cgctatgcta aaatgaagag acggcggagg ~gcgtagcac 17340 gtcgccaccg ccgccgaccc ggcactgccg cccaacgcgc ggcggcggcc ctgcttaacc 17400 gcgcacgtcg caccggccga cgggcggcca tgcgggccgc tcgaaggctg gccgcgggta 17460 ttgtcactgt gccccccagg tccaggcgac gagcggccgc cgcagcagcc gcggccatta 17520 gtgctatgac tcagggtcgc aggggcaacg tgtattgggt gcgcgactcg gttagcggcc 17580 tgcgcgtgcc cgtgcgcacc cgccccccgc gcaactagat tgcaagaaaa aactacttag 17640 actcgtactg ttgtatgtat -ccagcggcgg cggcgcgcaa cgaagctatg tccaagcgca 17700 aaatcaaaga agagatgctc caggtcatcg cgccggagat ctatggcccc ccgaagaagg 17760 aagagcagga ttacaagccc cgaaagctaa agcgggtcaa aaagaaaaag aaagatgatg 17820 atgatgaact tgacgacgag gtggaactgc tgcacgctac cgcgcccagg cgacgggtac 17880 agtggaaagg tcgacgcgta aaacgtgttt tgcgacccgg caccaccgta gtctttacgc 17940 ccggtgagcg ctccacccgc acctacaagc gcgtgtatga tgaggtgtac ggcgacgagg 18000 acctgcttga gcaggccaac gagcgcctcg gggagtttgc ctacggaaag cggcataagg 18060 acatgctggc gttgccgctg gacgagggca acccaacacc tagcctaaag cccgtaacac 18120 tgcagcaggt gctgcccgcg cttgcaccgt ccgaagaaaa gcgcggccta aagcgcgagt 18180 ctggtgactt ggcacccacc gtgcagctga tggtacccaa gcgccagcga ctggaagatg 18240 tcttggaaaa aatgaccgtg gaacctgggc tggagcccga ggtccgcgtg cggccaatca 18300 agcaggtggc gccgggactg ggcgtgcaga ccgtggacgt tcagataccc actaccagta 18360 gcaccagtat tgccaccgcc acagagggca tggagacaca aacgtccccg gttgcctcag 18420 cggtggcgga tgccgcggtg caggcggtcg ctgcggccgc gtccaagacc tctacggagg 18480 tgcaaacgga cccgtggatg tttcgcgttt cagccccccg gcgcccgcgc ggttcgagga 18540 agtacggcgc cgccagcgcg ctactgcccg aatatgccct acatccttcc attgcgccta 18600 cccccggcta tcgtggctac acctaccgcc ccagaagacg agcaactacc cgacgccgaa 18660 ccaccactgg aacccgccgc cgccgtcgcc gtcgccagcc cgtgctggcc ccgatttccg 18720 tgcgcagggt ggctcgcgaa ggaggcagga ccctggtgct gccaacagcg cgctaccacc 18780 ccagcatcgt ttaaaagccg gtctttgtgg ttcttgcaga tatggccctc acctgccgcc 18840 tccgtttccc ggtgccggga ttccgaggaa gaatgcaccg taggaggggc atggccggcc 18900 acggcctgac gggcggcatg cgtcgtgcgc accaccggcg gcggcgcgcg tcgcaccgtc 18960 gcatgcgcgg cggtatcctg cccctcctta ttccactgat cgccgcggcg attggcgccg 19020 tgcccggaat tgcatccgtg gccttgcagg cgcagagaca ctgattaaaa acaagttgca 19080 tgtggaaaaa tcaaaataaa aagtctggac tctcacgctc gcttggtcct gtaactattt 19140 tgtagaatgg aagacatcaa ctttgcgtct ctggccccgc gacacggctc gcgcccgttc 19200 atgggaaact ggcaagatat cggcaccagc aatatgagcg gtggcgcctt cagctggggc 19260 tcgctgtgga gcggcattaa aaatttcggt tccaccgtta agaactatgg cagcaaggcc 19320 tggaacagca gcacaggcca gatgctgagg gataagttga aagagcaaaa tttccaacaa 19380 aaggtggtag atggcctggc ctctggcatt agcggggtgg tggacctggc caaccaggca 19440 gtgcaaaata agattaacag taagcttgat ccccgccctc ccgtagagga gcctccaccg 19500 gccgtggaga cagtgtctcc agaggggcgt ggcgaaaagc gtccgcgccc cgacagggaa 19560 gaaactctgg tgacgcaaat agacgagcct ccctcgtacg aggaggcact aaagcaaggc 19620 ctgcccacca cccgtcccat cgcgcccatg gctaccggag tgctgggcca gcacacaccc 19680 gtaacgctgg acctgcctcc ccccgccgac acccagcaga aacctgtgct gccaggcccg 19740 caagttttac gcccgcaaga tataccatac cccttacgtt cccatagaca aggaggtaaa accgccgttg ttgtaacccg tcctagccgc gcgtccctgc gccgcgccgc cagcggtccg 19800 cgatcgttgc ggcccgtagc cagtggcaac tggcaaagca cactgaacag catcgtgggt 19860 ctgggggtgc aatccctgaa gcgccgacga tgcttctgaa tagctaacgt gtcgtatgtg 19920 tgtcatgtat gcgtccatgt cgccgccaga ggagctgctg agccgccgcg cgcccgcttt 19980 ccaagatggc taccccttcg atgatgccgc agtggtctta catgcacatc tcgggccagg 20040 acgcctcgga gtacctgagc cccgggctgg tgcagtttgc ccgcgccacc gagacgtact 20100 tcagcctgaa taacaagttt agaaacccca cggtggcgcc tacgcacgac gtgaccacag 20160 accggtccca gcgtttgacg ctgcggttca tccctgtgga ccgtgaggat actgcgtact 20220 cgtacaaggc gcggttcacc ctagctgtgg gtgataaccg tgtgctggac atggcttcca 20280 cgtactttga catccgcggc gtgctggaca ggggccctac ttttaagccc tactctggca 20340 ctgcctacaa cgccctggct cccaagggtg ccccaaatcc ttgcgaatgg gatgaagctg 20400 ctactgctct tgaaataaac ctagaagaag aggacgatga caacgaagac gaagtagacg 20460 agcaagctga gcagcaaaaa actcacgtat ttgggcaggc gccttattct ggtataaata 20520 ttacaaagga gggtattcaa ataggtgtcg aaggtcaaac acctaaatat gccgataaaa 20580 catttcaacc tgaacctcaa ataggagaat ctcagtggta cgaaactgaa attaatcatg 20640 cagctgggag agtccttaaa aagactaccc caatgaaacc atgttacggt tcatatgcaa 20700 aacccacaaa tgaaaatgga gggcaaggca ttcttgtaaa gcaacaaaat ggaaagctag 20760 aaagtcaagt ggaaatgcaa tttttctcaa ctactgaggc gaccgcaggc aatggtgata 20820 acttgactcc taaagtggta ttgtacagtg aagatgtaga tatagaaacc ccagacactc 20880 atatttctta catgcccact attaaggaag gtaactcacg agaactaatg ggccaacaat 20940 ctatgcccaa caggcctaat tacattgctt ttagggacaa ttttattggt ctaatgtatt 21000 acaacagcac gggtaatatg ggtgttctgg cgggccaagc atcgcagttg aatgctgttg 21060 tagatttgca agacagaaac acagagcttt cataccagct tttgcttgat tccattggtg 21120 atagaaccag gtacttttct atgtggaatc aggctgttga cagctatgat ccagatgtta 21180 gaattattga aaatcatgga actgaagatg aacttccaaa ttactgcttt ccactgggag 21240 gtgtgattaa tacagagact cttaccaagg taaaacctaa aacaggtcag gaaaatggat 21300 gggaaaaaga tgctacagaa ttttcagata aaaatgaaat aagagttgga aataattttg 21360 ccatggaaat caatctaaat gccaacctgt ggagaaattt cctgtactcc aacatagcgc 21420 tgtatttgcc cgacaagcta aagtacagtc cttccaacgt aaaaatttct gataacccaa 21480 acacctacga ctacatgaac aagcgagtgg tggctcccgg gttagtggac tgctacatta 21540 accttggagc acgctggtcc cttgactata tggacaacgt caacccattt aaccaccacc 21600 gcaatgctgg cctgcgctac cgctcaatgt tgctgggcaa tggtcgctat gtgcccttcc 21660 acatccaggt gcctcagaag ttctttgcca ttaaaaacct ccttctcctg ccgggctcat 21720 acacctacga gtggaacttc aggaaggatg ttaacatggt tctgcagagc tccctaggaa 21780 atgacctaag ggttgacgga gccagcatta agtttgatag catttgcctt tacgccacct 21840 tcttccccat ggcccacaac accgcctcca cgcttgaggc catgcttaga aacgacacca 21900 acgaccagtc ctttaacgac tatctctccg ccgccaacat gctctaccct atacccgcca 21960 acgctaccaa cgtgcccata tccatcccct cccgcaactg ggcggctttc cgcggctggg 22020 ccttcacgcg ccttaagact aaggaaaccc catcactggg ctcgggctac gacccttatt 22080 acacctactc tggctctata ccctacctag atggaacctt ttacctcaac cacaccttta 22140 agaaggtggc cattaccttt gactcttctg tcagctggcc tggcaatgac cgcctgctta 22200 cccccaacga gtttgaaatt aagcgctcag ttgacgggga gggttacaac gttgcccagt 22260 gtaacatgac caaagactgg ttcctggtac aaatgctagc taactacaac attggctacc 22320 agggcttcta tatcccagag agctacaagg accgcatgta ctccttcttt agaaacttcc 22380 agcccatgag ccgtcaggtg gtggatgata ctaaatacaa ggactaccaa caggtgggca 22440 tcctacacca acacaacaac tctggatttg ttggctacct tgcccccacc atgcgcgaag 22500 gacaggccta ccctgctaac ttcccctatc cgcttatagg caagaccgca gttgacagca 22560 ttacccagaa aaagtttctt tgcgatcgca ccctttggcg catcccattc tccagtaact 22620 ttatgtccat gggcgcactc acagacctgg gccaaaacct tctctacgcc aactccgccc 22680 acgcgctaga catgactttt gaggtggatc ccatggacga gcccaccctt ctttatgttt 22740 tgtttgaagt ctttgacgtg gtccgtgtgc accggccgca ccgcggcgtc atcgaaaccg 22800 tgtacctgcg cacgcccttc tcggccggca acgccacaac ataaagaagc aagcaacatc 22860 aacaacagct gccgccatgg gctccagtga gcaggaactg aaagccattg tcaaagatct 22920 tggttgtggg ccatattttt tgggcaccta tgacaagcgc tttccaggct ttgtttctcc 22980 acacaagctc gcctgcgcca tagtcaatac ggccggtcgc gagactgggg gcgtacactg 23040 gatggccttt gcctggaacc cgcactcaaa aacatgctac ctctttgagc cctttggctt 23100 ttctgaccag cgactcaagc aggtttacca gtttgagtac gagtcactcc tgcgccgtag 23160 cgccattgct tcttcccccg accgctgtat aacgctggaa aagtccaccc aaagcgtaca 23220 ggggcccaac tcggccgcct gtggactatt ctgctgcatg tttctccacg cctttgccaa 23280 ctggccccaa actcccatgg atcacaaccc caccatgaac cttattaccg gggtacccaa 23340 ctccatgctc aacagtcccc aggtacagcc caccctgcgt cgcaaccagg aacagctcta 23400 cagcttcctg gagcgccact cgccctactt ccgcagccac agtgcgcaga ttaggagcgc 23460 CA 02359795 2001-07-12 PCT~,P00/00265 cacttctttt tgtcacttga aaaacatgta aaaataatgt actagagaca ctttcaataa 23520 aggcaaatgc ttttatttgt acactctcgg gtgattattt acccccaccc ttgccgtctg 23580 cgccgtttaa aaatcaaagg ggttctgccg cgcatcgcta tgcgccactg gcagggacac 23640 gttgcgatac tggtgtttag tgctccactt aaactcaggc acaaccatcc gcggcagctc 23700 ggtgaagttt tcactccaca ggctgcgcac catcaccaac gcgtttagca ggtcgggcgc 23760 cgatatcttg aagtcgcagt tggggcctcc gccctgcgcg cgcgagttgc gatacacagg 23820 gttgcagcac tggaacacta tcagcgccgg gtggtgcacg ctggccagca cgctcttgtc 23880 ggagatcaga tccgcgtcca ggtcctccgc gttgctcagg gcgaacggag tcaactttgg 23940 tagctgcctt cccaaaaagg gcgcgtgccc aggctttgag ttgcactcgc accgtagtgg 24000 catcaaaagg tgaccgtgcc cggtctgggc .gttaggatac agcgcctgca taaaagcctt 24060 gatctgctta aaagccacct gagcctttgc gccttcagag aagaacatgc cgcaagactt 24120 gccggaaaac tgattggccg gacaggccgc gtcgtgcacg cagcaccttg cgtcggtgtt 24180 ggagatctgc accacatttc ggccccaccg gttcttcacg atcttggcct tgctagactg 24240 ctccttcagc gcgcgctgcc cgttttcgct cgtcacatcc atttcaatca cgtgctcctt 24300 atttatcata atgcttccgt gtagacactt aagctcgcct tcgatctcag cgcagcggtg 24360 cagccacaac gcgcagcccg tgggctcgtg atgcttgtag gtcacctctg caaacgactg 24420 caggtacgcc tgcaggaatc gccccatcat cgtcacaaag gtcttgttgc tggtgaaggt 24480 cagctgcaac ccgcggtgct cctcgttcag ccaggtcttg catacggccg ccagagcttc 24540 cacttggtca ggcagtagtt tgaagttcgc ctttagatcg ttatccacgt ggtacttgtc 24600 catcagcgcg cgcgcagcct ccatgccctt ctcccacgca gacacgatcg gcacactcag 24660 cgggttcatc accgtaattt cactttccgc ttcgctgggc tcttcctctt cctcttgcgt 24720 ccgcatacca cgcgccactg ggtcgtcttc attcagccgc cgcactgtgc c~cttacctcc 24780 tttgccatgc ttgattagca ccggtgggtt gctgaaaccc accatttgta gcgccacatc 24840 ttctctttct tcctcgctgt ccacgattac ctctggtgat ggcgggcgct cgggcttggg 24900 agaagggcgc ttctttttct tcttgggcgc aatggccaaa tccgccgccg aggtcgatgg 24960 ccgcgggctg ggtgtgcgcg gcaccagcgc gtcttgtgat gagtcttcct cgtcctcgga 25020 ctcgatacgc cgcctcatcc gcttttttgg gggcgcccgg ggaggcggcg gcgacgggga 25080 cggggacgac acgtcctcca tggttggggg acgtcgcgcc gcaccgcgtc cgcgctcggg 25140 ggtggtttcg cgctgctcct cttcccgact ggccatttcc ttctcctata ggcagaaaaa 25200 gatcatggag tcagtcgaga agaaggacag cctaaccgcc ccctctgagt tcgccaccac 25260 cgcctccacc gatgccgcca acgcgcctac caccttcccc gtcgaggcac ccccgcttga 25320 ggaggaggaa gtgattatcg agcaggaccc aggttttgta agcgaagacg acgaggaccg 25380 ctcagtacca acagaggata aaaagcaaga ccaggacaac gcagaggcaa acgaggaaca 25440 agtcgggcgg ggggacgaaa ggcatggcga ctacctagat gtgggagacg acgtgctgtt 25500 gaagcatctg cagcgccagt gcgccattat ctgcgacgcg ttgcaagagc gcagcgatgt 25560 gcccctcgcc atagcggatg tcagccttgc ctacgaacgc cacctattct caccgcgcgt 25620 accccccaaa cgccaagaaa acggcacatg cgagcccaac ccgcgcctca acttctaccc 25680 cgtatttgcc gtgccagagg tgcttgccac ctatcacatc tttttccaaa actgcaagat 25740 acccctatcc tgccgtgcca accgcagccg agcggacaag cagctggcct tgcggcaggg 25800 cgctgtcata cctgatatcg cctcgctcaa cgaagtgcca aaaatctttg agggtcttgg 25860 acgcgacgag aagcgcgcgg caaacgctct gcaacaggaa aacagcgaaa atgaaagtca 25920 ctctggagtg ttggtggaac tcgagggtga caacgcgcgc ctagccgtac taaaacgcag 25980 catcgaggtc acccactttg cctacccggc acttaaccta ccccccaagg tcatgagcac 26040 agtcatgagt gagctgatcg tgcgccgtgc gcagcccctg gagagggatg caaatttgca 26100 agaacaaaca gaggagggcc tacccgcagt tggcgacgag cagctagcgc gctggcttca 26160 aacgcgcgag cctgccgact tggaggagcg acgcaaacta atgatggccg cagtgctcgt 26220 taccgtggag cttgagtgca tgcagcggtt ctttgctgac ccggagatgc agcgcaagct 26280 agaggaaaca ttgcactaca cctttcgaca gggctacgta cgccaggcct gcaagatctc 26340 caacgtggag ctctgcaacc tggtctccta ccttggaatt ttgcacgaaa accgccttgg 26400 gcaaaacgtg cttcattcca cgctcaaggg cgaggcgcgc cgcgactacg tccgcgactg 26460 cgtttactta tttctatgct acacctgg~a gacggccatg ggcgtttggc agcagtgctt 26520 ggaggagtgc aacctcaagg agctgcagaa actgctaaag caaaacttga aggacctatg 26580 gacggccttc aacgagcgct ccgtggccgc gcacctggcg gacatcattt tccccgaacg 26690 cctgcttaaa accctgcaac agggtctgcc agacttcacc agtcaaagca tgttgcagaa 26700 ctttaggaac tttatcctag agcgctcagg aatcttgccc gccacctgct gtgcacttcc 26760 tagcgacttt gtgcccatta agtaccgcga atgccctccg ccgctttggg gccactgcta 26820 ccttctgcag ctagccaact accttgccta ccactctgac ataatggaag acgtgagcgg 26880 tgacggtcta ctggagtgtc actgtcgctg caacctatgc accccgcacc gctccctggt 26940 ttgcaattcg cagctgctta acgaaagtca aattatcggt acctttgagc tgcagggtcc 27000 ctcgcctgac gaaaagtccg cggctccggg gttgaaactc actccggggc tgtggacgtc 27060 ggcttacctt cgcaaatttg tacctgagga ctaccacgcc cacgagatta ggttctacga 27120 agaccaatcc cgcccgccaa atgcggagct taccgcctgc gtcattaccc agggccacat 27180 CA 02359795 2001-07-12 pCT~P00/00265 tcttggccaa ttgcaagcca tcaacaaagc ccgccaagag tttctgctac gaaagggacg 27240 gggggtttac ttggaccccc agtccggcga ggagctcaac ccaatccccc cgccgccgca 27300 gccctatcag cagcagccgc gggcccttgc ttcccaggat ggcacccaaa aagaagctgc 27360 agctgccgcc gccacccacg gacgaggagg aatactggga cagtcaggca gaggaggttt 27420 tggacgagga ggaggaggac atgatggaag actgggagag cctagacgag gaagcttccg 27480 aggtcgaaga ggtgtcagac gaaacaccgt caccctcggt cgcattcccc tcgccggcgc 27540 cccagaaatc ggcaaccggt tccagcatgg ctacaacctc cgctcctcag gcgccgccgg 27600 cactgcccgt tcgccgaccc aaccgtagat gggacaccac tggaaccagg gccggtaagt 27660 ccaagcagcc gccgccgtta gcccaagagc aacaacagcg ccaaggctac cgctcatggc 27720 gcgggcacaa gaacgccata gttgcttgct tgcaagactg tgggggcaac atctccttcg 27780 cccgccgctt tcttctctac catcacggcg tggccttccc ccgtaacatc ctgcattact 27840 accgtcatct ctacagccca tactgcaccg gcggcagcgg cagcggcagc aacagcagcg 27900 gccacacaga agcaaaggcg accggatagc aagactctga caaagcccaa gaaatccaca 27960 gcggcggcag cagcaggagg aggagcgctg cgtctggcgc ccaacgaacc cgtatcgacc 28020 cgcgagctta gaaacaggat ttttcccact ctgtatgcta tatttcaaca gagcaggggc 28080 caagaacaag agctgaaaat aaaaaacagg tctctgcgat ccctcacccg cagctgcctg 28140 tatcacaaaa gcgaagatca gcttcggcgc acgctggaag acgcggaggc tctcttcagt 28200 aaatactgcg cgctgactct taaggactag tttcgcgccc tttctcaaat ttaagcgcga 28260 aaactacgtc atctccagcg gccacacccg gcgccagcac ctgtcgtcag cgccattatg 28320 agcaaggaaa ttcccacgcc ctacatgtgg agttaccagc cacaaatggg acttgcggct 28380 ggagctgccc aagactactc aacccgaata aactacatga gcgcgggacc ccacatgata 28490 tcccgggtca acggaatccg cgcccaccga aaccgaattc tcttggaaca ggcggctatt 28500 accaccacac ctcgtaataa ccttaatccc cgtagttggc ccgctgccct c~gtgtaccag 28560 gaaagtcccg ctcccaccac tgtggtactt cccagagacg cccaggccga agttcagatg 28620 actaactcag gggcgcagct tgcgggcggc tttcgtcaca gggtgcggtc gcccgggcag 28680 ggtataactc acctgacaat cagagggcga ggtattcagc tcaacgacga gtcggtgagc 28740 tcctcgcttg gtctccgtcc ggacgggaca tttcagatcg gcggcgccgg ccgtccttca 28800 ttcacgcctc gtcaggcaat cctaactctg cagacctcgt cctctgagcc gcgctctgga 28860 ggcattggaa ctctgcaatt tattgaggag tttgtgccat cggtctactt taaccccttc 28920 tcgggacctc ccggccacta tccggatcaa tttattccta actttgacgc ggtaaaggac 28980 tcggcggacg gctacgactg aatgttaagt ggagaggcag agcaactgcg cctgaaacac 29040 ctggtccact gtcgccgcca caagtgcttt gcccgcgact ccggtgagtt ttgctacttt 29100 gaattgcccg aggatcatat cgagggcccg gcgcacggcg tccggcttac cgcccaggga 29160 gagcttgccc gtagcctgat tcgggagttt acccagcgcc ccctgctagt tgagcgggac 29220 aggggaccct gtgttctcac tgtgatttgc aactgtccta accttggatt acatcaagat 29280 ttaattaatt gccacatcct cttacacttt ttcatacatt gcccaagaat aaagaatcgt 29340 ttgtgttatg tttcaacgtg tttatttttc aattgcagaa aatttcaagt catttttcat 29400 tcagtagtat agccccacca ccacatagct tatacagatc accgtacctt aatcaaactc 29460 acagaaccct agtattcaac ctgccacctc cctcccaaca cacagagtac acagtccttt 29520 ctccccggct ggccttaaaa agcatcatat catgggtaac agacatattc ttaggtgtta 29580 tattccacac ggtttcctgt cgagccaaac gctcatcagt gatattaata aactccccgg 29640 gcagctcact taagttcatg tcgctgtcca gctgctgagc cacaggctgc tgtccaactt 29700 gcggttgctt aacgggcggc gaaggagaag tccacgccta catgggggta gagtcataat 29760 cgtgcatcag gatagggcgg tggtgctgca gcagcgcgcg aataaactgc tgccgccgcc 29820 gctccgtcct gcaggaatac aacatggcag tggtctcctc agcgatgatt cgcaccgccc 29880 gcagcataag gcgccttgtc ctccgggcac agcagcgcac cctgatctca cttaaatcag 29940 cacagtaact gcagcacagc accacaatat tgttcaaaat cccacagtgc aaggcgctgt 30000 atccaaagct catggcgggg accacagaac ccacgtggcc atcataccac aagcgcaggt 30060 agattaagtg gcgacccctc ataaacacgc tggacataaa cattacctct tttggcatgt 30120 tgtaattcac cacctcccgg taccatataa acctctgatt aaacatggcg ccatccacca 30180 ccatcctaaa ccagctggcc aaaacctgcc cgccggctat acactgcagg gaaccgggac 30240 tggaacaatg acagtggaga gcccaggact cgtaaccatg gatcatcatg ctcgtcatga 30300 tatcaatgtt ggcacaacac aggcacacgt gcatacactt cctcaggatt acaagctcct 30360 cccgcgttag aaccatatcc cagggaacaa cccattcctg aatcagcgta aatcccacac 30920 tgcagggaag acctcgcacg taactcacgt tgtgcattgt caaagtgtta cattcgggca 30480 gcagcggatg atcctccagt atggtagcgc gggtttctgt ctcaaaagga ggtagacgat 30540 ccctactgta cggagtgcgc cgagacaacc gagatcgtgt tggtcgtagt gtcatgccaa 3060b atggaacgcc ggacgtagtc atatttcctg aagcaaaacc aggtgcgggc gtgacaaaca 30660 gatctgcgtc tccggtctcg ccgcttagat cgctctgtgt agtagttgta gtatatccac 30720 tctctcaaag catccaggcg ccccctggct tcgggttcta tgtaaactcc ttcatgcgcc 30780 gctgccctga taacatccac caccgcagaa taagccacac ccagccaacc tacacattcg 30840 ttctgcgagt cacacacggg aggagcggga agagctggaa gaaccatgtt ttttttttta 30900 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 ttccaaaaga ttatccaaaa cctcaaaatg aagatctatt aagtgaacgc gctcccctcc 30960 ggtggcgtgg tcaaactcta cagccaaaga acagataatg gcatttgtaa gatgttgcac 31020 aatggcttcc aaaaggcaaa cggccctcac~gtccaagtgg acgtaaaggc taaacccttc 31080 agggtgaatc tcctctataa acattccagc accttcaacc atgcccaaat aattctcatc 31140 tcgccacctt ctcaatatat ctctaagcaa atcccgaata ttaagtccgg ccattgtaaa 31200 aatctgctcc agagcgccct ccaccttcag cctcaagcag cgaatcatga ttgcaaaaat 31260 tcaggttcct cacagacctg tataagattc aaaagcggaa cattaacaaa aataccgcga 31320 tcccgtaggt cccttcgcag ggccagctga acataatcgt gcaggtctgc acggaccagc 31380 gcggccactt ccccgccagg aaccttgaca aaagaaccca cactgattat gacacgcata 31440 ctcggagcta tgctaaccag cgtagccccg atgtaagctt tgttgcatgg gcggcgatat 31500 aaaatgcaag gtgctgctca aaaaatcagg caaagcctcg cgcaaaaaag aaagcacatc 31560 gtagtcatgc tcatgcagat aaaggcaggt aagctccgga accaccacag aaaaagacac 31620 catttttctc tcaaacatgt ctgcgggttt ctgcataaac acaaaataaa ataacaaaaa 31680 aacatttaaa cattagaagc ctgtcttaca acaggaaaaa caacccttat aagcataaga 31740 cggactacgg ccatgccggc gtgaccgtaa aaaaactggt caccgtgatt aaaaagcacc 31800 accgacagct cctcggtcat gtccggagtc ataatgtaag actcggtaaa cacatcaggt 31860 tgattcatcg gtcagtgcta aaaagcgacc gaaatagccc gggggaatac atacccgcag 31920 gcgtagagac aacattacag cccccatagg aggtataaca aaattaatag gagagaaaaa 31980 cacataaaca cctgaaaaac cctcctgcct aggcaaaata gcaccctccc gctccagaac 32040 aacatacagc gcttcacagc ggcagcctaa cagtcagcct taccagtaaa aaagaaaacc 32100 tattaaaaaa acaccactcg acacggcacc agctcaatca gtcacagtgt aaaaaagggc 32160 caagtgcaga gcgagtatat ataggactaa aaaatgacgt aacggttaaa gtccacaaaa 32220 aacacccaga aaaccgcacg cgaacctacg cccagaaacg aaagccaaaa aacccacaac 32280 ttcctcaaat cgtcacttcc gttttcccac gttacgtaac ttcccatttt aagaaaacta 32340 caattcccaa cacatacaag ttactccgcc ctaaaaccta cgtcacccgc cccgttccca 32400 cgccccgcgc cacgtcacaa actccacccc ctcattatca tattggcttc aatccaaaat 32460 aaggtatatt attgatgatg 32480 <210> 28 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 28 ctcaacaatt gtggatccgt actcc 25 <210> 29 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 29 gtgctcagca gatcttgcga ctgtg 25 <210> 30 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 30 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 ggcgcgttcg gatccactct cttcc 25 <210> 31 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 31 ctacatgcta ggcagatctc gttcggag 28 <210> 32 <211> 1240 <212> DNA
<213> adenovirus <400> 32 ggatccactc tcttccgcat cgctgtctgc gagggccagc tgttggggtg ~gtactccct 60 ctgaaaagcg ggcatgactt ctgcgctaag attgtcagtt tccaaaaacg ~ggaggattt 120 gatattcacc tggcccgcgg tgatgccttt gagggtggcc gcatccatct ggtcagaaaa 180 gacaatcttt ttgttgtcaa gcttggtggc aaacgacccg tagagggcgt tggacagcaa 240 cttggcgatg gagcgcaggg tttggttttt gtcgcgatcg gcgcgctcct tggccgcgat 300 gtttagctgc acgtattcgc gcgcaacgca ccgccattcg ggaaagacgg tggtgcgctc 360 gtcgggcacc aggtgcacgc gccaaccgcg gttgtgcagg gtgacaaggt caacgctggt 420 ggctacctct ccgcgtaggc gctcgttggt ccagcagagg cggccgccct tgcgcgagca 480 gaatggcggt agggggtcta gctgcgtctc gtccgggggg tctgcgtcca cggtaaagac 540 cccgggcagc aggcgcgcgt cgaagtagtc tatcttgcat ccttgcaagt ctagcgcctg 600 ctgccatgcg cgggcggcaa gcgcgcgctc gtatgggttg agtgggggac cccatggcat 660 ggggtgggtg agcgcggagg cgtacatgcc gcaaatgtcg taaacgtaga ggggctctct 720 gagtattcca agatatgtag ggtagcatct tccaccgcgg atgctggcgc gcacgtaatc 780 gtatagttcg tgcgagggag cgaggaggtc gggaccgagg ttgctacggg cgggctgctc 840 tgctcggaag actatctgcc tgaagatggc atgtgagttg gatgatatgg ttggacgctg 900 gaagacgttg aagctggcgt ctgtgagacc taccgcgtca cgcacgaagg aggcgtagga 960 gtcgcgcagc ttgttgacca gctcggcggt gacctgcacg tctagggcgc agtagtccag 1020 ggtttccttg atgatgtcat acttatcctg tccctttttt ttccacagct cgcggttgag 1080 gacaaactct tcgcggtctt tccagtactc ttggatcgga aacccgtcgg cctccgaacg 1140 agatccgtac tccgccgccg agggacctga gcgagtccgc atcgaccgga tcggaaaacc 1200 tctcgagaaa ggcgtctaac cagtcacagt cgcaagatct 1240 <210> 33 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 33 ggcgcgttcg gatccactct cttcc 25 <210> 34 <211> 20 <212> DNA
<213> Artificial Sequence <220>

WO 00/42208 CA 02359795 2001-07-12 pCT~, P00/00265 <223> Description of Artificial Sequence: primer <900> 34 gggagtagat ctcccaacag 20 <210> 35 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 35 cccttttttt tggatccctc gcgg 24 <210> 36 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 36 ctacatgcta ggcagatctc gttcggag 28 <210> 37 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 37 ctcaacaatt gttggatccg tactcc 26 <210> 38 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 38 gtgctcagca gatcttgcga ctgtg 25 <210> 39 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 39 ggcgcgttcg gatccactct cttcc 25 <210> 40 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 40 ctacatgcta ggcagatctc gttcggag 28 <210> 41 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 41 cccttttttt tggatccctc gcgg 29 <210> 42 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 42 gtgctcagca gatcttgcga ctgtg 25 <210> 43 <211> 8383 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 43 gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 920 attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540 atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780 gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840 ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gcttggtacc 900 gagctcggat ccactctctt ccgcatcgct gtctgcgagg gccagctgtt ggggtgagta 960 ctccctctga aaagcgggca tgacttctgc gctaagattg tcagtttcca aaaacgagga 1020 ggatttgata ttcacctggc ccgcggtgat gcctttgagg gtggccgcat ccatctggtc 1080 agaaaagaca atctttttgt tgtcaagctt ggtggcaaac gacccgtaga gggcgttgga 1140 cagcaacttg gcgatggagc gcagggtttg gtttttgtcg cgatcggcgc gctccttggc 1200 cgcgatgttt agctgcacgt attcgcgcgc aacgcaccgc cattcgggaa agacggtggt 1260 gcgctcgtcg ggcaccaggt gcacgcgcca accgcggttg tgcagggtga caaggtcaac 1320 gctggtggct acctctccgc gtaggcgctc gttggtccag cagaggcggc cgcccttgcg 1380 cgagcagaat ggcggtaggg ggtctagctg cgtctcgtcc ggggggtctg cgtccacggt 1440 aaagaccccg ggcagcaggc gcgcgtcgaa gtagtctatc ttgcatcctt gcaagtctag 1500 cgcctgctgc catgcgcggg cggcaagcgc gcgctcgtat gggttgagtg ggggacccca 1560 tggcatgggg tgggtgagcg cggaggcgta catgccgcaa atgtcgtaaa cgtagagggg 1620 ctctctgagt attccaagat atgtagggta gcatcttcca ccgcggatgc tggcgcgcac 1680 gtaatcgtat agttcgtgcg agggagcgag gaggtcggga ccgaggttgc tacgggcggg 1740 ctgctctgct cggaagacta tctgcctgaa gatggcatgt gagttggatg atatggttgg 1800 acgctggaag acgttgaagc tggcgtctgt gagacctacc gcgtcacgca cgaaggaggc 1860 gtaggagtcg cgcagcttgt tgaccagctc ggcggtgacc tgcacgtcta gggcgcagta 1920 gtccagggtt tccttgatga tgtcatactt atcctgtccc ttttttttcc acagctcgcg 1980 gttgaggaca aactcttcgc ggtctttcca gtactcttgg atcggaaacc cgtcggcctc 2040 cgaacgagat ccgtactccg ccgccgaggg acctgagcga gtccgcatcg accggatcgg 2100 aaaacctctc gagaaaggcg tctaaccagt cacagtcgca agatccaaga tgaagcgcgc 2160 aagaccgtct gaagatacct tcaaccccgt gtatccatat gacacggaaa ccggtcctcc 2220 aactgtgcct tttcttactc ctccctttgt atcccccaat gggtttcaag agagtccccc 2280 tggggtactc tctttgcgcc tatccgaacc tctagttacc tccaatggca tgcttgcgct 2340 caaaatgggc aacggcctct ctctggacga ggccggcaac cttacctccc aaaatgtaac 2400 cactgtgagc ccacctctca aaaaaaccaa gtcaaacata aacctggaaa tatctgcacc 2460 cctcacagtt acctcagaag ccctaactgt ggctgccgcc gcacctctaa tggtcgcggg 2520 caacacactc accatgcaat cacaggcccc gctaaccgtg cacgactcca aacttagcat 2580 tgccacccaa ggacccctca cagtgtcaga aggaaagcta gccctgcaaa catcaggccc 2640 cctcaccacc accgatagca gtacccttac tatcactgcc tcaccccctc taactactgc 2700 cactggtagc ttgggcattg acttgaaaga gcccatttat acacaaaatg gaaaactagg 2760 actaaagtac ggggctcctt tgcatgtaac agacgaccta aacactttga ccgtagcaac 2820 tggtccaggt gtgactatta ataatacttc cttgcaaact aaagttactg gagccttggg 2880 ttttgattca caaggcaata tgcaacttaa tgtagcagga ggactaagga ttgattctca 2940 aaacagacgc cttatacttg atgttagtta tccgtttgat gctcaaaacc aactaaatct 3000 aagactagga cagggccctc tttttataaa ctcagcccac aacttggata ttaactacaa 3060 caaaggcctt tacttgttta cagcttcaaa caattccaaa aagcttgagg ttaacctaag 3120 cactgccaag gggttgatgt ttgacgctac agccatagcc attaatgcag gagatgggct 3180 tgaatttggt tcacctaatg caccaaacac aaatcccctc aaaacaaaaa ttggccatgg 3240 cctagaattt gattcaaaca aggctatggt tcctaaacta ggaactggcc ttagttttga 3300 cagcacaggt gccattacag taggaaacaa aaataatgat aagctaactt tgtggaccac 3360 accagctcca tctcctaact gtagactaaa tgcagagaaa gatgctaaac tcactttggt 3420 cttaacaaaa tgtggcagtc aaatacttgc tacagtttca gttttggctg ttaaaggcag 3480 tttggctcca atatctggaa cagttcaaag tgctcatctt attataagat ttgacgaaaa 3540 tggagtgcta ctaaacaatt ccttcctgga cccagaatat tggaacttta gaaatggaga 3600 tcttactgaa ggcacagcct atacaaacgc tgttggattt atgcctaacc tatcagctta 3660 tccaaaatct cacggtaaaa ctgccaaaag taacattgtc agtcaagttt acttaaacgg 3720 agacaaaact aaacctgtaa cactaaccat tacactaaac ggtacacagg aaacaggaga 3780 cacaactcca agtgcatact ctatgtcatt ttcatgggac tggtctggcc acaactacat 3840 taatgaaata tttgccacat cctcttacac tttttcatac attgcccaag aataaaagaa 3900 gcggccgctc gagcatgcat ctagagggcc ctattctata gtgtcaccta aatgctagag 3960 ctcgctgatc agcctcgact gtgccttcta gttgccagcc atctgttgtt tgcccctccc 4020 ccgtgccttc cttgaccctg gaaggtgcca ctcccactgt cctttcctaa taaaatgagg 4080 aaattgcatc gcattgtctg agtaggtgtc attctattct ggggggtggg gtggggcagg 4140_ acagcaaggg ggaggattgg gaagacaata gcaggcatgc tggggatgcg gtgggctcta 4200 tggcttctga ggcggaaaga accagctggg gctctagggg gtatccccac gcgccctgta 4260 gcggcgcatt aagcgcggcg ggtgtggtgg ttacgcgcag cgtgaccgct acacttgcca 4320 gcgccctagc gcccgctcct ttcgctttct tcccttcctt tctcgccacg ttcgccggct 4380 ttccccgtca agctctaaat cggggcatcc ctttagggtt ccgatttagt gctttacggc 4440 acctcgaccc caaaaaactt gattagggtg atggttcacg tagtgggcca tcgccctgat 4500 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 agacggtttt tcgccctttg acgttggagt ccacgttctt taatagtgga ctcttgttcc 4560 aaactggaac aacactcaac cctatctcgg tctattcttt tgatttataa gggattttgg 4620 ggatttcggc ctattggtta aaaaatgagc tgatttaaca aaaatttaac gcgaattaat 4680 tctgtggaat gtgtgtcagt tagggtgtgg aaagtcccca ggctccccag gcaggcagaa 4740 gtatgcaaag catgcatctc aattagtcag caaccaggtg tggaaagtcc ccaggctccc 4800 cagcaggcag aagtatgcaa agcatgcatc tcaattagtc agcaaccata gtcccgcccc 9860 taactccgcc catcccgccc ctaactccgc ccagttccgc ccattctccg ccccatggct 4920 gactaatttt ttttatttat gcagaggccg aggccgcctc tgcctctgag ctattccaga 4980 agtagtgagg aggctttttt ggaggcctag gcttttgcaa aaagctcccg ggagcttgta 5040 tatccatttt cggatctgat caagagacag gatgaggatc gtttcgcatg attgaacaag 5100 atggattgca cgcaggttct ccggccgctt gggtggagag gctattcggc tatgactggg 5160 cacaacagac aatcggctgc tctgatgccg ccgtgttccg gctgtcagcg caggggcgcc 5220 cggttctttt tgtcaagacc gacctgtccg gtgccctgaa tgaactgcag gacgaggcag 5280 cgcggctatc gtggctggcc acgacgggcg ttccttgcgc agctgtgctc gacgttgtca 5340 ctgaagcggg aagggactgg ctgctattgg gcgaagtgcc ggggcaggat ctcctgtcat 5400 ctcaccttgc tcctgccgag aaagtatcca tcatggctga tgcaatgcgg cggctgcata 5460 cgcttgatcc ggctacctgc ccattcgacc accaagcgaa acatcgcatc gagcgagcac 5520 gtactcggat ggaagccggt cttgtcgatc aggatgatct ggacgaagag catcaggggc 5580 tcgcgccagc cgaactgttc gccaggctca aggcgcgcat gcccgacggc gaggatctcg 5640 tcgtgaccca tggcgatgcc tgcttgccga atatcatggt ggaaaatggc cgcttttctg 5700 gattcatcga ctgtggccgg ctgggtgtgg cggaccgcta tcaggacata gcgttggcta 5760 cccgtgatat tgctgaagag cttggcggcg aatgggctga ccgcttcctc gtgctttacg 5820 gtatcgccgc tcccgattcg cagcgcatcg ccttctatcg ccttcttgac gagttcttct 5880 gagcgggact ctggggttcg aaatgaccga ccaagcgacg cccaacctgc catcacgaga 5940 tttcgattcc accgccgcct tctatgaaag gttgggcttc ggaatcgttt tccgggacgc 6000 cggctggatg atcctccagc gcggggatct catgctggag ttcttcgccc accccaactt 6060 gtttattgca gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa 6120 agcatttttt tcactgcatt ctagttgtgg tttgtccaaa ctcatcaatg tatcttatca 6180 tgtctgtata ccgtcgacct ctagctagag cttggcgtaa tcatggtcat agctgtttcc 6240 tgtgtgaaat tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagtg 6300 taaagcctgg ggtgcctaat gagtgagcta actcacatta attgcgttgc gctcactgcc 6360 cgctttccag tcgggaaacc tgtcgtgcca gctgcattaa tgaatcggcc aacgcgcggg 6420 gagaggcggt ttgcgtattg ggcgctcttc cgcttcctcg ctcactgact cgctgcgctc 6480 ggtcgttcgg ctgcggcgag cggtatcagc tcactcaaag gcggtaatac ggttatccac 6540 agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa 6600 ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca 6660 caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc 6720 gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 6780 cctgtccgcc tttctccctt cgggaagcgt ggcgctttct caatgctcac gctgtaggta 6840 tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 6900 gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga 6960 cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 7020 tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg 7080 tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 7140 caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag 7200 aaaaaaagga tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa 7260 cgaaaactca cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat 7320 ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 7380 tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc 7440 atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 7500 tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc 7560 aataaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgcctc 7620 catccagtct attaattgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt 7680 gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 7740 ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa 7800 aaaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt 7860_ atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg 7920 cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgta tgcggcgacc 7980 gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa 8040 agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 8100 gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 8160 caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag 8220 ggcgacacgg aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta 8280 tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 8340 aggggttccg cgcacatttc cccgaaaagt gccacctgac gtc 8383 <210> 44 <211> 7960 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 44 gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 980 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540 atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780 gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840 ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctagc 900 gtttaaactt aagcttggta ccgagctcgg atccactctc ttccgcatcg ctgtctgcga 960 gggccagctg ttggggtgag tactccctct gaaaagcggg catgacttct gcgctaagat 1020 tgtcagtttc caaaaacgag gaggatttga tattcacctg gcccgcggtg atgcctttga 1080 gggtggccgc atccatctgg tcagaaaaga caatcttttt gttgtcaagc ttggtggcaa 1140 acgacccgta gagggcgttg gacagcaact tggcgatgga gcgcagggtt tggtttttgt 1200 cgcgatcggc gcgctccttg gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc 1260 gccattcggg aaagacggtg gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggt 1320 tgtgcagggt gacaaggtca acgctggtgg ctacctctcc gcgtaggcgc tcgttggtcc 1380 agcagaggcg gccgcccttg cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt 1440 ccggggggtc tgcgtccacg gtaaagaccc cgggcagcag gcgcgcgtcg aagtagtcta 1500 tcttgcatcc ttgcaagtct agcgcctgct gccatgcgcg ggcggcaagc gcgcgctcgt 1560 atgggttgag tgggggaccc catggcatgg ggtgggtgag cgcggaggcg tacatgccgc 1620 aaatgtcgta aacgtagagg ggctctctga gtattccaag atatgtaggg tagcatcttc 1680 caccgcggat gctggcgcgc acgtaatcgt atagttcgtg cgagggagcg aggaggtcgg 1740 gaccgaggtt gctacgggcg ggctgctctg ctcggaagac tatctgcctg aagatggcat 1800 gtgagttgga tgatatggtt ggacgctgga agacgttgaa gctggcgtct gtgagaccta 1860 ccgcgtcacg cacgaaggag gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga 1920 cctgcacgtc tagggcgcag tagtccaggg tttccttgat gatgtcatac ttatcctgtc 1980 cctttttttt ccacagctcg cggttgagga caaactcttc gcggtctttc cagtactctt 2040 ggatcggaaa cccgtcggcc tccgaacgag atccgtactc cgccgccgag ggacctgagc 2100 gagtccgcat cgaccggatc ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg 2160 caagatccaa gatgaagcgc gcaagaccgt ctgaagatac cttcaacccc gtgtatccat 2220 atgacacgga aaccggtcct ccaactgtgc cttttcttac tcctcccttt gtatccccca 2280 atgggtttca agagagtccc cctggggtac tctctttgcg cctatccgaa cctctagtta 2340 cctccaatgg catgcttgcg ctcaaaatgg gcaacggcct ctctctggac gaggccggca 2400 accttacctc ccaaaatgta accactgtga gcccacctct caaaaaaacc aagtcaaaca 2460 taaacctgga aatatctgca cccctcacag ttacctcaga agccctaact gtggctgccg 2520_ ccgcacctct aatggtcgcg ggcaacacac tcaccatgca atcacaggcc ccgctaaccg 2580 tgcacgactc caaacttagc attgccaccc aaggacccct cacagtgtca gaaggaaagc 2640 tagccctgca aacatcaggc cccctcacca ccaccgatag cagtaccctt actatcactg 2700 cctcaccccc tctaactact gccactggta gcttgggcat tgacttgaaa gagcccattt 2760 atacacaaaa tggaaaacta ggactaaagt acggggctcc tttgcatgta acagacgacc 2820 taaacacttt gaccgtagca actggtccag gtgtgactat taataatact tccttgcaaa 2880 ctaaagttac tggagccttg ggttttgatt cacaaggcaa tatgcaactt aatgtagcag 2940 gaggactaag gattgattct caaaacagac gccttatact tgatgttagt tatccgtttg 3000 atgctcaaaa ccaactaaat ctaagactag gacagggccc tctttttata aactcagccc 3060 acaacttgga tattaactac aacaaaggcc tttacttgtt tacagcttca aacaattcca 3120 aaaagcttga ggttaaccta agcactgcca aggggttgat gtttgacgct acagccatag 3180 ccattaatgc aggagatggg cttgaatttg gttcacctaa tgcaccaaac acaaatcccc 3240 tcaaaacaaa aattggccat ggcctagaat ttgattcaaa caaggctatg gttcctaaac 3300 taggaactgg ccttagtttt gacagcacag gtgccattac agtaggaaac aaaaataatg 3360 ataagctaac tttgtggacc acaccagctc catctcctaa ctgtagacta aatgcagaga 3420 aagatgctaa actcactttg gtcttaacaa aatgtggcag tcaaatactt gctacagttt 3480 cagttttggc tgttaaaggc agtttggctc caatatctgg aacagttcaa agtgctcatc 3540 ttattataag atttgacgaa aatggagtgc tactaaacaa ttccttcctg gacccagaat 3600 attggaactt tagaaatgga gatcttactg aaggcacagc ctatacaaac gctgttggat 3660 ttatgcctaa cctatcagct tatccaaaat ctcacggtaa aactgccaaa agtaacattg 3720 tcagtcaagt ttacttaaac ggagacaaaa ctaaacctgt aacactaacc attacactaa 3780 acggtacaca ggaaacagga gacacaactc caagtgcata ctctatgtca ttttcatggg 3840 actggtctgg ccacaactac attaatgaaa tatttgccac atcctcttac actttttcat 3900 acattgccca agaataaaag aagcggccgc tcgagtctag agggcccgtt taaacccgct 3960 gatcagcctc gactgtgcct tctagttgcc agccatctgt tgtttgcccc tcccccgtgc 4020 cttccttgac cctggaaggt gccactccca ctgtcctttc ctaataaaat gaggaaattg 4080 catcgcattg tctgagtagg tgtcattcta ttctgggggg tggggtgggg caggacagca 4140 agggggagga ttgggaagac aatagcaggc atgctgggga tgcggtgggc,tctatggctt 4200 ctgaggcgga aagaaccagc tggggctcta gggggtatcc ccacgcgccc tgtagcggcg 4260 cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt gccagcgccc 4320 tagcgcccgc tcctttcgct ttcttccctt cctttctcgc cacgttcgcc ggctttcccc 4380 gtcaagctct aaatcggggc atccctttag ggttccgatt tagtgcttta cggcacctcg 4440 accccaaaaa acttgattag ggtgatggtt cacgtagtgg gccatcgccc tgatagacgg 4500 tttttcgccc tttgacgttg gagtccacgt tctttaatag tggactcttg ttccaaactg 4560 gaacaacact caaccctatc tcggtctatt cttttgattt ataagggatt ttggggattt 4620 cggcctattg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg 4680 gaatgtgtgt cagttagggt gtggaaagtc cccaggctcc ccaggcaggc agaagtatgc 4740 aaagcatgca tctcaattag tcagcaacca ggtgtggaaa gtccccaggc tccccagcag 4800 gcagaagtat gcaaagcatg catctcaatt agtcagcaac catagtcccg cccctaactc 9860 cgcccatccc gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa 4920 ttttttttat ttatgcagag gccgaggccg cctctgcctc tgagctattc cagaagtagt 4980 gaggaggctt ttttggaggc ctaggctttt gcaaaaagct cccgggagct tgtatatcca 5040 ttttcggatc tgatcagcac gtgttgacaa ttaatcatcg gcatagtata tcggcatagt 5100 ataatacgac aaggtgagga actaaaccat ggccaagttg accagtgccg ttccggtgct 5160 caccgcgcgc gacgtcgccg gagcggtcga gttctggacc gaccggctcg ggttctcccg 5220 ggacttcgtg gaggacgact tcgccggtgt ggtccgggac gacgtgaccc tgttcatcag 5280 cgcggtccag gaccaggtgg tgccggacaa caccctggcc tgggtgtggg tgcgcggcct 5340 ggacgagctg tacgccgagt ggtcggaggt cgtgtccacg aacttccggg acgcctccgg 5400 gccggccatg accgagatcg gcgagcagcc gtgggggcgg gagttcgccc tgcgcgaccc 5460 ggccggcaac tgcgtgcact tcgtggccga ggagcaggac tgacacgtgc tacgagattt 5520 cgattccacc gccgccttct atgaaaggtt gggcttcgga atcgttttcc gggacgccgg 5580 ctggatgatc ctccagcgcg gggatctcat gctggagttc ttcgcccacc ccaacttgtt 5640 tattgcagct tataatggtt acaaataaag caatagcatc acaaatttca caaataaagc 5700 atttttttca ctgcattcta gttgtggttt gtccaaactc atcaatgtat cttatcatgt 5760 ctgtataccg tcgacctcta gctagagctt ggcgtaatca tggtcatagc tgtttcctgt 5820 gtgaaattgt tatccgctca caattccaca caacatacga gccggaagca taaagtgtaa 5880 agcctggggt gcctaatgag tgagctaact cacattaatt gcgttgcgct cactgcccgc 5940 tttccagtcg ggaaacctgt cgtgccagct gcattaatga atcggccaac gcgcggggag 6000 aggcggtttg cgtattgggc gctcttccgc ttcctcgctc actgactcgc tgcgctcggt 6060 cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg gtaatacggt tatccacaga 6120 atcaggggat aacgcaggaa agaacatgtg agcaaaaggc cagcaaaagg ccaggaaccg 6180 taaaaaggcc gcgttgctgg cgtttttcca taggctccgc ccccctgacg agcatcacaa 6240_ aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat accaggcgtt 6300 tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgccgctta ccggatacct 6360 gtccgccttt ctcccttcgg gaagcgtggc gctttctcaa tgctcacgct gtaggtatct 6420 cagttcggtg taggtcgttc gctccaagct gggctgtgtg cacgaacccc ccgttcagcc 6480 cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aacccggtaa gacacgactt 6540 atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggtatg taggcggtgc 6600 tacagagttc ttgaagtggt ggcctaacta cggctacact agaaggacag tatttggtat 6660 ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt ggtagctctt gatccggcaa 6720 acaaaccacc gctggtagcg gtggtttttt tgtttgcaag cagcagatta cgcgcagaaa 6780 aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc agtggaacga 6840 aaactcacgt taagggattt tggtcatgag attatcaaaa aggatcttca cctagatcct 6900 tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata tatgagtaaa cttggtctga 6960 cagttaccaa tgcttaatca gtgaggcacc tatctcagcg atctgtctat ttcgttcatc 7020 catagttgcc tgactccccg tcgtgtagat aactacgata cgggagggct taccatctgg 7080 ccccagtgct gcaatgatac cgcgagaccc acgctcaccg gctccagatt tatcagcaat 7140 aaaccagcca gccggaaggg ccgagcgcag aagtggtcct gcaactttat ccgcctccat 7200 ccagtctatt aattgttgcc gggaagctag agtaagtagt tcgccagtta atagtttgcg 7260 caacgttgtt gccattgcta caggcatcgt ggtgtcacgc tcgtcgtttg gtatggcttc 7320 attcagctcc ggttcccaac gatcaaggcg agttacatga tcccccatgt tgtgcaaaaa 7380 agcggttagc tccttcggtc ctccgatcgt tgtcagaagt aagttggccg cagtgttatc 7440 actcatggtt atggcagcac tgcataattc tcttactgtc atgccatccg taagatgctt 7500 ttctgtgact ggtgagtact caaccaagtc attctgagaa tagtgtatgc ggcgaccgag 7560 ttgctcttgc ccggcgtcaa tacgggataa taccgcgcca catagcagaa ctttaaaagt 7620 gctcatcatt ggaaaacgtt cttcggggcg aaaactctca aggatcttac cgctgttgag 7680 atccagttcg atgtaaccca ctcgtgcacc caactgatct tcagcatctt ttactttcac 7740 cagcgtttct gggtgagcaa aaacaggaag gcaaaatgcc gcaaaaaagg gaataagggc 7800 gacacggaaa tgttgaatac tcatactctt cctttttcaa tattattgaa gcatttatca 7860 gggttattgt ctcatgagcg gatacatatt tgaatgtatt tagaaaaata aacaaatagg 7920 ggttccgcgc acatttcccc gaaaagtgcc acctgacgtc ~ 7960 <210> 45 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 45 atgggatcca agatgaagcg cgcaagaccg 30 <210> 46 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 46 cactatagcg gccgcattct cagtcatctt 30 <210> 47 <211> 7989 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <900> 47 gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg 60 ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120 cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180 ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 360 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420 attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt 480 atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540 atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 660 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 720 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 780 gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840 ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctagc 900 gtttaaactt aagcttggta ccgagctcgg atccactctc ttccgcatcg ctgtctgcga 960 gggccagctg ttggggtgag tactccctct gaaaagcggg catgacttct gcgctaagat 1020 tgtcagtttc caaaaacgag gaggatttga tattcacctg gcccgcggtg atgcctttga 1080 gggtggccgc atccatctgg tcagaaaaga caatcttttt gttgtcaagc ttggtggcaa 1140 acgacccgta gagggcgttg gacagcaact tggcgatgga gcgcagggtt tggtttttgt 1200 cgcgatcggc gcgctccttg gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc 1260 gccattcggg aaagacggtg gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggt 1320 tgtgcagggt gacaaggtca acgctggtgg ctacctctcc gcgtaggcgc tcgttggtcc 1380 agcagaggcg gccgcccttg cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt 1440 ccggggggtc tgcgtccacg gtaaagaccc cgggcagcag gcgcgcgtcg aagtagtcta 1500 tcttgcatcc ttgcaagtct agcgcctgct gccatgcgcg ggcggcaagc gcgcgctcgt 1560 atgggttgag tgggggaccc catggcatgg ggtgggtgag cgcggaggcg t~acatgccgc 1620 aaatgtcgta aacgtagagg ggctctctga gtattccaag atatgtaggg tagcatcttc 1680 caccgcggat gctggcgcgc acgtaatcgt atagttcgtg cgagggagcg aggaggtcgg 1740 gaccgaggtt gctacgggcg ggctgctctg ctcggaagac tatctgcctg aagatggcat 1800 gtgagttgga tgatatggtt ggacgctgga agacgttgaa gctggcgtct gtgagaccta 1860 ccgcgtcacg cacgaaggag gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga 1920 cctgcacgtc tagggcgcag tagtccaggg tttccttgat gatgtcatac ttatcctgtc 1980 cctttttttt ccacagctcg cggttgagga caaactcttc gcggtctttc cagtactctt 2040 ggatcggaaa cccgtcggcc tccgaacgag atccgtactc cgccgccgag ggacctgagc 2100 gagtccgcat cgaccggatc ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg 2160 caagatccaa gatgaagcgc gcaagaccgt ctgaagatac cttcaacccc gtgtatccat 2220 atgacacgga aaccggtcct ccaactgtgc cttttcttac tcctcccttt gtatccccca 2280 atgggtttca agagagtccc cctggggtac tctctttgcg cctatccgaa cctctagtta 2340 cctccaatgg catgcttgcg ctcaaaatgg gcaacggcct ctctctggac gaggccggca 2400 accttacctc ccaaaatgta accactgtga gcccacctct caaaaaaacc aagtcaaaca 2460 taaacctgga aatatctgca cccctcacag ttacctcaga agccctaact gtggctgccg 2520 ccgcacctct aatggtcgcg ggcaacacac tcaccatgca atcacaggcc ccgctaaccg 2580 tgcacgactc caaacttagc attgccaccc aaggacccct cacagtgtca gaaggaaagc 2640 tagccctgca aacatcaggc cccctcacca ccaccgatag cagtaccctt actatcactg 2700 cctcaccccc tctaactact gccactggta gcttgggcat tgacttgaaa gagcccattt 2760 atacacaaaa tggaaaacta ggactaaagt acggggctcc tttgcatgta acagacgacc 2820 taaacacttt gaccgtagca actggtccag gtgtgactat taataatact tccttgcaaa 2880 ctaaagttac tggagccttg ggttttgatt cacaaggcaa tatgcaactt aatgtagcag 2940 gaggactaag gattgattct caaaacagac gccttatact tgatgttagt tatccgtttg 3000 atgctcaaaa ccaactaaat ctaagactag gacagggccc tctttttata aactcagccc 3060 acaacttgga tattaactac aacaaaggcc tttacttgtt tacagcttca aacaattcca 3120 aaaagcttga ggttaaccta agcactgcca aggggttgat gtttgacgct acagccatag~3180 ccattaatgc aggagatggg cttgaatttg gttcacctaa tgcaccaaac acaaatcccc 3240 tcaaaacaaa aattggccat ggcctagaat ttgattcaaa caaggctatg gttcctaaac 3300 taggaactgg ccttagtttt gacagcacag gtgccattac agtaggaaac aaaaataatg 3360 ataagctaac tttgtggacc ggtccaaaac cagaagccaa ctgcataatt gaatacggga 3420 aacaaaaccc agatagcaaa ctaactttaa tccttgtaaa aaatggagga attgttaatg 3480 gatatgtaac gctaatggga gcctcagact acgttaacac cttatttaaa aacaaaaatg 3540 tctccattaa tgtagaacta tactttgatg ccactggtca tatattacca gactcatctt 3600 ctcttaaaac agatctagaa ctaaaataca agcaaaccgc tgactttagt gcaagaggtt 3660 ttatgccaag tactacagcg tatccatttg tccttcctaa tgcgggaaca cataatgaaa 3720 attatatttt tggtcaatgc tactacaaag caagcgatgg tgcccttttt ccgttggaag 3780 ttactgttat gcttaataaa cgcctgccag atagtcgcac atcctatgtt atgacttttt 3840 tatggtcctt gaatgctggt ctagctccag aaactactca ggcaaccctc ataacctccc 3900 catttacctt ttcctatatt agagaagatg actgattttt aagaagcggc cgctcgagtc 3960 CA 02359795 2001-07-12 pCT~, p00/00265 tagagggccc gtttaaaccc gctgatcagc ctcgactgtg ccttctagtt gccagccatc 4020 tgttgtttgc ccctcccccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct 4080 ttcctaataa aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg 4140 gggtggggtg gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcatgctgg 4200 ggatgcggtg ggctctatgg cttctgaggc ggaaagaacc snccntagct ggggctctag 4260 ggggtatccc cacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg 4320 cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc 4380 ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcggggca tccctttagg 4440 gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc 4500 acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 4560 ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc 4620 ttttgattta taagggattt tggggatttc ggcctattgg ttaaaaaatg agctgattta 4680 acaaaaattt aacgcgaatt aattctgtgg aatgtgtgtc agttagggtg tggaaagtcc 4740 ccaggctccc caggcaggca gaagtatgca aagcatgcat ctcaattagt cagcaaccag 4800 gtgtggaaag tccccaggct ccccagcagg cagaagtatg caaagcatgc atctcaatta 4860 gtcagcaacc atagtcccgc ccctaactcc gcccatcccg cccctaactc cgcccagttc 4920 cgcccattct ccgccccatg gctgactaat tttttttatt tatgcagagg ccgaggccgc 4980 ctctgcctct gagctattcc agaagtagtg aggaggcttt tttggaggcc taggcttttg 5040 caaaaagctc ccgggagctt gtatatccat tttcggatct gatcagcacg tgttgacaat 5100 taatcatcgg catagtatat cggcatagta taatacgaca aggtgaggaa ctaaaccatg 5160 gccaagttga ccagtgccgt tccggtgctc accgcgcgcg acgtcgccgg agcggtcgag 5220 ttctggaccg accggctcgg gttctcccgg gacttcgtgg aggacgactt Cgccggtgtg 5280 gtccgggacg acgtgaccct gttcatcagc gcggtccagg accaggtggt gccggacaac 5340 accctggcct gggtgtgggt gcgcggcctg gacgagctgt acgccgagtg gtcggaggtc 5400 gtgtccacga acttccggga cgcctccggg ccggccatga ccgagatcgg cgagcagccg 5460 tgggggcggg agttcgccct gcgcgacccg gccggcaact gcgtgcactt cgtggccgag 5520 gagcaggact gacacgtgct acgagatttc gattccaccg ccgccttcta tgaaaggttg 5580 ggcttcggaa tcgttttccg ggacgccggc tggatgatcc tccagcgcgg ggatctcatg 5640 ctggagttct tcgcccaccc caacttgttt attgcagctt ataatggtta caaataaagc 5700 aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag ttgtggtttg 5760 tccaaactca tcaatgtatc ttatcatgtc tgtataccgt cgacctctag ctagagcttg 5820 gcgtaatcat ggtcatagct gtttcctgtg tgaaattgtt atccgctcac aattccacac 5880 aacatacgag ccggaagcat aaagtgtaaa gcctggggtg cctaatgagt gagctaactc 5940 acattaattg cgttgcgctc actgcccgct ttccagtcgg gaaacctgtc gtgccagctg 6000 cattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggcg ctcttccgct 6060 tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt atcagctcac 6120 tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa gaacatgtga 6180 gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat 6240 aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac 6300 ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct 6360 gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg 6420 ctttctcaat gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg 6480 ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt 6540 cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg 6600 attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac 6660 ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga 6720 aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt 6780 gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt 6840 tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga 6900 ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc 6960 taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct 7020 atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata 7080 actacgatac gggagggctt accatctggc cccagtgctg caatgatacc gcgagaccca 7140 cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga 7200 agtggtcctg caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga 7260 gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg ccattgctac aggcatcgtg 7320 gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga 7380 gttacatgat cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt 7440 gtcagaagta agttggccgc agtgttatca ctcatggtta tggcagcact gcataattct 7500 cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca 7560 ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat acgggataat 7620 accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga 7680 aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaacccac tcgtgcaccc 7740 aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg 7800 caaaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc 7860 ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt 7920 gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcca 7980 cctgacgtc 7989 <210> 48 <211> 7607 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 48 tctagaagat ccgctgtaca ggatgttcta gctactttat tagatccgct gtacaggatg 60 ttctagctac tttattagat ccgctgtaca ggatgttcta gctactttat tagatccgct 120 gtacaggatg ttctagctac tttattagat ccgtgtacag gatgttctag ctactttatt 180 agatcgatct cctggccgtt cggggtcaaa aaccaggttt ggctataaaa gggggtgggg 240 gcgcgttcgt cctcactctc ttccgcatcg ctgtctgcga gggccaggat ~gatcctgag 300 aacttcaggg tgagtttggg gacccttgat tgttctttct ttttcgctat ~gtaaaattc 360 atgttatatg gagggggcaa agttttcagg gtgttgttta gaatgggaag atgtcccttg 420 tatcaccatg gaccctcatg ataattttgt ttctttcact ttctactctg ttgacaacca 480 ttgtctcctc ttattttctt ttcattttct gtaacttttt cgttaaactt tagcttgcat 540 ttgtaacgaa tttttaaatt cacttttgtt tatttgtcag attgtaagta ctttctctaa 600 tcactttttt ttcaaggcaa tcagggtata ttatattgta cttcagcaca gttttagaga 660 acaattgtta taattaaatg ataaggtaga atatttctgc atataaattc tggctggcgt 720 ggaaatattc ttattggtag aaacaactac atcctggtca tcatcctgcc tttctcttta 780 tggttacaat gatatacact gtttgagatg aggataaaat actctgagtc caaaccgggc 840 ccctctgcta accatgttca tgccttcttc tttttcctac agctcctggg caacgtgctg 900 gttattgtgc tgtctcatca ttttggcaaa gaattagatc taagcttctg cagctcgagg 960 actcggtcga ctgaaaatga gacatattat ctgccacgga ggtgttatta ccgaagaaat 1020 ggccgccagt cttttggacc agctgatcga agaggtactg gctgataatc ttccacctcc 1080 tagccatttt gaaccaccta cccttcacga actgtatgat ttagacgtga cggcccccga 1140 agatcccaac gaggaggcgg tttcgcagat ttttcccgac tctgtaatgt tggcggtgca 1200 ggaagggatt gacttactca cttttccgcc ggcgcccggt tctccggagc cgcctcacct 1260 ttcccggcag cccgagcagc cggagcagag agccttgggt ccggtttcta tgccaaacct 1320 tgtaccggag gtgatcgatc ttacctgcca cgaggctggc tttccaccca gtgacgacga 1380 ggatgaagag ggtgaggagt ttgtgttaga ttatgtggag caccccgggc acggttgcag 1440 gtcttgtcat tatcaccgga ggaatacggg ggacccagat attatgtgtt cgctttgcta 1500 tatgaggacc tgtggcatgt ttgtctacag taagtgaaaa ttatgggcag tgggtgatag 1560 agtggtgggt ttggtgtggt aatttttttt ttaattttta cagttttgtg gtttaaagaa 1620 ttttgtattg tgattttttt aaaaggtcct gtgtctgaac ctgagcctga gcccgagcca 1680 gaaccggagc ctgcaagacc tacccgccgt cctaaaatgg cgcctgctat cctgagacgc 1740 ccgacatcac ctgtgtctag agaatgcaat agtagtacgg atagctgtga ctccggtcct 1800 tctaacacac ctcctgagat acacccggtg gtcccgctgt gccccattaa accagttgcc 1860 gtgagagttg gtgggcgtcg ccaggctgtg gaatgtatcg aggacttgct taacgagcct 1920 gggcaacctt tggacttgag ctgtaaacgc cccaggccat aaggtgtaaa cctgtgattg 1980 cgtgtgtggt taacgccttt gtttgctgaa tgagttgatg taagtttaat aaagggtgag 2040 ataatgttta acttgcatgg cgtgttaaat ggggcggggc ttaaagggta tataatgcgc 2100 cgtgggctaa tcttggttac atctgacctc atggaggctt gggagtgttt ggaagatttt 2160 tctgctgtgc gtaacttgct ggaacagagc tctaacagta cctcttggtt ttggaggttt 2220 ctgtggggct catcccaggc aaagttagtc tgcagaatta aggaggatta caagtgggaa 2280 tttgaagagc ttttgaaatc ctgtggtgag ctgtttgatt ctttgaatct gggtcaccag 2340 gcgcttttcc aagagaaggt catcaagact ttggattttt ccacaccggg gcgcgctgcg 2400 gctgctgttg cttttttgag ttttataaag gataaatgga gcgaagaaac ccatctgagc 2460 ggggggtacc tgctggattt tctggccatg catctgtgga gagcggttgt gagacacaag 2520 aatcgcctgc tactgttgtc ttccgtccgc ccggcgataa taccgacgga ggagcagcag 2580 cagcagcagg aggaagccag gcggcggcgg caggagcaga gcccatggaa cccgagagcc 2640 ggcctggacc ctcgggaatg aatgttgtac aggtggctga actgtatcca gaactgagac 2700 gcattttgac aattacagag gatgggcagg ggctaaaggg ggtaaagagg gagcgggggg 2760 cttgtgaggc tacagaggag gctaggaatc tagcttttag cttaatgacc agacaccgtc 2820 ctgagtgtat tacttttcaa cagatcaagg ataattgcgc taatgagctt gatctgctgg 2880 cgcagaagta ttccatagag cagctgacca cttactggct gcagccaggg gatgattttg 2940 aggaggctat tagggtatat gcaaaggtgg cacttaggcc agattgcaag tacaagatca 3000 gcaaacttgt aaatatcagg aattgttgct acatttctgg gaacggggcc gaggtggaga 3060 tagatacgga ggatagggtg gcctttagat gtagcatgat aaatatgtgg ccgggggtgc 3120 ttggcatgga cggggtggtt attatgaatg taaggtttac tggccccaat tttagcggta 3180 cggttttcct ggccaatacc aaccttatcc tacacggtgt aagcttctat gggtttaaca 3240 atacctgtgt ggaagcctgg accgatgtaa gggttcgggg ctgtgccttt tactgctgct 3300 ggaagggggt ggtgtgtcgc cccaaaagca gggcttcaat taagaaatgc ctctttgaaa 3360 ggtgtacctt gggtatcctg tctgagggta actccagggt gcgccacaat gtggcctccg 3420 actgtggttg cttcatgcta gtgaaaagcg tggctgtgat taagcataac atggtatgtg 3480 gcaactgcga ggacagggcc tctcagatgc tgacctgctc ggacggcaac tgtcacctgc 3540 tgaagaccat tcacgtagcc agccactctc gcaaggcctg gccagtgttt gagcataaca 3600 tactgacccg ctgttccttg catttgggta acaggagggg ggtgttccta ccttaccaat 3660 gcaatttgag tca.cactaag atattgcttg agcccgagag catgtccaag gtgaacctga.3720 acggggtgtt tgacatgacc atgaagatct ggaaggtgct gaggtacgat gagacccgca 3780 ccaggtgcag accctgcgag tgtggcggta aacatattag gaaccagcct gtgat.gctgg 3840 atgtgaccga ggagctgagg cccgatcact tggtgctggc ctgcacccgc gctgagtttg 3900 gctctagcga tgaagataca gattgaggta ctgaaatgtg tgggcgtggc ttaagggtgg 3960 gaaagaatat ataaggtggg ggtcttatgt agttttgtat ctgttttgca c~cagccgccg 9020 ccgccatgag caccaactcg tttgatggaa gcattgtgag ctcatatttg acaacgcgca 4080 tgcccccatg ggccggggtg cgtcagaatg tgatgggctc cagcattgat ggtcgccccg 4140 tcctgcccgc aaactctact accttgacct acgagaccgt gtctggaacg ccgttggaga 4200 ctgcagcctc cgccgccgct tcagccgctg cagccaccgc ccgcgggatt gtgactgact 4260 ttgctttcct gagcccgctt gcaagcagtg cagcttcccg ttcatccgcc cgcgatgaca 4320 agttgacggc tcttttggca caattggatt ctttgacccg ggaacttaat gtcgtttctc 4380 agcagctgtt ggatctgcgc cagcaggttt ctgccctgaa ggcttcctcc cctcccaatg 4440 cggtttaaaa cataaataaa aaaccagact ctgtttggat ttggatcaag caagtgtctt 4500 gctgtctcag ctgactgctt aagtcgcaag ccgaattgga tccaattcgg atcgatctta 4560 ttaaagcaga acttgtttat tgcagcttat aatggttaca aataaagcaa tagcatcaca 4620 aatttcacaa ataaagcatt tttttcactg cattctagtt gtggtttgtc caaactcatc 4680 aatgtatctt atcatgtctg gtcgactcta gactcttccg cttcctcgct cactgactcg 4740 ctgcgctcgg tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg 4800 ttatccacag aatcagggga taacgcagga aagaacatgt gagcaaaagg ccagcaaaag 4860 gccaggaacc gtaaaaaggc cgcgttgctg gcgtttttcc ataggctccg cccccctgac 4920 gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg actataaaga 4980 taccaggcgt ttccccctgg aagctccctc gtgcgctctc ctgttccgac cctgccgctt 5040 accggatacc tgtccgcctt tctcccttcg ggaagcgtgg cgctttctca tagctcacgc 5100 tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc 5160 cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc caacccggta 5220 agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag agcgaggtat 5280 gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca 5340 gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt tggtagctct 5400 tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt 5460 acgcgcagaa aaaaaggatc tcaagaagat cctttgatct tttctacggg gtctgacgct 5520 cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa aaggatcttc 5580 acctagatcc ttttaaatta aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa 5640 acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta 5700 tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat acgggagggc 5760 ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc ggctccagat 5820 ttatcagcaa taaaccagcc agccggaagg gccgagcgca gaagtggtcc tgcaacttta 5880 tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag ttcgccagtt 5940 aatagtttgc gcaacgttgt tgccattgct acaggcatcg tggtgtcacg ctcgtcgttt 6000 ggtatggctt cattcagctc cggttcccaa cgatcaaggc gagttacatg atcccccatg 6060 ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg ttgtcagaag taagttggcc 6120 gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt catgccatcc 6180 gtaagatgct tttctgtgac tggtgagtac tcaaccaagt cattctgaga atagtgtatg 6240 cggcgaccga gttgctcttg cccggcgtca atacgggata ataccgcgcc acatagcaga 6300 actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc aaggatctta 6360 ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgatc ttcagcatct 6420 tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag 6480 ggaataaggg cgacacggaa atgttgaata ctcatactct tcctttttca atattattga 6540 agcatttatc agggttattg tctcatgagc ggatacatat ttgaatgtat ttagaaaaat 6600 aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc 6660 attattatca tgacattaac ctataaaaat aggcgtatca cgaggcccct ttcgtctcgc 6720 gcgtttcggt gatgacggtg aaaacctctg acacatgcag ctcccggaga cggtcacagc 6780 ttgtctgtaa gcggatgccg ggagcagaca agcccgtcag ggcgcgtcag cgggtgttgg 6840 cgggtgtcgg ggctggctta actatgcggc atcagagcag attgtactga gagtgcacca 6900 tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca ggaaattgta 6960 agcgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac 7020 caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga gatagggttg 7080 agtgttgttc cagtttggaa caagagtcca ctattaaaga acgtggactc caacgtcaaa 7140 gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc ctaatcaagt 7200 tttttggggt cgaggtgccg taaagcacta aatcggaacc ctaaagggag cccccgattt 7260 agagcttgac~ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga 7320 gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacacccgcc 7380 gcgcttaatg cgccgctaca gggcgcgtcc cattcgccat tcaggctgcg caactgttgg 7440 gaagggcgat cggtgcgggc ctcttcgcta ttacgccagc tggcgaaagg gggatgtgct 7500 gcaaggcgat taagttgggt aacgccaggg ttttcccagt cacgacgttg taaaacgacg 7560 gccagtgaat tgtaatacga ctcactatag ggcgaattaa ttcgggg 7607 <210> 49 <211> 11600 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 49 gaattccgca ttgcagagat attgtattta agtgcctagc tcgatacaat aaacgccatt 60 tgaccattca ccacattggt gtgcacctcc aagcttgggc agaaatggtt gaactcccga 120 gagtgtccta cacctagggg agaagcagcc aaggggttgt ttcccaccaa ggacgacccg 180 tctgcgcaca aacggatgag cccatcagac aaagacatat tcattctctg ctgcaaactt 240 ggcatagctc tgctttgcct ggggctattg ggggaagttg cggttcgtgc tcgcagggct 300 ctcacccttg actcttttaa tagctcttct gtgcaagatt acaatctaaa caattcggag 360 aactcgacct tcctcctgag gcaaggacca cagccaactt cctcttacaa gccgcatcga 420 ttttgtcctt cagaaataga aataagaatg cttgctaaaa attatatttt taccaataag 480 accaatccaa taggtagatt attagttact atgttaagaa atgaatcatt atcttttagt 540 actattttta ctcaaattca gaagttagaa atgggaatag aaaatagaaa gagacgctca 600 acctcaattg aagaacaggt gcaaggacta ttgaccacag gcctagaagt aaaaaaggga 660 aaaaagagtg tttttgtcaa aataggagac aggtggtggc aaccagggac ttatagggga 720 ccttacatct acagaccaac agatgccccc ttaccatata caggaagata tgacttaaat 780 tgggataggt gggttacagt caatggctat aaagtgttat atagatccct cccttttcgt 840 gaaagactcg ccagagctag acctccttgg tgtatgttgt ctcaagaaga aaaagacgac 900 atgaaacaac aggtacatga ttatatttat ctaggaacag gaatgcactt ttggggaaag 960 attttccata ccaaggaggg gacagtggct ggactaatag aacattattc tgcaaaaact 1020 catggcatga gttattatga atagccttta ttggcccaac cttgcggttc ccagggctta 1080 agtaagtttt tggttacaaa ctgttcttaa aacgaggatg tgagacaagt ggtttcctga 1140 cttggtttgg tatcaaaggt tctgatctga gctctgagtg ttctattttc ctatgttctt 1200 ttggaattta tccaaatctt atgtaaatgc ttatgtaaac caagatataa aagagtgctg 1260 attttttgag taaacttgca acagtcctaa cattcacctc ttgtgtgttt gtgtctgttc 1320 gccatcccgt ctccgctcgt cacttatcct tcactttcca gagggtcccc ccgcagaccc 1380 cggcgaccct caggtcggcc gactgcggca gctggcgccc gaacagggac cctcggataa 1440 gtgacccttg tctctatttc tactatttgg tgtttgtctt gtattgtctc tttcttgtct 1500 ggctatcatc acaagagcgg aacggactca ccatagggac caagctagcg cttctcgtcg 1560 cgtccaagac cctcaaagat ttttggcact tcgttgagcg aggcgatatc aggtatgaca 1620 gcgccctgcc gcaaggccag ctgcttgtcc gctcggctgc ggttggcacg gcaggatagg 1680 ggtatcttgc agttttggaa aaagatgtga taggtggcaa gcacctctgg cacggcaaat 1740 acggggtaga agttgaggcg cgggttgggc tcgcatgtgc cgttttcttg gcgtttgggg 1800 ggtacgcgcg gtgagaatag gtggcgttcg taggcaaggc tgacatccgc tatggcgagg 1860 ggcacatcgc tgcgctcttg caacgcgtcg cagataatgg cgcactggcg ctgcagatgc 1920 ttcaacagca cgtcgtctcc cacatctagg tagtcgccat gcctttcgtc cccccgcccg 1980 acttgttcct cgtttgcctc tgcgttgtcc tggtcttgct ttttatcctc tgttggtact 2040 gagcggtcct cgtcgtcttc gcttacaaaa cctgggtcct gctcgataat cacttcctcc 2100 tcctcaagcg ggggtgcctc gacggggaag gtggtaggcg cgttggcggc atcggtggag 2160 gcggtggtgg cgaactcaga gggggcggtt aggctgtcct tcttctcgac tgactccatg 2220 atctttttct gcctatagga gaaggaaatg gccagtcggg aagaggagca gcgcgaaacc 2280 acccccgagc gcggacgcgg tgcggcgcga cgtcccccaa ccatggagga cgtgtcgtcc 2340 ccgtccccgt cgccgccgcc tccccgggcg cccccaaaaa agcggatgag gcggcgtatc 2400 gagtccgagg acgaggaaga ctcatcacaa gacgcgctgg tgccgcgcac acccagcccg 2460 cggccatcga cctcggcggc ggatttggcc attgcgccca agaagaaaaa gaagcgccct 2520 tctcccaagc ccgagcgccc gccatcacca gaggtaatcg tggacagcga ggaagaaaga 2580 gaagatgtgg cgctacaaat ggtgggtttc agcaacccac cggtgctaat caagcatggc 2640 aaaggaggta agcgcacagt gcggcggctg aatgaagacg acccagtggc gcgtggtatg 2700 cggacgcaag aggaagagga agagcccagc gaagcggaaa gtgaaattac ggtgatgaac 2760 ccgctgagtg tgccgatcgt gtctgcgtgg gagaagggca tggaggctgc gcgcgcgctg 2820 atggacaagt accacgtgga taacgatcta aaggcgaact tcaaactact gcctgaccaa 2880 gtggaagctc tggcggccgt atgcaagacc tggctgaacg aggagcaccg cgggttgcag 2940 ctgaccttca ccagcaacaa gacctttgtg acgatgatgg ggcgattcct gcaggcgtac 3000.
ctgcagtcgt ttgcagaggt gacctacaag catcacgagc ccacgggctg cgcgttgtgg 3060 ctgcaccgct gcgctgagat cgaaggcgag cttaagtgtc tacacggaag cattatgata 3120 aataaggagc acgtgattga aatggatgtg acgagcgaaa acgggcagcg ~gcgctgaag 3180 gagcagtcta gcaaggccaa gatcgtgaag aaccggtggg gccgaaatgt ggtgcagatc 3240 tccaacaccg acgcaaggtg ctgcgtgcac gacgcggcct gtccggccaa tcagttttcc 3300 ggcaagtctt gcggcatgtt cttctctgaa ggcgcaaagg ctcaggtggc ttttaagcag 3360 atcaaggctt ttatgcaggc gctgtatcct aacgcccaga ccgggcacgg tcaccttttg 3420 atgccactac ggtgcgagtg caactcaaag cctgggcacg cgcccttttt gggaaggcag 3480 ctaccaaagt tgactccgtt cgccctgagc aacgcggagg acctggacgc ggatctgatc 3540 tccgacaaga gcgtgctggc cagcgtgcac cacccggcgc tgatagtgtt ccagtgctgc 3600 aaccctgtgt atcgcaactc gcgcgcgcag ggcggaggcc ccaactgcga cttcaagata 3660 tcggcgcccg acctgctaaa cgcgttggtg atggtgcgca gcctgtggag tgaaaacttc 3720 accgagctgc cgcggatggt tgtgcctgag tttaagtgga gcactaaaca ccagtatcgc 3780 aacgtgtccc tgccagtggc gcatagcgat gcgcggcaga acccctttga tttttaaacg 3840 gcgcagacgg caagggtggg ggtaaataat cacccgagag tgtacaaata aaagcatttg 3900 cctttattga aagtgtctct agtacattat ttttacatgt ttttcaagtg acaaaaagaa 3960 gtggcgctcc taatctgcgc actgtggctg cggaagtagg gcgagtggcg ctccaggaag 4020 ctgtagagct gttcctggtt gcgacgcagg gtgggctgta cctggggact gttgagcatg 4080 gagttgggta ccccggtaat aaggttcatg gtggggttgt gatccatggg agtttggggc 4140 cagttggcaa aggcgtggag aaacatgcag cagaatagtc cacaggcggc cgagttgggc 4200 ccctgtacgc tttgggtgga cttttccagc gttatacagc ggtcggggga agaagcaatg 4260 gcgctacggc gcaggagtga ctcgtactca aactggtaaa cctgcttgag tcgctggtca 4320 gaaaagccaa agggctcaaa gaggtagcat gtttttgagt gcgggttcca ggcaaaggcc 4380 atccagtgta cgcccccagt ctcgcgaccg gccgtattga ctatggcgca ggcgagcttg 4440 tgtggagaaa caaagcctgg aaagcgcttg tcataggtgc ccaaaaaata tggcccacaa 4500 ccaagatctt tgacaatggc tttcagttcc tgctcactgg agcccatggc ggcagctgtt 4560 gttgatgttg cttgcttctt tatgttgtgg cgttgccggc cgagaagggc gtgcgcaggt 4620 acacggtttc gatgacgccg cggtgcggcc ggtgcacacg gaccacgtca aagacttcaa 4680 acaaaacata aagaagggtg ggctcgtcca tgggatccat atatagggcc cgggttataa 9740 ttacctcagg tcgacctcga gggatctttg tgaaggaacc ttacttctgt ggtgtgacat 4800 aattggacaa actacctaca gagatttaaa gctctaaggt aaatataaaa tttttaagtg 4860 tataatgtgt taaactactg attctaattg tttgtgtatt ttagattcca acctatggaa 4920 ctgatgaatg ggagcagtgg tggaatgcct ttaatgagga aaacctgttt tgctcagaag 4980 aaatgccatc tagtgatgat gaggctactg ctgactctca acattctact cctccaaaaa 5040 agaagagaaa ggtagaagac cccaaggact ttccttcaga attgctaagt tttttgagtc 5100 atgctgtgtt tagtaataga actcttgctt gctttgctat ttacaccaca aaggaaaaag 5160 ctgcactgct atacaagaaa attatggaaa aatattctgt aacctttata agtaggcata 5220_ acagttataa tcataacata ctgttttttc ttactccaca caggcataga gtgtctgcta 5280 ttaataacta tgctcaaaaa ttgtgtacct ttagcttttt aatttgtaaa ggggttaata 5340 aggaatattt gatgtatagt gccttgacta gagatcataa tcagccatac cacatttgta 5400 gaggttttac ttgctttaaa aaacctccca cacctccccc tgaacctgaa acataaaatg 5460 aatgcaattg ttgttgttaa cttgtttatt gcagcttata atggttacaa ataaagcaat 5520 agcatcacaa atttcacaaa taaagcattt ttttcactgc attctagttg tggtttgtcc 5580 aaactcatca atgtatctta tcatgtctgg atccggctgt ggaatgtgtg tcagttaggg 5640 tgtggaaagt ccccaggctc cccagcaggc agaagtatgc aaagcatgca tctcaattag 5700 tcagcaacca ggtgtggaaa gtccccaggc tccccagcag gcagaagtat gcaaagcatg 5760 catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc gcccctaact 5820 ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat ttatgcagag 5880 gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt ttttggaggc 5940 ctaggctttt gcaaaaagct tcacgctgcc gcaagcactc agggcgcaag ggctgctaaa 6000 ggaagcggaa cacgtagaaa gccagtccgc agaaacggtg ctgaccccgg atgaatgtca 6060 gctactgggc tatctggaca agggaaaacg caagcgcaaa gagaaagcag gtagcttgca 6120 gtgggcttac atggcgatag ctagactggg cggttttatg gacagcaagc gaaccggaat 6180 tgccagctgg ggcgccctct ggtaaggttg ggaagccctg caaagtaaac tggatggctt 6240 tcttgccgcc aaggatctga tggcgcaggg gatcaagatc tgatcaagag acaggatgag 6300 gatcgtttcg catgattgaa caagatggat tgcacgcagg ttctccggcc gcttgggtgg 6360 agaggctatt cggctatgac tgggcacaac agacaatcgg ctgctctgat gccgccgtgt 6420 tccggctgtc agcgcagggg cgcccggttc tttttgtcaa gaccgacctg tccggtgccc 6980 tgaatgaact gcaggacgag gcagcgcggc tatcgtggct ggccacgacg ggcgttcctt 6540 gcgcagctgt gctcgacgtt gtcactgaag cgggaaggga ctggctgcta ttgggcgaag 6600 tgccggggca ggatctcctg tcatctcacc ttgctcctgc cgagaaagta tccatcatgg 6660 ctgatgcaat gcggcggctg catacgcttg atccggctac ctgcccattc gaccaccaag 6720 cgaaacatcg catcgagcga gcacgtactc ggatggaagc cggtcttgtc gatcaggatg 6780 atctggacga agagcatcag gggctcgcgc cagccgaact gttcgccagg ctcaaggcgc 6840 gcatgcccga cggcgaggat ctcgtcgtga cccatggcga tgcctgcttg ccgaatatca 6900 tggtggaaaa tggccgcttt tctggattca tcgactgtgg ccggctgggt gtggcggacc 6960 gctatcagga catagcgttg gctacccgtg atattgctga agagcttggc ggcgaatggg 7020 ctgaccgctt cctcgtgctt tacggtatcg ccgctcccga ttcgcagcgc atcgccttct 7080 atcgccttct tgacgagttc ttctgagcgg gactctgggg ttcgaaatga ccgaccaagc 7140 gacgcccaac ctgccatcac gagatttcga ttccaccgcc gccttctatg aaaggttggg 7200 cttcggaatc gttttccggg acgccggctg gatgatcctc cagcgcgggg atctcatgct 7260 ggagttcttc gcccaccccg ggctcgatcc cctcgcgagt tggttcagct gctgcctgag 7320 gctggacgac ctcgcggagt tctaccggca gtgcaaatcc gtcggcatcc aggaaaccag 7380 cagcggctat ccgcgcatcc atgcccccga actgcaggag tggggaggca cgatggccgc 7440 tttggtcccg gatctttgtg aaggaacctt acttctgtgg tgtgacataa ttggacaaac 7500 tacctacaga gatttaaagc tctaaggtaa atataaaatt tttaagtgta taatgtgtta 7560 aactactgat tctaattgtt tgtgtatttt agattccaac ctatggaact gatgaatggg 7620 agcagtggtg gaatgccttt aatgaggaaa acctgttttg ctcagaagaa atgccatcta 7680 gtgatgatga ggctactgct gactctcaac attctactcc tccaaaaaag aagagaaagg 7740 tagaagaccc caaggacttt ccttcagaat tgctaagttt tttgagtcat gctgtgttta 7800 gtaatagaac tcttgcttgc tttgctattt acaccacaaa ggaaaaagct gcactgctat 7860 acaagaaaat tatggaaaaa tattctgtaa cctttataag taggcataac agttataatc 7920 ataacatact gttttttctt actccacaca ggcatagagt gtctgctatt aataactatg 7980 ctcaaaaatt gtgtaccttt agctttttaa tttgtaaagg ggttaataag gaatatttga 8040 tgtatagtgc cttgactaga gatcataatc agccatacca catttgtaga ggttttactt 8100 gctttaaaaa acctcccaca cctccccctg aacctgaaac ataaaatgaa tgcaattgtt 8160 gttgttaact tgtttattgc agcttataat ggttacaaat aaagcaatag catcacaaat 8220 ttcacaaata aagcattttt ttcactgcat tctagttgtg gtttgtccaa actcatcaat 8280 gtatcttatc atgtctggat ccccaggaag ctcctctgtg tcctcataaa ccctaacctc 8340 ctctacttga gaggacattc caatcatagg ctgcccatcc accctctgtg tcctcctgtt 8400 aattaggtca cttaacaaaa aggaaattgg gtaggggttt ttcacagacc gctttctaag 8460 ggtaatttta aaatatctgg gaagtccctt ccactgctgt gttccagaag tgttggtaaa 8520 cagcccacaa atgtcaacag cagaaacata caagctgtca gctttgcaca agggcccaac 8580 accctgctca tcaagaagca ctgtggttgc tgtgttagta atgtgcaaaa caggaggcac 8640 attttcccca cctgtgtagg ttccaaaata tctagtgttt tcatttttac ttggatcagg 8700 aacccagcac tccactggat aagcattatc cttatccaaa acagccttgt ggtcagtgtt 8760 catctgctga ctgtcaactg tagcattttt tggggttaca,gtttgagcag gatatttggt 8820 cctgtagttt gctaacacac cctgcagctc caaaggttcc ccaccaacag caaaaaaatg 8880 aaaatttgac ccttgaatgg gttttccagc accattttca tgagtttttt gtgtccctga 8940 atgcaagttt aacatagcag ttaccccaat aacctcagtt ttaacagtaa cagcttccca 9000 catcaaaata tttccacagg ttaagtcctc atttaaatta ggcaaaggaa ttcttgaaga 9060 cgaaagggcc tcgtgatacg cctattttta taggttaatg tcatgataat aatggtttct 9120 tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa cccctatttg tttatttttc 9180 taaatacatt caaatatgta tccgctcatg agacaataac cctgataaat gcttcaataa 9240 tattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat tccctttttt 9300 gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 9360 gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc 9420 cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa agttctgcta 9480 tgtggcgcgg tattatcccg tgttgacgcc gggcaagagc aactcggtcg ccgcatacac 9540 tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct tacggatggc 9600 atgacagtaa gagaattatg cagtgctgcc ataaccatga gtgataacac tgcggccaac 9660 ttacttctga caacgatcgg aggaccgaag gagctaaccg cttttttgca caacatgggg 9720 gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat accaaacgac 9780 gagcgtgaca ccacgatgcc tgcagcaatg gcaacaacgt tgcgcaaact attaactggc 9840 gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc ggataaagtt 9900 gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga taaatctgga 9960 gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg taagccctcc 10020 cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg aaatagacag 10080 atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca 10140 tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc 10200 ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca 10260 gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc 10320 tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta 10380 ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 10490 ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc 10500 gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 10560 ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac ~gggggttcg 10620 tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag 10680 ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc 10740 agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 10800 agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg 10860 gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc 10920 tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt 10980 accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca 11040 gtgagcgagg aagcggaaga gcgcctgatg cggtattttc tccttacgca tctgtgcggt 11100 atttcacacc gcatatggtg cactctcagt acaatctgct ctgatgccgc atagttaagc 11160 cagtatctgc tccctgcttg tgtgttggag gtcgctgagt agtgcgcgag caaaatttaa 11220 gctacaacaa ggcaaggctt gaccgacaat tgcatgaaga atctgcttag ggttaggcgt 11280 tttgcgctgc ttcgcgatgt acgggccaga tatacgcgta tctgagggga ctagggtgtg 11340 tttaggcgaa aagcggggct tcggttgtac gcggttagga gtcccctcag gatatagtag 11400 tttcgctttt gcatagggag ggggaaatgt agtcttatgc aatacacttg tagtcttgca 11460 acatggtaac gatgagttag caacatgcct tacaaggaga gaaaaagcac cgtgcatgcc 11520 gattggtgga agtaaggtgg tacgatcgtg ccttattagg aaggcaacag acgggtctga 11580 catggattgg acgaaccact 11600 <220>
<223> Description of Artificial Sequence: plasmid <400> 49 <210> 50 <211> 8238 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 50 gcggccgcca tcatcaataa tataccttat tttggattga agccaatatg ataatgaggg 60 ggtggagttt gtgacgtggc gcggggcgtg ggaacggggc gggtgacgta gtagtgtggc 120 ggaagtgtga tgttgcaagt gtggcggaac acatgtaagc gacggatgtg gcaaaagtga 180 cgtttttggt gtgcgccggt gtacacagga agtgacaatt ttcgcgcggt tttaggcgga 240 CA 02359795 2001-07-12 pCT~, P00/00265 tgttgtagta aatttgggcg taaccgagta agatttggcc attttcgcgg gaaaactgaa 300 taagaggaag tgaaatctga ataattttgt gttactcata gcgcgtaata tttgtctagg 360 gccgcgggga ctttgaccgt ttacgtggag actcgcccag ggcgcgcccc gatgtacggg 420 ccagatatac gcgtatctga ggggactagg gtgtgtttag gcgaaaagcg gggcttcggt 480 tgtacgcggt taggagtccc ctcaggatat agtagtttcg cttttgcata gggaggggga 540 aatgtagtct tatgcaatac tcttgtagtc ttgcaacatg gtaacgatga gttagcaaca 600 tgccttacaa ggagagaaaa agcaccgtgc atgccgattg gtggaagtaa ggtggtacga 660 tcgtgcctta ttaggaaggc aacagacggg tctgacatgg attggacgaa ccactgaatt 720 ccgcattgca gagatattgt atttaagtgc ctagctcgat acaataaacg ccatttgacc 780 attcaccaca ttggtgtgca cctccggccc atatggccac tctcttccgc atcgctgtct 840 gcgggggcca gctgttgggc tcgcggttga ggacaaactc ttcgcggtct ttccagtact 900 cttggatcgg aaacccgtcg gcctccgaac ggtactccgc cgccgaggga cctgagcgag 960 tccgcatcga ccggatcgga aaacctctcg agaaaggcgt gtaaccagtc acagtcgctc 1020 tagaactagt ggatcccccg ggctgcagga attcgatgat cttggtggcg tgaaactccc 1080 gcacctcttt ggcaagcgcc ttgtagaagc gcgtatggct tcgtacccct gccatcaaca 1140 cgcgtctgcg ttcgaccagg ctgcgcgttc tcgcggccat agcaaccgac gtacggcgtt 1200 gcgccctcgc cggcagcaag aagccacgga agtccgcctg gagcagaaaa tgcccacgct 1260 actgcgggtt tatatagacg gtcctcacgg gatggggaaa accaccacca cgcaactgct 1320 ggtggccctg ggttcgcgcg acgatatcgt ctacgtaccc gagccgatga cttactggca 1380 ggtgctgggg gcttccgaga caatcgcgaa catctacacc acacaacacc gcctcgacca 1440 gggtgagata tcggccgggg acgcggcggt ggtaatgaca agcgcccaga taacaatggg 1500 catgccttat gccgtgaccg acgccgttct ggctcctcat gtcggggggg aggctgggag 1560 ttcacatgcc ccgcccccgg ccctcaccct catcttcgac cgccatccca tcgccgccct 1620 cctgtgctac ccggccgcgc gataccttat gggcagcatg accccccagg ccgtgctggc 1680 gttcgtggcc ctcatcccgc cgaccttgcc cggcacaaac atcgtgttgg gggcccttcc 1740 ggaggacaga cacatcgacc gcctggccaa acgccagcgc cccggcgagc ggcttgacct 1800 ggctatgctg gccgcgattc gccgcgttta cgggctgctt gccaatacgg tgcggtatct 1860 gcagggcggc gggtcgtggt gggaggattg gggacagctt tcggggacgg ccgtgccgcc 1920 ccagggtgcc gagccccaga gcaacgcggg cccacgaccc catatcgggg acacgttatt 1980 taccctgttt cgggcccccg agttgctggc ccccaacggc gacctgtata acgtgtttgc 2040 ctgggccttg gacgtcttgg ccaaacgcct ccgtcccatg cacgtcttta tcctggatta 2100 cgaccaatcg cccgccggct gccgggacgc cctgctgcaa cttacctccg ggatggtcca 2160 gacccacgtc accaccccag gctccatacc gacgatctgc gacctggcgc gcacgtttgc 2220 ccgggagatg ggggaggcta actgactcga gaagcttggg cccatcgatc aagcttatcg 2280 ataccgtcga aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac 2340 aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat 2400 caatgtatct tatcatgtct ggatccgacc tcggatctgg aaggtgctga ggtacgatga 2460 gacccgcacc aggtgcagac cctgcgagtg tggcggtaaa catattagga accagcctgt 2520 gatgctggat gtgaccgagg agctgaggcc cgatcacttg gtgctggcct gcacccgcgc 2580 tgagtttggc tctagcgatg aagatacaga ttgaggtact gaaatgtgtg ggcgtggctt 2640 aagggtggga aagaatatat aaggtggggg tcttatgtag ttttgtatct gttttgcagc 2700 agccgccgcc gccatgagca ccaactcgtt tgatggaagc attgtgagct catatttgac 2760 aacgcgcatg cccccatggg ccggggtgcg tcagaatgtg atgggctcca gcattgatgg 2820 tcgccccgtc ctgcccgcaa actctactac cttgacctac gagaccgtgt ctggaacgcc 2880 gttggagact gcagcctccg ccgccgcttc agccgctgca gccaccgccc gcgggattgt 2940 gactgacttt gctttcctga gcccgcttgc aagcagtgca gcttcccgtt catccgcccg 3000 cgatgacaag ttgacggctc ttttggcaca attggattct ttgacccggg aacttaatgt 3060 cgtttctcag cagctgttgg atctgcgcca gcaggtttct gccctgaagg cttcctcccc 3120 tcccaatgcg gtttaaaaca taaataaaaa accagactct gtttggattt ggatcaagca 3180 agtgtcttgc tgtctttatt taggggtttt gcgcgcgcgg taggcccggg accagcggtc 3240 tcggtcgttg agggtcctgt gtattttttc caggacgtgg taaaggtgac tctggatgtt 3300 cagatacatg ggcataagcc cgtctctggg gtggaggtag caccactgca gagcttcatg 3360 ctgcggggtg gtgttgtaga tgatccagtc gtagcaggag cgctgggcgt ggtgcctaaa 3420 aatgtctttc agtagcaagc tgattgccag gggcaggccc ttggtgtaag tgtttacaaa 3480 gcggttaagc tgggatgggt gcatacgtgg ggatatgaga tgcatcttgg actgtatttt 3540 taggttggct atgttcccag ccatatccct ccggggattc atgttgtgca gaaccaccag 3600 cacagtgtat ccggtgcact tgggaaattt gtcatgtagc ttagaaggaa atgcgtggaa 3660 gaacttggag acgcccttgt gacctccaag attttccatg cattcgtcca taatgatggc 3720 aatgggccca cgggcggcgg cctgggcgaa gatatttctg ggatcactaa cgtcatagtt 3780 gtgttccagg atgagatcgt cataggccat ttttacaaag cgcgggcgga gggtgccaga 3840 ctgcggtata atggttccat ccggcccagg ggcgtagtta ccctcacaga tttgcatttc 3900 ccacgctttg agttcagatg gggggatcat gtctacctgc ggggcgatga agaaaacggt 3960 WO 00/42208 CA 02359795 2001-07-12 pCT~, P00/00265 ttccggggta ggggagatca gctgggaaga aagcaggttc ctgagcagct gcgacttacc 4020 gcagccggtg ggcccgtaaa tcacacctat taccggctgc aactggtagt taagagagct 4080 gcagctgccg tcatccctga gcaggggggc cacttcgtta agcatgtccc tgactcgcat 4140 gttttccctg accaaatccg ccagaaggcg ctcgccgccc agcgatagca gttcttgcaa 4200 ggaagcaaag tttttcaacg gtttgagacc gtccgccgta ggcatgcttt tgagcgtttg 4260 accaagcagt tccaggcggt cccacagctc ggtcacctgc tctacggcat ctcgatccag 4320 catatctcct cgtttcgcgg gttggggcgg ctttcgctgt acggcagtag tcggtgctcg 4380 tccagacggg ccagggtcat gtctttccac gggcgcaggg tcctcgtcag cgtagtctgg 4440 gtcacggtga aggggtgcgc tccgggctgc gcgctggcca gggtgcgctt gaggctggtc 4500 ctgctggtgc tgaagcgctg ccggtcttcg ccctgcgcgt cggccaggta gcatttgacc 9560 atggtgtcat agtccagccc ctccgcggcg tggcccttgg cgcgcagctt gcccttggag 4620 gaggcgccgc acgaggggca gtgcagactt ttgagggcgt agagcttggg cgcgagaaat 4680 accgattccg gggagtaggc atccgcgccg caggccccgc agacggtctc gcattccacg 4740 agccaggtga gctctggccg ttcggggtca aaaaccaggt ttcccccatg ctttttgatg 4800 cgtttcttac ctctggtttc catgagccgg tgtccacgct cggtgacgaa aaggctgtcc 4860 gtgtccccgt atacagactt gagaggcctg tcctcgagcg gtgttccgcg gtcctcctcg 4920 tatagaaact cggaccactc tgagacaaag gctcgcgtcc aggccagcac gaaggaggct 4980 aagtgggagg ggtagcggtc gttgtccact agggggtcca ctcgctccag ggtgtgaaga 5040 cacatgtcgc cctcttcggc atcaaggaag gtgattggtt tgtaggtgta ggccacgtga 5100 ccgggtgttc ctgaaggggg gctataaaag ggggtggggg cgcgttcgtc ctcactctct 5160 tccgcatcgc tgtctgcgag ggccagctgt tggggtgagt actccctctg aaaagcgggc 5220 atgacttctg cgctaagatt gtcagtttcc aaaaacgagg aggatttgat ~ttcacctgg 5280 cccgcggtga tgcctttgag ggtggccgca tccatctggt cagaaaagac aatctttttg 5340 ttgtcaagct tcgagggggg gcccggtacc cagcttttgt tccctttagt gagggttaat 5400 tgcgcgcttg gcgtaatcat ggtcatagct gtttcctgtg tgaaattgtt atccgctcac 5460 aattccacac aacatacgag ccggaagcat aaagtgtaaa gcctggggtg cctaatgagt 5520 gagctaactc acattaattg cgttgcgctc actgcccgct ttccagtcgg gaaacctgtc 5580 gtgccagctg cattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggcg 5640 ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt 5700 atcagctcac tcaaaggcgg taatacggtt atccacagaa tcaggggata acgcaggaaa 5760 gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc 5820 gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag 5880 gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt 5940 gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg 6000 aagcgtggcg ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg 6060 ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg 6120 taactatcgt cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac 6180 tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg 6240 gcctaactac ggctacacta gaaggacagt atttggtatc tgcgctctgc tgaagccagt 6300 taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg 6360 tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc 6420 tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt 6480 ggtcatgaga ttatcaaaaa ggatcttcac ctagatcctt ttaaattaaa aatgaagttt 6540 taaatcaatc taaagtatat atgagtaaac ttggtctgac agttaccaat gcttaatcag 6600 tgaggcacct atctcagcga tctgtctatt tcgttcatcc atagttgcct gactccccgt 6660 cgtgtagata actacgatac gggagggctt accatctggc cccagtgctg caatgatacc 6720 gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaagggc 6780 cgagcgcaga agtggtcctg caactttatc cgcctccatc cagtctatta attgttgccg 6840 ggaagctaga gtaagtagtt cgccagttaa tagtttgcgc aacgttgttg ccattgctac 6900 aggcatcgtg gtgtcacgct cgtcgtttgg tatggcttca ttcagctccg gttcccaacg 6960 atcaaggcga gttacatgat cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc 7020 tccgatcgtt gtcagaagta agttggccgc agtgttatca ctcatggtta tggcagcact 7080 gcataattct cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagtactc 7140 aaccaagtca ttctgagaat agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat 7200 acgggataat accgcgccac atagcagaac tttaaaagtg ctcatcattg gaaaacgttc 7260 ttcggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcga tgtaacccac 7320_ tcgtgcaccc aactgatctt cagcatcttt tactttcacc agcgtttctg ggtgagcaaa 7380 aacaggaagg caaaatgccg caaaaaaggg aataagggcg acacggaaat gttgaatact 7440 catactcttc ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg 7500 atacatattt gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg 7560 aaaagtgcca cctgacgcgc cctgtagcgg cgcattaagc gcggcgggtg tggtggttac 7620 gcgcagcgtg accgctacac ttgccagcgc cctagcgccc gctcctttcg ctttcttccc 7680 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 ttcctttctc gccacgttcg ccggctttcc ccgtcaagct ctaaatcggg ggctcccttt 7740 agggttccga tttagtgctt tacggcacct cgaccccaaa aaacttgatt agggtgatgg 7800 ttcacgtagt gggccatcgc cctgatagac ggtttttcgc cctttgacgt tggagtccac 7860 gttctttaat agtggactct tgttccaaac tggaacaaca ctcaacccta tctcggtcta 7920 ttcttttgat ttataaggga ttttgcgatt tcggcctatt ggttaaaaaa tgagctgatt 7980 taacaaaaat ttaacgcgaa ttttaacaaa atattaacgc ttacaatttc cattcgccat 8040 tcaggctgcg caactgttgg gaagggcgat cggtgcgggc ctcttcgcta ttacgccagc 8100 tggcgaaagg gggatgtgct gcaaggcgat taagttgggt aacgccaggg ttttcccagt 8160 cacgacgttg taaaacgacg gccagtgagc gcgcgtaata cgactcacta tagggcgaat 8220 tggagctcca ccgcggtg 8238 <210> 51 <211> 11 <212> DNA
<213> adenovirus <400> 51 cgcggatccc g 11 <210> 52 <211> 26 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 52 ctgacaaact cagatcttgt ttattg 26 <210> 53 <211> 21 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 53 gtcgactcta gaggatccag a 21 <210> 54 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 54 ccggactcta gatggcaacc atggcgctac 30 <210> 55 <211> 31 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 55 ggaggggaag cttggccctc agccagcctc t 31 <210> 56 <211> 48 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 56 tgtcttggat ccaagatgaa gcgcgcccgc cccagcgaag atgacttc 48 <210> 57 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 57 aaacacggcg gccgctcttt cattcttg 28 <210> 58 <211> 25 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 58 cgcgctgact cttaggacta gtttc 25 <210> 59 <211> 37 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 59 gcgcttaatt aacatcatca ataatatacc ttatttt 37 <210> 60 <211> 24 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 60 tgaagcgcgc aagaccgtct gaag 24 <210> 61 <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 61 cataacactg cagattcttt attcttgg 28 <210> 62 <211> 47 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 62 ggtacacagg aaacaggagg ttccggaggt ggaggagaca caactcc 47 <210> 63 <211> 6 <212> PRT
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: synthetic peptide <400> 63 Gly Gly Ser Gly Gly Gly <210> 64 <211> 7231 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 64 ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60 acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggttag gcgttttgcg 120 ctgcttcgcg atgtacgggc cagatatacg cgttgacatt gattattgac tagttattaa 180 tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg cgttacataa 240 cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt gacgtcaata 300 atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca atgggtggac 360 tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc aagtacgccc 420 cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacctta 480 tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac catggtgatg 540 cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg atttccaagt 600 ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg ggactttcca 660 aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt acggtgggag 720 WO 00/42208 CA 02359795 2001-07-12 pCT~P00/00265 gtctatataa gcagagctct ctggctaact agagaaccca ctgcttactg gcttatcgaa 780 attaatacga ctcactatag ggagacccaa gctggctagc gtttaaactt aagcttggta 840 ccgagctcgg atccactctc ttccgcatcg ctgtctgcga gggccagctg ttggggtgag 900 tactccctct gaaaagcggg catgacttct gcgctaagat tgtcagtttc caaaaacgag 960 gaggatttga tattcacctg gcccgcggtg atgcctttga gggtggccgc atccatctgg 1020 tcagaaaaga caat.cttttt gttgtcaagc ttggtggcaa acgacccgta gagggcgttg 1080 gacagcaact tggcgatgga gcgcagggtt tggtttttgt cgcgatcggc gcgctccttg 1140 gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc gccattcggg aaagacggtg 1200 gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggt tgtgcagggt gacaaggtca 1260 acgctggtgg ctacctctcc gcgtaggcgc tcgttggtcc agcagaggcg gccgcccttg 1320 cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt ccggggggtc tgcgtccacg 1380 gtaaagaccc cgggcagcag gcgcgcgtcg aagtagtcta tcttgcatcc ttgcaagtct 1440 agcgcctgct gccatgcgcg ggcggcaagc gcgcgctcgt atgggttgag tgggggaccc 1500 catggcatgg ggtgggtgag cgcggaggcg tacatgccgc aaatgtcgta aacgtagagg 1560 ggctctctga gtattccaag atatgtaggg tagcatcttc caccgcggat gctggcgcgc 1620 acgtaatcgt atagttcgtg cgagggagcg aggaggtcgg gaccgaggtt gctacgggcg 1680 ggctgctctg ctcggaagac tatctgcctg aagatggcat gtgagttgga tgatatggtt 1740 ggacgctgga agacgttgaa gctggcgtct gtgagaccta ccgcgtcacg cacgaaggag 1800 gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga cctgcacgtc tagggcgcag 1860 tagtccaggg tttccttgat gatgtcatac ttatcctgtc cctttttttt ccacagctcg 1920 cggttgagga caaactcttc gcggtctttc cagtactctt ggatcggaaa cccgtcggcc 1980 tccgaacgag atccgtactc cgccgccgag ggacctgagc gagtccgcat ~gaccggatc 2040 ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg caagatccaa gatgaagcgc 2100 gcccgcccca gcgaagatga cttcaacccc gtctacccct atggctacgc gcggaatcag 2160 aatatcccct tcctcactcc cccctttgtc tcctccgatg gattcaaaaa cttcccccct 2220 ggggtactgt cactcaaact ggctgatcca atcaccatta ccaatgggga tgtatccctc 2280 aaggtgggag gtggtctcac tttgcaagat ggaagcctaa ctgtaaaccc taaggctcca 2340 ctgcaagtta atactgataa aaaacttgag cttgcatatg ataatccatt tgaaagtagt 2400 gctaataaac ttagtttaaa agtaggacat ggattaaaag tattagatga aaaaagtgct 2460 gcggggttaa aagatttaat tggcaaactt gtggttttaa caggaaaagg aataggcact 2520 gaaaatttag aaaatacaga tggtagcagc agaggaattg gtataaatgt aagagcaaga 2580 gaagggttga catttgacaa tgatggatac ttggtagcat ggaacccaaa gtatgacacg 2640 cgcacacttt ggacaacacc agacacatct ccaaactgca caattgctca agataaggac 2700 tctaaactca ctttggtact tacaaagtgt ggaagtcaaa tattagctaa tgtgtctttg 2760 attgtggtcg caggaaagta ccacatcata aataataaga caaatccaaa aataaaaagt 2820 tttactatta aactgctatt taataagaac ggagtgcttt tagacaactc aaatcttgga 2880 aaagcttatt ggaactttag aagtggaaat tccaatgttt cgacagctta tgaaaaagca 2940 attggtttta tgcctaattt ggtagcgtat ccaaaaccca gtaattctaa aaaatatgca 3000 agagacatag tttatggaac tatatatctt ggtggaaaac ctgatcagcc agcagtcatt 3060 aaaactacct ttaaccaaga aactggatgt gaatactcta tcacatttaa ctttagttgg 3120 tccaaaacct atgaaaatgt tgaatttgaa accacctctt ttaccttctc ctatattgcc 3180 caagaatgaa agagcggccg ctcgagtcta gagggcccgt ttaaacccgc tgatcagcct 3240 cgactgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgtg ccttccttga 3300 ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt gcatcgcatt 3360 gtctgagtag gtgtcattct attctggggg gtggggtggg gcaggacagc aagggggagg 3420 attgggaaga caatagcagg catgctgggg atgcggtggg ctctatggct tctgaggcgg 3480 aa-agaaccag ctggggctct agggggtatc cccacgcgcc ctgtagcggc gcattaagcg 3540 cggcgggtgt ggtggttacg cgcagcgtga ccgctacact tgccagcgcc ctagcgcccg 3600 ctcctttcgc tttcttccct tcctttctcg,ccacgttcgc cggctttccc cgtcaagctc 3660 taaatcgggg catcccttta gggttccgat ttagtgcttt acggcacctc gaccccaaaa 3720 aacttgatta gggtgatggt tcacgtagtg ggccatcgcc ctgatagacg gtttttcgcc 3780 ctttgacgtt ggagtccacg ttctttaata gtggactctt gttccaaact ggaacaacac 3840 tcaaccctat ctcggtctat tcttttgatt tataagggat tttggggatt tcggcctatt 3900 ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa ttaattctgt ggaatgtgtg 3960 tcagttaggg tgtggaaagt ccccaggctc cccaggcagg cagaagtatg caaagcatgc 4020 atctcaatta gtcagcaacc aggtgtggaa agtccccagg ctccccagca ggcagaagta 4080 tgcaaagcat gcatctcaat tagtcagcaa ccatagtccc gcccctaact ccgcccatcc 4140 cgcccctaac tccgcccagt tccgcccatt ctccgcccca tggctgacta atttttttta 4200 tttatgcaga ggccgaggcc gcctctgcct ctgagctatt ccagaagtag tgaggaggct 4260 tttttggagg cctaggcttt tgcaaaaagc tcccgggagc ttgtatatcc attttcggat 4320 ctgatcagca cgtgttgaca attaatcatc ggcatagtat atcggcatag tataatacga 4380 caaggtgagg aactaaacca tggccaagtt gaccagtgcc gttccggtgc tcaccgcgcg 4440 atggtgtcat agtccagccc ctccgcggcg tggcccttgg cgcgcagctt gcccttgga CA 02359795 2001-07-12 pCT~P00/00265 cgacgtcgcc ggagcggtcg agttctggac cgaccggctc gggttctccc gggacttcgt 4500 ggaggacgac ttcgccggtg tggtccggga cgacgtgacc ctgttcatca gcgcggtcca 4560 ggaccaggtg gtgccggaca acaccctggc ctgggtgtgg gtgcgcggcc tggacgagct 4620 gtacgccgag tggtcggagg tcgtgtccac gaacttccgg gacgcctccg ggccggccat 4680 gaccgagatc ggcgagcagc cgtgggggcg ggagttcgcc ctgcgcgacc cggccggcaa 4740 ctgcgtgcac ttcgtggccg aggagcagga ctgacacgtg ctacgagatt tcgattccac 4800 cgccgccttc tatgaaaggt tgggcttcgg aatcgttttc cgggacgccg gctggatgat 4860 cctccagcgc ggggatctca tgctggagtt cttcgcccac cccaacttgt ttattgcagc 4920 ttataatggt tacaaataaa gcaatagcat cacaaatttc acaaataaag catttttttc 4980 actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg tctgtatacc 5040 gtcgacctct agctagagct tggcgtaatc atggtcatag ctgtttcctg tgtgaaattg 5100 ttatccgctc acaattccac acaacatacg agccggaagc ataaagtgta aagcctgggg 5160 tgcctaatga gtgagctaac tcacattaat tgcgttgcgc tcactgcccg ctttccagtc 5220 gggaaacctg tcgtgccagc tgcattaatg aatcggccaa cgcgcgggga gaggcggttt 5280 gcgtattggg cgctcttccg cttcctcgct cactgactcg ctgcgctcgg tcgttcggct 5340 gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga 5400 taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc 5460 cgcgttgctg gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg 5520 ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg 5580 aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt 5640 tctcccttcg ggaagcgtgg cgctttctca atgctcacgc tgtaggtatc tcagttcggt 5700 gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc c~cgaccgctg 5760 cgccttatcc ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact 5820 ggcagcagcc actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt 5880 cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct 5940 gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac 6000 cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 6060 tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaacg aaaactcacg 6120 ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta 6180 aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca 6240 atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 6300 ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc 6360 tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 6420 agccggaagg gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat 6480 taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 6540 tgccattgct acaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc 6600 cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag 6660 ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 6720 tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 6780 tggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 6840 cccggcgtca atacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 6900 tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 6960 gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc 7020 tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 7080 atgttgaata ctcatactct tcctttttca atattattga agcatttatc agggttattg 7140 tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 7200 cacatttccc cgaaaagtgc cacctgacgt c 7231 <210> 65 <211> 8484 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: plasmid <400> 65 ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg cgagcaaaat ttaagctaca 60 acaaggcaag gcttgaccga caattgcatg aagaatctgc ttagggttag gcgttttgcg 120 ctgcttcgcg atgtacgggc cagatatacg cgttgacatt gattattgac tagttattaa 180 tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg cgttacataa 240 WO 00/42208 CA 02359795 2001-07-12 pCT~, P00/00265 cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt gacgtcaata 300 atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca atgggtggac 360 tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc aagtacgccc 420 cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta catgacctta 480 tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac catggtgatg 540 cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg atttccaagt 600 ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg ggactttcca 660 aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt acggtgggag 720 gtctatataa gcagagctct ctggctaact agagaaccca ctgcttactg gcttatcgaa 780 attaatacga ctcactatag ggagacccaa gctggctagc gtttaaactt aagcttggta 840 ccgagctcgg atccactctc ttccgcatcg ctgtctgcga gggccagctg ttggggtgag 900 tactccctct gaaaagcggg catgacttct gcgctaagat tgtcagtttc caaaaacgag 960 gaggatttga tattcacctg gcccgcggtg atgcctttga gggtggccgc atccatctgg 1020 tcagaaaaga caatcttttt gttgtcaagc ttggtggcaa acgacccgta gagggcgttg 1080 gacagcaac't tggcgatgga gcgcagggtt tggtttttgt cgcgatcggc gcgctccttg 1140 gccgcgatgt ttagctgcac gtattcgcgc gcaacgcacc gccattcggg aaagacggtg 1200 gtgcgctcgt cgggcaccag gtgcacgcgc caaccgcggt tgtgcagggt gacaaggtca 1260 acgctggtgg ctacctctcc gcgtaggcgc tcgttggtcc agcagaggcg gccgcccttg 1320 cgcgagcaga atggcggtag ggggtctagc tgcgtctcgt ccggggggtc tgcgtccacg 1380 gtaaagaccc cgggcagcag gcgcgcgtcg aagtagtcta tcttgcatcc ttgcaagtct 1440 agcgcctgct gccatgcgcg ggcggcaagc gcgcgctcgt atgggttgag tgggggaccc 1500 catggcatgg ggtgggtgag cgcggaggcg tacatgccgc aaatgtcgta ~acgtagagg 1560 ggctctctga gtattccaag atatgtaggg tagcatcttc caccgcggat gctggcgcgc 1620 acgtaatcgt atagttcgtg cgagggagcg aggaggtcgg gaccgaggtt gctacgggcg 1680 ggctgctctg ctcggaagac tatctgcctg aagatggcat gtgagttgga tgatatggtt 1740 ggacgctgga agacgttgaa gctggcgtct gtgagaccta ccgcgtcacg cacgaaggag 1800 gcgtaggagt cgcgcagctt gttgaccagc tcggcggtga cctgcacgtc tagggcgcag 1860 tagtccaggg tttccttgat gatgtcatac ttatcctgtc cctttttttt ccacagctcg 1920 cggttgagga caaactcttc gcggtctttc cagtactctt ggatcggaaa cccgtcggcc 1980 tccgaacgag atccgtactc cgccgccgag ggacctgagc gagtccgcat cgaccggatc 2040 ggaaaacctc tcgagaaagg cgtctaacca gtcacagtcg caagatccaa gatgaagcgc 2100 gcaagaccgt ctgaagatac cttcaacccc gtgtatccat atgacacgga aaccggtcct 2160 ccaactgtgc cttttcttac tcctcccttt gtatccccca atgggtttca agagagtccc 2220 cctggggtac tctctttgcg cctatccgaa cctctagtta cctccaatgg catgcttgcg 2280 ctcaaaatgg gcaacggcct ctctctggac gaggccggca accttacctc ccaaaatgta 2340 accactgtga gcccacctct caaaaaaacc aagtcaaaca taaacctgga aatatctgca 2400 cccctcacag ttacctcaga agccctaact gtggctgccg ccgcacctct aatggtcgcg 2460 ggcaacacac tcaccatgca atcacaggcc ccgctaaccg tgcacgactc caaacttagc 2520 attgccaccc aaggacccct cacagtgtca gaaggaaagc tagccctgca aacatcaggc 2580 cccctcacca ccaccgatag cagtaccctt actatcactg cctcaccccc tctaactact 2640 gccactggta gcttgggcat tgacttgaaa gagcccattt atacacaaaa tggaaaacta 2700 ggactaaagt acggggctcc tttgcatgta acagacgacc taaacacttt gaccgtagca 2760 actggtccag gtgtgactat taataatact tccttgcaaa ctaaagttac tggagccttg 2820 ggttttgatt cacaaggcaa tatgcaactt aatgtagcag gaggactaag gattgattct 2880 caaaacagac gccttatact tgatgttagt tatccgtttg atgctcaaaa ccaactaaat 2940 ctaagactag gacagggccc tctttttata aactcagccc acaacttgga tattaactac 3000 aacaaaggcc tttacttgtt tacagcttca aacaattcca aaaagcttga ggttaaccta 3060 agcactgcca aggggttgat gtttgacgct acagccatag ccattaatgc aggagatggg 3120 cttgaatttg gttcacctaa tgcaccaaac acaaatcccc tcaaaacaaa aattggccat 3180 ggcctagaat ttgattcaaa caaggctatg gttcctaaac taggaactgg ccttagtttt 3240 gacagcacag gtgccattac agtaggaaac aaaaataatg ataagctaac tttgtggacc 3300 acaccagctc catctcctaa~ctgtagacta aatgcagaga aagatgctaa actcactttg 3360 gtcttaacaa aatgtggcag tcaaatactt gctacagttt cagttttggc tgttaaaggc 3420 agtttggctc caatatctgg aacagttcaa agtgctcatc ttattataag atttgacgaa 3480 aatggagtgc tactaaacaa ttccttcctg gacccagaat attggaactt tagaaatgga 3540 gatcttactg aaggcacagc ctatacaaac gctgttggat ttatgcctaa cctatcagct 3600 tatccaaaat ctcacggtaa aactgccaaa agtaacattg tcagtcaagt ttacttaaac 3660 ggagacaaaa ctaaacctgt aacactaacc attacactaa acggtacaca ggaaacagga 3720 gacacaactc caagtgcata ctctatgtca ttttcatggg actggtctgg ccacaactac 3780 attaatgaaa tatttgccac atcctcttac actttttcat acattgccca agaataaaag 3840 aagcggccgc tcgagtctag cgataatcaa cctctggatt acaaaatttg tgaaagattg 3900 actggtattc ttaactatgt tgctcctttt acgctatgtg gatacgctgc tttaatgcct 3960 ttgtatcatg ctattgcttc ccgtatggct ttcattttct cctccttgta taaatcctgg 4020 ttgctgtctc tttatgagga gttgtggccc gttgtcaggc aacgtggcgt ggtgtgcact 4080 gtgtttgctg acgcaacccc cactggttgg ggcattgcca ccacctgtca gctcctttcc 4140 gggactttcg ctttccccct ccctattgcc acggcggaac tcatcgccgc ctgccttgcc 4200 cgctgctgga caggggctcg gctgttgggc actgacaatt ccgtggtgtt gtcggggaag 4260 ctgacgtcct ttccatggct gctcgcctgt gttgccacct ggattctgcg cgggacgtcc 4320 ttctgctacg tcccttcggc cctcaatcca gcggaccttc cttcccgcgg cctgctgccg 4380 gctctgcggc ctcttccgcg tcttcgcctt cgccctcaga cgagtcggat ctccctttgg 4440 gccgcctccc cgcctgatcg ctagagggcc cgtttaaacc cgctgatcag cctcgactgt 4500 gccttctagt tgccagccat ctgttgtttg cccctccccc gtgccttcct tgaccctgga 4560 aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc attgtctgag 4620 taggtgtcat tctattctgg ggggtggggt ggggcaggac agcaaggggg aggattggga 4680 agacaatagc aggcatgctg gggatgcggt gggctctatg gcttctgagg cggaaagaac 4740 cagctggggc tctagggggt atccccacgc gccctgtagc ggcgcattaa gcgcggcggg 4800 tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc ccgctccttt 4860 cgctttcttc ccttcctttc tcgccacgtt cgccggcttt ccccgtcaag ctctaaatcg 4920 gggcatccct ttagggttcc gatttagtgc tttacggcac ctcgacccca aaaaacttga 4980 ttagggtgat ggttcacgta gtgggccatc gccctgatag acggtttttc gccctttgac 5040 gttggagtcc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc 5100 tatctcggtc tattcttttg atttataagg gattttgggg atttcggcct attggttaaa 5160 aaatgagctg atttaacaaa aatttaacgc gaattaattc tgtggaatgt gtgtcagtta 5220 gggtgtggaa agtccccagg ctccccaggc aggcagaagt atgcaaagca ~gcatctcaa 5280 ttagtcagca accaggtgtg gaaagtcccc aggctcccca gcaggcagaa gtatgcaaag 5340 catgcatctc aattagtcag caaccatagt cccgccccta actccgccca tcccgcccct 5400 aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt ttatttatgc 5460 agaggccgag gccgcctctg cctctgagct attccagaag tagtgaggag gcttttttgg 5520 aggcctaggc ttttgcaaaa agctcccggg agcttgtata tccattttcg gatctgatca 5580 gcacgtgttg acaattaatc atcggcatag tatatcggca tagtataata cgacaaggtg 5640 aggaactaaa ccatggccaa gttgaccagt gccgttccgg tgctcaccgc gcgcgacgtc 5700 gccggagcgg tcgagttctg gaccgaccgg ctcgggttct cccgggactt cgtggaggac 5760 gacttcgccg gtgtggtccg ggacgacgtg accctgttca tcagcgcggt ccaggaccag 5820 gtggtgccgg acaacaccct ggcctgggtg tgggtgcgcg gcctggacga gctgtacgcc 5880 gagtggtcgg aggtcgtgtc cacgaacttc cgggacgcct ccgggccggc catgaccgag-5940 atcggcgagc agccgtgggg gcgggagttc gccctgcgcg acccggccgg caactgcgtg 6000 cacttcgtgg ccgaggagca ggactgacac gtgctacgag atttcgattc caccgccgcc 6060 ttctatgaaa ggttgggctt cggaatcgtt ttccgggacg ccggctggat gatcctccag 6120 cgcggggatc tcatgctgga gttcttcgcc caccccaact tgtttattgc agcttataat 6180 ggttacaaat aaagcaatag catcacaaat ttcacaaata aagcattttt ttcactgcat 6240' tctagttgtg gtttgtccaa actcatcaat gtatcttatc atgtctgtat accgtcgacc 6300 tctagctaga gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa ttgttatccg 6360 ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg gggtgcctaa 6420 tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca gtcgggaaac 6480 ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg tttgcgtatt 6540 gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg gctgcggcga 6600 gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg ggataacgca 6660 ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa ggccgcgttg 6720 ctggcgtttt tccataggct ccgcccccct gacgagcatc acaaaaatcg acgctcaagt 6780 cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc tggaagctcc 6840 ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc ctttctccct 6900 tcgggaagcg tggcgctttc tcaatgctca cgctgtaggt atctcagttc ggtgtaggtc 6960 gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg ctgcgcctta 7020 tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc actggcagca 7080 gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcttgaag 7140 tggtggccta actacggcta cactagaagg acagtatttg gtatctgcgc tctgctgaag 7200 ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac caccgctggt 7260 agcggtggtt tttttgtttg caagcagcag attacgcgca gaaaaaaagg atctcaagaa 7320 gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc acgttaaggg 7380 attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa ttaaaaatga 7440 agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta ccaatgctta 7500 atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt tgcctgactc 7560 cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag tgctgcaatg 7620 ataccgcgag acccacgctc accggctcca gatttatcag caataaacca gccagccgga 7680 agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc tattaattgt 7740 tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt tgttgccatt 78'00 gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag. ctccggttcc 7860 caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt tagctccttc 7920 ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt tatcactcat ggttatggca 7980 gcactgcata attctcttac tgtcatgcca tccgtaagat gcttttctgt gactggtgag 8040 tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccggcg 8100 tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat cattggaaaa 8160 cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa 8220 cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga 8280 gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga 8340 atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta ttgtctcatg 8400 agcggataca tatttgaatg tatttagaaa aataaacaaa taggggttcc gcgcacattt 8460 ccccgaaaag tgccacctga cgtc 8484 <210> 66 <211> 53 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 66 gtcactcgag gactcggtcg actgaaaatg agacatatta tctgccacgg acc 53 <210> 67 <211> 36 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 67 cgagatcgat cacctccggt acaaggtttg gcatag 36 <210> 68 <211> 37 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 68 catgaagatc tggaaggtgc tgaggtacga tgagacc 37 <210> 69 <211> 51 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 69 gcgacttaag cagtcagctg agacagcaag acacttgctt gatccaaatc c 51 <210> 70 <211> 38 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 70 cacgaattcg tcagcgcttc tcgtcgcgtc caagaccc 38 <210> 7I
<211> 32 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 71 caccccgggg aggcggcggc gacggggacg gg 32 <210> 72 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: oligonucleotide <400> 72 atgggatcca agatgaagcg cgcaagaccg 30 <210> 73 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: oligonucleotide <400> 73 cataacctgc aggattcttt attcttgggc 30 <210> 74 <211> 47 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: oligonucleotide <900> 74 ggtacacagg aaacaggagg ttccggaggt ggaggagaca caactcc 47 <210> 75 <211> 30 <212> DNA
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <900> 75 atgggatcca agatgaagcg cgcaagaccg 30 <210> 76 <211> 30 <212> DNA.
<213> Artificial Sequence <220>
<223> Description of Artificial Sequence: primer <400> 76 cactatagcg gccgcattct cagtcatctt 30

Claims (93)

What is claimed is:
1. An isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third same or different TPL
exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL
exon 1, complete TPL exon 2 and complete TPL exon 3, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3.
2. The isolated nucleic acid molecule of claim 1, wherein said sequence is operatively linked to an intron containing an RNA processing signal.
3. The isolated nucleic acid molecule of claim 1 or 2 wherein said TPL
nucleotide sequence consists essentially of complete TPL exon 1 operatively linked to complete TPL exon 2 operatively linked to complete TPL exon 3.
4. The isolated nucleic acid molecule of claim 2 wherein said intron is native adenovirus intron 1.
5. The isolated nucleic acid molecule of any one of claims 1 to 4 wherein said TPL nucleotide sequence is shown in SEQ ID NO: 32.
6. The isolated nucleic acid molecule of claim 5 further comprising a promoter and a nucleic acid sequence which encodes an adenoviral structural protein, operatively linked to said promoter and said TPL sequence.
7. The isolated nucleic acid molecule of claim 6 wherein said adenoviral structural protein is a fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.
8. The isolated nucleic acid molecule of claim 7 wherein said chimeric protein comprises an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.
9. The isolated nucleic acid molecule of claim 7 wherein said molecule is contained in a plasmid selected from the group consisting of plasmids pCLF, pDV60, pDV67, pDV69, pDV80 and pDV90.
10. The isolated nucleic acid molecule of claim 9 wherein said molecule has a nucleotide sequence selected from the group consisting of sequences shown in SEQ
ID NO: 8, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 47, SEQ ID NO: 64 and SEQ ID NO:65.
11. An adenovirus vector complementing plasmid comprising an isolated nucleic acid molecule according to any one of claims 1 to 10.
12. An adenovirus vector packaging cell line comprising a stably integrated nucleic acid molecule as claimed in any one of claims 1 to 11, an operatively-linked promoter and a nucleic acid sequence which encodes an adenovirus structural protein, wherein said TPL sequence consists essentially of a first complete TPL exon operatively linked to a complete second TPL exon operatively linked to a complete third TPL exon.
13. The cell line of claim 12 wherein said first TPL exon is a complete or partial first TPL exon.
14. The cell line of claim 13 wherein said TPL molecule comprises complete TPL
exon 1 having the nucleotide sequence of SEQ ID NO: 32 or partial TPL exon 1 having the nucleotide of SEQ ID NO: 26.
15. The cell line of claim 12 wherein said promoter is an inducible promoter.
16. The cell line of claim 12 wherein said adenovirus structural protein is adenovirus fiber protein or a chimeric protein which includes an adenovirus fiber protein tail domain.
17. The cell line of claim 12 wherein said chimeric protein comprises an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.
18. The cell line of claim 12 wherein said nucleic acid molecule is selected from the group consisting of plasmids pDV60, pDV67, pDV69, pDV80 and pDV90.
19. The cell line of claim 18 wherein said nucleic acid molecule has a nucleotide sequence from the group consisting of sequences shown in SEQ ID NO: 43, SEQ ID
NO: 44 and SEQ ID NO: 47.
20. The cell line of claim 12 wherein said cell line is an epithelial cell line.
21. The cell line of claim 20 wherein said cell line supports the production of a recombinant adenovirus vector genome by complementation of a deficient viral gene in said vector genome.
22. The cell line of claim 21 wherein said cell line further produces an adenovirus protein and thereby complements a deficient adenovirus gene in said vector genome, and wherein said cell line complements an adenovirus early protein gene and a fiber gene.
23. The cell line of claim 22 wherein the deletion of said deficient adenovirus gene is complemented by the expression of said gene under the control of an inducible promoter.
24. A recombinant adenovirus particle comprising a recombinant adenovirus vector genome wherein said genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene in a packaging cell, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, and optionally an exogenous protein, said TPL nucleotide sequence comprising (a) first and second different TPL
exons or (b) first, second and third same or different TPL exons, said TPL
exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL
exon 1, complete TPL exon 2 and complete TPL exon 3.
25. The recombinant adenovirus particle of claim 24 wherein said adenovirus vector genome does not encode one or more functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3 and E4 protein.
26. The particle of claim 24 wherein said adenovirus vector genome is Ad5.Bgal..DELTA.F.
27. The particle of claim 24 wherein said adenovirus vector genome is contained in the adenovirus particle deposited under ATCC accession # VR2636 and corresponding to Ad5.Bgal..DELTA.F.
28. The particle of claim 24 wherein said particle lacks fiber protein or contains a modified fiber protein.
29. The particle of claim 24 wherein said particle comprises an adenovirus fiber protein or a chimeric protein having an adenovirus fiber protein tail domain, said chimeric protein comprising an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.
30. The particle of claim 24 wherein said exogenous protein is a therapeutic gene product.
31. A helper-independent fiberless recombinant adenovirus vector genome comprising genes which:
(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle in a packaging cell without complementation of said fiber gene or said genome lacks at least the fibre gene, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL
exons or (b) first, second and third same or different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL
exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3. and (b) encode an exogenous protein.
32. The adenovirus vector genome of claim 31 wherein said adenovirus vector genome does not encode one or more functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3 and E4 protein.
33. The adenovirus vector genome of claim 31 wherein said adenovirus vector . genome is Ad5.Bgal..DELTA.F.
34. The adenovirus vector genome of claim 33 wherein said adenovirus vector genome has a nucleotide sequence shown in SEQ ID NO:27 and corresponds to Ad5.Bgal..DELTA.F.
35. The adenovirus vector genome of claim 31 wherein said adenovirus vector genome is contained in the adenovirus particle deposited under ATCC accession VR-2636 corresponding to Ad5.Bgal..DELTA.F.
36. The adenovirus vector genome of claim 31 wherein said exogenous protein is a therapeutic gene product.
37. An isolated nucleic acid that comprises the adenovirus vector genome of claim 31.
38. A method for producing an adenovirus vector particle containing a helper-independent fiberless recombinant adenovirus vector genome, said method comprising providing a packaging cell line which complements replication and packaging of said genome and a helper-independent fiberless recombinant adenovirus vector genome which is deficient in expressing sufficient functional fiber protein to support assembly of fiber-containing particles, wherein said packaging cell comprises an isolated nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL
exon 1, complete TPL exon 2 and complete TPL exon 3 and, wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3, and harvesting said particles produced by said cell line.
39. The method of claim 38 wherein said packaging cell line complements adenovirus fiber protein.
40. The method of claim 38 wherein said adenovirus vector genome comprises genes that:
(a) express all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and (b) express an exogenous protein.
41. The method of claim 38 wherein said packaging cell line comprises a stably integrated first nucleic acid molecule alternatively operatively linked to a promoter, and said first nucleic acid is operatively linked to a second nucleic acid molecule encoding an adenovirus structural protein, wherein said first nucleic acid molecule comprises an adenovirus tripartite leader (TPL) nucleotide sequence operatively linked to an intron containing an RNA processing signal, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL
exon 3 and wherein said isolated nucleic acid molecule may not comprise the nucleic acid sequence consisting of partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3..
42. The method of claim 38 wherein said helper-independent fiberless recombinant adenovirus vector genome is introduced by infecting said cell line with a virus particle containing said genome.
43. The method of claim 42 wherein said particle is a particle comprising a helper-independent recombinant adenovirus vector genome comprising genes that:
(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and (b) encode an exogenous protein, wherein said particle comprises an adenovirus fiber protein or a chimeric protein that includes an adenovirus fiber protein tail domain.
44. The method of claim 38 wherein said helper-independent fiberless recombinant adenovirus vector genome is introduced into said cell line by transfecting said cell line with said helper-independent fiberless recombinant adenovirus vector genome
45. The method of claim 44 wherein said adenovirus vector genome comprises genes which:
(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and (b) encode an exogenous protein.
46. The method of claim 38 wherein said packaging cell line is transfected with a nucleic acid molecule encoding adenovirus fiber protein.
47. The method of claim 46 wherein said nucleic acid molecule is a nucleic acid molecule comprising an adenovirus tripartite leader (TPL) nucleotide sequence, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and said molecule further comprises a sequence encoding adenovirus fiber protein.
48. The method of claim 39 wherein said adenovirus fiber protein is a modified fiber protein.
49. The method of claim 38 further comprising the step of coating said particle with adenovirus fiber protein.
50. A method for delivery of an exogenous gene to a target cell comprising contacting said cell with an amount of a recombinant adenovirus particle of claim 24 sufficient to infect said cell.
51. The method of claim 50 wherein said exogenous gene encodes a therapeutic gene product.
52. The method of claim 51 wherein said recombinant adenovirus particle contains a modified fiber protein which binds a preselected target cell and directs delivery of the particle to said target cell.
53. The method of claim 50 wherein said recombinant adenovirus particle comprises a helper-independent fiberless recombinant adenovirus vector genome comprising genes that:
(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to package a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the fibre gene, and (b) encode an exogenous protein.
54. The method of claim 50 wherein said modified fiber protein has an amino terminal head domain which binds to .alpha.v integrins and thereby targets cells with .alpha.v integrin receptors.
55. The method of claim 50 wherein said contacting is conducted in vitro.
56. The method of claim 55 wherein said contacting is conducted on cells of a tissue which are first removed from the body of a patient, and the cells are subsequently returned to said patient.
57. The method of claim 50 wherein said contacting is conducted in vivo by administering said recombinant adenovirus particle to a tissue of said patient.
58. The method of claim 57 wherein said administering is intravenously, intraperitoneally, by aerosol, topically or by injection.
59. A method for pseudotyping recombinant viral vectors comprising complementing a missing fiber gene of a helper-independent or helper dependent fiberless recombinant adenovirus vector genome by expressing in packaging cells a fiber gene from a different adenoviral serotype than said recombinant adenovirus vector, thereby pseudotyping said vector.
60. A method for specifically targeting an adenovirus vector to a cell of choice comprising introducing a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome into a packaging cell line for producing a fiber gene-deleted adenovirus vector, wherein said gene for a missing fiber protein is complemented with a gene for a desired modification for targeting the vector to a cell of choice.
61. A method for producing a modified adenovirus comprising providing in vitro an exogenous fiber protein to a fiberless adenovirus.
62. The method of claim 61, wherein said fiber is provided by adding fiber protein in a suitable buffer to a fiberless virus preparation, thereby producing a modified adenovirus.
63. The method of claim 61, wherein a helper-independent or helper-dependent fiberless recombinant adenovirus vector genome is introduced into a packaging cell line to produce a fiberless adenovirus to which exogenous fiber protein will be provided.
64. A method for delivering a heterologous gene to EBV-infected B cells comprising infecting said B cells with a pseudotyped Ad5.beta.gal..DELTA.F
particle or other fiber-deleted adenovirus particle, said particle having a chimeric fiber including the receptor-binding knob domain of the adenovirus type 3 fiber.
65. The adenovirus particle of claim 24 wherein said adenovirus vector genome lacks a fibre gene or lacks a portion of the fibre gene sequence such that fibre protein is not expressed in sufficient quantities to support packaging.
66. The recombinant adenovirus particle of claim 24 comprising a helper-independent recombinant adenovirus vector genome comprising genes that:
(a) encode all adenovirus structural gene products but do not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene or said genome lacks at least the gene encoding fibre, and (b) optionally encodes an exogenous protein.
67. The recombinant adenovirus particle of claim 24 wherein said particle further comprises a nucleic acid encoding an exogenous protein.
68. A method for producing a modified adenovirus comprising providing a packaging cell line for producing a fiberless adenovirus helper-dependent fiberless recombinant adenovirus vector genome and a helper virus vector, wherein said cell line complements at least a deficient fiber protein gene, thereby producing the modified adenovirus.
69. The packaging cell line of claim 9 wherein said cell line is selected from the group consisting of 293, A549, W163, HeLa, Vero, 211, 211A and an epithelial cell line comprising the stably integrated nucleic acid molecule.
70. The recombinant adenovirus particle of claim 21 wherein said exogenous protein is selected from a group consisting of a tumor-suppressor protein, a biologically active fragment thereof, a suicide protein and a biologically active fragment thereof.
71. A composition for preparing a therapeutic vector, said composition comprising a plasmid comprising an adenovirus genome lacking a nucleotide sequence encoding a fiber protein or a genome that is incapable of expressing sufficient fiber to result in packaging.
72. A method of delivering a heterologous gene to a human or any animal comprising providing said heterologous gene to a target cell wherein said target cell is contacted in vivo or ex vivo with an amount of a recombinant adenovirus particle of claim 24 sufficient to infect said cell and thereby deliver the heterologous gene.
73. The recombinant adenovirus vector particle of either claim 24 or 31, wherein no fiber protein is expressed.
74. The recombinant adenovirus vector particle of claim 24, wherein said genome expresses insufficient fiber to allow incorporation of said protein into the particle such that the particle cannot use the fiber pathway for infection.
75. The recombinant adenovirus genome of claim 31, wherein said genome expresses insufficient fiber to allow incorporation of said protein into a particle such that the particle cannot use the fiber pathway for infection.
76. A method for producing a gutless adenoviral vector particle comprising:
a) delivering a helper adenovirus vector genome to an adenovirus vector packaging cell, wherein said helper adenovirus vector genome lacks any gene encoding adenovirus fiber protein or lacks the ability to encode sufficient adenovirus fiber protein to produce an adenoviral vector comprising fiber protein in the absence of complemetation by said packing cell and wherein said packaging cell comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to an adenoviral fiber protein or to a chimeric protein that includes an adenovirus fiber protein tail domain;
(b) delivering a gutless adenovirus vector genome to said packaging cell; and (c) recovering the gutless adenoviral vector particle produced by said cell.
77. The method of claim 76, wherein said helper adenovirus vector genome is delivered by viral infection.
78. The method of claim 77, wherein said gutless adenovirus vector genome is delivered by transfection.
79. The method of claim 76, wherein said gutless adenovirus vector genome comprises an operable packaging sequence.
80. The method of claim 79, wherein said helper adenovirus vector genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged as an adenoviral vector particle by said packaging cell.
81. The method of claim 79, wherein said helper adenovirus vector genome comprises recombinase sites flanking its packaging sequence and said packaging cell further comprises a nucleotide sequence encoding a recombinase.
82. The method of claim 81, wherein said recombinase site is a lox site and said recombinase is Cre.
83. A helper adenovirus particle comprising an adenovirus vector genome that does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene, wherein said genome has a mutation in its packaging sequence that renders said genome substantially incapable of being packaged.
84. The helper adenovirus particle of claim 83, wherein said mutation comprises a deletion of at least one nucleotide in said packaging sequence.
85. The helper adenovirus particle of claim 84, wherein said adenovirus vector genome does not encode functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3, and E4 proteins.
86. A helper adenovirus particle comprising an adenovirus vector genome with recombinase sites flanking its packaging sequence, wherein said vector genome does not encode or does not express sufficient adenovirus fiber protein to support packaging of a fiber-containing adenovirus particle without complementation of said fiber gene.
87. The helper adenovirus particle of claim 86, wherein said adenovirus vector genome does not encode functional proteins selected from the group consisting of E1A, E1B, E2A, E2B, E3, and E4 proteins.
88. An adenovirus particle comprising a gutless adenoviral vector genome and a fiberless capsid.
89. An adenovirus particle comprising a gutless adenoviral vector genome and a capsid comprising a modified fiber protein.
90. A packaging cell for the production of a fiberless or fiber-modified gutless adenovirus particle comprising an adenovirus vector complementing plasmid and a nucleotide sequence encoding a recombinase, wherein said complementing plasmid comprises the nucleic acid molecule of claim 2 operably linked to a promoter and to a nucleotide sequence encoding an adenoviral fiber protein or a chimeric adenoviral fiber protein.
91. The packaging cell of claim 90, wherein said complementing plasmid and said nucleotide sequence encoding a recombinase are stably integrated into the genome of said cell.
92. The packaging cell of claim 90, further comprising a helper adenovirus vector genome.
93. The packaging cell of claim 90, wherein said recombinase is Cre..
CA002359795A 1999-01-14 2000-01-14 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use Abandoned CA2359795A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11592099P 1999-01-14 1999-01-14
US60/115,920 1999-01-14
PCT/EP2000/000265 WO2000042208A1 (en) 1999-01-14 2000-01-14 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use

Publications (1)

Publication Number Publication Date
CA2359795A1 true CA2359795A1 (en) 2000-07-20

Family

ID=22364147

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002359795A Abandoned CA2359795A1 (en) 1999-01-14 2000-01-14 Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use

Country Status (7)

Country Link
EP (1) EP1141357A1 (en)
JP (1) JP2002534130A (en)
KR (1) KR100688631B1 (en)
AU (2) AU772630B2 (en)
CA (1) CA2359795A1 (en)
IL (1) IL144060A0 (en)
WO (1) WO2000042208A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110832072A (en) * 2017-04-21 2020-02-21 真基因太科公司 Cell lines for the production of non-replicative adenoviruses and methods for preparing said cell lines

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
CN1405312A (en) * 2001-01-18 2003-03-26 中山卫健生物科技有限公司 Recombinant virus capable of specific killing tumor relating to EB virus and constructing method thereof
CA2492423A1 (en) * 2001-07-15 2004-03-18 Keck Graduate Institute Exponential amplification of nucleic acids using nicking agents
AU2002337840B2 (en) 2001-10-11 2007-08-09 Msd Italia S.R.L. Hepatitis C virus vaccine
AU2007231692B8 (en) * 2001-10-11 2012-03-08 Msd Italia S.R.L. Hepatitis C virus vaccine
US8163892B2 (en) 2002-07-08 2012-04-24 Oncolys Biopharma, Inc. Oncolytic virus replicating selectively in tumor cells
JP2007525166A (en) 2003-03-28 2007-09-06 ザ・スクリップス・リサーチ・インスティテュート Adenovirus particles with increased infectivity to dendritic cells and particles with reduced infectivity to hepatocytes
ES2330826B1 (en) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. HIGH CAPACITY ADENOVIRUS PACKING SYSTEM.
KR20180122043A (en) * 2010-06-10 2018-11-09 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 Methods and systems for adenovirus interaction with desmoglein 2(dsg2)
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN108699566B (en) 2016-02-23 2023-06-30 萨克生物研究学院 Treatment of exogenous gene expression in adenoviruses with minimal effect on viral kinetics
CN110062630A (en) 2016-12-12 2019-07-26 萨克生物研究学院 Cancer target synthesizes adenovirus and application thereof
EP3864159A4 (en) * 2018-10-09 2022-11-02 Nikegen Limited Compositions and methods for preparing viral vectors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687829B2 (en) * 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
ATE209246T1 (en) * 1996-09-24 2001-12-15 Henkel Ecolab Gmbh & Co Ohg PRODUCTION OF COMPACT CLEANERS CONTAINING SURFACTANTS
ATE420182T1 (en) * 1996-09-25 2009-01-15 Scripps Research Inst PACKAGING CELL LINES USED TO FACILITATE THE DEVELOPMENT OF HIGHLY EFFICIENT ADENOVIRAL VECTORS
US5994132A (en) * 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
EP0892047A3 (en) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Human and murine semaphorin L

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110832072A (en) * 2017-04-21 2020-02-21 真基因太科公司 Cell lines for the production of non-replicative adenoviruses and methods for preparing said cell lines
CN110832072B (en) * 2017-04-21 2023-11-07 真基因太科公司 Cell line for producing non-replicating adenovirus and method for preparing said cell line

Also Published As

Publication number Publication date
WO2000042208A8 (en) 2002-05-10
AU2004201067A1 (en) 2004-04-08
EP1141357A1 (en) 2001-10-10
IL144060A0 (en) 2002-04-21
JP2002534130A (en) 2002-10-15
KR20030017483A (en) 2003-03-03
AU772630B2 (en) 2004-05-06
AU2437200A (en) 2000-08-01
WO2000042208A1 (en) 2000-07-20
KR100688631B1 (en) 2007-03-02

Similar Documents

Publication Publication Date Title
US20020193327A1 (en) Vectors for occular transduction and use therefor for genetic therapy
US6156567A (en) Truncated transcriptionally active cytomegalovirus promoters
US6090393A (en) Recombinant canine adenoviruses, method for making and uses thereof
AU2020260491B2 (en) Gene therapies for lysosomal disorders
AU772630B2 (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US20030157688A1 (en) Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
AU2023214366B2 (en) Gene therapies for lysosomal disorders
AU2020205228B2 (en) Gene therapies for lysosomal disorders
US20040219516A1 (en) Viral vectors containing recombination sites
KR20230019843A (en) Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US20030119104A1 (en) Chromosome-based platforms
US20040013648A1 (en) Vector system
US20040002060A1 (en) Fiber shaft modifications for efficient targeting
WO1998013499A2 (en) Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors
CN101208425A (en) Cell lines for production of replication-defective adenovirus
KR20220006527A (en) Gene therapy for lysosomal disorders
JP2003534775A (en) Methods for destabilizing proteins and uses thereof
CA3065946A1 (en) Enhanced modified viral capsid proteins
CA2519680A1 (en) Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
KR20210086645A (en) AAV triple-plasmid system
CN111094569A (en) Light-controlled viral protein, gene thereof, and viral vector containing same
WO2005081716A2 (en) DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
KR20230019063A (en) Triple function adeno-associated virus (AAV) vectors for the treatment of C9ORF72 associated diseases
KR20230031929A (en) Gorilla adenovirus nucleic acid sequences and amino acid sequences, vectors containing them, and uses thereof
KR20210151785A (en) Non-viral DNA vectors and their use for expression of FVIII therapeutics

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued